COURTESY COPY OF THE
PCT APPLICATION AS
ORIGINALLY FILED
WITH ABSTRACT

(19) World Intellectual Property Organization

International Bureau



: IDBOR BUILDIN I BERLEV KEN KAN BEN BERLEV BER

(43) International Publication Date 28 October 2004 (28.10.2004)

PCT

(10) International Publication Number WO 2004/092416 A1

(51) International Patent Classification⁷:

C12Q 1/68

(21) International Application Number:

PCT/US2004/010191

(22) International Filing Date: 2 April 2004

2 April 2004 (02.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/460,415 60/506,716 7 April 2003 (07.04.2003) US 30 September 2003 (30.09.2003) US

(71) Applicant (for all designated States except US): OHIO UNIVERSITY [US/US]; Technology Transfer Office, 20 East Circle Drive, Athens, 11 45701 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): KOPCHICK, John, J. [US/US]; 4 Orchard Lane, Athens, 36 45701 (US). KELDER, Bruce [US/US]; c/o Edison Biotechnology Institute (EBI), Konneker Research Laboratory 206B, Ohio University, Athens, Ohio 45701 (US). BOYCE, Keith S. [US/US]; 2589 Cole Road, Wexford, P 15090 (US). KRIETE, Andres [US/US]; 1222 Driftwood Drive, Pittsburgh, PA 15243 (US).
- (74) Agents: BROWDY AND NEIMARK, P.L.L.C. et al.; 624 Ninth Street N.W.IISuite 300, Washington, District of Columbia 20001-5303 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME

(57) Abstract: Mouse genes differentially expressed in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic liver by gene chip analysis have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against hyperinsulinemia or type 2 diabetes, or their sequelae.



15

20

25

30

35

JC09 Rec'd PCT/PTO 07 OCT 2005

DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME

1

This application claims the benefit under 35 USC 119(e) of prior U.S. provisional applications 60/460,415, filed April 7, 2003 (KOPCHICK6-USA), and 60/506,716, filed Sept. 30, 2003 (KOPCHICK6.1-USA), both of which are hereby incorporated by reference in their entirety.

10 Cross-Reference to Related Applications

The instant application adds 6 month expression data to the disclosure of US Prov. Appl. 60/460,415, filed April 7, 2003 (KOPCHICK6-USA).

In U.S. Provisional Appl. Ser. No. 60/458,398 docket Kelder1-USA), filed March 31, 2003, we describe the identification of genes differentially expressed in normal vs. hyperinsulinemic, hyperinsulinemic vs. type II diabetic, or normal vs. type II diabetic mouse liver. Forward- and reverse-substracted cDNA libraries were prepared, clones were isolated, and differentially expressed cDNA inserts were sequenced and compared with sequences in publicly available sequence databases. The corresponding mouse and human genes and proteins were identified. Favorable genes/proteins so identified included (1) NP_000767: cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3; (2) AAG31034: SYT/SSX4 fusion protein; and (3) NP_003158: sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1; sulfotransferase family 2A, dehydroepiandrosterone (DHEA) -preferring, member 1. Unfavorable proteins included (4) NP_004884: H2A histone family, member Y isoform 2; histone macroH2A1.2; histone macroH2A1.1; (5) AAH37738: Unknown (protein for MGC:33851); (6) NP_068839: integral membrane protein 2B; (7) CAA28659: S-protein; and (8) AAA51560: alpha-1-antichymotrypsin precursor. proteins included (9) NP_000769: cytochrome P450, subfamily IVA, polypeptide 11; fatty acid omega-hydroxylase; P450HL-omega; alkane-1 monooxygenase; lauric acid omega-hydroxylase; (10) NP_006206:serine (or cysteine) proteinase inhibitor, clade A ; (11) NP_004489: one cut domain, family member 1; hepatocyte nuclear factor 6, alpha; and (12) NP_775491: liver-specific uridine phosphorylase. Gene chip

technology was not used. Two of the genes (NM_007818 and NM 007822) were also identified in the present case.

The use of differential hybridization to identify genes and proteins is also described in our Ser. No. PCT/US00/12145 (Kopchick 3A-PCT), Ser. No. PCT/US00/12366 (Kopchick4A-PCT), and Ser. No. 60/400,052 (Kopchick5). All of the above applications are incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

10 Field of the Invention

The invention relates to various nucleic acid molecules and proteins, and their use in (1) diagnosing hyperinsulinemia and type II diabetes, or conditions associated with their development, and (2) protecting mammals (including humans) against them.

Description of the Background Art

Diabetes

5

15

20

25

30

35

Diabetes mellitus is a pleiotropic disease of great complexity. The two major types have been termed type I or insulin-dependent diabetes mellitus (IDDM) and type II or non-insulin-dependent diabetes mellitus (NIDDM). Type II diabetes is the predominant form found in the Western world; fewer than 8% of diabetic Americans have the type I disease.

Type I diabetics are often characterized by their low or absent levels of circulating endogenous insulin, i.e., hypoinsulinemia (1). Islet cell antibodies causing damage to the pancreas are frequently present at diagnosis. Injection of exogenous insulin is required to prevent ketosis and sustain life.

Early Type II diabetics are often characterized by hyperinsulinemia and resistance to insulin. Late Type II diabetics may be normoinsulinemic or hypoinsulinemic. Type II diabetics are usually not insulin dependent or prone to ketosis under normal circumstances.

Type II Diabetes

Type II diabetes (formerly known as non-insulin dependent diabetes, NIDDM) is the most common form of

3

elevated blood glucose (hyperglycemia). Type II diabetes is a metabolic disorder that affects approximately 17 million Americans. It is estimated that another 10 million individuals are "prone" to becoming diabetic. These vulnerable individuals can become resistant to insulin, a pancreatic hormone that signals glucose (blood sugar) uptake by fat and muscle. In order to maintain normal glucose levels, the islet cells of the pancreas produce more insulin, resulting in a condition called hyperinsulinemia. When the pancreas can no longer produce enough insulin to compensate for the insulin resistance, and thereby maintain normal glucose levels, Type II diabetes (hyperglycemia) results.

Complications of diabetes (end organ damage) include retinopathy, neuropathy, and nephropathy (traditionally designated as microvascular complications) as well as atherosclerosis (a macrovascular complication).

Early stages of hyperglycemia can usually be controlled by an alteration in diet and increasing the amount of exercise, but drug treatment, including insulin, may be required. It has been shown that meticulous blood glucose control can often slow down or halt the progression of diabetic complications if caught early enough (1). However, tight metabolic control is extremely difficult to achieve.

25

5

10

15

20

Little is known about the disease progression from the normoinsulinemic state to the hyperinsulinemic state, and from the hyperinsulinemic state to the Type II diabetic state.

30

35

As stated above, type II diabetes is a metabolic disorder that is characterized by insulin resistance and impaired glucose-stimulated insulin secretion (2,3,4). However, Type II diabetes and atherosclerotic disease are viewed as consequences of having the insulin resistance syndrome (IRS) for many years (5). The current theory of the pathogenesis of Type II diabetes is often referred to as the "insulin resistance/islet cell exhaustion" theory. According to this theory, a condition causing insulin

resistance compels the pancreatic islet cells to hypersecrete insulin in order to maintain glucose homeostasis. However, after many years of hypersecretion, the islet cells eventually fail and the symptoms of clinical diabetes are manifested. Therefore, this theory implies that, at some point, peripheral hyperinsulinemia will be an antecedent of Type II diabetes. Peripheral hyperinsulinemia can be viewed as the difference between what is produced by the β cell minus that which is taken up by the liver. Therefore, peripheral hyperinsulinemia can be caused by increased β cell production, decreased hepatic uptake or some combination of both. It is also important to note that it is not possible to determine the origin of insulin resistance once it is established since the onset of peripheral hyperinsulinemia leads to a condition of global insulin resistance.

Multiple environmental and genetic factors are involved in the development of insulin resistance, hyperinsulinemia and type II diabetes. An important risk factor for the development of insulin resistance, hyperinsulinemia and type II diabetes is obesity, particularly visceral obesity (6,7,8). Type II diabetes exists world-wide, but in developed societies, the prevalence has risen as the average age of the population increases and the average individual becomes more obese.

Obesity is a serious and growing problem in the United States. Obesity-related health risks include high blood pressure, hardening of the arteries, cardiovascular disease, and Type II diabetes (also known as non-insulin-dependent diabetes mellitus, Type II diabetes) (9,10,11). Recent studies show that 85% of the individuals with Type II diabetes are obese (12).

35 Growth Hormone

. 5

10

15

20

25

30

Growth hormone has many roles, ranging from regulation of protein, fat and carbohydrate metabolism to growth promotion. GH is produced in the somatrophic cells of the

10

15

25

30

35

anterior pituitary and exerts its effects either through the GH-induced action of IGF-I, in the case of growth promotion, or by direct interaction with the GHR on target cells including liver, muscle, adipose, and kidney cells.

Hyposecretion of GH during development leads to dwarfism, and hypersecretion before puberty leads to gigantism. In adults, hypersecretion of GH results in acromegaly, a clinical condition characterized by enlarged facial bones, hands, feet, fatigue and an increase in weight. Of those individuals with acromegaly, 25% develop type II diabetes. This may be due to insulin resistance caused by the high circulating levels of GH leading to high circulating levels of insulin (Kopchick et al., Annual Rev. Nutrition 1999. 19:437-61).

A further mode of GH action may be through the transcriptional regulation of a number of genes contributing to the physiological effects of GH.

20 Transgenic Mice

McGrane, et al., J. Biol. Chem. 263:11443-51 (1988) and Chen, et al., J. Biol. Chem., 269:15892-7 (1994) describe the genetic engineering of mice to express bovine growth hormone (bGH) or human growth hormone (hGH), respectively. These mice exhibited an enhanced growth phenotype. They also developed kidney lesions similar to those seen in diabetic glomerulosclerosis, see Yang, et al., Lab. Invest., 68:62-70 (1993). Ogueta, et al., J. Endocrinol., 165: 321-8 (2000) reported that transgenic mice expressing bovine GH develop arthritic disorder and self-antibodies.

Growth hormone genes and the proteins encoded by them can be converted into growth hormone antagonists by mutation, see Kopchick USP 5,350,836. Transgenic mice have been made that express the GH antagonists bGH-G119R or hGH G120R, and which exhibit a dwarf phenotype. Chen, et al., J. Biol. Chem., 263:15892-7 (1994); Chen, et al., Mol. Endocrinol, 5:1845-52 (1991); Chen, et al., Proc. Nat. Acad. Sci. USA 87:5061-5 (1990). These mice did not develop

kidney lesions. See Yang (1993), supra.

Chen, et al., Endocrinol, 136:660-7 (1995) compared the effect of streptozotocin treatment in normal nontransgenic mice, and in mice transgenic for (1) a GH receptor antagonist, the G119R mutant of bovine growth hormone or (2) the E117L-mutant of bGH. (According to Chen's ref. 24, these large GH transgenic streptozotocin-treated mice constitute an animal model for diabetes.)

Glomerulosclerosis was seen in diabetic (STZ-treated) nontransgenic mice and in diabetic bGH-E117L mice, but not in diabetic bGH-G119R (GH antagonist) mice.

Two of the proteins which mediate growth hormone activity are the growth hormone receptor and the growth hormone binding protein, encoded by the same gene in mice(GHR/BP). It is possible to genetically engineer mice so that the gene encoding these proteins is disrupted ("knocked-out"; inactivated), see Zhou, et al., Proc. Nat. Acad. Sci. (USA), 94:13215-20 (1997). Zhou, et al. inactivated the GHR/BP gene by replacing the 3' portion of exon 4 (which encodes a portion of the GH binding domains) and the 5' region of intron 4 with a neomycin gene cassette. The modified gene was introduced into the target mice by homologous recombination. Like mice expressing a GH antagonist, homozygous GHR/BP-KO mice exhibit a dwarf phenotype. GHR/BP-KO mice, made diabetic by streptozotocin treatment, are protected from the development of diabetesassociated nephropathy. Bellush, et al., Endocrinol., 141:163-8 (2000).

30

35

25

5

10

15

20

Differential/Subtractive Hybridization

Zhang, et al., Kidney International, 56:549-558 (1999) identified genes up-regulated in 5/6 nephrectomized (subtotal renal ablation) mouse kidney by a PCR-based subtraction method. Ten known and nine novel genes were identified. The ultimate goal was to identify genes involved in glomerular hyperfiltration and hypertrophy.

Melia, et al., Endocrinol., 139:688-95 (1998) applied

22, 2000).

5

10

15

20

25

30 -

35

subtractive hybridization methods for the identification of androgen-regulated genes in mouse kidney. The treatment mice were dosed with dihydrotestosterone, an androgen. Kidney androgen-regulated protein gene was used as a positive control, as it is known to be up-regulated by DHT.

See also Holland, et al., Abstract 607, "Identification of Genes Possibly Involved in Nephropathy of Bovine Growth Hormone Transgenic Mice" (Endocrine Society Meeting, June 22, 2000) and Coschigano, et al., Abstract 333, "Identification of Genes Potentially Involved in Kidney Protection During Diabetes" (Endocrine Society Meeting, June

The following differential hybridization articles may also be of interest:

Wada, et al., "Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis", Kidney Int, 59:1363-73 (2001);

Song, et al., "Cloning of a novel gene in the human kidney homologous to rat muncl3S: its potential role in diabetic nephropathy", Kidney Int., 53:1689-95 (1998);

Page, et al., "Isolation of diabetes-associated kidney genes using differential display", Biochem. Biophys. Res. Comm., 232:49-53 (1997)...

Peradi, "Subtractive hybridization claims: An efficient technique to detect overexpressed mRNAs in diabetic nephropathy," Kidney Int. 53:926-31 (1998).

Condorelli, EMBO J., 17:3858-66 (1998).

See also WO00/66784 (differential hybridization screening for brown adipose tissue); PCT/US00/12366, filed May 5, 2000 (differential hybridization screening for liver).

Identification of genes involved in hyperinsulinemia and type II diabetes

High-fat diets have been shown to induce both obesity and Type II diabetes in laboratory animals (13). Surwit and colleagues demonstrated that male C57BL/6J mice are extremely sensitive to the diabetogenic effects of a high-

8

fat diet when initiated at weaning. At six months of age, high-fat fed animals had significantly elevated fasting blood-glucose and insulin levels and also demonstrated a decrease in insulin sensitivity (14). Ahren and colleagues (15) reported evidence of insulin resistance as well as diminished glucose-stimulated insulin release, after feeding with a high-fat diet for 12 weeks. These mice also showed elevated levels of total cholesterol, triglycerides, and free fatty acids, another hallmark of Type II diabetes.

5

10

15

20

25

30

35

Our attention recently has focused on the generation of liver mRNA expression profiles and the identification of genes involved in the genesis of the obesity-induced hyperinsulinemia and type-II diabetes. To date, no one has attempted to study the actual progression from the normal condition to that of hyperinsulinemia or from hyperinsulinemia to Type II diabetes in an attempt to identify genes that are up-regulated or down-regulated as the disease progresses.

In previous studies aimed at identifying genes involved in diabetes-induced glomerulosclerosis, differential display and traditional subtractive hybridization techniques were used (16-20). While effective for the identification of a few genes (e.g. hmunc13, PED/PEA-15, lactate dehydrogenase, amiloride sensitive sodium channel, ubiquitin-like protein, mdr 1, and a-amyloid protein precursor as well as a few novel genes), these techniques can be quite labor intensive. The PCR-based method of subtractive hybridization requires less starting material, and allows the simultaneous isolation of all differentially expressed cDNAs into two groups (up-regulated and down-regulated).

However, the PCR-based method of subtractive hybridization is also quite labor-intensive, produced large numbers of false positive candidates and ultimately resulted in the identification of a relatively limited number of differentially expressed genes. (see Kelderl-USA application).

In order to expand the number of genes that can be analyzed simultaneously, several groups have begun to

10

utilize DNA microarray analysis to measure differences in gene expression between normal and diseased states. However, these experiments have been limited in regards to the number of experimental conditions analyzed. DNA microarray analysis has been performed on normal, obese and diabetic mice (21). Also, the obesity and diabetes in the mouse models examined were caused by a specific endogenous genetic mutation (22). The differentially expressed genes in the above models may be very different from genes differentially expressed due to diet-induced obesity and Type-II diabetes.

WO 2004/092416

10

PCT/US2004/010191

SUMMARY OF THE INVENTION

5

.,.10

15

25

30

35

Differential hybridization techniques have been used to identify mouse genes that are differentially expressed in mice, depending upon their development of hyperinsulinemia or type II diabetes.

In essence, complementary RNA derived from normal mice, or mouse models of hyperinsulinemia or type II diabetes, was screened for hybridization with oligonucleotide probes each specific to a particular mouse gene, each gene in turn representative of a particular mouse gene cluster (Unigene). Mouse genes which were differentially expressed (normal vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or normal vs. diabetic), as measured by different levels of hybridization of the respective cRNA samples with the particular probe corresponding to that mouse gene) were identified. Related human genes and proteins were identified by sequence comparisons to the mouse gene or protein.

After identifying related human genes and proteins, one may formulate agents useful in screening humans at risk for progression toward hyperinsulinemia or toward type II diabetes.

Since the progression is from normal to hyperinsulinemic, and thence from hyperinsulinemic to type II diabetic, one may define mammalian subjects as being more favored or less favored, with normal subjects being more favored than hyperinsulinemic subjects, and hyperinsulinemic subjects being more favored than type II diabetic subjects. The subjects' state may then be correlated with their gene expression activity.

Thus, "favorable" human genes/proteins are defined as those corresponding to mouse genes which were less strongly expressed in mouse hyperinsulinemic liver than in control liver, or less strongly expressed in mouse type II diabetic liver than in hyperinsulinemic liver. (The control liver is the liver of a mouse which is normal vis-a-vis fasting insulin and fasting glucose levels. The term "normal", as

11

used herein, means normal relative to those parameters, and does not necessitate that the mouse be normal in every respect.) Likewise, one may define "unfavorable" human genes/proteins as those corresponding to mouse genes which were more strongly expressed in mouse hyperinsulinemic liver than in control liver, or more strongly expressed in mouse type II diabetic liver than in hyperinsulinemic liver.

As used herein, the term "corresponding" does not mean identical, but rather implies the existence of a statistically significant sequence similarity, such as one sufficient to qualify the human protein or gene as a homologus protein or DNA as defined below. The greater the degree of relationship as thus defined (i.e., by the statistical significance of each alignment used to connect the mouse cDNA to the human protein or gene, measured by an E value), the more close the correspondence. The connection may be direct (mouse gene to human protein) or indirect (e.g., mouse gene to human gene, human gene to human protein). By "mouse gene", we mean the mouse gene from which the gene chip DNA in question was derived.

10

15

20

25

30

35

In general, the human genes/proteins which most closely correspond, directly or indirectly, to the mouse genes are preferred, such as the one(s) with the highest, top two highest, top three highest, top four highest, top five highest, and top ten highest E values for the final alignment in the connection process. The human genes/proteins deemed to correspond to our mouse cDNA clones are identified in the Master Tables.

A human gene/protein corresponding to a mouse cDNA which was more strongly expressed in hyperinsulinemic liver than in either normal or type II diabetic liver (i.e., C<HI, HI>D) will be deemed both "unfavorable", by virtue of the control:hyperinsulinemic comparison, and "favorable", by virtue of the hyperinsulinemic:diabetic comparison. This is one of several possible "mixed" expression patterns.

Thus, we can subdivide the "favorables" into wholly and partially favorables. Likewise, we can subdivide the unfavorables into wholly and partially unfavorables. The

genes/proteins with "mixed" expression patterns are, by definition, both partially favorable and partially unfavorable. In general, use of the wholly favorable or wholly unfavorable genes/proteins is preferred to use of the partially favorable or partially unfavorable ones.

. 5

10

15

20

25

30

Agents which bind the "favorable" and "unfavorable" nucleic acids (e.g., the agent is a substantially complementary nucleic acid hybridization probe), or the corresponding proteins (e.g., an antibody vs. the protein) may be used to evaluate whether a human subject is at increased or decreased risk for progression toward type II diabetes. A subject with one or more elevated "unfavorable" and/or one or more depressed "favorable" genes/proteins is at increased risk, and one with one or more elevated "favorable" and/or one or more depressed "unfavorable" genes/proteins is at decreased risk. One may further take into account whether the subject is normoinsulinemic or hyperinsulinemic at the time of the assay. If the subject is non-diabetic and normoinsulinemic, we are especially interested in the "favorable" and "unfavorable" genes/proteins corresponding to mouse genes differentially expressed in hyperinsulinemic vs. normal livers. subject is already hyperinsulinemic, yet non-diabetic, we are especially interested in the "favorable" and "unfavorable" genes/proteins corresponding to mouse genes differentially expressed in type II diabetic vs. hyperinsulinemic livers.

The assay may be used as a preliminary screening assay to select subjects for further analysis, or as a formal diagnostic assay.

The identification of the related genes and proteins may also be useful in protecting humans against these disorders.

Thus, Applicants contemplate:

10

15

20

25

30

35

- (1) use of the "favorable" mouse DNAs of the Master Tables (below) to isolate or identify related human DNAs;
- (2) use of human DNAs, related to favorable mouse DNAs, to express the corresponding human proteins;
- (3) use of the corresponding human proteins (and mouse proteins, if biologically active in humans), to protect against the disorder(s);
- (4) use of the corresponding mouse or human proteins, or nucleic acid probes derived from the mouse or human genes, in diagnostic agents, in assays to measure progression toward hyperinsulinemia or type II diabetes, or protection against the disorder(s), or to estimate related end organ damage such as kidney damage; and
- (5) use of the corresponding human or mose genes therapeutically in gene therapy, to protect against the disorder(s).

Moreover Applicants contemplate:

- (1) use of the "unfavorable" mouse DNAs of the Master Tables to isolate or identify related human DNAs;
- (2) use of the complement to the "unfavorable" mouse DNAs or related human DNAs, as antisense molecules to inhibit expression of the related human DNAs;
- (3) use of the mouse or human DNAs to express the corresponding mouse or human proteins;
- (4) use of the corresponding mouse or human proteins, in diagnostic agents, to measure progression toward hyperinsulinemia or type II diabetes, or protection against the disorder(s), or to estimate related end organ damage such as kidney damage;
- (5) use of the corresponding mouse or human proteins in assays to determine whether a substance binds to (and hence may neutralize) the protein; and
- (6) use of the neutralizing substance to protect against the disorder(s).

The related human DNAs may be identified by comparing the mouse sequence (or its AA translation product) to known human DNAs (and their AA translation products). If this is unsuccessful, human cDNA or genomic DNA libraries may be

screened using the mouse DNA as a probe.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

Subjects

WO 2004/092416

A mouse is considered to be a diabetic subject if, regardless of its fasting plasma insulin level, it has a fasting plasma glucose level of at least 190 mg/dL. A mouse is considered to be a hyperinsulinemic subject if its fasting plasma insulin level is at least 0.67 ng/mL and it does not qualify as a diabetic subject. A mouse is considered to be "normal" if it is neither diabetic nor hyperinsulinemic. Thus, normality is defined in a very limited manner.

A mouse is considered "obese" if its weight is at least 15% in excess of the mean weight for mice of its age and sex. A mouse which does not satisfy this standard may be characterized as "non-obese", the term "normal" being reserved for use in reference to glucose and insulin levels as previously described.

20

25

30

35

5

10

15

A human is considered a diabetic subject if, regardless of his or her fasting plasma insulin level, the fasting plasma glucose level is at least 126 mg/dL. A human is considered a hyperinsulinemic subject if the fasting plasma insulin level is more than 26 micro International Units/mL (it is believed that this is equivalent to 1.08 mg/mL), and does not qualify as a diabetic subject. A human is considered to be "normal" if it is neither diabetic nor hyperinsulinemic. Thus, normality is defined in a very limited manner.

A human is considered "obese" if the body mass index (BMI) (weight divided by height squared) is at least 30 kg/m². A human who does not satisfy this standard may be characterized as "non-obese", the term "normal" being reserved for use in reference to glucose and insulin levels as previously described.

A human is considered overweight if the BMI is at least 25 kg/m^2 . Thus, we define overweight to include obese

PCT/US2004/010191

individuals, consistent with the recommendations of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). A human who does not satisfy this standard may be characterized as "non-overweight."

5

According to the Report of the Expert Committe on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20: 1183-97 (1997), the following are risk factors for diabetes type II:

10

older (e.g., at least 45; see below)

excessive weight (see below)

15

first-degree relative with diabetes mellitus

member of high risk ethnic group (black, Hispanic, Native American, Asian)

20

history of gestational diabetes mellitus or delivering a baby weighing more than 9 pounds (4.032 kg)

hypertensive (>140/90 mm Hg)

25

HDL cholesterol level >35 mg/dL (0.90 mmol/L)

triglyceride level >=250 mg/dL (2.83 mmol/L)

impaired glucose homeostasis (110 to <126 mg/dL).

Hence, in a preferred embodiment, the diagnostic and protective methods of the present invention are applied to human subjects exhibiting one or more of the aforementioned risk factors. Likewise, in a preferred embodiment, they are applied to human subjects who, while not diabetic, exhibit

35

The risk of diabetes increases with age. Hence, in successive preferred embodiments, the age of the subjects is at least 45, at least 50, at least 55, at least 60, at least

10

15

20

25

30

35

65, at least 70, and at least 75.

With regard to excessive weight, NIDDK says that "The relative risk of diabetes increases by approximately 25 percent for each additional unit of BMI over 22." Hence, in successive preferred embodiments, the BMIs of the human subjects is at least 23, at least 24, at least 25 (i.e., overweight by our criterion), at least 26, at least 27, at least 28, at least 29, at least 30 (i.e., obese), at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, or over 40.

Genes/Proteins of Interest

Favorable genes/proteins are those corresponding to genes less strongly expressed in hyperinsulinemic liver than in normal liver, or in type II diabetic liver as compared to hyperinsulinemic liver. Unfavorable genes/proteins are those corresponding to genes more strongly expressed in hyperinsulinemic liver than in normal liver, or in type II diabetic liver as compared to hyperinsulinemic liver.

Mixed genes/proteins are those exhibiting a combination of favorable and unfavorable behavior. A mixed gene/protein can be used as would a favorable gene/protein if its favorable behavior outweighs the unfavorable. It can be used as would an unfavorable gene/protein if its unfavorable behavior outweighs the favorable. Preferably, they are used in conjunction with other agents that affect their balance of favorable and unfavorable behavior. Use of mixed genes/proteins is, in general, less desirable than use of purely favorable or purely unfavorable genes/proteins.

For each of the differentially expressed genes, corresponding mouse and human proteins have been identified, as set forth in the Master Tables.

Direct and Indirect Utility of Identified Nucleic Acid

18

Sequences and Related Molecules

The mouse or human genes (or fragments thereof) may be used directly. For diagnostic or screening purposes, they (or specific binding fragments thereof) may be labeled and used as hybridization probes. For therapeutic purposes, they (or specific binding fragments thereof) may be used as antisense reagents to inhibit the expression of the corresponding gene, or of a sufficiently homologous gene of another species.

Since each of the probes is representative of a full-length mouse gene, that is, it encodes an entire, functional protein, then it may be used in the expression of that protein. Likewise, if the corresponding human gene is known in full-length, it may be used to express the human protein. Such expression may be in cell culture, with the protein subsequently isolated and administered exogenously to subjects who would benefit therefrom, or in vivo, i.e., administration by gene therapy. Naturally, any DNA encoding the same protein, or a fragment or a mutant protein which retains the desired activity, may be used for the same purpose. The encoded protein of course has utility therapeutically and, in labeled or immobilized form, diagnostically.

The genes may also be used indirectly, that is, to identify other useful DNAs, proteins, or other molecules.

There thus are several ways that a human protein homologue of interest can be identified by database searching, including:

30

5

10

15

20

25

1) a DNA->DNA (BlastN) search for database DNAs closely related to the mouse gene identifies a known human gene, and the sequence of the human protein is deduced by the Genetic Code;

35

2) a DNA->Protein (BlastX) search for database proteins closely related to the translated DNA of the mouse gene identifies a known human protein; and

19

3) the sequence of the mouse protein is known or is deduced by the Genetic Code, and a Protein->Protein (BlastP) search for closely related database proteins identifies a known human protein.

5

10

15

20

Once a known human gene is identified, it may be used in further BlastN or BlastX searches to identify other human genes or proteins. Once a known human protein is identified, it may be used in further BlastP searches to identify other human proteins.

Searches may also take cognizance, intermediately, of known genes and proteins other than mouse or human ones, e.g., use the mouse sequence to identify a known rat sequence and then the rat sequence to identify a human one.

Thus, if we have identified a mouse gene, and it encodes a mouse protein which appears similar to a human protein, then that human protein may be used (especially in humans) for purposes analogous to the proposed use of the mouse protein in mice. Moreover, a specific binding fragment of an appropriate strand of the corresponding human gene or cDNA could be labeled and used as a hybridization probe (especially against samples of human mRNA or cDNA).

25

30

35

In determining whether the disclosed genes have significant similarities to known DNAs (and their translated AA sequences to known proteins), one would generally use the disclosed gene as a query sequence in a search of a sequence database. The results of several such searches are set forth in the Examples. Such results are dependent, to some degree, on the search parameters. Preferred parameters are set forth in Example 1. The results are also dependent on the content of the database. While the raw similarity score of a particular target (database) sequence will not vary with content (as long as it remains in the database), its informational value (in bits), expected value, and relative ranking can change. Generally speaking, the changes are small.

It will be appreciated that the nucleic acid and protein databases keep growing. Hence a later search may identify high scoring target sequences which were not uncovered by an earlier search because the target sequences were not previously part of a database.

Hence, in a preferred embodiment, the cognate DNAs and proteins include not only those set forth in the examples, but those which would have been highly ranked (top ten, more preferably top three, even more preferably top two, most preferably the top one) in a search run with the same parameters on the date of filing of this application.

If the known human DNA is appears to be a partial DNA, it may be used as a hybridization probe to isolate the full-length DNA. If the partial DNA encodes a biologically functional fragment of the cognate protein, it may be used in a manner similar to the full length DNA, i.e., to produce the functional fragment.

20

25

30

35

5

10

15

If we have indicated that an antagonist of a protein or other molecule is useful, then such an antagonist may be obtained by preparing a combinatorial library, as described below, of potential antagonists, and screening the library members for binding to the protein or other molecule in question. The binding members may then be further screened for the ability to antagonize the biological activity of the target. The antagonists may be used therapeutically, or, in suitably labeled or immobilized form, diagnostically.

If the identified DNA is related to a known protein, then substances known to interact with that protein (e.g., agonists, antagonists, substrates, receptors, second messengers, regulators, and so forth), and binding molecules which bind them, are also of utility. Such binding molecules can likewise be identified by screening a combinatorial library.

Isolation of Full Length cDNAs Using Partial cDNAs as probes

PCT/US2004/010191

If it is determined that a DNA of the present invention is a partial DNA, and the cognate full length DNA is not listed in a sequence database, the available DNA may be used as a hybridization probe to isolate the full-length cDNA from a suitable cDNA library.

Stringent hybridization conditions are appropriate, that is, conditions in which the hybridization temperature is 5-10 deg. C. below the Tm of the cDNA as a perfect duplex.

10

15

20

25

30

5

Identification and Isolation of Homologous Genes/cDNAs Using a cDNA Probe

It may be that the sequence databases available do not include the sequence of any homologous gene, or at least of the homologous gene for a species of interest. However, given the cDNAs set forth above, one may readily obtain the homologous gene.

The possession of one DNA (the "starting DNA") greatly facilitates the isolation of homologous genes/cDNAs. If only a partial DNA is known, this partial DNA may first be used as a probe to isolate the corresponding full length DNA for the same species, and that the latter may be used as the starting DNA in the search for homologous genes.

The starting DNA, or a fragment thereof, is used as a hybridization probe to screen a cDNA or genomic DNA library for clones containing inserts which encode either the entire homologous protein, or a recognizable fragment thereof. The minimum length of the hybridization probe is dictated by the need for specificity. If the size of the library in bases is L, and the GC content is 50%, then the probe should have a length of at least 1, where $L=4^1$. This will yield, on average, a single perfect match in random DNA of L bases. The human cDNA library is about 10^8 bases and the human genomic DNA library is about 10^{10} bases.

35

The library is preferably derived from an organism which is known, on biochemical evidence, to produce a homologous protein, and more preferably from the genomic DNA or mRNA of cells of that organism which are likely to be

22

relatively high producers of that protein. A cDNA library (which is derived from an mRNA library) is especially preferred.

. 5

10

15

20

25

30

35

If the organism in question is known to have substantially different codon preferences from that of the organism whose relevant cDNA or genomic DNA is known, a synthetic hybridization probe may be used which encodes the same amino acid sequence but whose codon utilization is more similar to that of the DNA of the target organism.

Alternatively, the synthetic probe may employ inosine as a substitute for those bases which are most likely to be divergent, or the probe may be a mixed probe which mixes the codons for the source DNA with the preferred codons (encoding the same amino acid) for the target organism.

By routine methods, the Tm of a perfect duplex of starting DNA is determined. One may then select a hybridization temperature which is sufficiently lower than the perfect duplex Tm to allow hybridization of the starting DNA (or other probe) to a target DNA which is divergent from the starting DNA. A 1% sequence divergence typically lowers the Tm of a duplex by 1-2°C, and the DNAs encoding homologous proteins of different species typically have sequence identities of around 50-80%. Preferably, the library is screened under conditions where the temperature is at least 20°C., more preferably at least 50°C., below the Since salt reduces the Tm, one perfect duplex Tm. ordinarily would carry out the search for DNAs encoding highly homologous proteins under relatively <u>low</u> salt hybridization conditions, e.g., <1M NaCl. The higher the salt concentration, and/or the lower the temperature, the greater the sequence divergence which is tolerated.

For the use of probes to identify homologous genes in other species, see, e.g., Schwinn, et al., J. Biol. Chem., 265:8183-89 (1990) (hamster 67-bp cDNA probe vs. human leukocyte genomic library; human 0.32kb DNA probe vs. bovine brain cDNA library, both with hybridization at 42°C in 6xSSC); Jenkins et al., J. Biol. Chem., 265:19624-31 (1990) (Chicken 770-bp cDNA probe vs. human genomic libraries;

hybridization at 40°C in 50% formamide and 5xSSC); Murata et al., J. Exp. Med., 175:341-51 (1992) (1.2-kb mouse cDNA probe v. human eosinophl cDNA library; hybridization at 65°C in 6xSSC); Guyer et al., J. Biol. Chem., 265:17307-17 (1990) (2.95-kb human genomic DNA probe vs. porcine genomic DNA library; hybridization at 42°C in 5xSSC). The conditions set forth in these articles may each be considered suitable for the purpose of isolating homologous genes.

Homologous Proteins and DNAs

A human protein can be said to be identifiable as homologous to a mouse gene (and hence to "correspond" to such gene) if

15

20

25

30

10

.5

- (1) its sequence can be aligned to the mouse gene, using BlastX with the default parameters set forth below, and the expected value (E) of the alignment (the probability that such an alignment would have occurred by chance alone) is less than e-10,
- (2) its sequence can be aligned to a human gene, using BlastX with the default parameters set forth below, and the cDNA of said human gene can be aligned to the mouse gene, using BlastN with the default parameters set forth below, and the E value for both alignments is less than e-10,
- (3) its sequence can be aligned to a mouse protein, using BlastP with the default parameters set forth below, and that mouse protein can be aligned to the mouse gene, using BlastX with the default parameters set forth below, and in both alignments the E value of the alignment is less than e-10.
- Naturally, if the human protein is encoded by the human gene of (2), or the mouse protein is encoded by the mouse gene of (3), the BlastX alignment will be satisfied.

Desirably, two or all three of these conditions (1)-(3) are

24

satisfied.

5

10

25

30

35

preferably, for any of the alignments noted above, and more preferably for all of them, the E value is less than e-15, more preferably less than e-20, still more preferably less than e-40, even more preferably less than e-60, considerably more preferably less than e-80, and most preferably less than e-100. More preferably, for those conditions in which the mouse cDNA clone is indirectly connected to the human protein by virtue of two or more successive alignments, the E value is so limited for all of said alignments in the connecting chain.

BlastN and BlastX report very low expected values as

"0.0". This does not truly mean that the expected value is
exactly zero (since any alignment could occur by chance),
but merely that it is so infinitesimal that it is not
reported. The documentation does not state the cutoff
value, alignments with explicit E values as low as e-178

(624 bits) have been reported as such, while a score of 636
bits was reported as "0.0".

Functionally homologous human proteins are also of interest. A human protein may be said to be functionally homologous to the mouse gene if (1)it can be aligned to the mouse gene, using BlastX with the default parameters set forth below, and the E value of the alignment is less than e-50, and (2) the human protein has at least one biological activity in common with the mouse protein.

The human proteins of interest also include those that are substantially and/or conservatively identical (as defined below) to the homologous and/or functionally homologous human proteins defined above.

10

15

20

25

30

35

Relevance of Favorable and Unfavorable Genes

If a gene is down-regulated in more favored mammals, or up-regulated in less favored mammals, (i.e., an "unfavorable gene") then several utilities are apparent.

First, the complementary strand of the gene, or a portion thereof, may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Elevated levels are indicative of progression, or propensity to progression, to a less favored state, and clinicians may take appropriate preventative, curative or ameliorative action.

Secondly, the messenger RNA product (or equivalent cDNA), the protein product, or a binding molecule specific for that product (e.g., an antibody which binds the product), or a downstream product which mediates the activity (e.g., a signaling intermediate) or a binding molecule (e.g., an antibody) therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said nucleic acid product, protein product, or downstream product (e.g., a signaling intermediate). Again, elevated levels are indicative of a present or future problem.

Thirdly, an agent which down-regulates expression of the gene may be used to reduce levels of the corresponding protein and thereby inhibit further damage. This agent could inhibit transcription of the gene in the subject, or translation of the corresponding messenger RNA. Possible inhibitors of transcription and translation include antisense molecules and repressor molecules. The agent could also inhibit a post-translational modification (e.g., glycosylation, phosphorylation, cleavage, GPI attachment) required for activity, or post-translationally modify the protein so as to inactivate it. Or it could be an agent which down- or up-regulated a positive or negative regulatory gene, respectively.

Fourthly, an agent which is an antagonist of the

26

messenger RNA product or protein product of the gene, or of a downstream product through which its activity is manifested (e.g., a signaling intermediate), may be used to inhibit its activity.

. 5

10

15

20

25

30

35

This antagonist could be an antibody, a peptide, a peptoid, a nucleic acid, a peptide nucleic acid (PNA) oligomer, a small organic molecule of a kind for which a combinatorial library exists (e.g., a benzodiazepine), etc. An antagonist is simply a binding molecule which, by binding, reduces or abolishes the undesired activity of its target. The antagonist, if not an oligomeric molecule, is preferably less than 500 daltons.

Fifthly, an agent which degrades, or abets the degradation of, that messenger RNA, its protein product or a downstream product which mediates its activity (e.g., a signaling intermediate), may be used to curb the effective period of activity of the protein.

If a gene is <u>up</u>-regulated in more favored mammals, or <u>down</u>-regulated in less favored animals then the utilities are converse to those stated above.

First, the complementary strand of the gene, or a portion thereof, may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Depressed levels are indicative of damage, or possibly of a propensity to damage, and clinicians may take appropriate preventative, curative or ameliorative action.

Secondly, the messenger RNA product, the equivalent cDNA, protein product, or a binding molecule specific for those products, or a downstream product, or a signaling intermediate, or a binding molecule therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said protein product or downstream product. Again, depressed levels are indicative of a present or future problem.

Thirdly, an agent which up-regulates expression of the gene may be used to increase levels of the corresponding protein and thereby inhibit further progression to a less

27 -

favored state. By way of example, it could be a vector which carries a copy of the gene, but which expresses the gene at higher levels than does the endogenous expression system. Or it could be an agent which up- or down-regulates a positive or negative regulatory gene.

Fourthly, an agent which is an agonist of the protein product of the gene, or of a downstream product through which its activity (of inhibition of progression to a less favored state) is manifested, or of a signaling intermediate may be used to foster its activity.

Fifthly, an agent which inhibits the degradation of that protein product or of a downstream product or of a signaling intermediate may be used to increase the effective period of activity of the protein.

15

20

25

30

35

10

Mutant Proteins

The present invention also contemplates mutant proteins (peptides) which are substantially identical (as defined below) to the parental protein (peptide). In general, the fewer the mutations, the more likely the mutant protein is to retain the activity of the parental protein. The effect of mutations is usually (but not always) additive. Certain individual mutations are more likely to be tolerated than others.

A protein is more likely to tolerate a mutation which

- (a) is a substitution rather than an insertion or deletion;
- (b) is an insertion or deletion at the terminus, rather than internally, or, if internal, is at a domain boundary, or a loop or turn, rather than in an alpha helix or beta strand;
- (c) affects a surface residue rather than an
 interior residue;
- (d) affects a part of the molecule distal to the binding site;
- (e) is a substitution of one amino acid for another of similar size, charge, and/or

hydrophobicity, and does not destroy a disulfide bond or other crosslink; and

(f) is at a site which is subject to substantial variation among a family of homologous proteins to which the protein of interest belongs.

These considerations can be used to design functional mutants.

Surface vs. Interior Residues

WO 2004/092416

5

10

15

20

25

30

35

Charged residues almost always lie on the surface of the protein. For uncharged residues, there is less certainty, but in general, hydrophilic residues are partitioned to the surface and hydrophobic residues to the interior. Of course, for a membrane protein, the membranespanning segments are likely to be rich in hydrophobic residues.

Surface residues may be identified experimentally by various labeling techniques, or by 3-D structure mapping techniques like X-ray diffraction and NMR. A 3-D model of a homologous protein can be helpful.

Binding Site Residues

Residues forming the binding site may be identified by (1) comparing the effects of labeling the surface residues before and after complexing the protein to its target, (2) labeling the binding site directly with affinity ligands, (3) fragmenting the protein and testing the fragments for binding activity, and (4) systematic mutagenesis (e.g., alanine-scanning mutagenesis) to determine which mutants destroy binding. If the binding site of a homologous protein is known, the binding site may be postulated by analogy.

Protein libraries may be constructed and screened that a large family (e.g., 10⁸) of related mutants may be evaluated simultaneously.

Hence, the mutations are preferably conservative modifications as defined below.

10

15

20

25

30

35

"Substantially Identical"

A mutant protein (peptide) is substantially identical to a reference protein (peptide) if (a) it has at least 10% of a specific binding activity or a non-nutritional biological activity of the reference protein, and (b) is at least 50% identical in amino acid sequence to the reference protein (peptide). It is "substantially structurally identical" if condition (b) applies, regardless of (a).

Percentage amino acid identity is determined by aligning the mutant and reference sequences according to a rigorous dynamic programming algorithm which globally aligns their sequences to maximize their similarity, the similarity being scored as the sum of scores for each aligned pair according to an unbiased PAM250 matrix, and a penalty for each internal gap of -12 for the first null of the gap and -4 for each additional null of the same gap. The percentage identity is the number of matches expressed as a percentage of the adjusted (i.e., counting inserted nulls) length of the reference sequence.

A mutant DNA sequence is substantially identical to a reference DNA sequence if they are structural sequences, and encoding mutant and reference proteins which are substantially identical as described above.

If instead they are regulatory sequences, they are substantially identical if the mutant sequence has at least 10% of the regulatory activity of the reference sequence, and is at least 50% identical in nucleotide sequence to the reference sequence. Percentage identity is determined as for proteins except that matches are scored +5, mismatches -4, the gap open penalty is -12, and the gap extension penalty (per additional null) is -4.

Preferably, sequence which are substantially identical exceed the minimum identity of 50% e.g., are 51%, 66%, 75%, 80%, 85%, 90%, 95% or 99% identical in sequence.

DNA sequences may also be considered "substantially identical" if they hybridize to each other under stringent conditions, i.e., conditions at which the Tm of the heteroduplex of the one strand of the mutant DNA and the

more complementary strand of the reference DNA is not in excess of 10°C. less than the Tm of the reference DNA homoduplex. Typically this will correspond to a percentage identity of 85-90%.

5

10

15

20

25

30

35

"Conservative Modifications"

"Conservative modifications" are defined as

- (a) conservative substitutions of amino acids as hereafter defined; or
- (b) single or multiple insertions (extension) or deletions (truncation) of amino acids at the termini.

Conservative modifications are preferred to other modifications. Conservative substitutions are preferred to other conservative modifications.

"Semi-Conservative Modifications" are modifications which are not conservative, but which are (a) semi-conservative substitutions as hereafter defined; or (b) single or multiple insertions or deletions internally, but at interdomain boundaries, in loops or in other segments of relatively high mobility. Semi-conservative modifications are preferred to nonconservative modifications. Semi-conservative substitutions are preferred to other semi-conservative modifications.

Non-conservative substitutions are preferred to other non-conservative modifications.

The term "conservative" is used here in an <u>a priori</u> sense, i.e., modifications which would be <u>expected</u> to preserve 3D structure and activity, based on analysis of the naturally occurring families of homologous proteins and of past experience with the effects of deliberate mutagenesis, rather than <u>post facto</u>, a modification already known to conserve activity. Of course, a modification which is conservative <u>a priori</u> may, and usually is, also conservative <u>post facto</u>.

Preferably, except at the termini, no more than about five amino acids are inserted or deleted at a particular locus, and the modifications are outside regions known to

10

15

20

25

30

35

contain binding sites important to activity.

Preferably, insertions or deletions are limited to the termini.

A conservative substitution is a substitution of one amino acid for another of the same exchange group, the exchange groups being defined as follows

- I Gly, Pro, Ser, Ala (Cys) (and any nonbiogenic, neutral amino acid with a hydrophobicity not exceeding that of the aforementioned a.a.'s)
- II Arg, Lys, His (and any nonbiogenic, positivelycharged amino acids)
- III Asp, Glu, Asn, Gln (and any nonbiogenic
 negatively-charged amino acids)
- IV Leu, Ile, Met, Val (Cys) (and any nonbiogenic, aliphatic, neutral amino acid with a hydrophobicity too high for I above)
- V Phe, Trp, Tyr (and any nonbiogenic, aromatic neutral amino acid with a hydrophobicity too high for I above).

Note that Cys belongs to both I and IV.

Residues Pro, Gly and Cys have special conformational roles. Cys participates in formation of disulfide bonds. Gly imparts flexibility to the chain. Pro imparts rigidity to the chain and disrupts α helices. These residues may be essential in certain regions of the polypeptide, but substitutable elsewhere.

One, two or three conservative substitutions are more likely to be tolerated than a larger number.

"Semi-conservative substitutions" are defined herein as being substitutions within supergroup I/II/III or within supergroup IV/V, but not within a single one of groups I-V. They also include replacement of any other amino acid with alanine. If a substitution is not conservative, it preferably is semi-conservative.

"Non-conservative substitutions" are substitutions which are not "conservative" or "semi-conservative".

"Highly conservative substitutions" are a subset of conservative substitutions, and are exchanges of amino acids

15

20

25

30

35

within the groups Phe/Tyr/Trp, Met/Leu/Ile/Val, His/Arg/Lys, Asp/Glu and Ser/Thr/Ala. They are more likely to be tolerated than other conservative substitutions. Again, the smaller the number of substitutions, the more likely they are to be tolerated.

"Conservatively Identical"

A protein (peptide) is conservatively identical to a reference protein (peptide) it differs from the latter, if at all, solely by conservative modifications, the protein (peptide remaining at least seven amino acids long if the reference protein (peptide) was at least seven amino acids long.

A protein is at least semi-conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by semi-conservative or conservative modifications.

A protein (peptide) is nearly conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by one or more conservative modifications and/or a single nonconservative substitution.

It is highly conservatively identical if it differs, if at all, solely by highly conservative substitutions. Highly conservatively identical proteins are preferred to those merely conservatively identical. An absolutely identical protein is even more preferred.

The core sequence of a reference protein (peptide) is the largest single fragment which retains at least 10% of a particular specific binding activity, if one is specified, or otherwise of at least one specific binding activity of the referent. If the referent has more than one specific binding activity, it may have more than one core sequence, and these may overlap or not.

If it is taught that a peptide of the present invention may have a particular similarity relationship (e.g., markedly identical) to a reference protein (peptide),

PCT/US2004/010191

preferred peptides are those which comprise a sequence having that relationship to a core sequence of the reference protein (peptide), but with internal insertions or deletions in either sequence excluded. Even more preferred peptides are those whose entire sequence has that relationship, with the same exclusion, to a core sequence of that reference protein (peptide).

Library

5

10

15

20

25

30

35

WO 2004/092416

The term "library" generally refers to a collection of chemical or biological entities which are related in origin, structure, and/or function, and which can be screened simultaneously for a property of interest.

Libraries may be classified by how they are constructed (natural vs. artificial diversity; combinatorial vs. noncombinatorial), how they are screened (hybridization, expression, display), or by the nature of the screened library members (peptides, nucleic acids, etc.).

In a "natural diversity" library, essentially all of the diversity arose without human intervention. This would be true, for example, of messenger RNA extracted from a nonengineered cell.

In a "synthetic diversity" library, essentially all of the diversity arose deliberately as a result of human intervention. This would be true for example of a combinatorial library; note that a small level of natural diversity could still arise as a result of spontaneous mutation. It would also be true of a noncombinatorial library of compounds collected from diverse sources, even if they were all natural products.

In a "non-natural diversity" library, at least some of the diversity arose deliberately through human intervention.

In a "controlled origin" library, the source of the diversity is limited in some way. A limitation might be to cells of a particular individual, to a particular species, or to a particular genus, or, more complexly, to individuals of a particular species who are of a particular age, sex,

PCT/US2004/010191

physical condition, geographical location, occupation and/or familial relationship. Alternatively or additionally, it might be to cells of a particular tissue or organ. Or it could be cells exposed to particular pharmacological, environmental, or pathogenic conditions. Or the library could be of chemicals, or a particular class of chemicals, produced by such cells.

In a "controlled structure" library, the library members are deliberately limited by the production conditions to particular chemical structures. For example, if they are oligomers, they may be limited in length and monomer composition, e.g. hexapeptides composed of the twenty genetically encoded amino acids.

15 <u>Hybridization Library</u>

WO 2004/092416

5

10

20

25

30

35

In a hybridization library, the library members are nucleic acids, and are screened using a nucleic acid hybridization probe. Bound nucleic acids may then be amplified, cloned, and/or sequenced.

Expression Library

In an expression library, the screened library members are gene expression products, but one may also speak of an underlying library of genes encoding those products. The library is made by subcloning DNA encoding the library members (or portions thereof) into expression vectors (or into cloning vectors which subsequently are used to construct expression vectors), each vector comprising an expressible gene encoding a particular library member, introducing the expression vectors into suitable cells, and expressing the genes so the expression products are produced.

In one embodiment, the expression products are secreted, so the library can be screened using an affinity reagent, such as an antibody or receptor. The bound expression products may be sequenced directly, or their sequences inferred by, e.g., sequencing at least the variable portion of the encoding DNA.

In a second embodiment, the cells are lysed, thereby exposing the expression products, and the latter are screened with the affinity reagent.

In a third embodiment, the cells express the library members in such a manner that they are displayed on the surface of the cells, or on the surface of viral particles produced by the cells. (See display libraries, below).

In a fourth embodiment, the screening is not for the ability of the expression product to bind to an affinity reagent, but rather for its ability to alter the phenotype of the host cell in a particular detectable manner. Here, the screened library members are transformed cells, but there is a first underlying library of expression products which mediate the behavior of the cells, and a second underlying library of genes which encode those products.

Display Library

WO 2004/092416

5

10

15

20

25

30

35

In a display library, the library members are each conjugated to, and displayed upon, a support of some kind. The support may be living (a cell or virus), or nonliving (e.g., a bead or plate).

If the support is a cell or virus, display will normally be effectuated by expressing a fusion protein which comprises the library member, a carrier moiety allowing integration of the fusion protein into the surface of the cell or virus, and optionally a lining moiety. In a variation on this theme, the cell coexpresses a first fusion comprising the library member and a linking moiety L1, and a second fusion comprising a linking moiety L2 and the carrier moiety. L1 and L2 interact to associate the first fusion with the second fusion and hence, indirectly, the library member with the surface of the cell or virus.

Soluble Library

In a soluble library, the library members are free in solution. A soluble library may be produced directly, or one may first make a display library and then release the library members from their supports.

Encapsulated Library

In an encapsulated library, the library members are inside cells or liposomes. Generally speaking, encapsulated libraries are used to store the library members for future use; the members are extracted in some way for screening purposes. However, if they differentially affect the phenotype of the cells, they may be screened indirectly by screening the cells.

10 <u>cDNA Library</u>

15

20

25

30

35

A cDNA library is usually prepared by extracting RNA from cells of particular origin, fractionating the RNA to isolate the messenger RNA (mRNA has a poly(A) tail, so this is usually done by oligo-dT affinity chromatography), synthesizing complementary DNA (cDNA) using reverse transcriptase, DNA polymerase, and other enzymes, subcloning the cDNA into vectors, and introducing the vectors into cells. Often, only mRNAs or cDNAs of particular sizes will be used, to make it more likely that the cDNA encodes a functional polypeptide.

A cDNA library explores the natural diversity of the transcribed DNAs of cells from a particular source. It is not a combinatorial library.

A cDNA library may be used to make a hybridization library, or it may be used as an (or to make) expression library.

Genomic DNA Library

A genomic DNA library is made by extracting DNA from a particular source, fragmenting the DNA, isolating fragments of a particular size range, subcloning the DNA fragments into vectors, and introducing the vectors into cells.

Like a cDNA library, a genomic DNA library is a natural diversity library, and not a combinatorial library. A genomic DNA library may be used the same way as a cDNA library.

Synthetic DNA library

10

15

20

25

30

35

A synthetic DNA library may be screened directly (as a hybridization library), or used in the creation of an expression or display library of peptides/proteins.

Combinatorial Libraries

The term "combinatorial library" refers to a library in which the individual members are either systematic or random combinations of a limited set of basic elements, the properties of each member being dependent on the choice and location of the elements incorporated into it. Typically, the members of the library are at least capable of being screened simultaneously. Randomization may be complete or partial; some positions may be randomized and others predetermined, and at random positions, the choices may be limited in a predetermined manner. The members of a combinatorial library may be oligomers or polymers of some kind, in which the variation occurs through the choice of monomeric building block at one or more positions of the oligomer or polymer, and possibly in terms of the connecting linkage, or the length of the oligomer or polymer, too. the members may be nonoligomeric molecules with a standard core structure, like the 1,4-benzodiazepine structure, with the variation being introduced by the choice of substituents at particular variable sites on the core structure. members may be nonoligomeric molecules assembled like a jigsaw puzzle, but wherein each piece has both one or more variable moieties (contributing to library diversity) and one or more constant moieties (providing the functionalities for coupling the piece in question to other pieces).

Thus, in a typical combinatorial library, chemical building blocks are at least partially randomly combined into a large number (as high as 10¹⁵) of different compounds, which are then simultaneously screened for binding (or other) activity against one or more targets.

In a "simple combinatorial library", all of the members belong to the same class of compounds (e.g., peptides) and can be synthesized simultaneously. A "composite combinatorial library" is a mixture of two or more simple

10

15

20

25

30

35

libraries, e.g., DNAs and peptides, or peptides, peptoids, and PNAs, or benzodiazepines and carbamates. The number of component simple libraries in a composite library will, of course, normally be smaller than the average number of members in each simple library, as otherwise the advantage of a library over individual synthesis is small.

Libraries of thousands, even millions, of random oligopeptides have been prepared by chemical synthesis (Houghten et al., Nature, 354:84-6(1991)), or gene expression (Marks et al., J Mol Biol, 222:581-97(1991)), displayed on chromatographic supports (Lam et al., Nature, 354:82-4(1991)), inside bacterial cells (Colas et al., Nature, 380:548-550(1996)), on bacterial pili (Lu, Bio/Technology, 13:366-372(1990)), or phage (Smith, Science, 228:1315-7(1985)), and screened for binding to a variety of targets including antibodies (Valadon et al., J Mol Biol, 261:11-22(1996)), cellular proteins (Schmitz et al., J Mol Biol, 260:664-677(1996)), viral proteins (Hong and Boulanger, Embo J, 14:4714-4727(1995)), bacterial proteins (Jacobsson and Frykberg, Biotechniques, 18:878-885(1995)), nucleic acids (Cheng et al., Gene, 171:1-8(1996)), and plastic (Siani et al., J Chem Inf Comput Sci, 34:588-593 (1994)).

Libraries of proteins (Ladner, USP 4,664,989), peptoids (Simon et al., Proc Natl Acad Sci U S A, 89:9367-71(1992)), nucleic acids (Ellington and Szostak, Nature, 246:818(1990)), carbohydrates, and small organic molecules (Eichler et al., Med Res Rev, 15:481-96(1995)) have also been prepared or suggested for drug screening purposes.

The first combinatorial libraries were composed of peptides or proteins, in which all or selected amino acid positions were randomized. Peptides and proteins can exhibit high and specific binding activity, and can act as catalysts. In consequence, they are of great importance in biological systems.

Nucleic acids have also been used in combinatorial libraries. Their great advantage is the ease with which a nucleic acid with appropriate binding activity can be

amplified. As a result, combinatorial libraries composed of nucleic acids can be of low redundancy and hence, of high diversity.

There has also been much interest in combinatorial libraries based on small molecules, which are more suited to pharmaceutical use, especially those which, like benzodiazepines, belong to a chemical class which has already yielded useful pharmacological agents. The techniques of combinatorial chemistry have been recognized as the most efficient means for finding small molecules that act on these targets. At present, small molecule combinatorial chemistry involves the synthesis of either pooled or discrete molecules that present varying arrays of functionality on a common scaffold. These compounds are grouped in libraries that are then screened against the target of interest either for binding or for inhibition of biological activity.

The size of a library is the number of molecules in it. The simple diversity of a library is the number of unique structures in it. There is no formal minimum or maximum diversity. If the library has a very low diversity, the library has little advantage over just synthesizing and screening the members individually. If the library is of very high diversity, it may be inconvenient to handle, at least without automatizing the process. The simple diversity of a library is preferably at least 10, 10E2, 10E3, 10E4, 10E6, 10E7, 10E8 or 10E9, the higher the better under most circumstances. The simple diversity is usually not more than 10E15, and more usually not more than 10E10.

The average sampling level is the size divided by the simple diversity. The expected average sampling level must be high enough to provide a reasonable assurance that, if a given structure were expected, as a consequence of the library design, to be present, that the actual average sampling level will be high enough so that the structure, if satisfying the screening criteria, will yield a positive result when the library is screened. Thus, the preferred average sampling level is a function of the detection limit,

which in turn is a function of the strength of the signal to be screened.

There are more complex measures of diversity than simple diversity. These attempt to take into account the degree of structural difference between the various unique sequences. These more complex measures are usually used in the context of small organic compound libraries, see below.

The library members may be presented as solutes in solution, or immobilized on some form of support. In the latter case, the support may be living (cell, virus) or nonliving (bead, plate, etc.). The supports may be separable (cells, virus particles, beads) so that binding and nonbinding members can be separated, or nonseparable (plate). In the latter case, the members will normally be placed on addressable positions on the support. The advantage of a soluble library is that there is no carrier moiety that could interfere with the binding of the members to the support. The advantage of an immobilized library is that it is easier to identify the structure of the members which were positive.

When screening a soluble library, or one with a separable support, the target is usually immobilized. When screening a library on a nonseparable support, the target will usually be labeled.

Oligonucleotide Libraries

5

10

15

20

25

30

35

An oligonucleotide library is a combinatorial library, at least some of whose members are single-stranded oligonucleotides having three or more nucleotides connected by phosphodiester or analogous bonds. The oligonucleotides may be linear, cyclic or branched, and may include non-nucleic acid moieties. The nucleotides are not limited to the nucleotides normally found in DNA or RNA. For examples of nucleotides modified to increase nuclease resistance and chemical stability of aptamers, see Chart 1 in Osborne and Ellington, Chem. Rev., 97: 349-70 (1997). For screening of RNA, see Ellington and Szostak, Nature, 346: 818-22 (1990).

There is no formal minimum or maximum size for these

15

20

25

30

35

oligonucleotides. However, the number of conformations which an oligonucleotide can assume increases exponentially with its length in bases. Hence, a longer oligonucleotide is more likely to be able to fold to adapt itself to a protein surface. On the other hand, while very long molecules can be synthesized and screened, unless they provide a much superior affinity to that of shorter molecules, they are not likely to be found in the selected population, for the reasons explained by Osborne and Ellington (1997). Hence, the libraries of the present invention are preferably composed of oligonucleotides having a length of 3 to 100 bases, more preferably 15 to 35 bases. The oligonucleotides in a given library may be of the same or of different lengths.

Oligonucleotide libraries have the advantage that libraries of very high diversity (e.g., 10^{15}) are feasible, and binding molecules are readily amplified in vitro by polymerase chain reaction (PCR). Moreover, nucleic acid molecules can have very high specificity and affinity to targets.

In a preferred embodiment, this invention prepares and screens oligonucleotide libraries by the SELEX method, as described in King and Famulok, Molec. Biol. Repts., 20: 97-107 (1994); L. Gold, C. Tuerk. Methods of producing nucleic acid ligands, US#5595877; Oliphant et al. Gene 44:177 (1986).

The term "aptamer" is conferred on those oligonucleotides which bind the target protein. Such aptamers may be used to characterize the target protein, both directly (through identification of the aptamer and the points of contact between the aptamer and the protein) and indirectly (by use of the aptamer as a ligand to modify the chemical reactivity of the protein).

In a classic oligonuclotide, each nucleotide (monomeric unit) is composed of a phosphate group, a sugar moiety, and either a purine or a pyrimidine base. In DNA, the sugar is deoxyribose and in RNA it is ribose. The nucleotides are linked by 5'-3' phosphodiester bonds.

10

15

20

25

30

35

The deoxyribose phosphate backbone of DNA can be modified to increase resistance to nuclease and to increase penetration of cell membranes. Derivatives such as mono- or dithiophosphates, methyl phosphonates, boranophosphates, formacetals, carbamates, siloxanes, and dimethylenethio-sulfoxideo-and-sulfono-linked species are known in the art.

Peptide Library

A peptide is composed of a plurality of amino acid residues joined together by peptidyl (-NHCO-) bonds. A biogenic peptide is a peptide in which the residues are all genetically encoded amino acid residues; it is not necessary that the biogenic peptide actually be produced by gene expression.

Amino acids are the basic building blocks with which peptides and proteins are constructed. Amino acids possess both an amino group $(-NH_2)$ and a carboxylic acid group (-COOH). Many amino acids, but not all, have the alpha amino acid structure NH_2 -CHR-COOH, where R is hydrogen, or any of a variety of functional groups.

Twenty amino acids are genetically encoded: Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Glutamic Acid, Glutamine, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, and Valine. Of these, all save Glycine are optically isomeric, however, only the L-form is found in humans. Nevertheless, the D-forms of these amino acids do have biological significance; D-Phe, for example, is a known analgesic.

Many other amino acids are also known, including: 2-Aminoadipic acid; 3-Aminoadipic acid; beta-Aminopropionic acid; 2-Aminobutyric acid; 4-Aminobutyric acid (Piperidinic acid); 6-Aminocaproic acid; 2-Aminoheptanoic acid; 2-Aminoisobutyric acid, 3-Aminoisobutyric acid; 2-Aminopimelic acid; 2,4-Diaminobutyric acid; Desmosine; 2,2'-Diaminopimelic acid; 2,3-Diaminopropionic acid; N-Ethylglycine; N-Ethylasparagine; Hydroxylysine; allo-

43

Hydroxylysine; 3-Hydroxyproline; 4-Hydroxyproline; Isodesmosine; allo-Isoleucine; N-Methylglycine (Sarcosine); N-Methylisoleucine; N-Methylvaline; Norvaline; Norleucine; and Ornithine.

5

10

15

20

25

30

35

Peptides are constructed by condensation of amino acids and/or smaller peptides. The amino group of one amino acid (or peptide) reacts with the carboxylic acid group of a second amino acid (or peptide) to form a peptide (-NHCO-) bond, releasing one molecule of water. Therefore, when an amino acid is incorporated into a peptide, it should, technically speaking, be referred to as an amino acid residue. The core of that residue is the moiety which excludes the -NH and -CO linking functionalities which connect it to other residues. This moiety consists of one or more main chain atoms (see below) and the attached side chains.

The main chain moiety of each amino acid consists of the -NH and -CO linking functionalities and a core main chain moiety. Usually the latter is a single carbon atom. However, the core main chain moiety may include additional carbon atoms, and may also include nitrogen, oxygen or sulfur atoms, which together form a single chain. In a preferred embodiment, the core main chain atoms consist solely of carbon atoms.

The side chains are attached to the core main chain atoms. For alpha amino acids, in which the side chain is attached to the alpha carbon, the C-1, C-2 and N-2 of each residue form the repeating unit of the main chain, and the word "side chain" refers to the C-3 and higher numbered carbon atoms and their substituents. It also includes H atoms attached to the main chain atoms.

Amino acids may be classified according to the number of carbon atoms which appear in the main chain between the carbonyl carbon and amino nitrogen atoms which participate in the peptide bonds. Among the 150 or so amino acids which occur in nature, alpha, beta, gamma and delta amino acids are known. These have 1-4 intermediary carbons. Only alpha amino acids occur in proteins. Proline is a special case of

10

15

20

25

30

35

an alpha amino acid; its side chain also binds to the peptide bond nitrogen.

For beta and higher order amino acids, there is a choice as to which main chain core carbon a side chain other than H is attached to. The preferred attachment site is the C-2 (alpha) carbon, i.e., the one adjacent to the carboxyl carbon of the -CO linking functionality. It is also possible for more than one main chain atom to carry a side chain other than H. However, in a preferred embodiment, only one main chain core atom carries a side chain other than H.

A main chain carbon atom may carry either one or two side chains; one is more common. A side chain may be attached to a main chain carbon atom by a single or a double bond; the former is more common.

A simple combinatorial peptide library is one whose members are peptides having three or more amino acids connected via peptide bonds.

The peptides may be linear, branched, or cyclic, and may covalently or noncovalently include nonpeptidyl moieties. The amino acids are not limited to the naturally occurring or to the genetically encoded amino acids.

A biased peptide library is one in which one or more (but not all) residues of the peptides are constant residues.

Cyclic Peptides

Many naturally occurring peptides are cyclic. Cyclization is a common mechanism for stabilization of peptide conformation thereby achieving improved association of the peptide with its ligand and hence improved biological activity. Cyclization is usually achieved by intra-chain cystine formation, by formation of peptide bond between side chains or between N- and C- terminals. Cyclization was usually achieved by peptides in solution, but several publications have appeared that describe cyclization of peptides on beads.

A peptide library may be an oligopeptide library or a protein library.

Oligopeptides

Preferably, the oligopeptides are at least five, six, seven or eight amino acids in length. Preferably, they are composed of less than 50, more preferably less than 20 amino acids.

In the case of an oligopeptide library, all or just some of the residues may be variable. The oligopeptide may be unconstrained, or constrained to a particular conformation by, e.g., the participation of constant cysteine residues in the formation of a constraining disulfide bond.

Proteins

5

10

15

20

25

30

35

Proteins, like oligopeptides, are composed of a plurality of amino acids, but the term protein is usually reserved for longer peptides, which are able to fold into a stable conformation. A protein may be composed of two or more polypeptide chains, held together by covalent or noncovalent crosslinks. These may occur in a homooligomeric or a heterooligomeric state.

A peptide is considered a protein if it (1) is at least 50 amino acids long, or (2) has at least two stabilizing covalent crosslinks (e.g., disulfide bonds). Thus, conotoxins are considered proteins.

Usually, the proteins of a protein library will be characterizable as having both constant residues (the same for all proteins in the library) and variable residues (which vary from member to member). This is simply because, for a given range of variation at each position, the sequence space (simple diversity) grows exponentially with the number of residue positions, so at some point it becomes inconvenient for all residues of a peptide to be variable positions. Since proteins are usually larger than oligopeptides, it is more common for protein libraries than oligopeptide libraries to feature variable positions.

In the case of a protein library, it is desirable to focus the mutations at those sites which are tolerant of mutation. These may be determined by alanine scanning

10

15

20

25

30

35

mutagenesis or by comparison of the protein sequence to that of homologous proteins of similar activity. It is also more likely that mutation of surface residues will directly affect binding. Surface residues may be determined by inspecting a 3D structure of the protein, or by labeling the surface and then ascertaining which residues have received labels. They may also be inferred by identifying regions of high hydrophilicity within the protein.

Because proteins are often altered at some sites but not others, protein libraries can be considered a special case of the biased peptide library.

There are several reasons that one might screen a protein library instead of an oligopeptide library, including (1) a particular protein, mutated in the library, has the desired activity to some degree already, and (2) the oligopeptides are not expected to have a sufficiently high affinity or specificity since they do not have a stable conformation.

When the protein library is based on a parental protein which does not have the desired activity, the parental protein will usually be one which is of high stability (melting point >= 50 deg. C.) and/or possessed of hypervariable regions.

The variable domains of an antibody possess hypervariable regions and hence, in some embodiments, the protein library comprises members which comprise a mutant of VH or VL chain, or a mutant of an antigen-specific binding fragment of such a chain. VH and VL chains are usually each about 110 amino acid residues, and are held in proximity by a disulfide bond between the adjoing CL and CH1 regions to form a variable domain. Together, the VH, VL, CL and CH1 form an Fab fragment.

In human heavy chains, the hypervariable regions are at 31-35, 49-65, 98-111 and 84-88, but only the first three are involved in antigen binding. There is variation among VH and VL chains at residues outside the hypervariable regions, but to a much lesser degree.

A sequence is considered a mutant of a VH or VL chain

10

15

20

25

30

35

if it is at least 80% identical to a naturally occurring VH or VL chain at all residues outside the hypervariable region.

In a preferred embodiment, such antibody library members comprise both at least one VH chain and at least one VL chain, at least one of which is a mutant chain, and which chains may be derived from the same or different antibodies. The VH and VL chains may be covalently joined by a suitable linker moiety, as in a "single chain antibody", or they may be noncovalently joined, as in a naturally occurring variable domain.

If the joining is noncovalent, and the library is displayed on cells or virus, then either the VH or the VL chain may be fused to the carrier surface/coat protein. The complementary chain may be co-expressed, or added exogenously to the library.

The members may further comprise some or all of an antibody constant heavy and/or constant light chain, or a mutant thereof.

Peptoid Library

A peptoid is an analogue of a peptide in which one or more of the peptide bonds (-NH-CO-) are replaced by pseudopeptide bonds, which may be the same or different. It is not necessary that all of the peptide bonds be replaced, i.e., a peptoid may include one or more conventional amino acid residues, e.g., proline.

A peptide bond has two small divalent linker elements, -NH- and -CO-. Thus, a preferred class of psuedopeptide bonds are those which consist of two small divalent linker elements. Each may be chosen independently from the group consisting of amine (-NH-), substituted amine (-NR-), carbonyl (-CO-), thiocarbonyl (-CS-), methylene (-CH2-), monosubstituted methylene (-CHR-), disubstituted methylene (-CR1R2-), ether (-O-) and thioether (-S-). The more preferred pseudopeptide bonds include:

N-modified -NRCO-Carba Ψ -CH₂-CH₂- 5 ·

10

15

20

25

30

35

Depsi Ψ -CO-OHydroxyethylene Ψ -CHOH-CH₂Ketomethylene Ψ -CO-CH₂Methylene-Oxy -CH₂-OReduced -CH₂-NHThiomethylene -CH₂-SThiopeptide -CS-NHRetro-Inverso -CO-NH-

A single peptoid molecule may include more than one kind of pseudopeptide bond.

For the purposes of introducing diversity into a peptoid library, one may vary (1) the side chains attached to the core main chain atoms of the monomers linked by the pseudopeptide bonds, and/or (2) the side chains (e.g., the -R of an -NRCO-) of the pseudopeptide bonds. Thus, in one embodiment, the monomeric units which are not amino acid residues are of the structure -NR1-CR2-CO-, where at least one of R1 and R2 are not hydrogen. If there is variability in the pseudopeptide bond, this is most conveniently done by using an -NRCO- or other pseudopeptide bond with an R group, and varying the R group. In this event, the R group will usually be any of the side chains characterizing the amino acids of peptides, as previously discussed.

If the R group of the pseudopeptide bond is not variable, it will usually be small, e.g., not more than 10 atoms (e.g., hydroxyl, amino, carboxyl, methyl, ethyl, propyl).

If the conjugation chemistries are compatible, a simple combinatorial library may include both peptides and peptoids.

Peptide Nucleic Acid Library

A PNA oligomer is here defined as one comprising a plurality of units, at least one of which is a PNA monomer which comprises a side chain comprising a nucleobase. For nucleobases, see USP 6,077,835.

The classic PNA oligomer is composed of (2-

49

aminoethyl)glycine units, with nucleobases attached by methylene carbonyl linkers. That is, it has the structure

$$H-(-HN-CH_2-CH_2-N(-CO-CH_2-B)-CH_2-CO-)_n$$
 -OH

5

10

15

20

25

30

35

where the outer parenthesized substructure is the PNA monomer.

In this structure, the nucleobase B is separated from the backbone N by three bonds, and the points of attachment of the side chains are separated by six bonds. The nucleobase may be any of the bases included in the nucleotides discussed in connection with oligonucleotide libraries. The bases of nucleotides A, G, T, C and U are preferred.

A PNA oligomer may further comprise one or more amino acid residues, especially glycine and proline.

One can readily envision related molecules in which (1) the -COCH2- linker is replaced by another linker, especially one composed of two small divalent linkers as defined previously, (2) a side chain is attached to one of the three main chain carbons not participating in the peptide bond (either instead or in addition to the side chain attached to the N of the classic PNA); and/or (3) the peptide bonds are replaced by pseudopeptide bonds as disclosed previously in the context of peptoids.

PNA oligomer libraries have been made; see e.g. Cook, 6,204,326.

Small Organic Compound Library

The small organic compound library ("compound library", for short) is a combinatorial library whose members are suitable for use as drugs if, indeed, they have the ability to mediate a biological activity of the target protein.

Peptides have certain disadvantages as drugs. These include susceptibility to degradation by serum proteases, and difficulty in penetrating cell membranes. Preferably, all or most of the compounds of the compound library avoid,

or at least do not suffer to the same degree, one or more of the pharmaceutical disadvantages of peptides.

5

10

15

20

25

30

35

In designing a compound library, it is helpful to bear in mind the methods of molecular modification typically used to obtain new drugs. Three basic kinds of modification may be identified: disjunction, in which a lead drug is simplified to identify its component pharmacophoric moieties; conjunction, in which two or more known pharmacophoric moieties, which may be the same or different, are associated, covalently or noncovalently, to form a new drug; and <u>alteration</u>, in which one moiety is replaced by another which may be similar or different, but which is not in effect a disjunction or conjunction. The use of the terms "disjunction", "conjunction" and "alteration" is intended only to connote the structural relationship of the end product to the original leads, and not how the new drugs are actually synthesized, although it is possible that the two are the same.

The process of disjunction is illustrated by the evolution of neostigmine (1931) and edrophonium (1952) from physostigmine (1925). Subsequent conjunction is illustrated by demecarium (1956) and ambenonium (1956).

Alterations may modify the size, polarity, or electron distribution of an original moiety. Alterations include ring closing or opening, formation of lower or higher homologues, introduction or saturation of double bonds, introduction of optically active centers, introduction, removal or replacement of bulky groups, isosteric or bioisosteric substitution, changes in the position or orientation of a group, introduction of alkylating groups, and introduction, removal or replacement of groups with a view toward inhibiting or promoting inductive (electrostatic) or conjugative (resonance) effects.

Thus, the substituents may include electron acceptors and/or electron donors. Typical electron donors (+I) include $-CH_3$, $-CH_2R$, $-CHR_2$, $-CR_3$ and $-COO^-$. Typical electron acceptors (-I) include $-NH_3+$, $-NR_3+$, $-NO_2$, -CN, -COOH, -COOR, -CHO, -COR, -COR,

10

15

20

25

30

35

 $-CR=CR_2$, and -C=CH.

The substituents may also include those which increase or decrease electronic density in conjugated systems. The former (+R) groups include -CH₃, -CR₃, -F, -Cl, -Br, -I, -OH, -OR, -OCOR, -SH, -SR, -NH₂, -NR₂, and -NHCOR. The later (-R) groups include -NO₂, -CN, -CHC, -COR, -COOH, -COOR, -CONH₂, -SO₂R and -CF₃.

Synthetically speaking, the modifications may be achieved by a variety of unit processes, including nucleophilic and electrophilic substitution, reduction and oxidation, addition elimination, double bond cleavage, and cyclization.

For the purpose of constructing a library, a compound, or a family of compounds, having one or more pharmacological activities (which need not be related to the known or suspected activities of the target protein), may be disjoined into two or more known or potential pharmacophoric moieties. Analogues of each of these moieties may be identified, and mixtures of these analogues reacted so as to reassemble compounds which have some similarity to the original lead compound. It is not necessary that all members of the library possess moieties analogous to all of the moieties of the lead compound.

The design of a library may be illustrated by the example of the benzodiazepines. Several benzodiazepine drugs, including chlordiazepoxide, diazepam and oxazepam, have been used as anti-anxiety drugs. Derivatives of benzodiazepines have widespread biological activities; derivatives have been reported to act not only as anxiolytics, but also as anticonvulsants; cholecystokinin (CCK) receptor subtype A or B, kappa opioid receptor, platelet activating factor, and HIV transactivator Tat antagonists, and GPIIbIIa, reverse transcriptase and ras farnesyltransferase inhibitors.

The benzodiazepine structure has been disjoined into a 2-aminobenzophenone, an amino acid, and an alkylating agent. See Bunin, et al., Proc. Nat. Acad. Sci. USA, 91:4708 (1994). Since only a few 2-aminobenzophenone derivatives

52

are commercially available, it was later disjoined into 2-aminoarylstannane, an acid chloride, an amino acid, and an alkylating agent. Bunin, et al., Meth. Enzymol., 267:448 (1996). The arylstannane may be considered the core structure upon which the other moieties are substituted, or all four may be considered equals which are conjoined to make each library member.

5 .

10

15

20

25

30

35

A basic library synthesis plan and member structure is shown in Figure 1 of Fowlkes, et al., U.S. Serial No. 08/740,671, incorporated by reference in its entirety. The acid chloride building block introduces variability at the R1 site. The R² site is introduced by the amino acid, and the R³ site by the alkylating agent. The R⁴ site is inherent in the arylstannane. Bunin, et al. generated a 1, 4benzodiazepine library of 11,200 different derivatives prepared from 20 acid chlorides, 35 amino acids, and 16 alkylating agents. (No diversity was introduced at R4; this group was used to couple the molecule to a solid phase.) According to the Available Chemicals Directory (HDL Information Systems, San Leandro CA), over 300 acid chlorides, 80 Fmoc-protected amino acids and 800 alkylating agents were available for purchase (and more, of course, could be synthesized). The particular moieties used were chosen to maximize structural dispersion, while limiting the numbers to those conveniently synthesized in the wells of a microtiter plate. In choosing between structurally similar compounds, preference was given to the least substituted compound.

The variable elements included both aliphatic and aromatic groups. Among the aliphatic groups, both acyclic and cyclic (mono- or poly-) structures, substituted or not, were tested. (While all of the acyclic groups were linear, it would have been feasible to introduce a branched aliphatic). The aromatic groups featured either single and multiple rings, fused or not, substituted or not, and with heteroatoms or not. The secondary substitutents included - NH₂, -OH, -OMe, -CN, -C1, -F, and -COOH. While not used, spacer moieties, such as -O-, -S-, -OO-, -CS-, -NH-, and -

53

NR-, could have been incorporated.

5

10

15

20

25

30

35

Bunin et al. suggest that instead of using a 1, 4-benzodiazepine as a core structure, one may instead use a 1, 4-benzodiazepine-2, 5-dione structure.

As noted by Bunin et al., it is advantageous, although not necessary, to use a linkage strategy which leaves no trace of the linking functionality, as this permits construction of a more diverse library.

Other combinatorial nonoligomeric compound libraries known or suggested in the art have been based on carbamates, mercaptoacylated pyrrolidines, phenolic agents, aminimides, N-acylamino ethers (made from amino alcohols, aromatic hydroxy acids, and carboxylic acids), N-alkylamino ethers (made from aromatic hydroxy acids, amino alcohols and aldehydes) 1, 4-piperazines, and 1, 4-piperazine-6-ones.

DeWitt, et al., Proc. Nat. Acad. Sci. (USA), 90:6909-13 (1993) describe the simultaneous but separate, synthesis of 40 discrete hydantoins and 40 discrete benzodiazepines. They carry out their synthesis on a solid support (inside a gas dispersion tube), in an array format, as opposed to other conventional simultaneous synthesis techniques (e.g., in a well, or on a pin). The hydantoins were synthesized by first simultaneously deprotecting and then treating each of five amino acid resins with each of eight isocyanates. The benzodiazepines were synthesized by treating each of five deprotected amino acid resins with each of eight 2-amino benzophenone imines.

Chen, et al., J. Am. Chem. Soc., 116:2661-62 (1994) described the preparation of a pilot (9 member) combinatorial library of formate esters. A polymer beadbound aldehyde preparation was "split" into three aliquots, each reacted with one of three different ylide reagents. The reaction products were combined, and then divided into three new aliquots, each of which was reacted with a different Michael donor. Compound identity was found to be determinable on a single bead basis by gas chromatography/mass spectroscopy analysis.

Holmes, USP 5,549,974 (1996) sets forth methodologies

54

for the combinatorial synthesis of libraries of thiazolidinones and metathiazanones. These libraries are made by combination of amines, carbonyl compounds, and thiols under cyclization conditions.

Ellman, USP 5,545,568 (1996) describes combinatorial synthesis of benzodiazepines, prostaglandins, beta-turn mimetics, and glycerol-based compounds. See also Ellman, USP 5,288,514.

Summerton, USP 5,506,337 (1996) discloses methods of preparing a combinatorial library formed predominantly of morpholino subunit structures.

10

30

35

Heterocylic combinatorial libraries are reviewed generally in Nefzi, et al., Chem. Rev., 97:449-472 (1997).

For pharmacological classes, see, e.g., Goth, Medical 15 Pharmacology: Principles and Concepts (C.V. Mosby Co.: 8th ed. 1976); Korolkovas and Burckhalter, Essentials of Medicinal Chemistry (John Wiley & Sons, Inc.: 1976). For synthetic methods, see, e.g., Warren, Organic Synthesis: The 20 Disconnection Approach (John Wiley & Sons, Ltd.: 1982); Fuson, Reactions of Organic Compounds (John Wiley & Sons: 1966); Payne and Payne, How to do an Organic Synthesis (Allyn and Bacon, Inc.: 1969); Greene, Protective Groups in Organic Synthesis (Wiley-Interscience). For selection of substituents, see e.g., Hansch and Leo, Substituent 25 Constants for Correlation Analysis in Chemistry and Biology (John Wiley & Sons: 1979).

The library is preferably synthesized so that the individual members remain identifiable so that, if a member is shown to be active, it is not necessary to analyze it. Several methods of identification have been proposed, including:

- (1) encoding, i.e., the attachment to each member of an identifier moiety which is more readily identified than the member proper. This has the disadvantage that the tag may itself influence the activity of the conjugate.
- (2) spatial addressing, e.g., each member is

synthesized only at a particular coordinate on or in a matrix, or in a particular chamber. This might be, for example, the location of a particular pin, or a particular well on a microtiter plate, or inside a "tea bag".

The present invention is not limited to any particular form of identification.

However, it is possible to simply characterize those members of the library which are found to be active, based on the characteristic spectroscopic indicia of the various building blocks.

Solid phase synthesis permits greater control over which derivatives are formed. However, the solid phase could interfere with activity. To overcome this problem, some or all of the molecules of each member could be liberated, after synthesis but before screening.

Examples of candidate simple libraries which might be evaluated include derivatives of the following:

Cyclic Compounds Containing One Hetero Atom

20 Heteronitrogen

pyrroles

pentasubstituted pyrroles

pyrrolidines

pyrrolines

prolines

indoles

beta-carbolines

pyridines

dihydropyridines

1,4-dihydropyridines

pyrido[2,3-d]pyrimidines

tetrahydro-3H-imidazo[4,5-c] pyridines

Isoquinolines

tetrahydroisoguinolines

quinolones

beta-lactams

azabicyclo[4.3.0]nonen-8-one amino acid Heterooxygen

25

5

10

15

30

35

furans

tetrahydrofurans

2,5-disubstituted tetrahydrofurans

pyrans

hydroxypyranones

tetrahydroxypyranones

gamma-butyrolactones

Heterosulfur

sulfolenes

10 Cyclic Compounds with Two or More Hetero atoms

Multiple heteronitrogens

imidazoles

pyrazoles

piperazines

15 diketopiperazines

arylpiperazines

benzylpiperazines

benzodiazepines

1,4-benzodiazepine-2,5-diones

20 hydantoins

5-alkoxyhydantoins

dihydropyrimidines

1,3-disubstituted-5,6-dihydopyrimidine-2,4-

25 diones

cyclic ureas

cyclic thioureas

quinazolines

chiral 3-substituted-quinazoline-2,4-

30 diones

5

triazoles

1,2,3-triazoles

purines

Heteronitrogen and Heterooxygen

35 dikelomorpholines

isoxazoles

isoxazolines

Heteronitrogen and Heterosulfur

57

thiazolidines

N-axylthiazolidines

dihydrothiazoles

2-methylene-2,3-dihydrothiazates

2-aminothiazoles

thiophenes

5

10

15

20

25

30

35

3-amino thiophenes

4-thiazolidinones

4-melathiazanones

benzisothiazolones

For details on synthesis of libraries, see Nefzi, et al., Chem. Rev., 97:449-72 (1997), and references cited therein.

Pharmaceutical Methods and Preparations

The preferred animal subject of the present invention is a mammal. By the term "mammal" is meant an individual belonging to the class Mammalia. The invention is particularly useful in the treatment of human subjects, although it is intended for veterinary and nutritional uses as well. Preferred nonhuman subjects are of the orders Primata (e.g., apes and monkeys), Artiodactyla or Perissodactyla (e.g., cows, pigs, sheep, horses, goats), Carnivora (e.g., cats, dogs), Rodenta (e.g., rats, mice, guinea pigs, hamsters), Lagomorpha (e.g., rabbits) or other pet, farm or laboratory mammals.

The term "protection", as used herein, is intended to include "prevention," "suppression" and "treatment."
"Prevention", strictly speaking, involves administration of the pharmaceutical prior to the induction of the disease (or other adverse clinical condition). "Suppression" involves administration of the composition prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after the appearance of the disease.

It will be understood that in human and veterinary medicine, it is not always possible to distinguish between "preventing" and "suppressing" since the ultimate inductive

58

event or events may be unknown, latent, or the patient is not ascertained until well after the occurrence of the event or events. Therefore, unless qualified, the term "prevention" will be understood to refer to both prevention in the strict sense, and to suppression.

5

10

15

20

25

30

35

The preventative or prophylactic use of a pharmaceutical involves identifying subjects who are at higher risk than the general population of contracting the disease, and administering the pharmaceutical to them in advance of the clinical appearance of the disease. The effectiveness of such use is measured by comparing the subsequent incidence or severity of the disease, or of particular symptoms of the disease, in the treated subjects against that in untreated subjects of the same high risk group.

While high risk factors vary from disease to disease, in general, these include (1) prior occurrence of the disease in one or more members of the same family, or, in the case of a contagious disease, in individuals with whom the subject has come into potentially contagious contact at a time when the earlier victim was likely to be contagious, (2) a prior occurrence of the disease in the subject, (3) prior occurrence of a related disease, or a condition known to increase the likelihood of the disease, in the subject; (4) appearance of a suspicious level of a marker of the disease, or a related disease or condition; (5) a subject who is immunologically compromised, e.g., by radiation treatment, HIV infection, drug use,, etc., or (6) membership in a particular group (e.g., a particular age, sex, race, ethnic group, etc.) which has been epidemiologically associated with that disease.

A prophylaxis or treatment may be curative, that is, directed at the underlying cause of a disease, or ameliorative, that is, directed at the symptoms of the disease, especially those which reduce the quality of life.

It should also be understood that to be useful, the protection provided need not be absolute, provided that it is sufficient to carry clinical value. An agent which

provides protection to a lesser degree than do competitive agents may still be of value if the other agents are ineffective for a particular individual, if it can be used in combination with other agents to enhance the level of protection, or if it is safer than competitive agents. It is desirable that there be a statistically significant (p=0.05 or less) improvement in the treated subject relative to an appropriate untreated control, and it is desirable that this improvement be at least 10%, more preferably at least 25%, still more preferably at least 50%, even more preferably at least 100%, in some indicia of the incidence or severity of the disease or of at least one symptom of the disease.

10

15

20

25

30

35

At least one of the drugs of the present invention may be administered, by any means that achieve their intended purpose, to protect a subject against a disease or other adverse condition. The form of administration may be systemic or topical. For example, administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. Parenteral administration can be by bolus injection or by gradual perfusion over time.

A typical regimen comprises administration of an effective amount of the drug, administered over a period ranging from a single dose, to dosing over a period of hours, days, weeks, months, or years.

It is understood that the suitable dosage of a drug of the present invention will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. However, the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation. This will typically involve adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight.

Prior to use in humans, a drug will first be evaluated

for safety and efficacy in laboratory animals. In human clinical studies, one would begin with a dose expected to be safe in humans, based on the preclinical data for the drug in question, and on customary doses for analogous drugs (if any). If this dose is effective, the dosage may be decreased, to determine the minimum effective dose, if If this dose is ineffective, it will be cautiously increased, with the patients monitored for signs of side See, e.g., Berkow et al, eds., The Merck Manual, 15th edition, Merck and Co., Rahway, N.J., 1987; Goodman et al., eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, Pergamon Press, Inc., Elmsford, N.Y., (1990); Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, MD. (1987), Ebadi, Pharmacology, Little, Brown and Co., Boston, (1985), which references and references cited therein, are entirely incorporated herein by reference.

5

10

15

20 -

25

30

35

The total dose required for each treatment may be administered by multiple doses or in a single dose. The protein may be administered alone or in conjunction with other therapeutics directed to the disease or directed to other symptoms thereof.

Typical pharmaceutical doses, for adult humans, are in the range of 1 ng to 10g per day, more often 1 mg to 1g per day.

The appropriate dosage form will depend on the disease, the pharmaceutical, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, solutions, ointments and parenteral depots. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra, which are entirely incorporated herein by reference, including all references cited therein.

In the case of peptide drugs, the drug may be administered in the form of an expression vector comprising a nucleic acid encoding the peptide; such a vector, after incorporation into the genetic complement of a cell of the

10

15

20

25

30

35

patient, directs synthesis of the peptide. Suitable vectors include genetically engineered poxviruses (vaccinia), adenoviruses, adeno-associated viruses, herpesviruses and lentiviruses which are or have been rendered nonpathogenic.

In addition to at least one drug as described herein, a pharmaceutical composition may contain suitable pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra, which are entirely incorporated herein by reference, included all references cited therein.

Assay Compositions and Methods

Target Organism

The invention contemplates that it may be appropriate to ascertain or to mediate the biological activity of a substance of this invention in a target organism.

The target organism may be a plant, animal, or microorganism.

In the case of a plant, it may be an economic plant, in which case the drug may be intended to increase the disease, weather or pest resistance, alter the growth characteristics, or otherwise improve the useful characteristics or mute undesirable characteristics of the plant. Or it may be a weed, in which case the drug may be intended to kill or otherwise inhibit the growth of the plant, or to alter its characteristics to convert it from a weed to an economic plant. The plant may be a tree, shrub, crop, grass, etc. The plant may be an algae (which are in some cases also microorganisms), or a vascular plant, especially gymnosperms (particularly conifers) and angiosperms. Angiosperms may be monocots or dicots. plants of greatest interest are rice, wheat, corn, alfalfa, soybeans, potatoes, peanuts, tomatoes, melons, apples, pears, plums, pineapples, fir, spruce, pine, cedar, and oak.

If the target organism is a microorganism, it may be

electrodes in the chip were used to create electrokinetic forces capable of driving molecules through these microchannels to perform electrophoretic separations. Ribosomal peaks were measured by fluorescence signal and displayed in an electropherogram. A successful total RNA sample featured 2 distinct ribosomal peaks (18S and 28S rRNA).

Biotinylated cRNA Hybridization Target.

Total RNA was prepared for use as a hybridization target as described in the manufacturer's instructions for CodeLink Expression Bioarrays(TM) (Amersham Biosciences). The CodeLink Expression Bioarrays utilize nucleic acid hybridization of a biotin-labeled complementary RNA(cRNA) target with DNA oligonucleotide probes attached to a gel matrix.

The biotin-labeled cRNA target is prepared by a linear amplification method. Poly (A) + RNA (within the total RNA population) is primed for reverse transcription by a DNA oligonucleotide containing a T7 RNA polymerase promoter 5' to a (dT) 24 sequence. After second-strand cDNA synthesis, the cDNA serves as the template in an *in vitro* transcription (IVT) reaction to produce the target cRNA. The IVT is performed in the presence of biotinylated nucleotides to label the target cRNA. This procedure results in a 50-200 fold linear amplification of the input poly (A) + RNA.

Hybridization Probes.

5

10

15

20

25

30

35

The oligonucleotide probes were provided by the Codelink Uniset Mouse I Bioarray (Amersham, product code 300013). Amine-terminated oligonucleotide probes are attached to a three-dimensional polyacrylamide gel matrix. There are 10,000 oligonucleotide probes, each specific to a well-characterized mouse gene. Each mouse gene is representative of a unique gene cluster from the fourth quarter 2001 Genbank Unigene build. There are also 500 control probes.

The sequences of the probes is proprietary to Amersham. However, for each probe, Amersham identifies the

corresponding mouse gene by NCBI accession number, OGS, LocusLink, Unigene Cluster ID, and description (name). This information should be available from Amersham. In the case of the differentially expressed probes, this information is duplicated in master table 1. For the complete list, see http://www4.amershambiosciences.com/aptrix/upp01077.nsf/Content/codelink literature

Under "Gene Lists", select "Uniset Human I", and a gene list, in Excel format, can be downloaded.

Hybridization

10

15

20

25

30

35

Using the cRNA target, the hbridization reaction mixture is prepared and loaded until array chambers for bioarray processing as set forth in the manufacturer's instructions for CodeLink Gene Expression BioarraysTM (Amerhsam Biosciences). Each sample is hybridized to an individual microarray. Hybridization is at 37°C. The hybridization buffer is prepared as set forth in the Motorola instructions. Hybridization to the microarray is detected with an avidinated fluorescent reagent, Streptavidin-Alexa Fluor ® 647 (Amersham).

Mouse Gene Expression Analysis

Processed arrays were scanned using a GenePix 4000B Microarray Scanner (Axon Instruments, Inc.); array images were acquired using the Amersham CodeLink™ Analysis Software (Release 2.2). The Amersham CodeLink™ Analysis Software gives an integrated optical density (IOD) value for every spot; a unique background value for that spot is subtracted, resulting in "raw" data points. Individual chips are then normalized by the Amersham Codelink™ software according to the median raw intensity for all 10,000 genes. A negative control threshold is also calculated according to the control probes. A significant difference in expression between samples was defined as a minimum of 2-fold change in expression values. Genes with expression values below the

WO 2004/092416

negative control threshold were eliminated from the analysis and then the expression data was analyzed to identify genes whose expression levels changed significantly with respect to:

5

Normal mice compared to hyperinsulinemic mice at 2, 4, 8 and 16 weeks, and 6 months, on normal vs. high-fat diet.

10

Normal mice compared to hyperinsulinemic/hyperglycemic mice at 2, 4, 8 and 16 weeks, and 6 months, on normal vs. high-fat diet.

15

20

30

35

Hyperinsulinemic compared to hyperinsulinemic/hyperglycemic mice at 2, 4, 8 and 16 weeks, and 6 months, on high-fat diets.

Database Searches Nucleotide sequences and predicted amino acid sequences were compared to public domain databases using the Blast 2.0 program (National Center for Biotechnology Information, National Institutes of Health). Nucleotide sequences were displayed using ABI prism Edit View 1.0.1 (PE Applied Biosystems, Foster City, CA).

Nucleotide database searches were conducted with the then current version of BLASTN 2.0.12, see Altschul, et al., 25

"Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res., 25:3389-3402 Searches employed the default parameters, unless

otherwise stated.

For blastN searches, the default was the blastN matrix (1,-3), with gap penalties of 5 for existence and 2 for extension.

Protein database searches were conducted with the thencurrent version of BLAST X, see Altschul et al. (1997), supra. Searches employed the default parameters, unless otherwise stated. The scoring matrix was BLOSUM62, with gap costs of 11 for existence and 1 for extension. The standard low complexity filter was used.

81

"ref" indicates that NCBI's RefSeq is the source The identifier that follows is a RefSeq accession number, not a GenBank accession number. "RefSeq sequences are derived from GenBank and provide non-redundant curated data representing our current knowledge of known genes. Some records include additional sequence information that was never submitted to an archival database but is available in the literature. A small number of sequences are provided through collaboration; the underlying primary sequence data is available in GenBank, but may not be available in any one GenBank record. RefSeg sequences are not submitted primary sequences. RefSeq records are owned by NCBI and therefore can be updated as needed to maintain current annotation or to incorporate additional sequence information." http://www.ncbi.nlm.nih.gov/LocusLink/refseq.html

It will be appreciated by those in the art that the exact results of a database search will change from day to day, as new sequences are added. Also, if you query with a longer version of the original sequence, the results will change. The results given here were obtained at one time and no guarantee is made that the exact same hits would be obtained in a search on the filing date. However, if an alignment between a particular query sequence and a particular database sequence is discussed, that alignment should not change (if the parameters and sequences remain unchanged).

Northern Analysis.

5

10

15

20

25

30

35

Northern analysis may be used to confirm the results. Favorable and unfavorable genes, identified as described above, or fragments thereof, will be used as probes in Northern hybridization analyses to confirm their differential expression. Total RNA isolated from Control, Hyperinsulinemic and Type-II Diabetic mice will be resolved by agarose gel electrophoresis through a 1% agarose, 1 % formaldehyde denaturing gel, transferred to positively charged nylon membrane, and hybridized to a probe labeled

with [32P] dCTP that was generated from the aforementioned gene or fragment using the Random Primed DNA Labeling Kit (Roche, Palo Alto, CA).

5 Real-Time RNA Analysis.

10

15

20

25

30

35

Real-time RNA analysis may also be used for confirmation. For "real-time" RNA analysis, RNA will be converted to cDNA and then probed with gene-specific primers made for each clone. "Real-time" incorporation of fluorescent dye will be measured to determine the amount of specific transcript present in each sample. Sample differences (control vs. hyperinsulinemic, hyperinsulinemic vs. diabetic, or control vs. diabetic) of 2-fold or greater (in either direction) will be considered differentially expressed. Confirmation using several independent animals is desirable.

In situ Hybridization

Another form of confirmation may be provided by nonisotopic in situ hybridizations (NISH) on selected human (obtained by Tissue Informatics) and mouse tissues using cRNA probes generated from mouse genes found to be up- or down-regulated during the disease progression. Nonisotopic in situ hybridizations may also be performed on mouse tissues using cRNA probes generated from all "novel" cDNA's identified through PCR subtractive hybridizations. cRNA's will hybridize to their corresponding messenger RNA's present in cells and will provide information regarding the particular cell types within a tissue that is expressing the particular gene as well as the relative level of gene The cRNA probes may be generated by in vitro transcription of template cDNA by Sp6 or T7 RNA polymerase in the presence of digoxigenin-11-UTP (Roche Molecular Biochemicals, Mannheim, Germany; Pardue, M.L. 1985. situ hybridization, Nucleic acid hybridization, a practical approach: IRL Press, Oxford, 179-202).

Transgenic Animals.

Transgenic expression may be used to confirm the results. In one embodiment, a mouse is engineered to overexpress the favorable or unfavorable mouse gene in question. In another embodiment, a mouse is engineered to express the corresponding favorable or unfavorable human gene. In a third embodiment, a nonhuman animal other than a mouse, such as a rat, rabbit, goat, sheep or pig, is engineered to express the favorable or unfavorable mouse or human gene.

Hyperquantitative Tissue Analysis

5

10

15

20

25

30

35

In addition to gene expression analysis the liver sections can also be analyzed using TissueInformatics, Inc's TissueAnalytics™ software. A single representative section may be cut from each liver block, placed on a slide, and stained with H&E. Digital images of each slide may be acquired using an research microscope and digital camera (Olympus E600 microscope and Sony DKC-ST5). These images were acquired at 20x magnification with a resolution of 0.64 A hyperquantitative analysis may be performed on the resulting images: First a digital image analysis can identify and annotate structural objects in a tissue using machine vision. These objects, that are constituents of the tissue, can be annotated because they are visually identifiable and have a biological meaning like hepatocytes, sinusoids, vacuoles. Subsequently a quantification of these structures regarding their geometric properties like area or stain intensities and their relationship to the field of view or per unit area in terms of a % coverage may be performed. Features or parameters for hyper-quantification are specific for each tissue, and may also include relations between features, measures of overall heterogeneity, including orientation, relative locations, and textures.

Correlation Analysis

Mathematical statistics provides a rich set of additional tools to analyze time resolved data sets of hyperquantitative and gene expression profiles for similarities, including rank correlation, the calculation of regression

84

and correlations coefficients, and clustering. Continuous functions may also be fitted through the data points of individual gene and tissue feature data. Relation between gene expression and hyper-quantitative tissue data may be linear or non-linear, in synchronous or asynchronous arrangements.

A Spearman rank correlation analysis using was done on the 2 classes of measurements (Genes and Tissues Features) to help identify other significant genes. A small number of genes that did not meet the 2-Fold difference for significance were added to the list of genes based on their correlation with tissue features.

10

15

85

Citation of documents herein is not intended as an admission that any of the documents cited herein is pertinent prior art, or an admission that the cited documents is considered material to the patentability of any of the claims of the present application. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicant and does not constitute any admission as to the correctness of the dates or contents of these documents.

:5

10

15

20

25

30

35

The appended claims are to be treated as a non-limiting recitation of preferred embodiments.

In addition to those set forth elsewhere, the following references are hereby incorporated by reference, in their most recent editions as of the time of filing of this application: Kay, Phage Display of Peptides and Proteins: A Laboratory Manual; the John Wiley and Sons Current Protocols series, including Ausubel, Current Protocols in Molecular Biology; Coligan, Current Protocols in Protein Science; Coligan, Current Protocols in Immunology; Current Protocols in Human Genetics; Current Protocols in Cytometry; Current Protocols in Pharmacology; Current Protocols in Neuroscience; Current Protocols in Cell Biology; Current Protocols in Toxicology; Current Protocols in Field Analytical Chemistry; Current Protocols in Nucleic Acid Chemistry; and Current Protocols in Human Genetics; the following Cold Spring Harbor Laboratory publications: Sambrook, Molecular Cloning: A Laboratory Manual; Harlow, Antibodies: A Laboratory Manual; Manipulating the Mouse Embryo: A Laboratory Manual; Methods in Yeast Genetics: A Cold Spring Harbor Laboratory Course Manual; Drosophila Protocols; Imaging Neurons: A Laboratory Manual; Development of Xenopus laevis: A Laboratory Manual; Antibodies: A Laboratory Manual; At the Bench: A Laboratory Navigator; Cells: A Laboratory Manual; Methods in Yeast Genetics: A Laboratory Course Manual; Discovering Neurons: The Experimental Basis of Neuroscience; Genome Analysis: A Laboratory Manual Series ; Laboratory DNA Science; Strategies for Protein Purification and Characterization: A

Laboratory Course Manual; Genetic Analysis of Pathogenic Bacteria: A Laboratory Manual; PCR Primer: A Laboratory Manual; Methods in Plant Molecular Biology: A Laboratory Course Manual; Manipulating the Mouse Embryo: A Laboratory Manual; Molecular Probes of the Nervous System; Experiments with Fission Yeast: A Laboratory Course Manual; A Short Course in Bacterial Genetics: A Laboratory Manual and Handbook for Escherichia coli and Related Bacteria; DNA Science: A First Course in Recombinant DNA Technology; Methods in Yeast Genetics: A Laboratory Course Manual; Molecular Biology of Plants: A Laboratory Course Manual.

All references cited herein, including journal articles or abstracts, published, corresponding, prior or otherwise related U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology

PCT/US2004/010191

.5

10

15

20

or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

Any description of a class or range as being useful or preferred in the practice of the invention shall be deemed a description of any subclass (e.g., a disclosed class with one or more disclosed members omitted) or subrange contained therein, as well as a separate description of each individual member or value in said class or range.

The description of preferred embodiments individually shall be deemed a description of any possible combination of such preferred embodiments, except for combinations which are impossible (e.g, mutually exclusive choices for an element of the invention) or which are expressly excluded by this specification.

If an embodiment of this invention is disclosed in the prior art, the description of the invention shall be deemed to include the invention as herein disclosed with such embodiment excised.

Introduction to Master Tables

The master tables reflect applicants' analysis of the gene chip data.

5

30

For each probe corresponding to a differentially expressed mouse gene, Master Table 1 identifies

- Col. 1: The mouse gene (upper) and mouse protein (lower)
 database accession #s.
 - Col. 2: The corresponding mouse Unigene Cluster, as of the 4th Quarter 2001 build.
- 15 Col. 3: The behavior (differential expression) observed for the mouse gene. This column identifies the gene as favorable(F) or unfavorable (U) on the basis of its differential behavior. There are three possible comparisons, HI-D, C-HI, and C-D, where C=control (normal), HI=hyperinsulinemic, and D=diabetic.

 If the level of the gene in the former state is at least two-fold that in the latter state, it is considered unfavorable. If the level of the gene in the former state
- is not more than half (i.e., not more than negative two fold) that in the latter state, it is considered favorable.
 - Col. 4: A related human protein, identified by its database accession number. Usually, several such proteins are identified relative to each mouse gene. These proteins have been identified by BLAST searches, as explained in cols. 6-8.
 - Col. 5: The name of the related human protein.
- 35 Col. 6: The score (in bits) for the alignment performed by the BLAST program.

89

Col. 7: The E-value for the alignment performed by the BLAST program. It is worth noting that Unigene considers a Blastx E Value of less than 1e-6 to be a "match" to the reference sequence of a cluster.

5

Col. 8: The BLAST search strategy used. MG indicates that the mouse gene was used as the query sequence in a BlastX search. MP means that the mouse protein was used as the query sequence in a BlastP search. HGP means that first the mouse gene was used in a BlastN search for a human gene, and then the human gene was used in a BLASTX search for the human protein.

15

20

10

Master Table 1 is divided into three subtables on the basis of the Behavior" in col. 3. If a gene has at least one favorable behavior, and no unfavorable ones, it is put into Subtable 1A. In the opposite case, it is put into Subtable 1B. If its behavior is mixed, i.e., at least one favorable and at least one unfavorable, it is put into Subtable 1C.

Master Table 2 has just three columns.

25 Col. 1: Mouse gene.

Col. 2: behavior. Same as col. 3 in Master table 1.

Col. 3: Human protein classes. Based on the related human proteins defined in Master Table 1, Master Table 2 generalizes, if possible as to classes of human proteins which are expected to have similar behavior. For a given mouse gene, several human protein classes may be listed because of the diversity of the human proteins found to be related. In some cases, the stated human protein classes may be hierarchial, e.g., one may be a subset of another. In other cases, the stated classes may be non-overlapping but related. And in yet other cases, the stated classes may be

62

algae, bacteria, fungi, or a virus (although the biological activity of a virus must be determined in a virus-infected cell). The microorganism may be human or other animal or plant pathogen, or it may be nonpathogenic. It may be a soil or water organism, or one which normally lives inside other living things.

If the target organism is an animal, it may be a vertebrate or a nonvertebrate animal. Nonvertebrate animals are chiefly of interest when they act as pathogens or parasites, and the drugs are intended to act as biocidic or biostatic agents. Nonvertebrate animals of interest include worms, mollusks, and arthropods.

The target organism may also be a vertebrate animal, i.e., a mammal, bird, reptile, fish or amphibian. Among mammals, the target animal preferably belongs to the order Primata (humans, apes and monkeys), Artiodactyla (e.g., cows, pigs, sheep, goats, horses), Rodenta (e.g., mice, rats) Lagomorpha (e.g., rabbits, hares), or Carnivora (e.g., cats, dogs). Among birds, the target animals are preferably of the orders Anseriformes (e.g., ducks, geese, swans) or Galliformes (e.g., quails, grouse, pheasants, turkeys and chickens). Among fish, the target animal is preferably of the order Clupeiformes (e.g., sardines, shad, anchovies, whitefish, salmon).

25

30

35

10

15

20

Target Tissues

The term "target tissue" refers to any whole animal, physiological system, whole organ, part of organ, miscellaneous tissue, cell, or cell component (e.g., the cell membrane) of a target animal in which biological activity may be measured.

Routinely in mammals one would choose to compare and contrast the biological impact on virtually any and all tissues which express the subject receptor protein. The main tissues to use are: brain, heart, lung, kidney, liver, pancreas, skin, intestines, adipose, stomach, skeletal muscle, adrenal glands, breast, prostate, vasculature, retina, cornea, thyroid gland, parathyroid glands, thymus,

10

20

25

30

35

bone marrow, bone, etc.

Another classification would be by cell type: B cells, T cells, macrophages, neutrophils, eosinophils, mast cells, platelets, megakaryocytes, erythrocytes, bone marrow stomal cells, fibroblasts, neurons, astrocytes, neuroglia, microglia, epithelial cells (from any organ, e.g. skin, breast, prostate, lung, intestines etc), cardiac muscle cells, smooth muscle cells, striated muscle cells, osteoblasts, osteocytes, chondroblasts, chondrocytes, keratinocytes, melanocytes, etc.

Of course, in the case of a unicellular organism, there is no distinction between the "target organism" and the "target tissue".

15 Screening Assays

Assays intended to determine the binding or the biological activity of a substance are called preliminary screening assays.

Screening assays will typically be either in vitro (cell-free) assays (for binding to an immobilized receptor) or cell-based assays (for alterations in the phenotype of the cell). They will not involve screening of whole multicellular organisms, or isolated organs. The comments on diagnostic biological assays apply mutatis mutandis to screening cell-based assays.

In Vitro vs. In Vivo Assays

The term in vivo is descriptive of an event, such as binding or enzymatic action, which occurs within a living organism. The organism in question may, however, be genetically modified. The term in vitro refers to an event which occurs outside a living organism. Parts of an organism (e.g., a membrane, or an isolated biochemical) are used, together with artificial substrates and/or conditions. For the purpose of the present invention, the term in vitro excludes events occurring inside or on an intact cell, whether of a unicellular or multicellular organism.

In vivo assays include both cell-based assays, and

organismic assays. The cell-based assays include both assays on unicellular organisms, and assays on isolated cells or cell cultures derived from multicellular organisms. The cell cultures may be mixed, provided that they are not organized into tissues or organs. The term organismic assay refers to assays on whole multicellular organisms, and assays on isolated organs or tissues of such organisms.

In vitro Diagnostic Methods and Reagents

10

20

25

30

35

5

The in vitro assays of the present invention may be applied to any suitable analyte-containing sample, and may be qualitative or quantitative in nature.

15 Sample

The sample will normally be a biological fluid, such as blood, urine, lymph, semen, milk, or cerebrospinal fluid, or a fraction or derivative thereof, or a biological tissue, in the form of, e.g., a tissue section or homogenate. However, the sample conceivably could be (or derived from) a food or beverage, a pharmaceutical or diagnostic composition, soil, or surface or ground water. If a biological fluid or tissue, it may be taken from a human or other mammal, vertebrate or animal, or from a plant. The preferred sample is blood, or a fraction or derivative thereof.

Binding and Reaction Assays

The assay may be a binding assay, in which one step involves the binding of a diagnostic reagent to the analyte, or a reaction assay, which involves the reaction of a reagent with the analyte. The reagents used in a binding assay may be classified as to the nature of their interaction with analyte: (1) analyte analogues, or (2) analyte binding molecules (ABM). They may be labeled or insolubilized.

In a reaction assay, the assay may look for a direct reaction between the analyte and a reagent which is reactive with the analyte, or if the analyte is an enzyme or enzyme inhibitor, for a reaction catalyzed or inhibited by the analyte. The reagent may be a reactant, a catalyst, or an inhibitor for the reaction.

An assay may involve a cascade of steps in which the product of one step acts as the target for the next step. These steps may be binding steps, reaction steps, or a combination thereof.

Signal Producing System (SPS)

10

15

20

25

30

35

5

In order to detect the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system (SPS) in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent (or, in a quantitative assay, on the amount of the analyte). The detectable signal may be one which is visually detectable, or one detectable only with Possible signals include production of colored instruments. or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or emission of radiation by an assay component or product, and precipitation or agglutination of a component or product. The term "signal" is intended to include the discontinuance of an existing signal, or a change in the rate of change of an observable parameter, rather than a change in its absolute value. The signal may be monitored manually or automatically.

In a reaction assay, the signal is often a product of the reaction. In a binding assay, it is normally provided by a label borne by a labeled reagent.

Labels

The component of the signal producing system which is most intimately associated with the diagnostic reagent is called the "label". A label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, an agglutinable particle.

The radioactive isotope can be detected by such means

66

as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful for the purpose of the present invention include ³H, ¹²⁵I, ¹³¹I, ³⁵S, ¹⁴C, ³²P and ³³P. ¹²⁵I is preferred for antibody labeling.

5

10

15

20

25

30

35

The label may also be a fluorophore. When the fluorescently labeled reagent is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, ophthaldehyde and fluorescamine.

Alternatively, fluorescence-emitting metals such as ¹²⁵Eu, or others of the lanthanide series, may be incorporated into a diagnostic reagent using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) of ethylenediamine-tetraacetic acid (EDTA).

The label may also be a chemiluminescent compound. The presence of the chemiluminescently labeled reagent is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used for labeling. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

Enzyme labels, such as horseradish peroxidase and alkaline phosphatase, are preferred. When an enzyme label is used, the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears.

An enzyme analyte may act as its own label if an enzyme inhibitor is used as a diagnostic reagent.

Binding Assay Formats

5

10

15

20

25

30

35

Binding assays may be divided into two basic types, heterogeneous and homogeneous. In heterogeneous assays, the interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free label. In homogeneous assays, the interaction does affect the activity of the label, and therefore analyte levels can be deduced without the need for a separation step.

In one embodiment, the ABM is insolubilized by coupling it to a macromolecular support, and analyte in the sample is allowed to compete with a known quantity of a labeled or specifically labelable analyte analogue. The "analyte analogue" is a molecule capable of competing with analyte for binding to the ABM, and the term is intended to include analyte itself. It may be labeled already, or it may be labeled subsequently by specifically binding the label to a moiety differentiating the analyte analogue from analyte. The solid and liquid phases are separated, and the labeled analyte analogue in one phase is quantified. The higher the level of analyte analogue in the solid phase, i.e., sticking to the ABM, the lower the level of analyte in the sample.

In a "sandwich assay", both an insolubilized ABM, and a labeled ABM are employed. The analyte is captured by the insolubilized ABM and is tagged by the labeled ABM, forming a ternary complex. The reagents may be added to the sample in either order, or simultaneously. The ABMs may be the same or different. The amount of labeled ABM in the ternary complex is directly proportional to the amount of analyte in the sample.

The two embodiments described above are both heterogeneous assays. However, homogeneous assays are conceivable. The key is that the label be affected by whether or not the complex is formed.

68

Conjugation Methods

5

10

15

20

25

30

35

A label may be conjugated, directly or indirectly (e.g., through a labeled anti-ABM antibody), covalently (e.g., with SPDP) or noncovalently, to the ABM, to produce a diagnostic reagent. Similarly, the ABM may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent.

Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.

The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target. Thus the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc.

Biological Assays

A biological assay measures or detects a biological response of a biological entity to a substance.

The biological entity may be a whole organism, an isolated organ or tissue, freshly isolated cells, an immortalized cell line, or a subcellular component (such as a membrane; this term should not be construed as including an isolated receptor). The entity may be, or may be derived from, an organism which occurs in nature, or which is modified in some way. Modifications may be genetic (including radiation and chemical mutants, and genetic engineering) or somatic (e.g., surgical, chemical, etc.). In the case of a multicellular entity, the modifications may affect some or all cells. The entity need not be the target organism, or a derivative thereof, if there is a reasonable correlation between bioassay activity in the assay entity and biological activity in the target organism.

The entity is placed in a particular environment, which may be more or less natural. For example, a culture medium may, but need not, contain serum or serum substitutes, and it may, but need not, include a support matrix of some kind, it may be still, or agitated. It may contain particular biological or chemical agents, or have particular physical parameters (e.g., temperature), that are intended to nourish or challenge the biological entity.

5

10

15

20

25

30

35

There must also be a detectable biological marker for the response. At the cellular level, the most common markers are cell survival and proliferation, cell behavior (clustering, motility), cell morphology (shape, color), and biochemical activity (overall DNA synthesis, overall protein synthesis, and specific metabolic activities, such as utilization of particular nutrients, e.g., consumption of oxygen, production of CO_2 , production of organic acids, uptake or discharge of ions).

The direct signal produced by the biological marker may be transformed by a signal producing system into a different signal which is more observable, for example, a fluorescent or colorimetric signal.

The entity, environment, marker and signal producing system are chosen to achieve a clinically acceptable level of sensitivity, specificity and accuracy.

In some cases, the goal will be to identify substances which mediate the biological activity of a natural biological entity, and the assay is carried out directly with that entity. In other cases, the biological entity is used simply as a model of some more complex (or otherwise inconvenient to work with) biological entity. In that event, the model biological entity is used because activity in the model system is considered more predictive of activity in the ultimate natural biological entity than is simple binding activity in an in vitro system. The model entity is used instead of the ultimate entity because the former is more expensive or slower to work with, or because ethical considerations forbid working with the ultimate entity yet.

70

The model entity may be naturally occurring, if the model entity usefully models the ultimate entity under some conditions. Or it may be non-naturally occurring, with modifications that increase its resemblance to the ultimate entity.

Transgenic animals, such as transgenic mice, rats, and rabbits, have been found useful as model systems.

In cell-based model assays, where the biological activity is mediated by binding to a receptor (target protein), the receptor may be functionally connected to a signal (biological marker) producing system, which may be endogenous or exogenous to the cell.

There are a number of techniques of doing this.

15 "Zero-Hybrid" Systems

5

10

20

25

In these systems, the binding of a peptide to the target protein results in a screenable or selectable phenotypic change, without resort to fusing the target protein (or a ligand binding moiety thereof) to an endogenous protein. It may be that the target protein is endogenous to the host cell, or is substantially identical to an endogenous receptor so that it can take advantage of the latter's native signal transduction pathway. Or sufficient elements of the signal transduction pathway normally associated with the target protein may be engineered into the cell so that the cell signals binding to the target protein.

"One-Hybrid" Systems

In these systems, a chimera receptor, a hybrid of the target protein and an endogenous receptor, is used. The chimeric receptor has the ligand binding characteristics of the target protein and the signal transduction characteristics of the endogenous receptor. Thus, the normal signal transduction pathway of the endogenous receptor is subverted.

Preferably, the endogenous receptor is inactivated, or the conditions of the assay avoid activation of the

71

endogenous receptor, to improve the signal-to-noise ratio. See Fowlkes USP 5,789,184 for a yeast system.

Another type of "one-hybrid" system combines a peptide: DNA-binding domain fusion with an unfused target receptor that possesses an activation domain.

"Two-Hybrid" System

In a preferred embodiment, the cell-based assay is a two hybrid system. This term implies that the ligand is incorporated into a first hybrid protein, and the receptor into a second hybrid protein. The first hybrid also comprises component A of a signal generating system, and the second hybrid comprises component B of that system.

Components A and B, by themselves, are insufficient to generate a signal. However, if the ligand binds the receptor, components A and B are brought into sufficiently close proximity so that they can cooperate to generate a signal.

Components A and B may naturally occur, or be substantially identical to moieties which naturally occur, as components of a single naturally occurring biomolecule, or they may naturally occur, or be substantially identical to moieties which naturally occur, as separate naturally occurring biomolecules which interact in nature.

25

30

35

5

10

15

20

Two-Hybrid System: Transcription Factor Type

In a preferred "two-hybrid" embodiment, one member of a peptide ligand:receptor binding pair is expressed as a fusion to a DNA-binding domain (DBD) from a transcription factor (this fusion protein is called the "bait"), and the other is expressed as a fusion to a transactivation domain (TAD) (this fusion protein is called the "fish", the "prey", or the "catch"). The transactivation domain should be complementary to the DNA-binding domain, i.e., it should interact with the latter so as to activate transcription of a specially designed reporter gene that carries a binding site for the DNA-binding domain. Naturally, the two fusion proteins must likewise be complementary.

PCT/US2004/010191

. ..5

10

15

20

25

30

35

This complementarity may be achieved by use of the complementary and separable DNA-binding and transcriptional activator domains of a single transcriptional activator protein, or one may use complementary domains derived from different proteins. The domains may be identical to the native domains, or mutants thereof. The assay members may be fused directly to the DBD or TAD, or fused through an intermediated linker.

The target DNA operator may be the native operator sequence, or a mutant operator. Mutations in the operator may be coordinated with mutations in the DBD and the TAD. An example of a suitable transcription activation system is one comprising the DNA-binding domain from the bacterial repressor LexA and the activation domain from the yeast transcription factor Gal4, with the reporter gene operably linked to the LexA operator.

It is not necessary to employ the intact target receptor; just the ligand-binding moiety is sufficient.

The two fusion proteins may be expressed from the same or different vectors. Likewise, the activatable reporter gene may be expressed from the same vector as either fusion protein (or both proteins), or from a third vector.

Potential DNA-binding domains include Gal4, LexA, and mutant domains substantially identical to the above.

Potential activation domains include E. coli B42, Gal4 activation domain II, and HSV VP16, and mutant domains substantially identical to the above.

Potential operators include the native operators for the desired activation domain, and mutant domains substantially identical to the native operator.

The fusion proteins may comprise nuclear localization signals.

The assay system will include a signal producing system, too. The first element of this system is a reporter gene operably linked to an operator responsive to the DBD and TAD of choice. The expression of this reporter gene will result, directly or indirectly, in a selectable or screenable phenotype (the signal). The signal producing

10

15

20

25

30

35

system may include, besides the reporter gene, additional genetic or biochemical elements which cooperate in the production of the signal. Such an element could be, for example, a selective agent in the cell growth medium. There may be more than one signal producing system, and the system may include more than one reporter gene.

The sensitivity of the system may be adjusted by, e.g., use of competitive inhibitors of any step in the activation or signal production process, increasing or decreasing the number of operators, using a stronger or weaker DBD or TAD, etc.

When the signal is the death or survival of the cell in question, or proliferation or nonproliferation of the cell in question, the assay is said to be a selection. When the signal merely results in a detectable phenotype by which the signaling cell may be differentiated from the same cell in a nonsignaling state (either way being a living cell), the assay is a screen. However, the term "screening assay" may be used in a broader sense to include a selection. When the narrower sense is intended, we will use the term "nonselective screen".

Various screening and selection systems are discussed in Ladner, USP 5,198,346.

Screening and selection may be for or against the peptide: target protein or compound:target protein interaction.

Preferred assay cells are microbial (bacterial, yeast, algal, protozooal), invertebrate, vertebrate (esp. mammalian, particularly human). The best developed two-hybrid assays are yeast and mammalian systems.

Normally, two hybrid assays are used to determine whether a protein X and a protein Y interact, by virtue of their ability to reconstitute the interaction of the DBD and the TAD. However, augmented two-hybrid assays have been used to detect interactions that depend on a third, non-protein ligand.

For more guidance on two-hybrid assays, see Brent and Finley, Jr., Ann. Rev. Genet., 31:663-704 (1997); Fremont-

Racine, et al., Nature Genetics, 277-281 (16 July 1997);
Allen, et al., TIBS, 511-16 (Dec. 1995); LeCrenier, et al.,
BioEssays, 20:1-6 (1998); Xu, et al., Proc. Nat. Acad. sci.
(USA), 94:12473-8 (Nov. 1992); Esotak, et al., Mol. Cell.
Biol., 15:5820-9 (1995); Yang, et al., Nucleic Acids Res.,
23:1152-6 (1995); Bendixen, et al., Nucleic Acids Res.,
22:1778-9 (1994); Fuller, et al., BioTechniques, 25:85-92
(July 1998); Cohen, et al., PNAS (USA) 95:14272-7 (1998);
Kolonin and Finley, Jr., PNAS (USA) 95:14266-71 (1998). See
also Vasavada, et al., PNAS (USA), 88:10686-90 (1991)
(contingent replication assay), and Rehrauer, et al., J.
Biol. Chem., 271:23865-73 91996) (LexA repressor cleavage assay).

Two-Hybrid Systems: reporter Enzyme type
In another embodiment, the components A and B
reconstitute an enzyme which is not a transcription factor.

As in the last example, the effect of the reconstitution of the enzyme is a phenotypic change which may be a screenable change, a selectable change, or both.

In vivo Diagnostic Uses

20

25

30

35

Radio-labeled ABM may be administered to the human or animal subject. Administration is typically by injection, e.g., intravenous or arterial or other means of administration in a quantity sufficient to permit subsequent dynamic and/or static imaging using suitable radio-detecting devices. The dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radio-imaging agents as a guide.

Typically, the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study. The amount of radio-labeled ABM accumulated at a given point in time in relevant target organs can then be quantified.

A particularly suitable radio-detecting device is a

10

15

20

25

30

35

scintillation camera, such as a gamma camera. scintillation camera is a stationary device that can be used to image distribution of radio-labeled ABM. The detection device in the camera senses the radioactive decay, the distribution of which can be recorded. Data produced by the imaging system can be digitized. The digitized information can be analyzed over time discontinuously or continuously. The digitized data can be processed to produce images, called frames, of the pattern of uptake of the radio-labeled ABM in the target organ at a discrete point in time. most continuous (dynamic) studies, quantitative data is obtained by observing changes in distributions of radioactive decay in target organs over time. In other words, a time-activity analysis of the data will illustrate uptake through clearance of the radio-labeled binding protein by the target organs with time.

Various factors should be taken into consideration in selecting an appropriate radioisotope. The radioisotope must be selected with a view to obtaining good quality resolution upon imaging, should be safe for diagnostic use in humans and animals, and should preferably have a short physical half-life so as to decrease the amount of radiation received by the body. The radioisotope used should preferably be pharmacologically inert, and, in the quantities administered, should not have any substantial physiological effect.

The ABM may be radio-labeled with different isotopes of iodine, for example ¹²³I, ¹²⁵I, or ¹³¹I (see for example, U.S. Patent 4,609,725). The extent of radio-labeling must, however be monitored, since it will affect the calculations made based on the imaging results (i.e. a diiodinated ABM will result in twice the radiation count of a similar monoiodinated ABM over the same time frame).

In applications to human subjects, it may be desirable to use radioisotopes other than ¹²⁵I for labeling in order to decrease the total dosimetry exposure of the human body and to optimize the detectability of the labeled molecule (though this radioisotope can be used if circumstances

10

15

20

30

35

require). Ready availability for clinical use is also a factor. Accordingly, for human applications, preferred radio-labels are for example, ^{99m}Tc, ⁶⁷Ga, ⁶⁸Ga, ⁹⁰Y, ¹¹¹In, ^{113m}In, ¹²³I, ¹⁸⁶Re, ¹⁸⁸Re or ²¹¹At.

The radio-labeled ABM may be prepared by various methods. These include radio-halogenation by the chloramine - T method or the lactoperoxidase method and subsequent purification by HPLC (high pressure liquid chromatography), for example as described by J. Gutkowska et al in "Endocrinology and Metabolism Clinics of America: (1987) 16 (1):183. Other known methods of radio-labeling can be used, such as IODOBEADS™.

There are a number of different methods of delivering the radio-labeled ABM to the end-user. It may be administered by any means that enables the active agent to reach the agent's site of action in the body of a mammal. Because proteins are subject to being digested when administered orally, parenteral administration, i.e., intravenous, subcutaneous, intramuscular, would ordinarily be used to optimize absorption of an ABM, such as an antibody, which is a protein.

EXAMPLES

25 Animal Models.

Obesity and subsequent hyperinsulinemia and hyperglycemia were induced by feeding a group of 3 week old mice (50 C57B1/6 males) a high-fat diet (Bio-Serve, Frenchtown, NJ, #F1850 High Carbohydrate-High Fat). Another group of 3 week old mice (20 C57B1/6 males) were fed the normal control diet (PMI Nutrition International Inc., Brentwood, MO, Prolab RMH3000). The mice were placed onto the respective diets immediately following weaning. Animal weights were determined weekly. Fasting blood-glucose and plasma insulin measurements were determined after 2, 4, 8 and 16 weeks, and 6 months, on the respective diets.

Normal weight, normal fasting blood glucose and normal fasting plasma insulin levels are defined as the respective

15

20

. 25

30

mean values of the animals fed the control diet.

Two of the "most typical" animals were selected for each group (Control, hyperinsulinemic and Diabetic) at each time point (2,4,8, and 16 weeks, and 6 months, after commencement of diet) for sacrifice. The selected mice were sacrificed and liver tissue obtained and frozen in liquid notrogen until processed for RNA isolation.

Fasting Blood Glucose Levels.

Blood glucose levels was measured from a drop of blood taken from the tip of the tail of fasted (6 hr) mice using a Lifescan Genuine One Touch glucometer. All measurements occurred between 3:00 pm and 5:00 pm.

Plasma insulin measurements.

Blood was collected from the tail of fasted (6hr) mice into a heparinized capillary tube and stored on ice. All collections occurred between 3:00 pm and 5:00 pm. Plasma was separated from red blood cells by centrifugation for 10 minutes at 8000 x g and then stored at -20°C. Insulin concentrations were determined using the Rat Insulin ELISA kit and rat insulin standards (ALPCO) essentially as instructed by the manufacturer. Values were adjusted by a factor of 1.23 as determined by the manufacturer to correct for the species difference in cross-reactivity with the antibody.

RNA isolation.

Total RNA was isolated from livers using the RNA STAT-60 Total RNA/mRNA Isolation Reagent according to the manufacturer's instructions (Tel-Test, Friendswood, TX).

Sample Quantification and Quality Assessment

Total RNA was quantified and assessed for quality on a Bioanalyzer RNA 6000 Nano chip (Agilent). Each chip contained an interconnected set of gel-filled channels that allowed for molecular sieving of nucleic acids. Pin-

90

non-overlapping and unrelated. Combinations of the above are also possible.

5

10

15

20

In addition to the classes stated, the corresponding human gene clusters are also of interest. These may be obtained in a number of ways. First, one may search on Unigene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) for the identified human protein. Review the "hits" (each of which is a Unigene record) for those prefixed by "Hs." Secondly, one may access the Unigene record for the mouse gene cluster (which is given in Master Table 1), and then click on "Homologene". This will bring up a new page which includes the section "Possible Homologous Genes". One of the entries should be a Homo sapiens gene (considered by Unigene to be the most related human gene); click on its Unigene record link.

Additional information of interest may be accessed by searching with the mouse gene accession # in the Mouse Gene Informatics database, at http://www.informatics.jax.org/.

Master Table 1: Subtable 1A Favorable Genes/Proteins

Mouse Gene	Umgene	Behavior Human		Human Protein Name	Score	E-Value
Protein			Protein			
NM_007630	Mm.22592 F:(HI-D) NP_00469	F:(HI-D)	NP_004692.1	2.1 cyclin B2	٠.	
NP 031656.1		-5.28			694	0
			NP_114172.1	cyclin B1; G2/mitotic-specific cyclin B1	382	1.00e-106
			XP_172630.1	similar to cyclin B2	239	6.00e-63
NM_007913	Mm.18195	F:(HI-D)	Mm.18195 F:(HI-D) NP_001955.1	early growth response 1; G0S30		
NP 031939.1	. 6	-2.66			783	0
			XP_005040.2	similar to Early growth response protein 3 (EGR-3) (Zinc finger protein pilot)	275	3.00e-73
			NP_004421.1	early growth response 3	274	6.00e-73
AF127033	Mm.3760	F:(HI-D)	F:(HI-D) NP_004095.3	5.3 fatty acid synthase		
AAG02285.1		-2.1			3961	0
			G01880	fatty-acid synthase (EC 2.3.1.85) (version 2)	3945	0
			P49327	Fatty acid synthase [Includes: EC 2.3.1.38; EC 2.3.1.39; EC 2.3.1.41; EC 1.1.1.100;		
				EC 4.2.1.61; EC 1.3.1.10; EC 3.1.2.14]	3778	0
			B57788	fatty-acid synthase (EC 2.3.1.85) (HepG2 cell variant)	3740	0
			AAH07267.1	Unknown (protein for IMAGE:3138929)	1533	0 .
			AAB35516.1	fatty acid synthase; FAS [Homo sapiens]	728	0
			AAH07305.1	Unknown (protein for MGC:15706)	685	0
			AAH14634.1	Unknown (protein for IMAGE:3535581)	553	1.00e-156
NM_011169	Mm.2752	F:(HI-D)	F:(HI-D) NP_000940.1	prolactin receptor		
NP_035299.1		-2.08			789	0
			AAK32703.1	prolactin receptor isoform delta S1 precursor	605	1.00e-173
			AAL23915.1	prolactin receptor short isoform 1a	512	1.00e-145
			AAD49855.1	intermediate prolactin receptor isoform	509	1.00e-144
			AAL23914.1	prolactin receptor short isoform 1b	448	1.00e-125

ហ

20

ហ

NM 013490	Mm.5262	F:(HI-D)	AAH36471.1	Mm.5262 F:(HI-D) AAH36471.1 Similar to choline kinase	L	
NP_038518.1		-2.04			679	0
			NP_001268.1	choline kinase	999	0
			NP_005189.2	choline/ethanolamine kinase isoform a	433	1.00e-121
NM_013888	Mm.32550	F:(HI-D)	Mm.32550 F:(HI-D) NP_068572.1	1 J domain containing protein 1		
NP_038916.1		-2.04			310	3.00e-84
NM_019499	Mm.43444	F:(HI-D)	Mm.43444 F:(HI-D) NP_002349.1	MAD2-like 1; MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; mitotic arrest		
NP_062372.1		-2.04		deficient, yeast, homolog-like 1	382	1.00e-106
			21465465	Chain A, Crystal Structure Of Mad1-Mad2 Reveals A Conserved Mad2 Binding		
				Motif In Mad1 And Cdc20	380	1.00e-102
			18655665	Chain A, The Mad2 Spindle Checkpoint Protein Undergoes Similar Major		
				Conformational Changes Upon Binding To Either Mad1 Or Cdc20	368	1.00e-102
			7245371	Chain A, Solution Structure Of The Spindle Assembly Checkpoint Protein Human		
				Mad2	348	5.00e-96
NM_011850	Mm.34209	F:(HI-D)	Mm.34209 F:(HI-D) NP_068804.1	short heterodimer partner; orphan nuclear receptor SHP; small heterodimer		
NP_035980.1		-2.03		partner; nuclear receptor subfamily 0, group B, member 2	404	1.00e-112
			AAC41998.1	nuclear hormone receptor	402	1.00e-112
AF213393	Mm.38377	F:(HI-D)	Mm.38377 F:(HI-D) NP_009099.1	1 ATP-binding cassette, sub-family A member 8		-
AAF31432.1		-2.02			280	2.00e-75
			NP_525022.1	ATP-binding cassette, sub-family A (ABC1), member 9	267	2.00e-71
			AAN32751.1	ATP-binding cassette sub-family A member 9	267	2.00e-71
			NP_525021.1	ATP-binding cassette, sub-family A (ABC1), member 10	244	8.00e-65
			.1	ABC transporter ABCA6	227	2.00e-59
			NP_525023.1	ATP-binding cassette, sub-family A (ABC1), member 6	227	2.00e-59
			_]	unnamed protein product	227	2.00e-59
			CAB93535.3	ATP-binding cassette protein	199	3.00e-51
ļ			NP_061142.1	ATP-binding cassette protein of the (ABCA subfamily)	199	3.00e-51
			BAB71700.1	unnamed protein product	199	3.00e-51
			BAB67781.1	KIAA1888 protein	199	3.00e-51

			BAB71208.1	unnamed protein product	199	7.00e-51
NM 013646	Mm.8858	F:(HI-D)	1	RAR-related orphan receptor A, isoform a; RAR-related orphan receptor alpha;		
		-2.02		retinoic acid receptor-related orphan receptor alpha; transcription factor RZR-alpha;		
l				ROR-alpha	954	0
			NP_002934.1	RAR-related orphan receptor A, isoform c; RAR-related orphan receptor alpha;		
				retinoic acid receptor-related orphan receptor alpha; transcription factor RZR-alpha;		
				ROR-alpha	968	0
			NP_599022.1	RAR-related orphan receptor A, isoform b; RAR-related orphan receptor alpha;		
				retinoic acid receptor-related orphan receptor alpha; transcription factor RZR-alpha;		
				ROR-alpha	968	0
			NP_599024.1	RAR-related orphan receptor A, isoform d; RAR-related orphan receptor alpha;		
`				retinoic acid receptor-related orphan receptor alpha; transcription factor RZR-alpha;		
				ROR-alpha	968	0
			A56856	retinoid-related orphan receptor RZR-alpha - human	893	0
			NP_008845.2	RAR-related orphan receptor B; RAR-related orphan receptor beta; retinoic		
				acid-binding receptor beta; nuclear receptor RZR-beta	561	1.00e-160
			CAD13276.1	bA133M9.1 (RAR-related orphan receptor B)	561	1.00e-159
			Q92753	NUCLEAR RECEPTOR ROR-BETA (NUCLEAR RECEPTOR RZR-BETA)	559	1.00e-159
NM_009425	Mm.1062	F:(HI-D)	NP_003801.1	F:(HI-D) NP_003801.1 tumor necrosis factor (ligand) superfamily, member 10; Apo-2 ligand; TNF-related		
NP_033451.1		-10.21		apoptosis inducing ligand TRAIL	345	9.00e-95
			6980394	Chain A, Crystal Structure Of Apo2ITRAIL	266	4.00e-71
			6435529	Chain B, Crystal Structure Of Trail-Dr5 Complex	248	2.00e-65
			10835510	Chain D, Crystal Structure Of Trail-Sdr5	248	2.00e-65
AK018485		F:(C-HI)-				
2204249A	Mm.23336 2.45	2.45	NP_699169	hypothetical protein FLJ90165	211	5.00e-90
						-

Ŋ

NM 008182 Mm.19742	F:(C-HI)	NP 665683.1	Mm.19742 F:(C-HI) NP 665683.1 Iqutathione S-transferase A1; GST, class alpha, 1; glutathione S-alkyltransferase	Ŀ	
2	-9.17,	I	A1; glutathione S-aryltransferase A1; S-(hydroxyalkyl)glutathione lyase A1;	• .	•
	F:(C-D)		glutathione S-aralkyltransferase A1; GST-epsilon; glutathione S-transferase 2	٠	
	-5.68			328	8.00e-90
		152381	glutathione transferase (EC 2.5.1.18) - human	327	1.00e-89
		071.1	TPA: glutathione transferase A5	327	1.00e-89
		442977	Chain A, Glutathione S-Transferase A1-1 (E.C.2.5.1.18)	326	3.00e-89
		1127144	Chain A, Glutathione Transferase A1-1 Complexed With An Ethacrynic Acid		
-			Glutathione Conjugate (Mutant R15k)	325	6.00e-89
		XP_167100.2	similar to Glutathione S-transferase A1 (GTH1) (HA subunit 1) (GST-epsilon)		•
			(GSTA1-1) (GST class-alpha)	325	6.00e-89
		Q16772	Glutathione S-transferase A3-3 (GST class-alpha)	324	1.00e-88
		NP_000838.2	glutathione S-transferase A3	322	3.00e-88
		A49365	glutathione transferase (EC-2.5.1.18) alpha-3 [similarity] - human	322	4.00e-88
	,	AAA74634.1	glutathione S-transferase A3	322	4.00e-88
		S20331	glutathione transferase (EC 2.5.1.18) - human	318	5.00e-87
		S27110	glutathione transferase (EC 2.5.1.18) A2 - human	317	1.00e-86
		S24330	thione transferase (EC 2.5.1.18) alpha-2 (clone GTH2) - human	316	3.00e-66
		NP_000837.2	thione S-transferase A2; glutathione S-transferase 2; GST, class alpha, 2; liver		
			GST2; glutathione S-alkyltransferase A2; glutathione S-aryltransferase A2;		
			S-(hydroxyalkyl)glutathione lyase A2; glutathione S-aralkyltransferase A2;	٠.	
			GST-gamma; HA subunit 2	315	4.00e-86
		CAB92770.1	dJ152L7.3 (glutathione S-transferase A2)	315	4.00e-86
		S77958	glutathione transferase (EC 2.5.1.18) alpha-2 (clone GTH2 (+)) - human	309	3.00e-84
		A56801	glutathione transferase (EC 2.5.1.18) alpha y - human	309	4.00e-84
NM_028089 Mm.14258 F:(C-HI)	F:(C-HI)	NP_000763.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18;		
NP_082365.1 1	-4.31,		cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17;		
	F:(C-D)		microsomal monooxygenase; flavoprotein-linked monooxygenase		
	-5.26			766	0
		P33260	Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)	764	0

AAB23864.2	Cytochrome P-450	736	0
NP_000762.2			
I			
	microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked		
	топоохуденаѕе	736	0
BAA00123.1	cytochrome P-450	736	0
P11713	Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase)		
	(P-450MP)	729	0
AAA52157.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	729	0
226295	cytochrome P450	728	0
NP_000760.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19;		
_	mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic	_	
	monooxygenase; flavoprotein-linked monooxygenase	726	0
F38462	S-mephenytoin 4'-hydroxylase (EC 1.14.14) cytochrome P450 2C19 - human	722	0
P10632	Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2)		
	(S-mephenytoin 4-hydroxylase)	709	0
AAH20596.1	Unknown (protein for MGC:22146)	707	0
AAA52160.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	706	0
NP_000761.2	cytochrome P450, subfamily IIC, polypeptide 8 isoform 1; mephenytoin		
	4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase;		
	flavoprotein-linked monooxygenase; P450 form 1	706	0
S66382	cytochrome P450 2C8 - human	704	0
AAB35292.1	cytochrome P450 arachidonic acid epoxygenase isoform, Cyp 2C8 [human, kidney,		
-	Peptide Partial, 485 aa]	704	0
AAA52161.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	969	0
152418	cytochrome P450 - human	662	0
G38462	chrome P450 2C17 - human (fragment)	593	1.00e-169

			726 0			724 0		723 0	723 0	722 0	715 0	0			0 869	693 0	644 0	0 689	525 1.00e-149	284 2.00e-76	278 1.00e-74	278 2.00e-74	277 3.00e-74	277 3.00e-74	77 4.00e-74		277 4.00e-74	77 4.00e-74	77 000 2 27
_			7.2			72		72	72	2.2	1.4	711			39	39	79	9	25	38	27	27	27	27	277		27	277	276
Mm.21193 F:(C-HI) NP_000768.1 cytochrome P450, subfamily IIIA, polypeptide 5; niphedipine oxidase; aryl	hydrocarbon hydroxylase; xenobiotic monooxygenase; microsomal	monooxygenase; flavoprotein-linked monooxygenase		cytochrome P450, subfamily IIIA, polypeptide 4; nifedipine oxidase; P450-III, steroid	inducible; glucocorticoid-inducible P450; cytochrome P450, subfamily IIIA	(niphedipine oxidase), polypeptide 3	Cytochrome P450 3A4 (Quinine 3-monooxygenase) (CYPIIIA4) (Nifedipine	oxidase) (NF-25) (P450-PCN1)	cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3	cytochrome P-450 nifedipine oxidase	cytochrome P450-3A4	cytochrome P450 nifedipine oxidase	cytochrome P450, subfamily IIIA, polypeptide 7; aryl hydrocarbon hydroxylase;	microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked	monooxygenase	cytochrome P450 variant 3A7	cytochrome P450 polypeptide 43 isoform 2; cytochrome P450 polypeptide 43	NP_073731.1 cytochrome P450 polypeptide 43 isoform 1; cytochrome P450 polypeptide 43	cytochrome P450 polypeptide 43 isoform 3; cytochrome P450 polypeptide 43	cytochrome P450 subfamily IIIA polypeptide 43	thromboxane synthase	thromboxane A synthase 1 (platelet, cytochrome P450, subfamily V), isoform	TXS-I; TXA synthase	thromboxane synthase	Thrombovana A synthaso (TYA synthaso) (TYS)				
NP_000768.1				NP_059488.2			P08684		NP_000767.1	AAA35744.1	AAF13598.1	AAA35747.1	NP_000756.1	-		AAG48618.1	NP_476436.1	NP_073731.1	NP_476437.1	AAG33012.1	AAF99272.1	AAF99279.1	AAF99274.1	AAF99278.1	AAF99276.1	NP_001052.1		AAF99275.1	727/00
F:(C-HI)	-4.29,	F:(C-D)	-8.15																										
Mm.21193																													
NM_007818	NP_031844.1																									·			

IJ

15

5.00e-74 8.00e-74 1.00e-73 1.00e-73 4.00e-65 4.00e-52 4.00e-74 276 6.00e-74	2181818	264 3.00e-70
276 5. 276 8 276 8 275 1 275 1 276 8 278 248 288 248 498 498 otease 276	e e e e e e e e e e e e e e e e e e e	
ubfamily V), isoforr nin), member 1; pr inhibitor 2 (anti-el umin), member 9;	bumin), member 8 Ilbumin), member 8 albumin), member 5 (CA-2) (Leupin)	6-98) Deletioi III (6-98)
romboxane-A synthase (EC 5.3.99.5) - human iromboxane synthase hromboxane synthase hromboxane synthase hromboxane synthase hromboxane synthase thromboxane synthase thromboxane synthase thromboxane synthase thromboxane synthase thromboxane synthase thromboxane A synthase thromboxane A synthase thromboxane A synthase thromboxane A synthase inhibitor, clade B (ovalbumin), member 1; protease inhibitor 2 (anti-elastase), monocyte/neutrophil; protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived monocyte/neutrophil derived monocyte/neutrophil derived monocyte/neutrophil derived monocyte/neutrophil protease inhibitor, clade B (ovalbumin), member 9; protease monocyte/neutrophil derived	serine (or cystelle) proteinase inhibitor, clade B (ovalbumin), member 8; protease inhibitor 9 (ovalbumin type, bomapin) serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8; protease inhibitor 10 (ovalbumin type) serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6; protease inhibitor 8 (ovalbumin type) serine (or cysteine) proteinase inhibitor) serine (or cysteine) proteinase inhibitor) inhibitor proteinal thrombin inhibitor 6 (placental thrombin inhibitor - human placental thrombin inhibitor - human placental thrombin inhibitor - human care placental thrombin inhibitor	leupin preculsor similar to Squamous cell carcinoma anny Human Plasminogen Activator Inhibitor-2.[loop (66-98) Deletion in the Reactive Center Loop With Peptide Mimicking The Reactive Center Loop squamous cell carcinoma antigen 1
thromboxane-A synthase (EC 5.3.99.5) - human thromboxane synthase thromboxane synthase thromboxane synthase thromboxane synthase thromboxane synthase thromboxane synthase thromboxane A synthase thromboxane (or cysteine) proteinase inhibitor, clade inhibitor 2 (anti-elastase), monocyte/neutrophil derived	erine (or cysteine) proteinase inhibitor, clanhibitor 9 (ovalbumin type, bomapin) serine (or cysteine) proteinase inhibitor, inhibitor 10 (ovalbumin type, bomapin) serine (or cysteine) proteinase inhibitor, inhibitor 8 (ovalbumin type) serine (or cysteine) proteinase inhibitor) serine (or cysteine) proteinase inhibitor) inhibitor 6 (placental thrombin inhibitor – human placental thrombin inhibitor – human	upin preculsor imilar to Squamous cell carcinoma imilar to Squamousen Activator Inhibit Human Plasminogen Activator Inhibit With Peptide Mimicking The Reactiv With Peptide Mimicking The Reactiv squamous cell carcinoma antigen 1
thromboxane-A synthase (EC 5.3.99) thromboxane synthase thromboxane synthase thromboxane synthase thromboxane synthase thromboxane A synthase thromboxane A synthase TXS-II; TXA synthase TXS-II; TXA synthase intromboxane (or cysteine) proteinase intromboxane (or cysteine) proteinase intrinhibitor 2 (anti-elastase), monocyte/neutrophil derived	serir inhik	leupin preculsor 151.4 similar to Squamous cell 17 Human Plasminogen Act 17 With Peptide Mimicking 13 squamous cell carcinom 3
3161 thr AA07011.1 thr AE99277.1 th AH14117.1 th NP_112246.1 th	皇皇	138202 138202 XP 036951.4 15988197 2118383
Mm.46316 F:(C-F)		
NIM_025429 NIP_079705.1		15

					1.00e-106	1.00e-106	1.00e-106	9.00e-93	5,00e-50						0	0		1.00e-160		4.00e-97		4.00e-97			1.00e-95
					384	384	382	338	196				1035	\$ \$ p \ 2	1033	1030		562		352		352	350		348
NM_008341 Mm.21300 F:(C-HI) AAH35263.1 Similar to insulin-like growth factor binding protein 1						IGF-binding preprotein (AA -25 to 234)	insulin-like growth factor binding protein 1	insulin-like growth factor binding protein 1	small IGF-binding-protein	asparagine synthetase; glutamine-dependent asparagine synthetase; TS11 cell	cycle control protein			Asparagine synthetase [glutamine-hydrolyzing] (Glutamine-dependent asparagine	synthetase) (TS11 cell cycle control protein)	aspartate-ammonia ligase (EC 6.3.1.1) - human	similar to asparagine synthetase; glutamine-dependent asparagine synthetase;	TS11 cell cycle control protein	Chain A, Ligand-Free Human Glutathione S-Transferase M1a-1a		similar to Glutathione S-transferase Mu 1 (GSTM1-1) (HB subunit 4) (GTH4)	(GSTM1a-1a) (GSTM1b-1b) (GST class-mu 1)	glutathione transferase M1	Chain A, Ligand-Free Human Glutathione S-Transferase M2-2 (E.C.2.5.1.18),	Monoclinic Crystal Form
AAH35263.1									110.1	664.2				P08243		AJHUNI	XP_095404.4				XP_002155.1		AAA59203.1	4557966	
F:(C-HI)	-3.37,	F:(C-D)	-3.47,	F:(HI-D)	-2.63					F:(C-HI) NP_001	-3.11,	F:(C-D)	-2.11						F:(C-HI)	-3.03					
Mm.21300										Mm.2942	-						-		Mm.37199 F:(C-HI) 4388890						
NM_008341	NP_032367.1									U38940	AAA85125.1								103953	AAA37748.1					

	NP 000839.1	NP 000839.1 Iglutathione S-transferase M2; glutathione S-transferase 4; GST, muscle; GST		
	:- !	class-mu 2; glutathione S-transferase Mu 2; glutathione S-alkyltransferase M2;		
		glutathione S-aryltransferase M2, S-(hydroxyalkyl)glutathione lyase M2; glutathione		
		S-aralkyltransferase M2	348	1.00e-95
	494185	Chain, Glutathione S-Transferase (Human, Class Mu) (Gstm2-2) Form A		
		(E.C.2.5.1.18) Mutant With Trp 214 Replaced By Phe (W214f)	344	1.00e-94
	6980588	Chain A, Ligand-Free Homodimeric Human Glutathione S-Transferase M4- 4		
		(E.C.2.5.1.18)	342	7.00e-94
	NP_000841.1	glutathione S-transferase M4 isoform 1; glutathione S-transferase, Mu-4;		
		glutathione S-alkyltransferase M4; glutathione S-aryltransferase M4;		
		S-(hydroxyalkyl)glutathione lyase M4; glutathione S-aralkyltransferase M4;		
		GTS-Mu2; GST class-mu 4	342	7.00e-94
	AAA57346.1	glutathione transferase M4	340	2.00e-93
	S32425	glutathione transferase (EC 2.5.1.18) class mu, GSTM4 (version 2)	338	8.00e-93
	P46439	Glutathione S-transferase Mu 5 (GSTM5-5) (GST class-Mu 5)	337	1.00e-92
	NP_000842.2	glutathione S-transferase M5; glutathione S-transferase, Mu-5; glutathione		,
	•'	S-alkyltransferase M5; glutathione S-aryltransferase M5;		-
-		S-(hydroxyalkyl)glutathione lyase M5; glutathione S-aralkyltransferase M5; GST		
		class-mu 5	336	3.00e-92
	CAA48636.1	glutathione S-transferase	302	6.00e-82
	AAH17836.1	Similar to glutathione S-transferase M2 (muscle)	299	5.00e-81
	XP_042722.1	similar to Glutathione S-transferase Mu 3 (GSTM3-3) (GST class-mu 3)		
		(hGSTM3-3)	297	2.00e-80
	AAH08790.1	Unknown (protein for MGC:3704)	297	2.00e-80
	5822511	Chain B, Ligand-Free Heterodimeric Human Glutathione S-Transferase M2-3 (Ec		
		2.5.1.18), Monoclinic Crystal Form	297	2.00e-80
	NP_671489.1	hione S-transferase M4 isoform 2; glutathione S-transferase, Mu-4; glutathione	·	
		S-alkyltransferase M4; glutathione S-aryltransferase M4;		
		S-(hydroxyalkyl)glutathione lyase M4; glutathione S-aralkyltransferase M4;		
		GTS-Mu2; GST class-mu 4	296	3.00e-80

Ŋ

			A35295	glutathione transferase (EC 2.5.1.18) class mu, GSTM3	294	2.00e-79
			XP_167023.1	similar to glutathione transferase M2	277	2.00e-74
			NP_666533.1	glutathione S-transferase M1 isoform 2; HB subunit 4; glutathione		
			-	S-alkyltransferase; glutathione S-transferase, Mu-1; glutathione S-aryltransferase;		
				S-(hydroxyalkyl)glutathione lyase; glutathione S-aralkyltransferase; GST class-mu 1	270	2.00e-72
NM_013459	Mm.4407	F:(C-HI) P00746	P00746	Complement factor D precursor (C3 convertase activator) (Properdin factor D)		
NP_038487.1		-2.94		(Adipsin)	370	1.00e-102
			CAC48304.1	adipsin/complement factor D precursor	358	4.00e-99
			67580	complement factor D (EC 3.4.21.46) precursor [validated] - human (fragment)	352	5.00e-97
			6730437	Chain A, Proenzyme Of Human Complement Factor D, Recombinant Profactor D	340	1.00e-93
			1633237	Chain , Mutant Of Factor D With Enhanced Catalytic Activity	330	1.00e-90
			5542120	Chain, Human Complement Factor D In Complex With Isatoic Anhydride Inhibitor	329	3.00e-90
			XP_084037.1	XP_084037.1 similar to Complement factor D precursor (C3 convertase activator) (Properdin		
				factor D) (Adipsin)	328	8.00e-90
			NP_001919.1	adipsin/complement factor D precursor	324	1.00e-88
NM_016810	Mm.20931 F:(C-HI)	F:(C-HI)	NP_004862.1	golgi SNAP receptor complex member 1; Golgi SNARE 28 kDa		
NP_058090.1		-2.86			477	1.00e-134
				GOS28/P28 protein	452	1.00e-127
				Similar to golgi SNAP receptor complex member 1	218	1.00e-56
AK006128	Mm.23942 F:(C-HI)	F:(C-HI)	AAD01430.1	MRP3		
BAB24422.1		-2.71			365	1.00e-101
			AAD38185.1	MRP3s1 protein	365	1.00e-101
		•	NP_003777.2	ATP-binding cassette, sub-family C, member 3 isoform MRP3; canicular		
				multispecific organic anion transporter	365	1.00e-101
			CAA76658.2	multidrug resistance protein 3 (ABCC3)	365	1.00e-101
			146.1	multidrug resistance-associated protein(MRP)-like protein-2 (MLP-2)	365	1.00e-101
	İ		\neg	canalicular multispecific organic anion transporter	364	1.00e-100
			1.	multidrug resistance-associated protein homolog	350	2.00e-96
				multidrug resistance associated protein	331	1.00e-90
			AAH01636.1	Unknown (protein for IMAGE:3355848)	313	3.00e-85

	1 TO COOK 1	CATA Line and the state of the		
	NP_063954.1	INF_063934.1 ATP-binding cassette, sub-family C, member 1, isolotin 4, multiple utug resistance		
		protein 1; multidrug resistance protein; multiple drug resistance-associated protein	313	3.00e-85
	AAB83979.1	multidrug resistance protein	313	3.00e-85
	NP_063953.1	NP_063953.1 ATP-binding cassette, sub-family C, member 1, isoform 3; multiple drug resistance		
		protein 1; multidrug resistance protein; multiple drug resistance-associated protein	313	3.00e-85
	NP_004987.1	ATP-binding cassette, sub-family C, member 1, isoform 1; multiple drug resistance		
		protein 1; multidrug resistance protein; multiple drug resistance-associated protein	313	3.00e-85
	DVHUAR	multidrug resistance protein (cell line H69AR)	313	3.00e-85
	NP_063915.1	ATP-binding cassette, sub-family C, member 1, isoform 2; multiple drug resistance		
		protein 1; multidrug resistance protein; multiple drug resistance-associated protein	313	3.00e-85
	NP_063957.1	.1 ATP-binding cassette, sub-family C, member 1, isoform 7; multiple drug resistance		
		protein 1; multidrug resistance protein; multiple drug resistance-associated protein	313	3.00e-85
	AAC15784.1	Multiple drug resistance gene MRP1 (5' partial)	313	3.00e-85
	AAB83982.1	multidrug resistance protein	313	3.00e-85
	AAB83980.1	multidrug resistance protein	313	3.00e-85
	NP_063956.1	ATP-binding cassette, sub-family C, member 1, isoform 6; multiple drug resistance		
		protein 1; multidrug resistance protein; multiple drug resistance-associated protein	313	3.00e-85
	AAB83981.1	multidrug resistance protein	313	3.00e-85
	AAB09422.1	canalicular multispecific organic anion transporter	279	5.00e-75
	NP_000383.1	ATP-binding cassette, sub-family C (CFTR/MRP), member 2; canalicular	,	
		multispecific organic anion transporter	277	2.00e-74
	S71841	multidrug resistance protein, canalicular	276	3.00e-74
	CAB45309.1	multidrug resistance protein 2 (MRP2)	276	3.00e-74
NM_008742 Mm.20070 F:(C	Mm.20070 F:(C-HI) NP_002518.1	.1 neurotrophin 3 precursor		
NP_032768.1 3 -2.68	38		449	1.00e-141
	5542321	Chain A, Human Neurotrophin-3	255	5.00e-68
	1421251	Chain B, Neurotrophin Mol_id: 1; Molecule: Brain Derived Neurotrophic Factor;		
		Chain: A; Synonym: Bdnf; Engineered: Yes; Mol_id: 2; Molecule: Neurotrophin 3;		
		Chain: B; Synonym: Nt3; Engineered: Yes; Other_details: Heterodimer	249	4.00e-66

വ

P01584 Interleukin-1 AAA59136.1 interleukin 1 1827779 Chain , Interl 230947 Chain , Interl 494152 Chain , Interl 230798 Chain , Interl 230798 Chain , Interl NP_004557.1 6-phosphofru JC4626 6-phosphofru JC4626 6-phosphofru AAC62000.1 inducible 6-p				-
/m.19669 F:(C-HI)			352	3.00e-97
m.19669 F:(C-HI)	P01584	Interleukin-1 beta precursor (IL-1 beta) (Catabolin)	350	1.00e-96
m.19669 F:(C-HI)	AAA59136.1	interleukin 1	345	6.00e-95
fm.19669 F:(C-HI)	AAC03536.1	interleukin 1 beta	240	2.00e-63
fm.19669 F:(C-HI)	1827779	Chain , Interleukin-1 Beta From Joint X-Ray And Nmr Refinement	239	2.00e-63
4m.19669 F:(C-HI) -2.63	230947	Chain , Interleukin-1Beta (IL-1Beta) (Mutant With Cys 8 Replaced By Ala (C8A)	239	3.00e-63
/m.19669 F:(C-HI) -2.63	494152	Chain , Interleukin-1 Beta (Human) Mutant With Thr 9 Replaced By Gly (T9g)	239	3.00e-63
Mm.19669 F:(C-HI)	230410	Chain , Interleukin-1Beta (IL-1Beta) (Mutant With Cys 71 Replaced By Ala) (C71A)	236	3.00e-62
/m. 19669 F:(C-HI) -2.63	230798	Chain , Interleukin-1Beta (IL-1Beta) (Mutant With Cys 71 Replaced By Ser) (C71S)	236	4.00e-62
-2.63	NP_004557.1	7.1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase		
			1030	0
	<u> </u>	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase	1028	0
	JC4626	6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2, 6-bisphosphate		
		2-phosphatase (EC 3.1.3.46)	1028	0
	AAC62000.1	inducible 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase	1005	0
	CAA06605.1	6-phosphofructo-2-kinase	669	0
	060825	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (6PF-2-K/Fru-2,6-P2ASE		
_		heart-type isozyme) (PFK-2/FBPase-2) [Includes: 6-phosphofructo-2-kinase;		
		Fructose-2,6-bisphosphatase]	697	0
	NP_006203.1	NP_006203.1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2;		-
		Fructose-2,6-bisphosphatase, cardiac isozyme	688	0
	BAB19681.1	6-phosphofructo-2-kinase heart isoform	680	0
	NP_004558.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	.670	0
	JC5871	6-phosphofructo-2-kinase (EC 2.7.1.105) / fructose-2, 6-bisphosphate		
		2-phosphatase (EC 3.1.3.46)	699	0
	NP_002616.1	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1;		
		Fructose-2,6-bisphosphatase	668	0

വ

			P16118	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (6PF-2-K/Fru-2,6-P2ASE		
				liver isozyme) [Includes: 6-phosphofructo-2-kinase; Fructose-2,6-bisphosphatase]	668	0
			CAB06077.1	6-phosphofructo-2-kinase	289	1.00e-167
MM_009998	Mm.14177 F:(C-HI)	F:(C-HI)	NP_000758.1	8.1 cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6		
NP_034128.1		-2.61,			_	
		F:(C-D)				
		-2.33			701	0
			AAF13602.1	cytochrome P450-2B6	692	0
			AAA52143.1	cytochrome P450-IIB	511	1.00e-144
NM_008988	Mm.10689	F:(C-HI)	Mm.10689 F:(C-HI) XP_116965.2	5.2 similar to punc		
NP_033014.1		-2.6			695	0
			NP_066013.1	DDM36	390	1.00e-108
			AAD13399.1	putative neuronal cell adhesion molecule	384	1.00e-106
			AAA35751.1	colorectal tumor suppressor (put.); putative	254	7.00e-67
			NP_005206.1	deleted in colorectal carcinoma	254	7.00e-67
NM_010166	Mm.1430	F:(C-HI)	Q99504	Eyes absent homolog 3		
NP_034296.1		-2.57			778	0
			CAA71311.1	EYA3	763	0
			NP_001981.1	eyes absent homolog 3 (Drosophila);	644	0
			AAH14193.1	Unknown (protein for IMAGE:4110403)	438	1.00e-122
			NP_004091.1	eyes absent homolog 4 (Drosophila);	436	1.00e-122
			NP_000494.2	eyes absent 1 isoform b; Eyes absent, Drosophila, homolog of, 1; Melnick-Fraser		
				syndrome	431	1.00e-120
			CAA71309.1	EYA1A	431	1.00e-120
			AAH08803.1	Similar to eyes absent (Drosophila) homolog 2	399	1.00e-110
	,		AAH00289.1	Similar to eyes absent (Drosophila) homolog 2	394	1.00e-109
			000167	Eyes absent homolog 2	394	1.00e-109
			AAC09362.1	eyes absent homolog	394	1.00e-109
			NP_005235.2	eyes absent homolog 2	392	1.00e-108
			AAL73437.1	EYA1D	380	1.00e-104

Ŋ

	AAB42065.1 EYA2 homolog	omolog	318	3.00e-86
Mm.28301 F:(C-HI) NP_001893.2 cystat	ΙĔ	cystathionase isoform 1; cystathionine gamma-lyase; homoserine deaminase;		
-2.55, homose F:(C-D)	an.	homoserine dehydratase; cysteine desulfhydrase		
-2.57			574	1.00e-163
P32929 Cystath	· = 1	Cystathionine gamma-lyase	574	1.00e-163
CAC12901.1 bA420	7	bA42O15.1.2 (cystathionase (cystathionine gamma-lyase))	480	1.00e-135
JC1362 cystath	ı⊭	cystathionine gamma-lyase (EC 4.4.1.1)	480	1.00e-135
Mm.92685 F:(C-HI) NP_109591.1 serine	<u>ا</u> ت	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1; protease		
	<u>-</u>	inhibitor 2 (anti-elastase), monocyte/neutrophil; protease inhibitor 2 (anti-elastase),		
Ω	5	monocyte/neutrophil derived	-	
-2.4			345	1.00e-138
NP_004146.1 serine	ビ	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; protease		,
inhibit	능	inhibitor 9 (ovalbumin type)	200	5.00e-79
NP_002631.1 serine	<u>ت</u>	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8; protease		
_		inhibitor 8 (ovalburnin type)	207	2.00e-76
NP_005015.1 serine (· •	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 10; protease		
inhibito	<u> </u>	inhibitor 10 (ovalbumin type, bomapin)	179	4.00e-75
NP_004559.2 serine	<u>ا</u> ت	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6; protease		
inhibite	≒	inhibitor 6 (placental thrombin inhibitor)	192	4.00e-75
15988197 Chain	ıΨ	Chain A, Human Plasminogen Activator Inhibitor-2.[loop (66-98) Deletionmutant]		-
Comp	e)	Complexed With Peptide Mimicking The Reactive Center Loop	199	5.00e-75
539661 placent	LO I	placental thrombin inhibitor - human	190	3.00e-74
Mm.24118 F:(C-HI) NP_000845.1 glutathi	יטי	glutathione S-transferase theta 2		
-2.46,				
F:(C-D)				
-2.25	ı		375	1.00e-104
AAG02373.1 glutath	.⊵	glutathione S-transferase theta 2	375	1.00e-104
AAC13317.1 glutath	<u>.</u> e	glutathione S-transferase theta 2	364	1.00e-101

Ŋ

			XP 056016.1	XP 056016.1 Similar to Glutathione S-transferase theta 1 (GST class-theta) (Glutathione		
			l	transferase T1-1)	239	3.00e-63
			NP_000844.1	glutathione S-transferase theta 1	239	4.00e-63
			AAH07065.1	glutathione S-transferase theta 1	236	2.00e-62
AK018485	Mm.23336 F:(C-HI)	F:(C-HI)		similar to data source:SPTR, source key:Q60928, evidence:ISS~putative~similar to	_	
BAB31233.1		-2.46		GAMMA-GLUTAMYLTRANSPEPTIDASE PRECURSOR (EC 2.3.2.2) (GAMMA-		
				GLUTAMYLTRANSFERASE) (GGT)	261	1.00e-105
			NP_699169.1	hypothetical protein FLJ90165	211	5.00e-90
NM_010924	Mm.8362	F:(C-HI)	NP_006160.1	nicotinamide N-methyltransferase		
NP_035054.1		-2.45,				
		F:(C-D)				
		-2.19			458	1.00e-129
			AAD04723.1	thioether S-methyltransferase-like; similar to P40936 (PID:g731019)	268	1.00e-71
			050560	Indolethylamine N-methyltransferase (Aromatic alkylamine N-methyltransferase)		
		_	•	(Indolamine N-methyltransferase) (Arylamine N-methyltransferase) (Amine		
				N-methyltransferase)	266	3.00e-71
			NP_006765.3	indolethylamine N-methyltransferase; thioester S-methyltransferase-like	265	6.00e-71
			AAH33813.1	Unknown (protein for IMAGE:5209218)	263	2.00e-70
NM_021307	Mm.82678	F:(C-HI)	٠.	ZNF228 protein		
NP_067282.1		-2.44			1078	0
			XP_009363.3	similar to ZNF228 protein	1078	0
			NP_037512.1	zinc finger protein 228	1073	0
			NP_057528.1	zinc finger protein 226; Kruppel-associated box protein	621	1.00e-177
			O9NYT6	Zinc finger protein 226	621	1.00e-177
			AAF88103.1	zinc finger protein 226	619	1.00e-176
			NP_004225.2	zinc finger protein 93 homolog; zinc finger protein homologous to mouse Zfp93;		
		-		zinc finger protein homologous to Zfp93 in mouse; zinc finger protein 93 homolog	_	
				(mouse)	579	579 1.00e-165
			AAF88107.1	Hypothetical zinc finger-like protein	579	1.00e-164

15

		XP 091906.2	similar to Zinc finaer protein 229	550	1.00e-156
		AAF76875.1	zinc finger protein	539	1.00e-152
		NP_003416.1	zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide); Zinc		
			finger protein-45 (a Kruppel-associated box (KRAB) domain	533	1.00e-151
		AAF63030.1	Zinc finger protein ZNF45	530	1.00e-150
NM_008295 Mm	Mm.17910 F:(C-HI)	II) NP_000853.1	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1;		
NP_032321.1	-2.43,		Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid		
	F:(C-D)	_		- 1.	
	-5.64,				
	F:(HI-D)	<u> </u>			
	-2.32			528	1.00e-149
		AAA51831.1	3-beta-hydroxysteroid dehydrogenase/delta-5-delta-4-isomerase	526	1.00e-149
	•	NP_000189.1	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2;		
		*	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid	513	1.00e-145
		AAA36001.1	3-beta-hydroxysteroid dehydrogenase gene	481	1.00e-136
		CAC19801.1	dJ871G17.4 (novel 3-beta hydroxysteroid dehydrogenase/isomerase family		
			member)	360	3.00e-99
		AAM08704.1	3-beta-hydroxysteroid dehydrogenase	353	5.00e-97
		XP_060821.1	similar to dJ871G17.4 (novel 3-beta hydroxysteroid dehydrogenase/isomerase		
			family member)	335	1.00e-91
		XP_060827.5	similar to 3-beta-hydroxysteroid dehydrogenase	258	2.00e-68
		XP_089334.1	similar to 3 BETA-HYDROXYSTEROID DEHYDROGENASE/DELTA		
			5>4-ISOMERASE (3BETA-HSD)	238	1.00e-62
		AAG37824.1	3 beta-hydroxy-delta 5-C27-steroid oxidoreductase	225	2.00e-58
		NP_079469.2	3 beta-hydroxy-delta 5-C27-steroid oxidoreductase	223	8.00e-58
		XP_060822.5	similar to dJ871G17.6 (novel 3-beta hydroxysteroid dehydrogenase/isomerase		
-			family member)	213	6.00e-55
		CAC19803.1	dJ871G17.6 (novel 3-beta hydroxysteroid dehydrogenase/isomerase family		
	•		member)	202	8.00e-52
		AAD14414.1	3 beta-hydroxysteroid dehydrogenase homolog pseudogene	199	7.00e-51
,					

		0	0			0	0				0	0	0	0		0	0	1.00e-180		1.00e-178				0	0	0	0
		699	299			653	650				650	650	648	646		645	645	629		624				948	948	947	944
NM_010001 Mm.38963 F:(C-HI) NP_000763.1 cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18;	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase		Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19;	mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic	monooxygenase; flavoprotein-linked monooxygenase	cytochrome P-450	NP_000762.2 cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC	(mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase;	microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked	monooxygenase	cytochrome P-450	S-mephenytoin 4'-hydroxylase (EC 1.14.14) cytochrome P450 2C19 - human	cytochrome P450	Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase)	(P-450MP)	cytochrome P-450 S-mephenytoin 4-hydroxylase	cytochrome P450 - human	Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2)	(S-mephenytoin 4-hydroxylase)	aldehyde dehydrogenase (NAD) (EC 1.2.1.3) 5 precursor, mitochondrial				bA113O24.2 (aldehyde dehydrogenase 1 family, member B1 (ALDH5 ALDHX))	aldehyde dehydrogenase 1 family, member B1; aldehyde dehydrogenase 5	Aldehyde dehydrogenase X, mitochondrial precursor (ALDH class 2)
NP_000763.1			P33260	NP_000760.1			BAA00123.1	NP_000762.2				AAB23864.2	F38462	1506290A	P11713	·	AAA52157.1	152418	P10632		A40872				CAD13246.1	NP_000683.2	P30837
F:(C-HI)	-2.43, F:(C-D)	-2.56																			F:(C-HI)	-2.39,	F:(C-D)	-2.05			
Mm.38963						-								·			•		,.	-	Mm.24457 F:(C-HI)						
NM_010001	NP_034131.1																				AK012213	BAB28101.1				-	

	-		XP 007012.1	similar to Aldehyde dehydrogenase, mitochondrial precursor (ALDH class 2)		_
	-			(ALDHI) (ALDH-E2)	756	0
			6137677	Chain A, Human Mitochondrial Aldehyde Dehydrogenase Complexed With Nad+		
				And Mn2+	756	0
			AAA51693.1	aldehyde dehydrogenase	755	0
			1-:	aldehyde dehydrogenase 2 family (mitochondrial); aldehyde dehydrogenase 2,		
				mitochondrial	741	0
	-		CAA68290.1	precursor polypeptide (AA -36 to 479)	738	0
			094788	Aldehyde dehydrogenase 1A2 (Retinaldehyde-specific dehydrogenase type 2)		_
				(RALDH(II)) (RALDH-2)	684	0
			NP 003879.1	aldehyde dehydrogenase 1 family, member A2; retinaldehyde dehydrogenase 2	684	0
	-		AAC51652.1	aldehyde dehydrogenase 1	655	0
			NP 000680.2	aldehyde dehydrogenase 1A1; aldehyde dehydrogenase 1, soluble; aldehyde		
	_		1	dehydrogenase, liver cytosolic; ALDH class 1; acetaldehyde dehydrogenase 1;		
				retinal dehydrogenase 1	655	0
			NP 000684.1	aldehyde dehydrogenase 1A3; aldehyde dehydrogenase 6	650	0
			AAB59500.1	aldehyde dehydrogenase 2 (EC 1.2.1.3)	604	1.00e-172
	İ		AAH30589.1	Similar to aldehyde dehydrogenase 1 family, member A2	599	1.00e-171
			BAA34786.1	RALDH2-T	598	1.00e-170
			139431	aldehyde dehydrogenase I - human (fragment).	467	1.00e-131
			NP 036322.2	formyltetrahydrofolate dehydrogenase isoform a	438	1.00e-122
			XP 090294.1	similar to 10-formyltetrahydrofolate dehydrogenase	434	1.00e-121
			075891	10-formyltetrahydrofolate dehydrogenase (10-FTHFDH)	433	1.00e-121
NM 023154 Mp	n.29553 F:	(C-H)	Mm.29553 F:(C-HI) AAH08250.1	Similar to RIKEN cDNA 0610025L15 gene		
NP 075643.1	-2	-2.39,				
	<u>ii.</u>	F:(C-D)				
	-2	-2.48			456	1.00e-128
			AAG09063.1	protein expressed in thyroid	437	1.00e-123
			NP 055112.1	protein expressed in thyroid	434	1.00e-122

Mm.130	00 F:(C-HI)	Mm.13000 F:(C-HI) BAB61863.1	histidase		
	-2.39,				
	F:(C-D)				
	-2.21			1216	0
		NP_002099.1	histidine ammonia-lyase; Histidine ammonia-lyase (histidase)	1215	0
n.154	78 F:(C-HI)	Mm.15478 F:(C-HI) NP_057431.1	putative N-acetyltransferase Camello 2		
	-2.39,				
	F:(C-D)				
	-2.04			223	4.00e-58
		NP_003951.2	N-acetyltransferase 8; kidney- and liver-specific gene product; kidney- and		
		,	liver-specific gene	216	3.00e-56
		BAA71643.1	GLA	216	4.00e-56
	,	AAH12626.1	kidney- and liver-specific gene	214	1.00e-55
		T44342	hypothetical protein TSC501	214	1.00e-55
fm.103	Mm.10372 F:(C-HI)	CAA06304.1	phosphodiesterase 3A		
∞	-2.35,				
	F:(C-D)				
	-2.43			1379	0
	-	Q14432	cGMP-inhibited 3',5'-cyclic phosphodiesterase A (Cyclic GMP inhibited		
			phosphodiesterase A) (CGI-PDE A)	1379	0
		NP_000912.2	phosphodiesterase 3A, cGMP-inhibited	1379	0
		A44093	cGMP-inhibited cAMP phosphodiesterase (EC 3.1.4), myocardial form - human	1378	0
		CAA64774.1	cyclic nucleotide phosphodiesterase	2/9	0
-		NP_000913.1	phosphodiesterase 3B, cGMP-inhibited	677	0
Im.286	97 F:(C-HI)	Mm.28697 F:(C-HI) XP_045585.1	similar to RIKEN cDNA 2310032D16		
	-2.33			929	0
		BAA92672.1	KIAA1434 protein	929	0
		BAA91994.1	unnamed protein product	444	1.00e-124

		071		_	337 4.00e-92	320 7.00e-87	288 2.00e-77			1663			1640 0	345 2.00e-94	282 2.00e-75				288 1.00e-168	416 1.00e-115	318 2.00e-86					555 1.00e-158
UDP-glucose dehydrogenase				uridine diphosphoglucose dehydrogenase (EC 1)	UDP glucose 6-dehydrogenase	uridine diphospho-glucose dehydrogenase	uridine diphospho-glucose dehydrogenase	leukemia inhibitory factor receptor precursor				leukaemia inhibitory factor receptor, LIF receptor [human, placenta, Peptide, 1078	aa]	oncostatin M receptor	leukemia inhibitory factor receptor	glucose-6-phosphatase, catalytic				Unknown (protein for MGC:22459)	islet-specific glucose-6-phosphatase catalytic subunit-related p	3.1 hypothetical protein dJ726C3.2 [hypothetical protein dJ726C3.2
Mm.10709 F:(C-HI) NP_003350.1		-		JE0353	AAC05135.1	-	1	F:(C-HI) NP_002301.1				AAB23884.1		NP 003990.1	AAB61897.1	NP_000142.1		-		AAH20700.1	NP_066999.1	NP_079503.1				AAH34415.1
F:(C-H)	-2.32,	F:(C-D)	-2.00					F:(C-HI)	-2.31,	F:(C-D)	-2.46					F:(C-HI)	-2.28,	F:(C-D)	-2.14			F:(C-HI)	-2.25,	F:(C-D)	-2.16	
Mm.10709			-					Mm.3174								Mm.18064 F:(C-HI) NP_000142						Mm.46448 F:(C-HI) NP_079503				
NM_009466	NP_033492.1							NM_013584	NP_038612.1							NM_008061	NP_032087.1					NM_025631	NP_079907.1			

		1.00e-159	1.00e-158		1	_		00.000	0.000	2.00e-98	1.00e-95	4.00e-70	4.00e-61	8.00e-58	000	0.00-00	1.00e-53		٥	Ô		0	0			0	0		1.00e-178
		558 1	555 1		+		-	OH C	\perp	357	348	245	233	222	1	2 3	503		1013	1013		977	974		·	799	962		.624 1
				hypomencal protein un 12000.2		ADP-ribosylation factor 4-like				ADP-ribosylation factor 4-like; ADP-ribosylation factor-like 6	_			_		similar to ADP-ribosylation-like 4	-	malate dehydrogenase (oxaloacetate-decarboxylating) (NADP) (EC 1.1.1.40)		NADP-dependent malic enzyme	cytosolic malic enzyme 1; malic enzyme, cytoplasmic; malic enzyme 1, soluble;	NADP-dependent malic enzyme; malate dehydrogenase; pyruvic-malic carboxylase	1	malic enzyme 3, NADP(+)-dependent, mitochondrial; malic enzyme,	NADP+-dependent, mitochondrial; pyruvic-malic carboxylase; malate	dehydrogenase; NADP-ME	1		
			NP 0/9503.1	AAH34415.1		AAH00043.1				NTP 0016521	A A A 03779 1	TOUGHT THE	AF 043690.2	NF 003/29.1	NP_005728.2	XP 166703.1	BAA75473.1	JC4160		AAB01380.1	NP 002386.1	i	AAC50613.1	NP 006671.1	1		A A H 2 2 4 7 2 1	NTD 002387 1	TAT
F:(C-HI)	-2.25,	<u> </u>				F:(C-HI)	-2.24,	F:(C-D)	-2.03									١.											
	,		Mm.46448 -2.16			Mm.5376	<u>.</u>											Mm.14815 F:(C-HI)	<u> </u>										
			NP_079907.1			NM 025404	NP 079680.1	l										NM 008615	1 179 CEU OIN	11. C.									

₽		. ~	XP_085281.2	similar to RIKEN cDNA 1700095F04	305	1.00e-82
		7	١	for Inches with the second sec	229	4.00e-60
BAC04065.1			propr	unnamed protein product. proprotein convertase subtilisin/kexin type 2; subtilisin-like prohormone proprotein convertase 2; neuroendocrine convertase 2; KEX2-like	7	
endopr		endopr	endopr	endoprotease 2; proprotein convertase PC5	1244	0
			endopro	stease (NEC2)	892	0
			dJ531H	dJ531H16.1 (proprotein convertase subtilisin/kexin type 1 preproprotein; prohormone convertase		
3; proh			3; proh	3; prohormone convertase 1; neuroendocrine convertase 1; proprotein convertase	509	e-144
1 M. 10783 F·(CHI) NP 002603.1 pyruva			1 pyruva	1 pyruvate dehydrogenase kinase, isoenzyme 4	764	0
					562	1.00e-159
NP_002601.1	NP_002601.1	1	pyruva	pyruvate dehydrogenase kinase, isoenzyme i	556	1.00e-158
NP_002602.2 pyruva	\sim	\sim	pyruva	pyruvate dehydrogenase kinase, isoelitzyille z	554	1.00e-157
			pyruva	pyruvate dehydrogenase (lipoamide)) kiilase (LO 2::::::::::::::::::::::::::::::::::::	527	1.00e-149
382.1	382.1	382.1	pyruve	pyruvate dehydrogenase kinase, isoanzyme o		
II) Q16772	Q1 <i>677</i> 2		Glutath 	Glutathione S-transferase A5-5 (G5) class dipres		
-2.17,	-2.17,					
F:(C-D)	F:(C-D)				264	
			_	0.0000000000000000000000000000000000000	263	
338.2	338.2	338.2	_	glutathione 3-transierase Ao	261	1.00e-69
7-	1	1		glutathione stransferase A1; GST, class alpha, 1; glutathione S-alkyltransferase		
NF_002063.1 gludaii A1; glu	-	-		A1; glutathione S-aryltransferase A1; S-(hydroxyalkyl)glutathione lyase A1;	26.	1 008-69
Glutati			alutati	olutathione S-aralkyltransferase A1; GST-epsilon; glutathione S-transferase 2	3 8	1
Τ.	Τ.	Τ.	of rep	olinathione S-transferase A3	07	\perp
1.7			glutan	glutations transferase (FC 25.1.18) A2	259	_1
			ginie	glutatrilorie transferace (EC 2 5 1 18) alpha-2 (clone GTH2) - human	259	
٦,			gluta	glutatnione transferase (LO 2.3) Transferase A2)	259	9 5.00e-69
CAB92770.1 dJ152	_	_]	197152	Lr.3 (giulatillolle O-ugiporogo - /-	l	

			442977	Chain A, Glutathione S-Transferase A1-1 (E.C.2.5.1.18)	259	5.00e-69
			NP_000837.2	glutathione S-transferase A2; glutathione S-transferase 2; GST, class alpha, 2; liver		
			٠.	GST2; glutathione S-alkyltransferase A2; glutathione S-aryltransferase A2;		
				S-(hydroxyalkyl)glutathione lyase A2; glutathione S-aralkyltransferase A2;		:-
				GST-gamma; HA subunit 2	258	6.00e-69
			1127144	Chain A, Glutathione Transferase A1-1 Complexed With An Ethacrynic Acid		
				Glutathione Conjugate (Mutant R15k)	258	2.00e-68
			S20331	glutathione transferase (EC 2.5.1.18)	256	2.00e-68
			DAA00071.1	TPA: glutathione transferase A5	256	3.00e-68
			152381	glutathione transferase (EC 2.5.1.18)	254	9.00e-68
		,	XP_167100.2	similar to Glutathione S-transferase A1 (GTH1) (HA subunit 1) (GST-epsilon)		
				(GSTA1-1) (GST class-alpha)	253	3.00e-67
			A56801	glutathione transferase (EC 2.5.1.18) alpha y	252	5.00e-67
			S77958	glutathione transferase (EC 2.5.1.18) alpha-2 (clone GTH2 (+)) - human	248	7.00e-66
			NP_001503.1	glutathione S-transferase A4; glutathione S-alkyltransferase A4; glutathione		
				S-aryltransferase A4; S-(hydroxyalkyl)glutathione lyase A4; glutathione		
				S-aralkyltransferase A4; glutathione transferase A4-4; GST class-alpha; glutathione		
				S-transferase, alpha 4	244	1.00e-64
NM_011146	Mm.3020	F:(C-HI)	F:(C-HI) NP_056953.2	peroxisome proliferative activated receptor gamma, isoform 2; PPAR-gamma;		
NP_035276.1		-2.17		peroxisome proliferator activated receptor gamma	953	0
			BAA18949.1	PPAR gamma2	939	0
			S42489	peroxisome proliferator activated receptor - human	922	0
			CAA62152.1	peroxisome proliferator activated receptor gamma	916	0
			NP_005028.3	peroxisome proliferative activated receptor gamma, isoform 1; PPAR-gamma;		
				peroxisome proliferator activated receptor gamma	914	0
			BAA23354.1	ome proliferator activated-receptor gamma	904	0
			20150106	Chain A, Crystal Structure Of The Ligand Binding Domain Of Human Ppar-Gamma		
				In Complex With The Agonist Az 242	511	1.00e-144
NM_007395	Mm.5070	F:(C-HI)	NP_004293.1	activin A type IB receptor precursor; serine(threonine) protein kinase		
NP 031421.1		-2.16			931	0

			792000	Acyl-CoA desaturase (Stearovi-CoA desaturase) (Eatty acid desaturase)		
				(Dolfacatures)	Č	
				(Delia(9)-desalurase)	969	1.00e-170
			AAH05807.1	Unknown (protein for MGC:10264)	592	1.00e-169
			CAA73998.1	stearoyl CoA desaturase	589	1.00e-168
			AAF71040.1	PRO0998	579	1.00e-165
			AAH06288.1	Unknown (protein for MGC:10270)	422	1.00e-118
			I54779	stearoyl-CoA desaturase - human (fragment)	377	1.00e-104
			CAD38567.1	hypothetical protein	216	6.00e-56
NM_007824	Mm.57029	F:(C-HI)	P22680	Cytochrome P450 7A1 (Cholesterol 7-alpha-monooxygenase) (CYPVII)	<u> </u>	
NP_031850.1		-2.14,		(Cholesterol 7-alpha-hydroxylase)		
		F:(C-D)	٠			
		-3.09			865	0
			NP_000771.1	cytochrome P450, subfamily VIIA, polypeptide 1; cholesterol 7-alpha-hydroxylase;		
				cholesterol 7 alpha-monooxygenase	861	0
			AAC95426.1	oxysterol 7alpha-hydroxylase	342	8.00e-94
			NP_004811.1	cytochrome P450, subfamily VIIB, polypeptide 1; oxysterol 7alpha-hydroxylase	342	8.00e-94
			NP_004382.1	cytochrome P450, subfamily VIIIB, polypeptide 1; 7		-
				alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase; sterol 12-alpha-	298	2.00e-80
,			AAC63037.1	sterol 12-alpha hydroxylase CYP8B1	279	7.00e-75
			AAA61350.1	CYP7	259	9.00e-69
	Mm.19588 F:(C-HI)	F:(C-HI)	NP_056537.1	calcyon		
BAB22492.1		-2.14,				
		F:(C-D)				
		-2.15			336	5.00e-92
		F:(C-HI)				
AK002979	Mm.19588 F:(C-D)	E:(C-D)				
1.		-2.15	NP_056537.1	calcyon	336	5.00e-92
						_

activin A type IB receptor, isoform b precursor; serine(threonine) protein kinase activin type I recentor SKR2 solice form 2
activin A type IB receptor, isoform c precursor; serine(threonine) protein kinase
transforming growth factor, beta receptor I (activin A receptor type II-like kinase,
53kDa); transforming growth factor, beta receptor I (activin A receptor type II-like
Chain A, Cytoplasmic Domain Of Unphosphorylated Type I Tgf-Beta Receptor
bone morphogenetic protein receptor, type IB; serine/threonine receptor kinase
bone morphogenetic protein receptor, type IA precursor; activin A receptor, type
activin A type I receptor precursor; hydroxyalkyl-protein kinase; activin A receptor,
£
Serine/threonine-protein kinase receptor R3 precursor (SKR3) (Activin receptor-like
kinase 1) (ALK-1) (TGF-B superfamily receptor type I) (TSR-I)
activin A receptor type II-like 1; Activin A receptor, type II-like kinase 1
transforming growth factor beta receptor type IIB precursor
-
-

NW 011817	Mm 0653	F-(C-HI)	F-/C-HI) RA A 84543 1	nadd45-ralatad protein		
		-2.13			313	2.00e-85
Ų: 			NP_006696.1	growth arrest and DNA-damage-inducible, gamma; GADD45-gamma; gadd-related		
				protein, 17 kD	307	2.00e-83
			AAK00414.1	growth arrest and DNA damage inducible protein gamma	303	3.00e-82
NM_027000	Mm.41800 F:(C-HI)	F:(C-HI)	XP_040267.1	similar to Nucleolar GTP-binding protein 1 (Chronic renal failure gene protein)		
NP_081276.1		-2.13		(GTP-binding protein NGB)	966	0
			BAA91752	unnamed protein product	994	0
			NP_036473.1	G protein-binding protein CRFG; GTP-binding protein	991	0
			AAH33784.1	G protein-binding protein CRFG	982	0
			AAC24364.1	putative G-binding protein	828	0
NM_007815	Mm.20764 F:(C-HI)	F:(C-HI)	NP_000763.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18;		
NP_031841.1		-2.11,		cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17;		
		F:(C-D)		microsomal monooxygenase; flavoprotein-linked monooxygenase		
		-2.78			725	0
			P33260	Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)	723	0
			NP_000760.1	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19;		
				mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic		
				monooxygenase; flavoprotein-linked monooxygenase	711	0
			AAB23864.2	cytochrome P-450	710	
			BAA00123.1	cytochrome P-450	710	0
			NP_000762.2	cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC		
-				(mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase;		
				microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked		
				monooxygenase	710	0
			1506290A	cytochrome P450	902	0
			AAA52157.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	206	0
			P11713	Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase)		
				(P-450MP)	200	0
			F38462	S-mephenytoin 4'-hydroxylase (EC 1.14.14) cytochrome P450 2C19 - human	705	0

			152418	cytochrome P450 - human	9/9	5
			P10632	Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2)		
				(S-mephenytoin 4-hydroxylase)	999	0
			AAH20596.1	Unknown (protein for MGC:22146)	667	0
			61.2	cytochrome P450, subfamily IIC, polypeptide 8 isoform 1; mephenytoin		
			}	4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase;		
				flavoprotein-linked monooxygenase; P450 form 1	665	0
			AAA52160.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	664	0
			866382	cytochrome P450 2C8 - human	999	0
			AAB35292.1	cytochrome P450 arachidonic acid epoxygenase isoform, Cyp 2C8 [human, kidney,		
			•	Peptide Partial, 485 aal	664	0
		-	AAA52161.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	099	0
			A A A 52159 1	pytochrome P-450 S-mephenytoin 4-hydroxylase	598	1.00e-170
AK006487	Mm.27196 F:(C-HI) NP_6201	F:(C-H)	NP_620134.1			
BAB24612.1		-2.1			445	1.00e-125
NM 008587	Mm.4582	F:(C-HI) AAG331	AAG33129.1	MER receptor tyrosine kinase	1	
NP 032613.1		-2.1			1550)
			NP 006334.1	c-mer proto-oncogene tyrosine kinase	1548	0
			B41527	transforming protein (axl(-)) - human	.620	1.00e-177
			NP 001690.2	AXL receptor tyrosine kinase isoform 2; AXL transforming sequence/gene;		
				oncogene AXL	619	
			AAH32229.1	Unknown (protein for MGC:34202)	619	1.00e-177
			NP 068713.2	AXL receptor tyrosine kinase isoform 1; AXL transforming sequence/gene;		
			l	oncogene AXL	619	$\overline{}$
			P30530	Tyrosine-protein kinase receptor UFO precursor (AXL oncogene)	619	
			CAA40338.1	unnamed protein product	619	1.00e-176
			006418	Tyrosine-protein kinase receptor TYRO3 precursor (Tyrosine-protein kinase RSE)		
				(Tyrosine-protein kinase SKY) (Tyrosine-protein kinase DTK) (Protein-tyrosine		
				Kinase bvk)	601	1.00e-171

			NP 006284.1	TYRO3 protein tyrosine kinase; Brt; Dtk; Sky; Tif; Tyro3 protein tyrosine kinase		
BAA21781.1 protein-tyrosine kinase 505 138412				(sea-related receptor tyrosine kinase)	009	1.00e-171
138.1.2 receptor tyrosine kinase - human 415			BAA21781.1	protein-tyrosine kinase	595	1.00e-169
AAA1299251 Similar to TYRO3 protein tyrosine kinase AAH299251 Similar to TYRO3 protein tyrosine kinase AAH299251 Similar to TYRO3 protein tyrosine kinase AAH299251 TYRO3			T38412	receptor tyrosine kinase - human	502	1.00e-141
AAA5395.1 Similar to TYRO3 protein tyrosine kinase	1	+	A 56379	ZP3 receptor precursor - human	415	1.00e-118
CAA51396.1 TYRO3 Mm.8534 F:(C-Hi) P00333			A A H 29925 1	Similar to TYRO3 protein tyrosine kinase	417	1.00e-116
Mm. 8534 F.(C-HI) Protests Epidermal growth factor receptor precursor (Receptor protein-Lyrosine kinase 1.2.09, 1.2.09, 2.2.09, 2.2.09 ErbB-1) 1160 2.2.09 AAA52371.1 aberrant epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor (avian erythroblastic leukemia growth factor receptor (avian erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral oncogene homolog-like 4 1141 AAC50802.1 pidermal growth factor receptor precursor AAC50802.1 pidermal growth factor receptor precursor 7700 AAC50802.1 pidermal growth factor receptor precursor RP_001973.1 v-erb-a erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral oncogene homolog-like 4 7700 NP_001973.1 v-erb-b2 erythroblastic leukemia viral oncogene homolog-like 4 AA36223 kinase-related transforming protein (erbB3) (EC 2.7.1.) precursor - humain gene ERBB 3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB 3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB 3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB 3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4; v-erb-a erythroblastic leukemia viral oncogene homolog 4; v-erb-a eryt		 - 	CAA51396 1	TYBO3	364	1.00e-100
Fr(C-D)	$\neg \neg$	_) P00533	Epidermal growth factor receptor precursor (Receptor protein-tyrosine kinase		
F.(C-D) 2.69 AAA52371.1 aberrant epidermal growth factor receptor NP_005219.1 epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor AAG35786.1 p110 epidermal growth factor receptor AAG35780.1 truncated epidermal growth factor receptor AAG35780.1 truncated epidermal growth factor receptor AAC30802.1 EGF (1 is 2nd base in codon) NP_005226.1 v-erb-a erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4; avian erythroblastic leukemia viral oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 NP_001973.1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (ErbB3) Extracellular Domain 602				ErbB-1)		
AAA52371.1 aberrant epidermal growth factor receptor NP 005219.1 epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor AAG35786.1 p110 epidermal growth factor receptor AAG35780.1 truncated epidermal growth factor receptor CAA25282.1 EGF (1 is 2nd base in codon) AAC50802.1 epidermal growth factor receptor AAC50802.1 epidermal growth factor receptor AAC50802.1 epidermal growth factor receptor precursor NP 005226.1 v-erb-a erythroblastic leukemia viral oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 NP 001973.1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (suran) A36223 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human P21860 Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain (602)		F:(C-D)			1160	
aberrant epidermal growth factor receptor epidermal growth factor receptor (enythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor p110 epidermal growth factor receptor truncated epidermal growth factor receptor truncated epidermal growth factor receptor hemolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 leukemia viral oncogene homolog-like 4 leukemia viral oncogene homolog-like 4 leukemia viral oncogene homolog-like 4 leukemia viral oncogene homolog-like 4 leukemia viral oncogene homolog-like 3 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 kinase-related transforming protein (erbB3) Extracellular Domain cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain	_	-2.69			3 3	
1 epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor 1 p110 epidermal growth factor receptor 1 truncated epidermal growth factor receptor 1 truncated epidermal growth factor receptor 1 truncated epidermal growth factor receptor 1 epidermal growth factor receptor 1 epidermal growth factor receptor precursor 1 epidermal growth factor receptor progene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation 1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation 1 gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation 2 gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation 2 gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation 2 gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation 3 (avian); Transformation 3 (avian); Transformation 3 (avian); Transformation 3 (avian); Transformation 3 (avian); Transformation 4 (avianse-related transforming protein (erbB3) (EC 2.7.1) precursor - human 602 (avian); Transformation 603 (avian			AAA52371.1	aberrant epidermal growth factor receptor	1160	>T
homolog, avian); epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor 1 p110 epidermal growth factor receptor 1 truncated epidermal growth factor receptor 2 truncated epidermal growth factor receptor 2 epidermal growth factor receptor 3 epidermal growth factor receptor 2 epidermal growth factor receptor 2 epidermal growth factor receptor 3 epidermal growth factor receptor 3 epidermal growth factor receptor 4 epidermal growth factor receptor 3 epidermal growth factor receptor 3 epidermal growth factor receptor 4 epidermal growth factor receptor 4 epidermal growth factor receptor 6 epidermal growth factor receptor 6 epidermal growth factor receptor 6 epidermal growth factor receptor 6 epidermal growth factor receptor 6 epidermal growth factor 6 epidermal factor 6 epidermal growth factor 6 epidermal growth factor 6 epidermal factor 6 epidermal growth factor 6 epidermal factor 6 epidermal growth factor 6 epidermal factor 6 epidermal growth factor 6 epidermal factor 6 epidermal factor 6 epidermal growth factor 6 epidermal factor 6 epid			NP 005219.1	epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene		
viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor 1 p110 epidermal growth factor receptor 1 truncated epidermal growth factor receptor 1 truncated epidermal growth factor receptor 2 EGF (1 is 2nd base in codon) 3 epidermal growth factor receptor 4 epidermal growth factor receptor 5 epidermal growth factor receptor precursor 6 epidermal growth factor receptor precursor 7 epidermal growth factor receptor precursor 7 epidermal growth factor receptor precursor 8 leukemia viral (v-erb-b2) oncogene homolog 4; v-erb-a avian erythroblastic 8 leukemia viral (v-erb-b2) oncogene homolog 3 (avian); Transformation 8 leukemia viral oncogene homolog-like 4 8 leukemia viral oncogene homolog 3 (avian); Transformation 9 dene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 9 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human 9 Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type 9 ell surface receptor HER3) 9 Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain			1	homolog, avian); epidermal growth factor receptor (avian erythroblastic leukemia		
truncated epidermal growth factor receptor truncated epidermal growth factor receptor truncated epidermal growth factor receptor epidermal growth factor receptor epidermal growth factor receptor telefermal growth factor telefermal growth factor receptor telefermal growth factor teleferm				viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor	1157	0
truncated epidermal growth factor receptor EGF (1 is 2nd base in codon) epidermal growth factor receptor v-erb-a erythroblastic leukemia viral oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (ErbB3) Extracellular Domain			AAG35786.1	p110 epidermal growth factor receptor	1141	0
epidermal growth factor receptor epidermal growth factor receptor epidermal growth factor receptor epidermal growth factor receptor precursor v-erb-a erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain			AAG35790.1	truncated epidermal growth factor receptor	1141	0
epidermal growth factor receptor epidermal growth factor receptor precursor v-erb-a erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602	-		CAA25282.1	EGF (1 is 2nd base in codon)	942	0
epidermal growth factor receptor precursor v-erb-a erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602			1007208A	epidermal growth factor receptor	884	0
 v-erb-a erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human cell surface receptor HER3) cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 	-		AAC50802.1	epidermal growth factor receptor precursor	8	
leukemia viral (v-erb-b2) oncogene homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4 1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 Kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602	-		NP 005226.1	v-erb-a enythroblastic leukemia viral oncogene homolog 4; avian erythroblastic		
leukemia viral oncogene homolog-like 4 973.1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 Kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human 602 Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type 602 cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602			l ——	leukemia viral (v-erb-b2) oncogene homolog 4; v-erb-a avian erythroblastic		
973.1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602				leukemia viral oncogene homolog-like 4	4	
gene ERBB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 603 kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human 602 Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602	_		NP 001973.1		_	
kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human 602 Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602		-	l		4	
Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type 602 cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602			A36223	kinase-related transforming protein (erbB3) (EC 2.7.1) precursor - human	602	
cell surface receptor HER3) Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain 602			P21860	Receptor protein-tyrosine kinase erbB-3 precursor (c-erbB3) (Tyrosine kinase-type		
Chain A, Structure Of The Her3 (Erbb3) Extracellular Domain				cell surface receptor HER3)	602	
		-	22219397	Chain A. Structure Of The Her3 (Erbb3) Extracellular Domain	602	

			P04626	Receptor protein-tyrosine kinase erbB-2 precursor (p185erbB2) (NEU		
				proto-oncogene) (C-erbB-2) (Tyrosine kinase-type cell surface receptor HER2)		
				(MLN 19)	569	1.00e-162
			NP 004439.1	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma		
			!	derived oncogene homolog; Avian erythroblastic leukemia viral (v-erb-b2) oncogene	47	
				homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2		
				(neuro/glioblastoma derived oncogene homolog)	569	1.00e-162
			AAH02706.1	Similar to v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3	292	2.00e-78
			AAD56009.2	herstatin	283	9.00e-76
NM 010145	Mm.9075	F:(C-HI)	AAC41694.1	microsomal epoxide hydrolase		
NP_034275.1		-2.09,				
		F:(C-D)				
		-2.09			818	0
			NP 000111.1	epoxide hydrolase 1, microsomal (xenobiotic); Epoxide hydroxylase 1, microsomal		
				(xenobiotic)	818	0
			AAA52389.1	epoxide hydrolase	816	0
			CAA68486.1	precusor polypeptide (AA -20 to 435)	811	0
			AAA59580.1	microsomal epoxide hydrolase (EC 3.3.2.3).	585	1.00e-167
9L9600 MN	Mm.26787	F:(C-HI)	Mm.26787 F:(C-HI) BAB40305.1	aldeyde oxidase		
NP 033806.1		-2.08	·		2204	0
			006278	Aldehyde oxidase	2174	0
			NP 001150.2	aldehyde oxidase 1	2171	0
		 	P47989	Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase (XD);		
				Xanthine oxidase (XO) (Xanthine oxidoreductase)]	1262	0
			AAA75287.1	xanthine dehydrogenase	1261	0
			NP_000370.1	xanthene dehydrogenase; xanthine oxidase; xanthine dehydrogenase	1255	0
			XP 002472.7	similar to Xanthine dehydrogenase/oxidase	915	0
		_	XP_172060.1	XP_172060.1 similar to ALDEHYDE OXIDASE HOMOLOG-1~data source:SPTR, source		
			_	key:Q9ESH4, evidence:ISS~putative	838	0

NM_010012	Mm.20889	F:(C-HI)	NP_004382.1	Mm.20889 F:(C-HI) NP_004382.1 cytochrome P450, subfamily VIIIB, polypeptide 1; 7		
NP_034142.1		-2.08		alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase; sterol		
				12-alpha-hydroxylase	711	0
			AAC63037.1	sterol 12-alpha hydroxylase CYP8B1	629	0
			AAG31784.1	prostacyclin synthase	334	2.00e-91
			BAA28219.1	prostacyclin synthase	332	9.00e-91
			NP_000952.1	prostaglandin I2 (prostacyclin) synthase	332	9.00e-91
			1	prostacyclin synthase	332	9.00e-91
			AAG31785.1	prostacyclin synthase	330	4.00e-90
			AAG31783.1	prostacyclin synthase	328	1.00e-89
NM_011921	Mm.14609 F:(C-HI)	F:(C-HI)	AAC51652.1	aldehyde dehydrogenase 1		
NP_036051.1		-2.08			830	
			NP_000680.2	aldehyde dehydrogenase 1A1; aldehyde dehydrogenase 1, soluble; aldehyde		
				dehydrogenase, liver cytosolic; ALDH class 1; acetaldehyde dehydrogenase 1;		
				retinal dehydrogenase 1	830	0
			NP_003879.1	aldehyde dehydrogenase 1 family, member A2; retinaldehyde dehydrogenase 2	708	0
			094788	Aldehyde dehydrogenase 1A2 (Retinaldehyde-specific dehydrogenase type 2)		
				(RALDH(II)) (RALDH-2)	706	0
			NP_000684.1	aldehyde dehydrogenase 1A3; aldehyde dehydrogenase 6	682	O
			XP_007012.1	similar to Aldehyde dehydrogenase, mitochondrial precursor (ALDH class 2)		
				(ALDHI) (ALDH-E2)	· 657	0
			AAA51693.1	aldehyde dehydrogenase	656	0
	·		6137677	Chain A, Human Mitochondrial Aldehyde Dehydrogenase Complexed With Nad+		
				And Mn2+	654	0
			NP_000681.1	aldehyde dehydrogenase 2 family (mitochondrial); aldehyde dehydrogenase 2,		
				mitochondrial	652	0
			CAA68290.1	precursor polypeptide (AA -36 to 479)	649	0
				aldehyde dehydrogenase (NAD) (EC 1.2.1.3) 5 precursor, mitochondrial	645	0
			NP_000683.2	aldehyde dehydrogenase 1 family, member B1; aldehyde dehydrogenase 5	645	0
			CAD13246.1	1 bA113O24.2 (aldehyde dehydrogenase 1 family, member B1 (ALDH5 ALDHX))	645	0

			P30837	Aldehyde dehydrogenase X, mitochondrial precursor (ALDH class 2)	642	0
			BAA34786.1	RALDH2-T	635	0
			AAH30589.1	Similar to aldehyde dehydrogenase 1 family, member A2	. 622	1.00e-178
			139431	aldehyde dehydrogenase I - human (fragment).	604	1.00e-172
			AAB59500.1	aldehyde dehydrogenase 2 (EC 1.2.1.3)	543	1.00e-154
			NP_036322.2	formyltetrahydrofolate dehydrogenase isoform a	447	1.00e-125
			075891	10-formyltetrahydrofolate dehydrogenase (10-FTHFDH)	444	1.00e-124
			XP_090294.1	similar to 10-formyltetrahydrofolate dehydrogenase	431	1,00e-120
NM_018776	Mm.33962	F:(C-HI)	Mm.33962 F:(C-HI) AAD02422.1	cytokine receptor related protein 4		
NP_061246.1		-2.07,				
		F:(C-D)				
		-2.11			793	0.
			AAH23567.1	cytokine receptor-like factor 3	787	0
			NP_057070.1	cytokine receptor-like molecule 9	786	0
			XP_065910.1	similar to cytokine receptor-like molecule 9	293	1.00e-78
NM_007474	Mm.9970	F:(C-HI)	F:(C-HI) NP_001160.1	aquaporin 8		
NP_031500.1		-2.07			354	2.00e-97
			AAF19050.1	aquaporin 8	353	5.00e-97
NM_023737	Mm.28100	F:(C-HI)	Mm.28100 F:(C-HI) NP_001957.1	enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase		
NP 076226.1		-2.07			474	1.00e-133
			AAB19482.1	3-hydroxyacyl-CoA dehydrogenase; peroxisomal enoyl-CoA hydratase	366	1.00e-101
AK005535	Mm.29483	F:(C-HI)	Mm.29483 F:(C-HI) NP_570901.1	solute carrier family 39 (zinc transporter), member 4		
BAB24106.1		-2.06,	·			. ,
		F:(C-D)				
		-2.16	,		200	0
			NP_060237.1	solute carrier family 39 (zinc transporter), member 4	578	1.00e-172
NM_009864	Mm.35605 F:(C-HI)	F:(C-HI)	CAA79356.1	E-cadherin		
NP 033994.1		-2.05	,		1253	0

		NP 004351.1	NP 004351.1 cadherin 1, type 1 preproprotein; calcium-dependent adhesion protein, epithelial;		
			cadherin 1, E-cadherin (epithelial); uvomorulin; cell-CAM 120/80; Arc-1	1249	0
		BAA88957.1	E-cadherin	1238	0
		CAA84586:1	E-cadherin	1179	
		AAA61259.1	uvomorulin	1151	0
		BAA88956.1	E-cadherin	981	0
		P22223	Cadherin-3 precursor (Placental-cadherin) (P-cadherin)	749	0
		NP_001784.2	cadherin 3, type 1 preproprotein; P-cadherin; placental cadherin; cadherin 3,		
			P-cadherin (placental); calcium-dependent adhesion protein, placental	746	0
		P19022	Neural-cadherin precursor (N-cadherin) (Cadherin-2)	581	1.00e-165
		NP_001783.2	cadherin 2, type 1 preproprotein; N-cadherin 1; cadherin 2, N-cadherin (neuronal);		
			neural cadherin; calcium-dependent adhesion protein, neuronal	581	1.00e-165
		AAB22854.1	N-cadherin	581	1.00e-165
		IJHUCN	cadherin 2 precursor - human	219	1.00e-164
		AAH36470.1	cadherin 2, type 1, N-cadherin (neuronal)	574	1.00e-163
		NP_001785.2	cadherin 4, type 1 preproprotein; cadherin 4, R-cadherin (retinal); R-cadherin;		
			retinal cadherin	556	1.00e-158
		P55283	Cadherin-4 precursor (Retinal-cadherin) (R-cadherin) (R-CAD)	540	1.00e-153
4		AAA03236.1	N-cadherin	539	1.00e-152
		CAA40773.1	N-cadherin	526	1.00e-148
		BAC03677.1	unnamed protein product	523	1.00e-147
NM_023341 Mm.2833	Mm.28337 F:(C-HI) BAB91363	.1	chaperone-ABC1-like		
NP_075830.1	-2.05			702	0
		BAC11143.1	unnamed protein product	700	0
		NP_064632.1	chaperone, ABC1 activity of bc1 complex like	700	0
		AAH13114.2	Similar to RIKEN cDNA 0610012P18 gene	451	1.00e-150
		NP_079152.2	hypothetical protein FLJ12229	449	1,00e-125
		AAH27473.1	Unknown (protein for MGC:36739)	440	1.00e-123
		AAG17245.1	unknown	312	2.00e-84

AF071068 AAC75566 1	Mm.1290	6 F:(C-HI)	NP_000781.1	Mm.12906 F:(C-HI) NP_000781.1 dopa decarboxylase (aromatic L-amino acid decarboxylase)		
1.0000000		-2.04, F:(C-D)		decarboxylase decarboxylase); aromatic L-amino acid		
		-2.29			1	
			AAD40482.1	aromatic decarhoxylase	878	- 80
			P19113	Histidine decarboxylase (HDC)	876	9
			NP 002103.1	histidine description	525	5 1 Ma-140
NM_009263 NP_033289.1	Mm.321	F:(C-HI) -2.04	BAC1163.	unnamed protein product	525	
			P10451	Osteopontin precursor (Bone sialoprotein 1) (Urinary stone protein)	305	5 2.00e-82
			156986	phosphoprotein 1) (SPP-1) (Nephropontin) (Uropontin)	302	
			NP_000573.1	secreted phosphoprotein 1 (ostennartin home in the contraction of the	298	2.00e-80
				activation 1); Secreted phosphoprotein-1 (osteopontin hone cining the		<u>L</u> .
				OPN-b - human	276	8.00e-74
NM 053200	Mm 12000 F.10 1 m		\Box	OPN-c - human (fragment).	270	4.00e-72
	7		NP_036254.1	carboxylesterase 3; brain carboxylesterase BR3	248	2.00e-65
			BAB85656.1	brain carboxylesterson bb-o	1092	
		1	T.,	Unknown (protein for Moo occ.)	900	
		2	3	arboxylesterase 1 (monocuto)	806	
1	1			carboxylesterase; carboxylesterase 2 (liver)		
			650.1	carboxylesterase	902	0
1	1		I61085	carboxylesterase - human	904	
1	1	Ą	175.1	egasyn	903	0
		À	P23141	ver carboxylesterase precinsor (April	902	0
			3 8	(ACAT) (Monocyte/macrophage serine esterase) (HMSE) (Serine esterase 1)		
		¥	31.2	acyl coenzyme A:cholesterol acyltransferms	905	C
	1	A4	A48809 Ca	carboxylesterase - himan	897	7
						5

			157004	carboxvlesterase - human (fragment).	816	0
			147 1	serine esterase N-ferminal truncated (503 AA)	812	0
			$\neg \Box$	carboxylesterase	689	0
			BAA84995.1	brain carboxylesterase hBr1	672	0
AK007964	Mm.21754	F:(C-HI)	Mm.21754 F:(C-HI) AAH20819.1	cholinephosphotransferase 1		
BAB25375.1		-2.03,				
		F:(C-D) -2.36			604	0
			NP_064629.1	choline phosphotransferase 1; cholinephosphotransferase 1;	Š	
				cholinephosphotransferase 1 alpha	109	
			NP 006081.1	choline/ethanolaminephosphotransferase	451	1.00e-130
			AAI.39005.1	MSTP022	421	1.00e-117
			AAD44019.1	AAPT1-like protein	393	1.00e-109
			AAF87948.1	cholinephosphotransferase 1 beta	320	3.00e-98
			AAF61194.1	PRO1101	283	4.00e-80
NM 009748	Mm.23564 F:(C-HI)	F:(C-HI)	NP_005859.1	Golgi vesicular membrane trafficking protein p18; Bet1 (S. cerevisiae) homolog;		
NP_033878.1		-2.03,		Bet1p homolog		
		F:(C-D)				i d
		-2.15			194	4.00e-50
NM 019811	Mm.22719	F:(C-HI)	Mm.22719 F:(C-HI) NP_061147.1	acetyl-CoA synthetase isoform a; cytoplasmic acetyl-coenzyme A synthetase;		
NP 062785.1		-2.03,		acetate-CoA ligase; acyl-activating enzyme; acetate thiokinase; acetyl-CoA		
		F:(C-D)		synthetase		
		-2.11			1314	5
			AAH12172.1	Similar to acetyl-CoA synthetase	1312	0
			BAC03849.1	unnamed protein product	1302	0
			NP_644803.1	acetyl-CoA synthetase isoform b; cytoplasmic acetyl-coenzyme A synthetase;		
				acetate-CoA ligase; acyl-activating enzyme; acetate thiokinase; acetyl-CoA		
				synthetase	1137	0
			AAH10141.1	Unknown (protein for MGC:19474)	825	0

			BAB14127.1	unnamed protein product	824	0
			CAB61786.2	dJ18C9.1.1 (similar to acetyl-coenzyme A synthetase, isoform 1)	701	0
			CAB93422.4	dJ1161H23.1 (similar to acetyl-coenzyme A synthetase)	673	0
			CAC33037.2	dJ18C9.1.2 (similar to acetyl-coenzyme A synthetase, isoform 2)	525	0
			CAB75500.1	dJ568C11.3 (novel AMP-binding enzyme similar to acetyl-coenzyme A synthethase		
				(acetate-coA ligase))	421	1.00e-148
			XP_042770.2	similar to dJ568C11.3 (novel AMP-binding enzyme similar to acetyl-coenzyme A		-
			-	synthethase (acetate-coA ligase))	410	1.00e-117
			BAC03853.1	unnamed protein product	404	1.00e-112
			BAB47475.1	KIAA1846 protein	. 335	2.00e-91
			NP_078836.1	hypothetical protein FLJ21963	325	3.00e-88
			CAC33039.2	dJ18C9.1.3 (similar to acetyl-coenzyme A synthetase, isoform 3)	218	4.00e-56
NM_011834	Mm.35020	F:(C-HI)	Mm.35020 F:(C-HI) NP_057312.1	L-kynurenine/alpha-aminoadipate aminotransferase; kynurenine aminotransferase		
NP_035964.1		-2.03			669	0
			AAH31068.1	Similar to L-kynurenine/alpha-aminoadipate aminotransferase	661	0
NM_009221	Mm.17484	F:(C-HI)	Mm.17484 F:(C-HI) NP_000336.1	alpha-synuclein isoform NACP140; non A4 component of amyloid precursor		
NP_033247.1		-2.02			201	2.00e-51
			AAC02114.1	NACP/alpha-synuclein	197	3.00e-50
NM_011125	Mm.6105	F:(C-HI)	AAH19847.1	phospholipid transfer protein	_	
NP_035255.1		-2.01			744	0
			NP_006218.1	phospholipid transfer protein	744	0
			CAC36020.1	dJ337O18.1.2 (Phospholipid Transfer Protein (Lipid Transfer Protein II) (isoform 2))	634	0
			AAH05045.1	Similar to phospholipid transfer protein	633	0
NM_010062	Mm.41853 F:(C-HI)	F:(C-HI)	NP_001366.1	deoxyribonuclease II, lysosomal; DNase II, lysosomal		
NP_034192.1		-2.00,				-
		F:(C-D)				
		-2.4			520	1.00e-147
			T45071	hypothetical protein R31240_2 [imported]	494	1.00e-139

			NP_067056.1	NP_067056.1 deoxyribonuclease II beta, isoform 1 precursor; DNase II-like acid DNase;		
				endonuclease DLAD	227	5.00e-59
			AAL34449.1	endonuclease DLAD	227	5.00e-59
NM_007811 Mm	142230	Mm.42230 F:(C-HI)	NP_000774.2	cytochrome P450, subfamily XXVIA, polypeptide 1, isoform 1; P450, retinoic		
NP_031837.1		-17.03,	_	acid-inactivating, 1; retinoic acid-metabolizing cytochrome; retinoic acid		
-		F:(C-D)		4-hydroxylase		
	'	-3.81			901	0
			043174	Cytochrome P450 26 (Retinoic acid-metabolizing cytochrome) (P450RAI)		
				(hP450RAI) (Retinoic acid 4-hydroxylase)	968	0
			NP_476498.1	cytochrome P450, subfamily XXVIA, polypeptide 1, isoform 2; P450, retinoic		
				acid-inactivating, 1; retinoic acid-metabolizing cytochrome; retinoic acid		
				4-hydroxylase	813	
			NP_063938.1	NP_063938.1 cytochrome P450 retinoid metabolizing protein	391	e-108
NM_053215 Mm.	1.16036	:(C-HI)	NP_001068.1	UDP glycosyltransferase 2 family, polypeptide B17; UDP-glucuronyltransferase,		
NP_444445.1 2	<u> </u>	-1.98,		family 2, beta-17		
	<u></u>	F:(C-D)				:
		-3.23			728	
			XP_011097.5	similar to UDP-glucuronosyltransferase 2B15 precursor, microsomal (UDPGT)		
				(UDPGTH-3) (HLUG4)	715	0
		4 '.	NP_001067.1	UDP glycosyltransferase 2 family, polypeptide B15; UDP-glucuronyltransferase,		
				family 2, beta-15	715	0
			AAD55093.1	UDP-glucuronosyltransferase 2B15	712	0
		•	XP_050345.4	similar to UDP-glucuronosyltransferase 2B4 precursor, microsomal (UDPGT)		
			·	(Hyodeoxycholic acid) (HLUG25) (UDPGTH-1)	705	0
·			AAC95002.1	UDP-glucuronosyltransferase 2B4 precursor.	703	0
			JN0619	glucuronosyltransferase (EC 2.4.1.17) 2B-4 precursor - human	702	0
			AAC32272.1	UDP glucuronosyltransferase 2B4 precursor	269	0
	_		NP_001065.1	UDP glycosyltransferase 2 family, polypeptide B7; UDP-glucuronyltransferase,		
				family 2, beta-7	692	
	_		S11309	glucuronosyltransferase (EC 2.4.1.17) - human	691	0

			AAH30974.1	UDP glycosyltransferase 2 family, polypeptide B7	069	0
			NP_066962.1	UDP glycosyltransferase 2 family, polypeptide B4; UDP-glucuronyltransferase,		
				family 2, beta-4	688	0
			NP_001064.1	UDP glycosyltransferase 2 family, polypeptide B11	677	0
			JE0200	orphan UDP-glucuronosyltransferase (EC 2.4)	229	0
			NP_001066.1	UDP glycosyltransferase 2 family, polypeptide B10	099	0
			NP_444267.1	UDP glycosyltransferase 2 family, polypeptide B28	999	0
			NP_006789.1	UDP glycosyltransferase 2 family, polypeptide A1; UDP glucuronosyltransferase 2		
				family, polypeptide A1	579	1.00e-165
NM_022411			NP_003975.1	solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2;		
-		F:(C-D)-		sodium-coupled citrate transporter		
NP_071856.1 Mm.57258	Mm.57258	5.56			796	0
			AAN86530.1	Na+-coupled citrate transporter protein	531	1.00e-150
			AAF73251.1	sodium-dependent high-affinity dicarboxylate transporter	453	1.00e-127
			6LMM80	Solute carrier family 13, member 3 (Sodium-dependent high-affinity dicarboxylate		
				transporter 2) (Na(+)/dicarboxylate cotransporter 3) (NaDC-3) (hNaDC3).	. 450	1.00e-126
			AAH35966.1	similar to solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3	450	1.00e-126
			BAB71262.1	unnamed protein product	449	1.00e-126
			CAC18857.1	dJ257E24.2.1 (sodium-dependent high-affinity dicarboxylate transporter (NADC3,		
				SDCT2) (isoform 1))	448	1.00e-125
			NP_071889.2	solute carrier family 13 (sodium/sulfate symporters), member 1; solute carrier family 13		
				(sodium/sulphate symporters), member 1	429	1.00e-120
			BAB15477.1	unnamed protein product	427	1.00e-119
			BAC04834.1	unnamed protein product	409	1.00e-113
			AAH30689.1	similar to solute carrier family 13	387	1.00e-107
			Q9UKG4	Solute carrier family 13, member 4 (Na+/sulfate cotransporter SUT-1).	385	1.00e-106
			CAD34590.1	solutė carrier family 13 (sodium-dependent dicarboxylate transporter), member 2	226	7.00e-59

NM 018866				chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); B-cell-homing chemokine		
		F:(C-D)-		(ligand for Burkitt's lymphoma receptor-1);small inducible cytokine B subfamily		
NP_061354.1 Mm.10116 3.52	Mm.10116	3.52	NP_006410.1	(Cys-X-Cys motif), member 13 (B-cell chemoattractant)	97	3.00e-20
NM_009270						
		F:(C-D)-			_	
NP_033296.1	Mm.22663 3.44	3.44	AAD10823	squalene epoxidase	871	0
			NP_003120	squalene monooxygenase	857	0
			BAA11209	squalene epoxidase	589	1.00e-168
NM_017379			NP_061816.1	tubulin, alpha-like 2; tubulin, alpha 8		
		F:(C-D)-				
NP_059075.1 Mm.32884 3.1	Mm.32884	3.1			867	0
			NP_005992.1	tubulin, alpha 2 isoform 1	808	0
			AAC39578.1	alpha tubulin	908	0
			NP_116093.1	tubulin alpha 6	804	0
			NP_006000.2	tubulin, alpha 3; tubulin, alpha, brain-specific; hum-a-tub1; hum-a-tub2	804	0
			P05209	Tubulin alpha-1 chain (Alpha-tubulin 1).	804	0
			NP_005991:1	tubulin, alpha 1; testis-specific alpha tubulin; tubulin alpha-1 chain	800	0
			NP_006073.1	tubulin, alpha, ubiquitous	799	0
			CAA30026.1	alpha-tubulin	798	0
			CAA25855.1	alpha-tubulin	962	0
			XP_053177.4	similar to Tubulin alpha-3/alpha-7 chain (Alpha-tubulin 3/7)	793	0
			NP_524575.1	tubulin, alpha 2 isoform 2	723	0
			NP_079079.1	hypothetical protein FLJ21665	99	0
			XP_084610.2	similar to tubulin alpha-1 chain - Chinese hamster	616	1.00e-176
			AAA91575.1	alpha-tubulin	609	1.00e-174
			AAD33872.1	alpha-tubulin	591	1.00e-169
			AAH21564.1	Similar to tubulin alpha 2	427	1.00e-119
			AAH01805.1	Unknown (protein for IMAGE:3543670)	371	1.00e-102

LΩ

XP 212565.1	similar to tubulin, beta 5	347	3.00e-95
AAH20946.1	Beta 5-tubulin	346	4.00e-95
P04350	Tubulin beta-5 chain (Tubulin 5 beta).	344	1.00e-94
NP 115914.1	tubulin beta-5	344	1.00e-94
AAH03021.1	Unknown (protein for IMAGE:2823044)	344	2.00e-94
BAB14016.1	unnamed protein product	344	2.00e-94
AAH29529.1	tubulin, beta, 2	343	4.00e-94
NP 006079.1	tubulin, beta, 2	343	4.00e-94
P07437	Tubulin beta-1 chain	343	4.00e-94
NP 006078.2	tubulin, beta, 5	342	6.00e-94
Q13509	Tubulin beta-4 chain (Tubulin beta-III).	342	7.00e-94
AAH24038.1	Similar to tubulin, beta, 2	342	7.00e-94
NP 006077.1	tubulin, beta, 4	341	1.00e-93
NP_001060.1	tubulin, beta polypeptide	341	2.00e-93
T08726	tubulin beta chain - human	341	2.00e-93
AAN87335.1	class IVb beta tubulin	341	2.00e-93
AAN85571.1	class II beta tubulin isotype	340	2.00e-93
AAH01352.1	Tubulin, beta polypeptide paralog	340	3.00e-93
XP_047083.4	similar to tubulin beta	338	8.00e-93
AAL32434.1	beta-tubulin 4Q	337	2.00e-92
138369	beta-tubulin - human (fragment)	335	7.00e-92
NP_110400.1	beta tubulin 1, class VI	332	1.00e-90
0805287A	tubulin beta	330	3.00e-90
0808321A	tubulin beta	325	7.00e-89
AAH20171.1	Unknown (protein for MGC:1707)	325	7.00e-89
NP_079295.1	hypothetical protein FLJ13940	306	4.00e-87
AAH01678.1	Unknown (protein for IMAGE:2821278)	316	4.00e-86
798660	Tubulin beta-4q chain	315	1.00e-85
AAB48456.1	beta-tubulin	313	5.00e-85
XP_170637.2	.2 similar to beta-tubulin 4Q	268	1.00e-71

20

			AAH33064.1	. I TVBA6 motesin		
			AAB88188.1	_	265	5 1.00e-70
			AAH01896.1		259	
	+	_	XP_209082	2.1 similar to beta-tubulin 40	259	L
	1	_	XP_209955		257	\perp
	1	_	CAB43252.1	_	250	
	1	1	NP 057346.1	_	239	_
		_	AAH31101.	1 Epsilon-tubulin	212	
			88	1.1 Similar to tubulin, beta 5	211	\perp
			P23258	Tubulin gamma-1 chain (Gamma-1 tubulin) (Gamma talania	211	L
	+	_		(GCP-1).		
	1		21	1 hubulin, gamma 2	208	2.00e-53
		1	UBHUG	tubulin gamma chain - human	206	L
	1				205	
		F:(C-D)-				
		2.8				
AK005060		F:(C-HI)-	 -			
F29758	Mm.29125 2.6	2.6	AAH22526	Similar to aloning of the state of the		
			NP 112569	alanine-glyoxylate amnotransferase 2-like 1	020	
			NP 699204	hymothetical	000	5
				hypometical protein MGC45484	000	0
			ND 11410C	alanine-glyoxylate aminotransferase 2 precursor; beta-alanine-nymyate amino-	620	1.00e-177
			NE 114100	beta-ALAAT II	·	
			INF_110310	hypothetical protein MGC15875	273	7.00e-73
NM 021475					218	4.00e-56
		(4.5):3				
NP_067450.1	Mm.36742 2.74	T.(C-D)- 2.74	NP 055294			
			NP 068547	a disintegran protease; ADAM-like protein decysin 1	200	
			Т	distriction and inetalloproteinase domain 28 isoform 3 preproprotein	000	1.00e-168
			T	a distilicenti and metalloproteinase domain 28 isoform 1 premonentalia	915	9.00e-87
			11F V08348	a disintegrin and metalloproteinase domain 28 icaform 2	319	9.00e-87
				25 redutil 2 preproprotem	319	9.00P-87

				ADAM 7 precursor (A disintegrin and metalloproteinase domain 7) (Sperm		
			O9H2U9	maturation-related glycoprotein GP-83).	265	2.00e-70
			NP 001100	a disintegrin and metalloproteinase domain 8 precursor	226	1.00e-58
			A A M49575	disintegrin/metalloprotemase domain 9 short protein precursor	213	1.00e-54
			NP 003807	a disinteerin and metalloproteinase domain 9 preproprotein; meltrin gamma	213	1.00e-54
·				a disintegrin and metalloproteinase domain 33 isoform beta preproprotein; disintegrin and		
			NP 694882	reprolysin metalloproteinase family protein; metalloprotease disintegrin	196	9.00e-50
				a disintegrin and metalloproteinase domain 33 isoform alpha preproprotein; disintegrin and		
			NP 079496	reprolysin metalloproteinase family protein; metalloprotease disintegrin	196	9.00e-50
			AAM80482	a disintegrin and metalloprotease domain 33	196	9.00e-50
NM 007703						
l		F:(C-D)-				
NP 031729.1	Mm.21806 2.71	2.71	NP_689523	elongation of very long chain fatty acids like 3	38/	1.00e-107
1			A'AG17875	CIG30	320	3.00e-96
				ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2,		
			NP 076995	SUR4/Elo3-like, yeast); long-chain fatty-acyl elongase	234	2.00e-61
			BAC11225	unnamed protein product	232	1.00e-60
					_	
NM_013878		F:(C-D)-				
NP 038906.1	Mm.46268 2.63	2,63	NP 057450	calcium binding protein 2 isoform 1; CaBP2	359	
			NP 112481	calcium binding protein 2 isoform 2; CaBP2	286	2.00e-77
				calcium binding protein 1 isoform 1; calbrain; calcium binding protein 5; calcium binding		
			NP 112482	protein 1; calbrain	256	
			AAH15006	Similar to calcium binding protein 1 (calbrain)	253	3.00e-67
			AAH30201	Similar to calcium binding protein 1	234	1.00e-61
				calcium binding protein 1 isoform 2; calbrain; calcium binding protein 5; calcium binding		
			NP 004267	protein 1; calbrain	233	
			NP 062829	calcium binding protein 5	224	1.00e-58

					211	0 000 55
			AAH33167	Unknown (protein for MGC:45795)	717	7.005-00
			NP 660201	calcium binding protein 4	211	9.00e-55
NM 011087			NP_077294.1	leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains),		_
	Mm.19346 F:(C-D)-	F:(C-D)-		member 6; immunoglobulin-like transcript 8		
NP 035217.1	2	2.49			407	1.00e-113
$\overline{}$			AAC51892.1	immunoglobulin-like transcript 5 protein	400	1.00e-111
			AAC51902.1	immunoglobulin-like transcript 5	400	1.00e-111
			AAC51893.1	immunoglobulin-like transcript 5 protein	400	1.00e-111
			AAB88120.1	immunoglobulin-like transcript 5; ILT5	399	1.00e-110
			AAB87667.1	leucocyte immunoglobulin-like receptor-3; LIR-3	399	1.00e-110
			AAC51888.1	immunoglobulin-like transcript 5 protein	399	1.00e-110
			AAC51894.1	immunoglobulin-like transcript 5 protein	399	1.00e-110
			AAC51889.1	immunoglobulin-like transcript 5 protein	399	1.00e-110
			AAC51895.1	immunoglobulin-like transcript 5 protein	399	1.00e-110
			AAC51901.1	immunoglobulin-like transcript 5	397	1.00e-110
			NP_006855.1	leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains),		
				member 3; leukocyte immunoglobulin-like receptor 3	396	1.00e-109
			AAC51896.1	immunoglobulin-like transcript 5 protein	396	1.00e-109
			AAC51890.1	immunoglobulin-like transcript 5 protein	395	1.00e-109
			AAC51891.1	immunoglobulin-like transcript 5 protein	395	1.00e-109
			AAC51900.1	immunoglobulin-like transcript 5	394	1.00e-109
			AAC51897.1	immunoglobulin-like transcript 5 protein	394	1.00e-109
			AAC51887.1	immunoglobulin-like transcript 5 protein	393	1.00e-109
			AAD02203.1	immunoglobulin-like transcript 7; ILT7	393	1.00e-108
			AAL36993.1	immunoglobulin-like transcript-7	382	1.00e-105
			AAC51178.1	immunoglobulin-like transcript 1c	382	1.00e-105
			AAD50364.1	immunoglobulin-like transcript 1c	382	1.00e-105
			AAD17990.1	immunoglobulin-like transcript 1c variant 3	380	1.00e-105
			AAD50365.1	immunoglobulin-like transcript 1c	380	1.00e-105

 $\vec{\vdash}$

H

 $\tilde{\sim}$

\1 \1

AAD17991.1	immunoglobulin-like transcript 1 c variant 4	380	1.00e-105
AAC51176.1	immunoglobulin-like transcript la	376	1.00e-104
JC5897	killer cell inhibitory receptor p91 precursor	376	1.00e-104
NP_006854.1	leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1;		
	leukocyte immunoglobulin-like receptor 6	375	1.00e-103
NP_006857.1	leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2;		
	leukocyte immunoglobulin-like receptor 7	375	1.00e-103
NP_006831.1	leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains),		
	member 5	371	1.00e-102
AAM18038.1	leucocyte immunoglobulin-like receptor	359	2.00e-98
AAM18036.1	leucocyte immunoglobulin-like receptor	358	2.00e-98
AAC51885.1	immunoglobulin-like transcript 6	358	3.00e-98
AAB68666.1	monocyte inhibitory receptor precursor	358	3.00e-98
AAM18040.1	leucocyte immunoglobulin-like receptor .	357	8.00e-98
AAM18041.1	leucocyte immunoglobulin-like receptor	357	8.00e-98
AAM18035.1	leucocyte immunoglobulin-like receptor	356	1.00e-97
AAM18037.1	leucocyte immunoglobulin-like receptor	356	1.00e-97
AAH28208.1	leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3	356	1.00e-97
AAB87661.1	leucocyte immunoglobulin-like receptor-4; LIR-4	355	3.00e-97
AAB68667.1	monocyte inhibitory receptor precursor	353	7.00e-97
AAH36827.1	Unknown (protein for MGC:46153)	352	1.00e-96
NP_005865.1	leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains),		
	member 2; leukocyte immunoglobulin-like receptor 2	352	1.00e-96
AAL36990.1	leukocyte immunoglobulin-like receptor-2	352	1.00e-96
AAC51883.1	immunoglobulin-like transcript 4	352	1.00e-96
AAC51880.1	immunoglobulin-like transcript 2b	351	4.00e-96
 AAL36991.1	leukocyte immunoglobulin-like receptor-2	350	6.00e-96
AAB88119.1	immunoglobulin-like transcript 4; ILT4	350	7.00e-96
AAB67711.1	MIR-10	350	7.00e-96

		NP 006660.1	1.1 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains),		
_	····	l 	member 1; leukocyte immunoglobulin-like receptor 1; CD85 autigen	349	1.00e-95
		AAC51879.1	immunoglobulin-like transcript 2a	345	2.00e-94
		AAG08984.1	leukocyte immunoglobulin-like receptor 1	345	2.00e-94
		AAB63522.1	leucocyte immunoglobulin-like receptor-1	345	2.00e-94
		AAC51881.1	immunoglobulin-like transcript 2c	345	2.00e-94
		AAL36989.1	leukocyte immunoglobulin-like receptor-1	345	2.00e-94
		AAB67710.1	MIR-7	345	2.00e-94
		AAL36988.1	leukocyte immunoglobulin-like receptor-1	345	2.00e-94
		XP_115639.1	similar to leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM		
	•		domains), member 6; immunoglobulin-like transcript 8	271	6.00e-72
		NP_077293.1	1.1 leukocyte immunoglobulin-like receptor, subfamily A, member 5; immunoglobulin-like		
			transcript 10	260	8.00e-69
		AAC99762.1	immunoglobulin-like transcript 10 protein	258	5.00e-68
		BAC03380.1	FLJ00275 protein	241	4.00e-63
		BAB71361.1	unnamed protein product	241	6.00e-63
		AAC51886.1	immunoglobulin-like transcript 6a	218	6.00e-56
NM_010849					.`
	F:(C-D)-				
NP_034979.2 Mm.2444	14 2.45	BAA01374	p67 myc protein	593	1.00e-169
			v-myc myelocytomatosis viral oncogene homolog; Avian myelocytomatosis viral (v-myc)		
,		NP_002458	oncogene homolog; C-MYC; v-myc avian myelocytomatosis viral oncogene homolog	586	1.00e-167
		1001205A	с-тус депе	566	1.00e-161
		AAA88095	truncated c-myc-P64 protein	336	7.00e-92
		CAA25288	exon 2	335	1.00e-91
	•	AAA59884	c-myc protein	283	9.00e-76
		AAA88092	c-myc-P64 protein	275	2.00e-73

 $\ddot{}$

ä

0 20.

 α

-	410	Carrier 1	מכטבטט מדא	1		
. :-	415	formyl peptide receptor-like 2	NP_002021			
115	419	N-formyl peptide receptor-like 2 protein	AAA52474	·	İ	
12	501	FMLP-related receptor II	AAA58481			
18	502	formyl peptide receptor-like 1; lipoxin A4 receptor (formyl peptide receptor related)	NP_001453		Mm.57142	NP_032065.1
				F:(C-D)-		650800 WN
t	-					
198	15	unnamed protein product	BAC04385.1			
126	426	hydroxylase 3, Tyr	1306389C			
426	42	tyrosine hydroxylase (AA 1-524)	CAA68472.1			
18	426	Tyrosine 3-monooxygenase (Tyrosine 3-hydroxylase) (TH).	P07101			
19	426	tyrosine hydroxylase	NP_000351.1			
19	426	hydroxylase 2,Тут	1306389В			
13	427	Bound 7,8-Dihydro-L-Biopterin.				
		Chain A, Crystal Structure Of Double Truncated Human Phenylalanine Hydroxylase With	1DMWA			
Ţζ	429	Human Phenylalanine Hydroxylase Dimer, Residues 117 - 424.	HAMI			
្រុ	432	Chain A, Catalytic Domain Of Human Phenylalanine Hydroxylase Fe(Ii).	1J8TA			
18	436	Chain A, Tetrameric Human Phenylalanine Hydroxylase	2PAHA	*		
18	489	phenylalanine hydroxylase	AAH26251.1			
١ŏ	490	phenylalanine hydroxylase	AAL78816.1			
۳	491	_	NP 000268.1			
10	606	7,8-Dihydro-L-Biopterin Cofactor And Fe(Iii).	`			
		Chain A, Crystal Structure Of Human Tryptophan Hydroxylase With Bound	1MLWA		-	
ĭ	662	neuronal tryptophan hydroxylase	AAM28946.1			
/ 2	812	tryptophan hydroxylase	AAA67050.1			
Ü	62.5	Tryptophan 5-hydroxylase 1 (Tryptophan 5-monooxygenase 1).	P17752			-
٦ [02/			2.42	Mm.4421	NP_033440.1
1		(tryptophan 5-monooxygenase)		F:(C-D)-		
		Typtopnan nydroxytase i (tryptopitati J-tilonooxygetitase); tryptopitati J-tilonooxygetitase);	NP_004170.1			NM_009414

									NP_031890.1		NM_007864						NP_075631.1	NM_023142	7000								
									Mm.27256								Mm.30010 2.39										
									2.38	F:(C-D)-	- •						2.39	F:(C-D)-									
AAB84250	BAA86546	AAB07736	NP_066943	NP_001355	NP_004078	Q12959.		AAD56173	NP_001356			Q92747	AAH39594	NP_006400		AAH47889	NP_005711			Q99788		NP_004063	AAC51258	AAA36362	A42009	P21462	
Tax interaction protein 15	KIAA 1232 protein	PSD-95	discs, large, homolog 3; neuroendocrinė-dlg	discs, large homolog 2, chapsyn-110; chapsyn-110	discs, large (Drosophila) homolog 1	(hDlg).	Presynaptic protein SAP97 (Synapse-associated protein 97) (Discs, large homolog 1)	post-synaptic density 95	discs, large (Drosophila) homolog 4			Actin-related protein 2/3 complex subunit 1A (SOP2-like protein).	actin related protein 2/3 complex, subunit 1A, 41kDa	pombe sop2-like); SOP2-like protein	actin related protein 2/3 complex subunit 1A; actin binding protein (Schizosaccharomyces	actin related protein 2/3 complex, subunit 1A,	related protein 2/3 complex, subunit 1A (41 kD)	actin related protein 2/3 complex subunit 1B; ARP2/3 protein complex subunit p41; actin		ChemR23).	Chemokine receptor-like 1 (G-protein coupled receptor DEZ) (G protein-coupled receptor	chemokine-like receptor 1	orphan G-protein coupled receptor Dez isoform a	N-formylpeptide receptor fMLP-R98	N-formyl peptide receptor	(N-formylpeptide chemoattractant receptor).	fMet-Leu-Phe receptor (fMLP receptor) (N-formyl peptide receptor)(FPR)
514	590	625	956	965	1049	1057		1427	1427			539	543	543		543	734			201		201	201	404	406	407	
1.00e-145	1.00e-168	1.00e-179	0	0	0	0		0	0			1.00e-153	1.00e-154	Г		1.00e-154	0			2.00e-51		2.00e-51	2.00e-51	1.00e-113	1.00e-113		

		tyrosylprotein kinase; hydroxyaryl-protein kinase				
		factor receptor 1; N-sam tyrosine kinase; FLG protein; protein-tyrosine kinase;		-	•	
		heparin-binding growth factor receptor; FMS-like tyrosine kinase 2; basic fibroblast growth				
	1462	fibroblast growth factor receptor 1 isoform 9 precursor; fms-related tyrosine kinase-2;	NP_075599.1	·		
		syndrome)				
	1550	similar to fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer	AAH18128.1			
	1553	FGF receptor-1 precursor	AAA35835.1			
		syndrome)				
0	1553	similar to fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer	AAH15035.1			
		tyrosylprotein kinase; hydroxyaryl-protein kinase				
		factor receptor 1; N-sam tyrosine kinase; FLG protein; protein-tyrosine kinase;				
		heparin-binding growth factor receptor; FMS-like tyrosine kinase 2; basic fibroblast growth		_		:
	1555	fibroblast growth factor receptor 1 isoform 2 precursor; fms-related tyrosine kinase-2;	NP_056934.2		·	
	1560	heparin-binding growth factor receptor	AAA35958.1			
	1561	precursor polypeptide (AA -21 to 801)	CAA36101.1			
		tyrosylprotein kinase; hydroxyaryl-protein kinase	-	2.35	Mm.3157	NP 034336.1
		factor receptor 1; N-sam tyrosine kinase; FLG protein; protein-tyrosine kinase;		F:(C-D)-		
		heparin-binding growth factor receptor; FMS-like tyrosine kinase 2; basic fibroblast growth				NM_010206
	1562	fibroblast growth factor receptor 1 isoform 1 precursor; fins-related tyrosine kinase-2;	NP_000595.1	•		
4.00e-6	234	encephalopsin splice variant 1-2-5-6	AAO15717			
1.00e-155	547	opsin 3 (encephalopsin, panopsin); opsin 3 (encephalopsin)	NP_055137			
1.00e-139) M	Opsin 3 (Encephalopsin) (Panopsin).	Q9H1Y3	2.36	Mm.32744	NP 034228.1 Mm.32744 2.36
	. · }			F:(C-D)-		
						NM_010098
	L					
5.00e-95	34/	hypothetical protein	CAD38582			
200	֭֡֝֝֝֟֜֜֝֜֜֜֜֜֓֓֓֓֜֜֜֜֓֓֓֓֓֜֜֜֜֜֓֓֓֓֓֜֜֜֓֓֓֓֡֓֜֜֜֓֓֡֓֜֡֓֜					

J	L		
J	Ĺ,	,	

		<u> </u>	<u> </u>			_			_		_	_				_	_	1	- 1	_	_	_	7				7
•																				•							
												·												-			
		NP_075258.1				NP_075261.1				NP_075597.1	AAK94205.1	C40862				NP_000132.1	CAA68679.1	AAA75007.1	AAA35837.1				NP_075594.1			,	NP_075593.1
kinase	K-sam protein; protein tyrosine kinase, receptor like 14; For receptor, bacteria-expressed	fibroblast growth factor receptor 2 isoform 2 precursor; keratinocyte growth factor receptor;	kinase	kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase; hydroxyaryl-protein	K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed	fibroblast growth factor receptor 2 isoform 5 precursor; keratinocyte growth factor receptor;	tyrosylprotein kinase; hydroxyaryl-protein kinase	factor receptor 1; N-sam tyrosine kinase; FLG protein; protein-tyrosine kinase;	heparin-binding growth factor receptor; FMS-like tyrosine kinase 2; basic fibroblast growth	fibroblast growth factor receptor 1 isoform 7 precursor; fins-related tyrosine kinase-2;	keratinocyte growth factor receptor 2 isoform BEK	heparin-binding growth factor receptor variant alpha-a2	kinase	kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase; hydroxyaryl-protein	K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed	fibroblast growth factor receptor 2 isoform 1 precursor; keratinocyte growth factor receptor;	tyrosine kinase	basic fibroblast growth factor receptor protein	fibroblast growth factor receptor (FGFI) transmembrane form	tyrosylprotein kinase; hydroxyaryl-protein kinase	factor receptor 1; N-sam tyrosine kinase; FLG protein; protein-tyrosine kinase;	heparin-binding growth factor receptor; FMS-like tyrosine kinase 2; basic fibroblast growth	fibroblast growth factor receptor 1 isoform 4 precursor; fins-related tyrosine kinase-2;	tyrosylprotein kinase; hydroxyaryl-protein kinase	factor receptor 1; N-sam tyrosine kinase; FLG protein; protein-tyrosine kinase;	heparin-binding growth factor receptor, FMS-like tyrosine kinase 2; basic fibroblast growth	fibroblast growth factor receptor 1 isoform 3 precursor; fins-related tyrosine kinase-2;
		1101				1135				1140	1141	1142				1147	1221	1347	1349				1350				1357
		0				0				0	0					0	C	٥	و				c				0

l		J	
۱	٥	כ	

m KGFR 10 precursor; keratinocyte growth factor 1094 110 precursor; keratinocyte growth factor 1090 111 precursor; keratinocyte growth factor 11 (bacteria-expressed kinase, keratinocyte 13 precursor; keratinocyte growth factor receptor; 14; FGF receptor; bacteria-expressed 15; tyrosylprotein kinase; hydroxyaryl-protein 166 17 precursor; keratinocyte growth factor receptor; 173 18 precursor; keratinocyte growth factor receptor; 18 precursor; keratinocyte growth factor receptor; 18 precursor; keratinocyte growth factor receptor; 1035 1036 1037 1038 1038 1038 1039 1039 1039 1031 1031 1031 1032 1033 1035 1035 1035 1035 1035 1035	kinase			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; kpressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, ceratinocyte growth factor receptor; FGF receptor; bacteria-expressed otein kinase; hydroxyaryl-protein keratinocyte growth factor like 14; FGF receptor; tor BEK; tyrosylprotein kinase; cratinocyte growth factor receptor; eratinocyte growth factor receptor; fGF receptor; bacteria-expressed	kinase; fibroblast growth factor receptor BEK; tyrosýlprotein kinase; hydroxyaryl-protein			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; kpressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, ceratinocyte growth factor receptor; FGF receptor; bacteria-expressed stein kinase; hydroxyaryl-protein keratinocyte growth factor like 14; FGF receptor; tor BEK; tyrosylprotein kinase; eratinocyte growth factor receptor;	K-sam protein; protein tyrosine kinase, receptor like 14; FGI			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; spressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, ceratinocyte growth factor receptor; FGF receptor; bacteria-expressed otein kinase; hydroxyaryl-protein skeratinocyte growth factor like 14; FGF receptor; like 14; FGF receptor;	fibroblast growth factor receptor 2 isoform 8 precursor; keratinocyte growth factor receptor;	NP_075264.2		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; kpressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, ceratinocyte growth factor receptor; FGF receptor; bacteria-expressed stein kinase; hydroxyaryl-protein keratinocyte growth factor like 14; FGF receptor;	hydroxyaryl-protein kinase			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; xpressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, ceratinocyte growth factor receptor; FGF receptor; bacteria-expressed stein kinase; hydroxyaryl-protein keratinocyte growth factor like 14; FGF receptor;	bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase;		-	
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; pressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, reratinocyte growth factor receptor; FGF receptor; bacteria-expressed otein kinase; hydroxyaryl-protein seratinocyte growth factor	receptor; K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor;	_		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; expressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, ceratinocyte growth factor receptor; FGF receptor; bacteria-expressed stein kinase; hydroxyaryl-protein	fibroblast growth factor receptor 2 isoform 12 precursor;	NP_075419.1		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; kpressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, ceratinocyte growth factor receptor; FGF receptor; bacteria-expressed otein kinase; hydroxyaryl-protein	keratinocyte growth factor receptor 2 isoform K-sam-IIC3	AAK94208.1		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; xpressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, reratinocyte growth factor receptor; FGF receptor; bacteria-expressed tein kinase; hydroxyaryl-protein	kinase			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; tor BEK; tyrosylprotein kinase; spressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, reratinocyte growth factor receptor; FGF receptor; bacteria-expressed	kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase; hydroxyaryl-protein			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; xpressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome, ceratinocyte growth factor receptor;	K-sam protein; protein tyrosine kinase, receptor like 14; FGI	_		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; kpressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome,	fibroblast growth factor receptor 2 isoform 6 precursor,	NP_075262.1		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; expressed kinase, keratinocyte n Syndrome, Pfeiffer syndrome,	Jackson-Weiss syndrome)			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; kpressed kinase, keratinocyte	growth factor receptor, craniofacial dysostosis 1, Crouzon Syndrome, Pfeiffer syndrome,			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase;	Similar to fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte	AAH39243.1		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase;	hydroxyaryl-protein kinase			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor r like 14; FGF receptor;	bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase;	_		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase; keratinocyte growth factor	receptor; K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor;			
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase;	fibroblast growth factor receptor 2 isoform 11 precursor.	NP_075418.1		
keratinocyte growth factor r like 14; FGF receptor; tor BEK; tyrosylprotein kinase;	hydroxyaryl-protein kinase			
keratinocyte growth factor r like 14; FGF receptor;	bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase;			
keratinocyte growth factor	receptor; K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor;			
	NP_075417.1 fibroblast growth factor receptor 2 isoform 10 precursor; ker	NP_075417.1		
	keratinocyte growth factor receptor 2 isoform KGFR	AAK94206.1		
	keratinocyte growth factor receptor 2 isoform K-sam-IIC2	AAK94209.1		
or 1098	keratinocyte growth factor receptor precursor	A41794		

			1000	
	NP_075420.1	fibroblast growth factor receptor 2 isotorm 13 precursor; keratmocyte growth factor	1032	>
 ·		receptor; K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor;		
 		bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase;		
		hydroxyaryl-protein kinase	_	
	BAA89300.1	K-sam-IIO2	1029	0
	NP_075263.1	fibroblast growth factor receptor 2 isoform 7 precursor; keratinocyte growth factor receptor;	1026	0
		K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed		
		kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase; hydroxyaryl-protein		
		kinase		
	BAA89296.1	K-sam-IIH1	1026	Ó
	BAA89297.1	K-sam-IIH2	1024	0
	BAA89301.1	K-sam-IIO3	1023	0
	BAA89299.1	K-sam-IIO1	1023	0
	BAA89298.1	K-sam-IIH3	1023	0
	NP_000133.1	fibroblast growth factor receptor 3 isoform 1 precursor; hydroxyaryl-protein kinase;	696	0
		tyrosine kinase JTK4		
	AAM22078.1	fibroblast growth factor receptor 3	696	0
-	Q01742	Fibroblast growth factor receptor BFR-2 precursor	196	0
	AAA58470.1	growth factor receptor	964	0
	TVHU2F	fibroblast growth factor receptor flg-2 precursor	963	0
	A35969	heparin-binding growth factor receptor K-sam precursor	953	0
	AAM22079.1	fibroblast growth factor receptor 3	806	0
	AAD31561.1	fibroblast growth factor receptor 2 isoform IgIIc isoform	905	0
	AAD31560.1	fibroblast growth receptor 2 IgIIIb isoform	828	0
	P22455	Fibroblast growth factor receptor 4 precursor (FGFR-4).	844	0
	CAA74200.1	fibroblast growth factor 4	843	0
	NP_002002.2	fibroblast growth factor receptor 4 isoform 1 precursor; tyrosine kinase related to fibroblast	843	0
		growth factor receptor; tyrosylprotein kinase; protein-tyrosine kinase; hydroxyaryl-protein		
		kinase		
	TVHUF4	fibroblast growth factor receptor 4 precursor	840	0

7

-1

 $\tilde{\alpha}$

		ND 075252 1	ND 075252 1 febroblast growth factor recentor 4 isoform 2 precursor; tyrosine kinase related to fibroblast	817	0
		1.767610-141	ingrocusts grown frameworks brings, profein-tyrosine kinase; hydroxyaryl-profein		
			growth factor receptor, tyrosytprotein annact, protein tyrosing annact of the contract of the		
,			Kinase	916	
		AAF27432.1	fibroblast growth factor receptor 4, soluble-torm splice variant	010	
		BAC45037.1	isoform of FGFR2	/0/	5 6
		AAK51435.1	fibroblast growth factor receptor 4 variant	738	
		NP 075259.1	fibroblast growth factor receptor 2 isoform 3 precursor; keratinocyte growth factor receptor;	687	o
			K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed		
			kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase; hydroxyaryl-protein		
			kinase		
		1FGKA	Chain A, Crystal Structure Of The Tyrosine Kinase Domain Of Fibroblast Growth Factor	628	628 e-179
		_	Receptor 1		
		NP_075254.1	fibroblast growth factor receptor 3 isoform 2 precursor; hydroxyaryl-protein kinase;	620	620 e-177
			tyrosine kinase JTK4		
		1GJOA	Chain A, The Fgft2 Tyrosine Kinase Domain	579	e-165
		AAB31749.1	fibroblast growth factor receptor subtype 1, FGFR1 {extracellular binding domain	472	472 e-132
			D(II)-D(III)} [human, A159 endometrial carcinoma cells, Peptide Partial, 279 aa].		
		1EVTC	Chain C, Crystal Structure Of Fgf1 In Complex With The Extracellular Ligand Binding	463	e-130
			Domain Of Fgf Receptor 1 (Fgfr1).		
		1CVSC	Chain C, Crystal Structure Of A Dimeric Fgf2-Fgfr1 Complex	461	e-129
		NP_075265.1	fibroblast growth factor receptor 2 isoform 9 precursor; keratinocyte growth factor receptor;	375	e-103
			K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed	-	
	_		kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase; hydroxyaryl-protein		
	_		kinase		
		NP_075595.1	fibroblast growth factor receptor 1 isoform 5 precursor; fins-related tyrosine kinase-2;	365	e-100
•		l	heparin-binding growth factor receptor; FMS-like tyrosine kinase 2; basic fibroblast growth	_	
			factor receptor 1; N-sam tyrosine kinase; FLG protein; protein-tyrosine kinase;		
			tyrosylprotein kinase; hydroxyaryl-protein kinase		
		1EV2E	Chain E, Crystal Structure Of Fgf2 In Complex With The Extracellular Ligand Binding	359	9.00e-99
-			Domain Of Fgf Receptor 2 (Fgfr2).		

		1E00B	Chain B, Crystal Structure Of A Ternary Fgf1-Fgft2-Heparin Complex.	359	9.00e-99
		NP_075596.1	NP_075596.1 fibroblast growth factor receptor 1 isoform 6 precursor; fins-related tyrosine kinase-2;	359	1.00e-98
			repaint building grown factor receptor, i modified through a mass 2, dasic motoriast grown factor receptor 1; N-sam tyrosine kinase; FLG protein; protein-tyrosine kinase;		
			tyrosylprotein kinase; hydroxyaryl-protein kinase		
		1II4E	Chain E, Crystal Structure Of Ser252trp Apert Mutant Fgf Receptor 2 (Fgfr2) In Complex	357	6.00e-98
			With Fgf2		
		1IILE	Chain E, Crystal Structure Of Pro253arg Apert Mutant Fgf Receptor 2 (Fgft2) In Complex	356	9.00e-98
			With Fgf2.		
		1DJSA	Chain A, Ligand-Binding Portion Of Fibroblast Growth Factor Receptor 2 In Complex	354	4.00e-97
			With Fgf1		
		AAC16450.1	vascular endothelial growth factor receptor 2	328	2.00e-89
	 	NP_002244.1	kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain	328	2.00e-89
			receptor		
		CAA43837.1	membrane protein	328	3.00e-89
		JC1402	protein-tyrosine kinase (EC 2.7.1.112) KDR	328	3.00e-89
		I38153	gene retII protein - human	327	6.00e-89
		CAA31408.1	ret tyrosine kinase (AA 1 - 860)	326	1.00e-88
		NP_065681.1	ret proto-oncogene isoform c; RET transforming sequence; hydroxyaryl-protein kinase;	326	1.00e-88
			cadherin family member 12; oncogene RET		
		AAH04257.1	ret proto-oncogene (multiple endocrine neoplasia MEN2A, MEN2B and medullary thyroid	326	1.00e-88
_			carcinoma 1, Hirschsprung disease)		
		NP_065680.1	ret proto-oncogene isoform b; RET transforming sequence; hydroxyaryl-protein kinase;	326	1.00e-88
			cadherin family member 12; oncogene RET		
		NP_066124.1	ret proto-oncogene isoform a; RET transforming sequence; hydroxyaryl-protein kinase;	326	1.00e-88
			cadherin family member 12; oncogene RET		
		AAA36786.1	tyrosine kinase	325	1.00e-88
		AAA60266.1	RET tyrosine kinase/cAMP protein kinase A subunit RI	324	4.00e-88
		1VR2A	Chain A, Human Vascular Endothelial Growth Factor Receptor 2 (Kdr) Kinase Domain.	323	5.00e-88
		JN0291	protein-tyrosine kinase (EC 2.7.1.112) (clone lambda-ret-5)	323	5.00e-88

		000014	11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	202	5 00e-88
		JN0290	protein-tyrosine kinase (EC 2.7.1.112) (clone latinoda-ret-1)	720	2.005-00
		B34735	protein-tyrosine kinase (EC 2.7.1.112) (ret) - human (fragment).	323	7.00e-88
		AAA36524.1	papillary thyroid carcinoma-encoded protein	323	7.00e-88
		NP_002010.1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability	323	9.00e-88
			factor receptor)		
		CAB46483.1	RET tyrosine kinase receptor	322	2.00e-87
		AAC16449.1	vascular endothelial growth factor receptor	322	2.00e-87
		INUNB	Chain B, Crystal Structure Analysis Of The Fgf10-Fgft2b Complex	310	5.00e-84
		AAG17219.1	unknown	248	3.00e-65
		NP_005415.1	tyrosine kinase with immunoglobulin and epidermal growth factor homology domains;	248	3.00e-65
			Tyrosine kinase with immunoglobulin and epidermal growth factor		
ţ		S24066	protein-tyrosine kinase (EC 2.7.1.112), receptor type tie precursor	244	3.00e-64
		1FVRA	Chain A, Tie2 Kinase Domain	242	2.00e-63
		NP_000450.1	TEK tyrosine kinase, endothelial	242	2.00e-63
		AAH35514.1	TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)	241	4.00e-63
		NP 075260.1	fibroblast growth factor receptor 2 isoform 4 precursor; keratinocyte growth factor receptor;	236	1.00e-61
			K-sam protein; protein tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed		
		,	kinase; fibroblast growth factor receptor BEK; tyrosylprotein kinase; hydroxyaryl-protein		
			kinase		
		AAB22215.1	insulin-like growth factor I receptor, IGF-IR [human, Peptide, 1367 aa].	233	7.00e-61
		NP_000866.1	insulin-like growth factor 1 receptor precursor	233	7.00e-61
		1M7NA	Chain A, Crystal Structure Of Unactivated Apo Insulin-Like Growth Factor-1 Receptor	233	7.00e-61
			Kinase Domain		
NM_011781		NP_003804.1	a disintegrin and metalloproteinase domain 21 preproprotein	740	0
	F:(C-D)-				
NP_035911.1 Mm.85003	3 2.33				
		NP_003805.2	a disintegrin and metalloproteinase domain 20 preproprotein	739	0
		043506	ADAM 20 precursor (A disintegrin and metalloproteinase domain 20).	733	0
		NP 068552.1	a disintegrin and metalloproteinase domain 29 isoform 2 preproprotein	717	0

Q9UKF5 NP_055084 AAF22163. AAC52042. NP_003807 Q9UKF2 AAH28372.	2,	717	0
NP_055084 AAF22163 AAC52042 NP_003807 Q9UKF2 AAH28372	1.2		
AAF22163. AAC52042 NP_003807 Q9UKF2 AAH28372	•	717	0
AAC52042 NP_003807 Q9UKF2 AAH28372	. I disintegrin and metalloproteinase domain 29	715	0
NP_003807 Q9UKF2 AAH28372	2.1 ADAM 21; testis-specific metalloprotease-like membrane protein	556	1.00e-158
Q9UKF2 AAH28372	7.1 ADAM 30 precursor (A disintegrin and metalloproteinase domain 30).	474	1.00e-133
AAH28372	ADAM 30 precursor (A disintegrin and metalloproteinase domain 30).	469	1.00e-132
	2.1 a disintegrin and metalloproteinase domain 30	469	1.00e-132
AAF03781	.1 metallaproteinase-disintegrin beta	469	1.00e-131
AAM49575	5.1 disintegrin/metalloproteinase domain 9 short protein precursor	422	1.00e-117
BAA03499	7	420	1.00e-117
S71949	metalloproteinase 12 (EC 3.4.24) precursor	391	1.00e-108
NP 659441	1.1 a disintegrin and metalloprotease domain 32; hypothetical protein MGC26899	346	8.00e-95
AAH26085.	5.1 Similar to a disintegrin and metalloproteinase domain 18	345	1.00e-94
NP_003465.2	5.2 a disintegrin and metalloprotease domain 12 isoform 1 preproprotein; A disintegrin and	328	2.00e-89
	metalloproteinase domain 12 (Meltrin-alpha, mouse, homolog of); meltrin alpha		
О9Н013	ADAM 19 precursor (A disintegrin and metalloproteinase domain 19) (Meltrin beta)	328	3.00e-89
	(Metalloprotease and disintegrin dentritic antigen marker) (MADDAM).		-,
NP_150377	<u></u>	327	4.00e-89
CAC20585.		327	4.00e-89
NP_075525.	5.2 a disintegrin and metalloproteinase domain 19 isoform 1 preproprotein; meltrin beta	327	4.00e-89
NP_067673.	_	327	5.00e-89
	metalloproteinase domain 12 (Meltrin-alpha, mouse, homolog of); meltrin alpha		
AAC08703.2		327	5.00e-89
099965	ADAM 2 precursor (A disintegrin and metalloproteinase domain 2)(Fertilin beta subunit)	324	4.00e-88
NP_001455.2	2.2 a disintegrin and metalloproteinase domain 2 proprotein; fertilin beta (a disintegrin and	323	5.00e-88
	metalloproteinase domain 2); fertilin beta		
AAC51110.1		323	7.00e-88
AAF22162.1	1 disintegrin and metalloproteinase domain 19	323	9.00e-88

A A H34957 1 similar to fe	similar to fertilin beta protein	311	2.00e-84
Τ.	a disinfegrin and metalloproteinase domain 18 proprotein	309	1.00e-83
7.		309	1.00e-83
. [┈	a disinfecting and metallomrotease domain 33	305	2.00e-82
7	a disintegrin and metalloproteinase domain 33 isoform alpha preproprotein; disintegrin and	305	2.00e-82
	reprolysin metalloproteinase family protein; metalloprotease disintegrin		
CAC16509.2 dJ964F7.1 (d1964F7.1 (novel disintegrin and reprolysin metalloproteinase family protein)	305	2.00e-82
T	ADAM 7 precursor (A disintegrin and metalloproteinase domain 7) (Sperm	299	1.00e-80
	maturation-related glycoprotein GP-83).		
NP 055080.1 a disintegrii	a disintegrin and metalloproteinase domain 28 isoform 1 preproprotein	293	6.00e-79
-	a disintegrin and metalloproteinase domain 28 isoform 2 preproprotein	293	1.00e-78
	a disintegrin and metalloproteinase domain 33 isoform beta preproprotein; disintegrin and	280	5.00e-75
	reprolysin metalloproteinase family protein; metalloprotease disintegrin		
NP 001100.1 a disintegri	a disintegrin and metalloproteinase domain 8 precursor	263	1.00e-69
_	A disintegrin and metalloproteinase domain 15 preproprotein	263	1.00e-69
7	a disintegrin and metalloproteinase domain 15 preproprotein; metargidin	263	1.00e-69
G02390 disintegrin-	disintegrin-like metalloproteinase MDC15 (EC 3.4.24)	263	1.00e-69
07.1	Unknown (protein for IMAGE:5295041)	261	3.00e-69
	sperm maturation-related glycoprotein GP-83	258	4.00e-68
AAD55251.1 metalloprot	metalloproteinase-disintegrin ADAM22-3	254	4.00e-67
	metalloprotease/disintegrin-like protein	254	4.00e-67
NP_068369.1 a disintegri	a disintegrin and metalloproteinase domain 22 isoform 1 proprotein; MDC2 delta	254	4.00e-67
	disintegrin-like metalloproteinase (EC 3.4.24), splice form 2	254	4.00e-67
NP 004185.1 a disintegri	a disintegrin and metalloproteinase domain 22 isoform 4 proprotein; MDC2 delta	254	4.00e-67
7	a disintegrin and metalloprotease domain 11 isoform 1 preproprotein;	254	4.00e-67
	metalloproteinase-like, disintegrin-like, cysteine-rich protein		
O75078 ADAM 11	ADAM 11 precursor (A disintegrin and metalloproteinase domain 11)	254	4.00e-67
(Metallopro	(Metalloproteinase-like, disintegrin-like, and cysteine-rich protein) (MDC).		
NP_068368.2 a disintegri	a disintegrin and metalloproteinase domain 22 isoform 2 proprotein; MDC2 delta	254	4.00e-67
AAF73288.1 metallopro	metalloprotease-like, disintegrin-like, cysteine-rich protein 2 delta	254	4.00e-67

Ŋ

					254	4.00e-67
			AAF22476.2	MDCZ	-	
			NP_057435.2	a disintegrin and metalloproteinase domain 22 isoform 3 proprotein; MDC2 delta	724	4.00e-07
			NP 068367.1	a disintegrin and metalloproteinase domain 22 isoform 5 proprotein; MDC2 delta	254	4.00e-67
			NP 003803.1	a disintegrin and metalloproteinase domain 23 preproprotein	241	3.00e-63
			A A H24214 1	Triknown (nrotein for TMAGE:3604198)	226	1.00e-58
			1.0010011.1	11.1	226	1.00e-58
			AAH33132.1	Unknown (protein 101 livracia, 2012,000)	1 0	000
			NP_068547.1	a disintegrin and metalloproteinase domain 28 isoform 3 preproprotein	C77	3.00e-38
			BAA06671.1	metalloprotease/disintegrin-like protein	201	4.00e-51
			NP 067625.1	a disintegrin and metalloprotease domain 11 isoform 2 preproprotein;	199	2.00e-50
			·	metalloproteinase-like, disintegrin-like, cysteine-rich protein		
NM 011461					313	
ł		F:(C-D)-				
NP 035591.2 Mm.21642 2.31	Mm.21642	2.31	NP_689536	hypothetical protein MGC40611		4.00e-85
						 -
NM_009021					2353	
	•	F:(C-D)-				
NP_033047.1 Mm.4736	Mm.4736	2.27	CAC20424	retinoid-acid induced protein 1		0
			CAC20423	retinoid-acid induced protein 1	2353	5
		·	BAB47449	KIAA1820 protein	2256	o -
			NP_060044	retinoic acid induced 1 isoform 1	2249	o
			CAD39127	hypothetical protein	1704	0
			NP_689469	refinoic acid induced 1 isoform 2	1480	0
			CAD39144	hypothetical protein	689	0
			T43490	hypothetical protein DKFZp434A139.1 - human	524	1.00e-148
			NP 109590	retinoic acid induced 1 isoform 3	260	2.00e-68
			<u>,</u>	-		
NM_021468						
		F:(C-D)-				
NP_067443.1 Mm.42188 2.18	Mm.42188	3 2.18	NP_006368	UNC13 (C. elegans)-like; homolog of rat Munc13 (diacylglycerol-binding)	2958	o
			ı			

വ

			BAA82984	XIAA1032 protein	1598	0
			XP_038604	similar to KIAA1032 protein	1478	0
			BAC03675	unnamed protein product	1404	0
			XP. 085234	similar to Munc13-3	1328	0
			CAD39069	hypothetical protein	915	0
X03796		F:(C-D)-	NP_005156.1	aldolase C, fructose-bisphosphate; Aldolase C, fructose-bisphosphatase	443	1.00e-125
CAA27422.1	NULL	2.14				
			CAA30270.1	aldolase C	443	1.00e-125
			NP 000025.1	aldolase A; fructose-bisphosphate aldolase; Aldolase A, fructose-bisphosphatase	388	1.00e-108
			1ALD	Aldolase A (E.C.4.1.2.13)	386	1.00e-107
	-		CAA30979.1	aldolase A	380	1.00e-105
			NP 000026.1	aldolase B, fructose-bisphosphate; Aldolase B, fructose-bisphosphatase	335	4.00e-92
			P05062	Fructose-bisphosphate aldolase B (Liver-type aldolase).	335	4.00e-92
			AAA51691.1	aldolase B	334	8.00e-92
			BAA00125.1	aldolase B	334	8.00e-92
			1005A	Chain A, Fructose 1,6-Bisphosphate Aldolase From Human Liver Tissue.	333	1.00e-91
			AAH29399.1	Similar to aldolase B, fructose-bisphosphate	333	1.00e-91
			1313294A	aldolase B	328	3.00e-90
			AAH00367.1	Similar to aldolase A, fructose-bisphosphate	241	9.00e-64
			AAH16170.1	Similar to aldolase A, fructose-bisphosphate	239	2.00e-63
17.			÷.			
NM_007489			NP_001169.2	aryl hydrocarbon receptor nuclear translocator-like	1219	0
	•	F:(C-D)-				
NP_031515.1 Mm.12177 2.13	Mm.12177	2.13				
		1.4	JC5405	brain and muscle Ah receptor nuclear translocator-like protein, BMAL1b	1218	0
			AAH41129.1	Unknown (protein for MGC:47515)	1204	0
			000327	BMAL1 protein (Brain and muscle ARNT-like 1) (Member of PAS protein 3)	1130	0
				(Basic-helix-loop-helix-PAS orphan MOP3) (BHLH-PAS protein JAP3).		
			AAC51213.1	PAS protein 3	1102	0

20

Ŋ

	_		1 4 4 5 3 4 6 5 3 4	H IS cope of the	560	1 000-150
		-	AAG24032.1	CYCIC-IIKG IACIOI CLLIF		7.700.1
			AAL50339.1	brain-muscle-ARNT-like transcription factor 2a	557	1.00e-158
			AAL50340.1	brain-muscle-ARNT-like transcription factor 2b	551	1.00e-156
			AAL50341.1	brain-muscle-ARNT-like transcription factor 2c	545	1.00e-154
			AAL50342.1	brain-muscle-ARNT-like transcription factor 2d	545	1.00e-154
			AAF71306.1	bHLH-PAS transcription factor MOP9	685	1.00e-153
			AAF71307.1	bHLH-PAS transcription factor MOP9	538	1.00e-152
			AAH00172.2	Similar to transcription factor BMAL2	536	1.00e-152
		1	BAB01485.1	transcription factor BMAL2	233	1.00e-151
			JC5407	brain and muscle Ah receptor nuclear translocator-like protein, BMAL1e	478	1.00e-134
			PC4288	brain and muscle Ah receptor nuclear translocator-like protein, BMAL1d	451	1.00e-126
			BAA19936.1	BMAL1c	350	4.00e-96
			NP_001659.1	aryl hydrocarbon receptor nuclear translocator isoform 1; dioxin receptor, nuclear	328	3.00e-89
				translocator; hypoxia-inducible factor 1, beta subunit		
			CAD38953.1	hypothetical protein	323	1.00e-87
			Q9HBZ2	Aryl hydrocarbon receptor nuclear translocator 2 (ARNT protein 2).	318	3.00e-86
			AAH36099.1	Unknown (protein for MGC:33872)	318	3.00e-86
			NP_055677.1	aryl-hydrocarbon receptor nuclear translocator 2; aryl hydrocarbon receptor nuclear	317	7.00e-86
				translocator 2		
			AAC03365.1	aryl hydrocarbon receptor nuclear translocator; Arnt	235	2.00e-61
NM_013533			-		821	0
	<u> </u>	F:(C-D)-			•	
NP_038561.1 Mm.2514		2.13	NP_062832	protein 'A' isoform 2; protein 'A'		;
			AAH07918	Similar to protein A	400	1.00e-111
			NP_055264	protein 'A' isoform 1; protein 'A'	400	1.00e-111
			AAC50467	protein A-3	569	2.00e-71

വ

-		(U)).				
NP 038626 1 Mm 4235	Mm 4235	2.12	NP 000890	mast cell growth factor, isoform b, precursor	398	1.00e-110
11070000 111			Т	Chain A, Hunan Recombinant Stem Cell Factor	391	1.00e-108
			985	KIT ligand isoform a, precursor; mast cell growth factor; stem cell factor precursor	352	3.00e-96
			AAD22048	stem cell factor precursor	348	3.00e-95
			1EXZA	Chain A, Structure Of Stem Cell Factor	218	3.00e-56
NM_007753			NP_001861.1	mast cell carboxypeptidase A3 precursor	719	0
		F:(C-D)-				
NP_031779.1 Mm.1135	Mm.1135	2.08				
			AAH12613.1	Mast cell carboxypeptidase A3 precursor	716	0
			AAB22578.2	mast cell carboxypeptidase A; MC-CPA	557	1.00e-158
			P15086	Carboxypeptidase B precursor (Pancreas-specific protein) (PASP).	446	1.00e-125
			CAA12163.1	procarboxypeptidase B	444	1.00e-124
			IKWMA	Chain A, Human Procarboxypeptidase B: Three-Dimensional Structure And Implications	442	1.00e-124
				For Thrombin-Activatable Fibrinolysis Inhibitor (Tafi).		
			NP_001862.1	pancreatic carboxypeptidase B1 precursor; pancreas-specific protein	438	1.00e-123
			DAA00037.1	TPA: carboxypeptidase A-6; CPA6	358	8.00e-99
			NP_065094.2	carboxypeptidase B precursor	358	1.00e-98
			AAH07057.1	carboxypeptidase B2 (plasma)	330	2.00e-90
		-	NP_001863.1	plasma carboxypeptidase B2 isoform a preproprotein; carboxypeptidase U;	330	4.00e-90
				thrombin-activatable fibrinolysis inhibitor; carboxypeptidase B-like protein;		
				thrombin-activable fibrinolysis inhibitor		
			NP_057436.1	carboxypeptidase A4; carboxypeptidase A3	299	7.00e-81
			NP_775100.1	carboxypeptidase O	298	2.00e-80
			DA:A00036.1	TPA: carboxypeptidase O; CPO	. 298	2.00e-80
			P48052	Carboxypeptidase A2 precursor	296	4.00e-80
			1AYE	Human Procarboxypeptidase A2	294	2.00e-79
			NP_001860.1	carboxypeptidase A2 (pancreatic)	294	2.00e÷79

		1.500/01154		+67	
		AAH05279.1	Pancreatic carboxypeptidase A1 precursor	293	4.00e-79
L		NP_001859.1	pancreatic carboxypeptidase A1 precursor; Carboxypeptidase A	291	1.00e-78
		AAL37611.1	carboxypeptidase A5	286	6.00e-77
		AAH42996.1	Similar to carboxypeptidase A5	286	6.00e-77
		AAH39362.1	CPA5 protein	285	1.00e-76
	Ī	1DTDA	Chain A, Crystal Structure Of The Complex Between The Leech Carboxypeptidase	. 267	3.00e-71
			Inhibitor And The Human Carboxypeptidase A2 (Lci-Cpa2).		
		AAM19307.1	metallocarboxypeptidase A6	240	3.00e-63
		NP_057497.2	plasma carboxypeptidase B2 isoform b; carboxypeptidase U; thrombin-activatable	235	1.00e-61
-			fibrinolysis inhibitor; carboxypeptidase B-like protein; thrombin-activable fibrinolysis		
_			inhibitor		-
		BAA90475.1	carboxypeptidase B-like protein	235	1.00e-61
_		BAC04122.1	unnamed protein product	211	2.00e-54
-		AAF91231.1	carboxypeptidase B precursor	200	3.00e-51
		-			
	. **			464	
F:(F:(C-D)-	_			
Mm.32518 2.07		NP_037378	cardiotrophin-like cytokine; neurotrophin-1/B-cell stimulating factor-3		1.00e-131
-					
				204	
Mm.10823 F:(C-D) 9 2.07	,	NP 006106	preferentially expressed antigen in melanoma; melanoma antigen preferentially expressed in tumors; Opa-interacting protein OIP4; preferentially expressed antigen of melanoma		5.00e-52
		AAH39731	preferentially expressed antigen in melanoma	204	5.00e-52
				•	
_					
F:((F:(C-D)-	`			
Mm.4179 2.07		NP_006138	interferon regulatory factor 6; Popliteala pterygium syndrome	923	0
		NP_116032	interferon regulatory factor 5 isoform b	444	1.00e-124
		NP_002191	interferon regulatory factor 5 isoform a	429	1.00e-119

ហ

 $\ddot{\rightarrow}$

20

_																								
6.00e-57 2.00e-56	2.00e-55	5.00e-53	4.00e-50	 	i i	1.00e-175		1.00e-1/1	1.00e-96	1.00e-80	3.00e-67	4.00e-71		7.00e-61		2.00e-59			1.00e-164			5.00e-88	2.00e-85	
221	216	208	198	 	;	611	5	00	351	298	254	233		233		228			578			186	182	
lymphocyte specific interferon regulatory factor/interferon regulatory factor 4 Interferon regulatory factor 4 (IRF-4) (Lymphocyte specific interferon regulatory factor) (TSIRF) (NF-EMS) (Multiple myeloma oncogene 1).	interferon regulatory factor 4; multiple myeloma oncogene 1	ICSAT transcription factor	interferon consensus sequence binding protein 1; H-ICSBP; interferon regulatory factor 8			coxsackie and adenovirus receptor protein	coxsackie virus and adenovirus receptor; 46 kD coxsackievirus and adenovirus receptor	(CAR) protein	coxsackie-adenovirus-receptor isoform CAR4/7	similar to coxsackie-adenovirus-receptor isoform CAR4/7	coxsackie-adenovirus-receptor isoform CAR3/7	Chain A, Dimeric Structure Of The Coxsackie Virus And Adenovirus Receptor D1 Domain	Chain B, Knob Domain From Adenovirus Serotype 12 In Complex With Domain 1 Of Its	Cellular Receptor Car	Chain R, Cyro-Em Structure Of Coxsackievirus B3(M Strain) With Its Cellular Receptor,	Coxsackievirus And Adenovirus Receptor (Car).	-		sterol-C4-methyl oxidase-like; C-4 methyl sterol			hymothetical protein FL J40154	acyl-malonyl condensing enzyme	
AAC50779	NP 002451	BAA11335	NP_002154			AAD31772		NP_001329	AAL68880	XP 208848	AAL 68879	1F5WA		1KACB.	-	1 JEWR			NP 006736	I	·	NP 689675	NP_473369	
					F:(C-D)-	2.06						,							F:(C-D)- 2.04		E.(C.D.)	2.04		
						Mm.8702												-	Mm.30119			Mm 6211		
				NM_009988	1	NP_034118.1 Mm.8702 2.06												NM_025436	F:(C NP 079712.1 Mm.30119 2.04		NM_019871	NP 063924 1 Mm 6211		

_			1.00e-126	1.00e-121	2.00e-63			0				0	0	0				0	0	0	1.00e-158	5.00e-96			5.00e-96			1.00e-100	3.00e-99
		456	449	434	241			778				775	774	773				705	703	703	258	349			349		364	361	360
		B-cell translocation gene 3; abundant in neuroepithelium area	protein ANA - human	Unknown (protein for MGC:8928)	ANA		cytochrome P450		cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2;	dioxin-inducible P3-450; P450 form 4; microsomal monooxygenase; xenobiotic	monooxygenase; aryl hydrocarbon hydroxylase; flavoprotein-linked	monooxygenase	cytochrome P450-1A2	cytochrome P450 4	cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1;	flavoprotein-linked monooxygenase; cytochrome P1-450, dioxin-inducible; aryl	hydrocarbon hydroxylase; P450 form 6; xenobiotic monooxygenase; microsomal	monooxygenase	cytochrome P-450-1	cytochrome P(1)-450	similar to CYTOCHROME P450 1A2 (CYPIA2) (P450-P3) (P(3)450) (P450 4)	cytochrome P450 CYP1B1	cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1; aryl hydrocarbon	hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase;	flavoprotein-linked monooxygenase	suppressor of cytokine signaling-2; STAT induced STAT inhibitor-2;	cytokine-inducible SH2 protein 2	STAT induced STAT inhibitor 2 - human	cytokine-inducible SH2 protein 2 - human
· <u>-</u>		NP_006797	T09539	AAH11957	Г		AAK25728.1		NP_000752.1				AAF13599.1	AAA35738.1	NP_000490.1				AAA52139.1	CAA26458.1	XP_044660.4	AAC50809.1	NP_000095.1			NP_003868.1		JC5626	JC5760
	F:(C-D)-	2.02					F:(C-D)	-3.27											-						i	F:(C-D) 1	-2.51		
		Mm.2823				- 11 73 Company	Mm.15537																			Mm.4132			
NM 009770		NP_033900.1	-				NM_009993	NP_034123.1			 									មក							NP_031732.1		

3.00e-99 3.00e-96	0	7.00e-81 1.00e-1	1.00e	1.00e	1.006-1	1.00e	6.00e-9	6.00e-	6.00e-	1.00e-	3.006-9	8.00e-9	2.00e-9
359	790	300	373	364	364	364	353	347	347	345	344	343	341
CIS2 suppressor of cytokine signalling-2; HSSOCS-2 tumor necrosis factor, alpha-induced protein 2	similar to coenzyme A diphosphatase	hypothetical protein FLJ38281	similar to zinc finger protein 14 (KOX 6); GIOT-4 for gonadotropin inducible transcription repressor-4	zinc finger protein 14 (KOX 6); GIOT-4 for gonadotropin inducible transcription repressor-4	hypothetical protein FLJ90396	similar to zinc finger protein 14 (KOX 6); GIOT-4 for gonadotropin inducible transcription repressor-4	similar to zinc finger protein 91 (HPF7, HTF10)	ZNF180	zinc finger protein 180 (HHZ168)	zinc finger protein 136 (clone pHZ-20)	hypothetical protein FLJ40981	hypothetical protein FLJ21628	BC37295_1
BAA22536.1 AAC98896.1 NP_006282.1	XP_058753.1	NP_689814.1	XP_091960.1	NP_066358.1	NP_699189.1	XP_091958.1	XP_091968.4	AAF71790.1	NP_037388.1	NP_003428.1	NP_689815.1	NP_085116.1	AAD23607.1
F:(C-D)	-2.5 F:(C-D)	-2.42 F:(C-D)	1:7										
Mm.4348	-2.5 Mm.27889 F:(C-D)	-2.42 Mm.15981 F:(C-D)						·	·		·		
NM_009396	NP_033422.1 AK004924	BAB23675.1 NM_029813 NP_084089.1											

		BAC04309.1	unnamed protein product	338	2.00e-9
		BAB21801.1	KIAA1710 protein	337	3.00e-9
		XP_032812.1	similar to hypothetical protein FLJ40981	337	3.00e-9
		XP_031283.1	similar to Hypothetical zinc finger protein KIAA1710	337	3.00e-9
		P35789	Zinc finger protein 93 (Zinc finger protein HTF34)	336	8.006-9
		NP_003427.1	zinc finger protein 135 (clone pHZ-17)	336	1.00e-9
		NP_653290.2	hypothetical protein FLJ32191	335	1.006-9
		BAB71257.1	unnamed protein product	333	8.006-9
		BAC04764.1	unnamed protein product	332	2.00e-9
		NP_003420.1	zinc finger protein 85 (HPF4, HTF1)	330	5.006-9
		BAA86512.1	KIAA1198 protein	328	3.006-8
		XP_032674.1	similar to Hypothetical zinc finger protein KIAA1198	328	3.00e-8
·		NP_660338.1	similar to Zinc finger protein 136	327	4.00e-8
14		BAB71272.1	unnamed protein product	327	6.006-8
·	·	XP_065387.2	similar to Zinc finger protein 135	326	1.00e-8

•				
	XP_086070.1	similar to Zinc finger protein 93 (Zinc finger protein HTF34)	325	1.00e-8 8
	NP_003421.1	zinc finger protein 91 (HPF7, HTF10)	325	1.00e-8 8
	XP_068538.2	similar to Zinc finger protein 93 (Zinc finger protein HTF34)	325	2.00e-8 8
	XP_028314.1	similar to KRAB zinc finger protein KR18	. 324	3.00e-8
	XP_115658.2	similar to Zinc finger protein 208	324	3.00e-8
	T14757	hypothetical protein DKFZp572C163.1 - human (fragment)	324	3.00e-8 8
	XP_091983.1	similar to Zinc finger protein 135	324	4.00e-8
	CAB94232.2	zinc finger protein	323	5.00e-8
	NP_003419.1	zinc finger protein 84 (HPF2)	323	5.00e-8
	B32891	finger protein 2, placental - human	323	5.00e-8
	 NP_055295.1	zinc finger protein AF020591	323	7.00e-8
	AAC51180.1	kruppel-related zinc finger protein	323	9.00e-8 8
	XP_092097.1	similar to Zinc finger protein 93 (Zinc finger protein HTF34)	322	1.00e-8 7
	AAH36110.1	Similar to zinc finger protein 208	322	1.00e-8 7
	BAC04610.1	unnamed protein product	322	2.00e-8

đN	NP_612143.1 h	hypothetical protein FLJ31526	322	2.00e-8 7
€Z	NP_067039.1 z	zinc finger protein 71; endothelial zinc finger protein induced by tumor necrosis factor albha	321	3.00e-8
NP	NP_003399.1 z	zinc finger protein 37 homolog (mouse); Zinc finger protein-37, mouse, homolog of;	321	3.006-8
BA	Z BAC04064.1 u	zinc tinger protein nomologous to zipor in mouse unnamed protein product	321	3.00e-8
60	Q9Y6Q3 Z	Zinc finger protein ZFP-37	321	3.00e-8
AA	AAD23608.1 E	BC37295_2 (partial)	321	3.00e-8
AA	AAL58442.1 z	zinc finger protein 328	321	3.00e-8
BA	BAB47481.1	KIAA1852 protein	321	3.00e-8
AA	AAH37209.1	Unknown (protein for MGC:41936)	320	4.00e-8
X	XP_171752.1	similar to zinc finger protein 29	320	4.00e-8
XP	XP_092090.2	similar to Hypothetical zinc finger protein KIAA1473	320	6.00e-8
BA	BAA24050.1 2	Zinc-finger protein	320	6.00e-8
AN .	NP_443092.1	kruppel-like zinc finger protein	319	1.00e-8
X.	XP_171940.1	similar to BC37295_1	318	2.00e-8
以	NP_653294.1	hypothetical protein FLJ30932	318	2.00e-8
	-	_		

XP_064929.5	s similar to Zinc finger protein 20 (Zinc finger protein KOX13) (DKFZp572P0920)	318	2.00e-8
NP_079009.1	hypothetical protein FLJ14345	318	2.00e-8
	NP_003416.1 zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide); Zinc finger protein-45 (a Kruppel-associated box (KRAB) domain	318	2.006-8
	Zinc finger protein ZNF45	318	2.00e-8
NP_008889.1	zinc finger protein 16 (KOX 9)	318	2.00e-8
	hypothetical protein	318	2.00e-8
	similar to Zinc finger protein 85	318	2.006-8
	Zinc finger protein 16 (Zinc finger protein KOX9)	318	2.00e-8
'N	zinc finger protein 43 (HTF6)	318	3.00e-8
XP_086128.1 si	similar to Zinc finger protein 35 (Zfp-35)	318	3.006-8
XP_065116.3 si	similar to zinc finger protein 91 (HPF7, HTF10)	317	4.00e-8
N	zinc finger protein 43 (HTF6)	317	4.00e-8
	Similar to zinc finger protein 208	317	6 4.00e-8
	zinc finger protein ZFP	317	5.00e-8
<u>N</u>	zinc finger protein 177	317	5.00e-8
-	_	_	,-

	XP_087503.1	similar to zinc finger protein 91 (HPF7, HTF10)	317	5.00e-8
	XP_033888.3	similar to Zinc finger protein 41	317	6.00e-
-	CAC88162.1	bB479F17.3 (zinc finger protein 41)	317	6.00e-
	NP_700359.1	zinc finger protein 41	317	6.00e-
	A54661	zinc finger protein ZNF41 - human (fragment)	317	6.00e-
	AAH22992.1	Unknown (protein for MGC:29879)	317	6.008-8
	XP_166367.1	similar to Zinc finger protein 184	317	6.00e-
·	BAC04216.1	unnamed protein product	316	8.00e-
	NP_065704.1	zinc finger protein 287	316	8.00e-
	NP_061025.3	zinc finger protein 331; zinc finger protein 463; C2H2-like zinc finger protein	315	1.00e-
	AAF78075.1	KRAB zinc finger protein	315	1.006~
	AAH36714.1	Unknown (protein for IMAGE:4846514)	315	2.00e-
	T12489	hypothetical protein DKFZp572P0920.1 - human (fragment)	315	2.00e-
	XP_032810.1	similar to Zinc finger protein 20 (Zinc finger protein KOX13) (DKFZp572P0920)	315	2.00e-
	AAF88107.1.	Hypothetical zinc finger-like protein	315	2.00e-8
]	_	_	 -

	NP_612203.1	TRAF6-inhibitory zinc finger protein; TRAF6-binding zinc finger protein	314	3.00e-8
	XP_092088.3	similar to zinc finger protein 91 (HPF7, HTF10)	314	3.00e-
	XP_047554.4	similar to Hypothetical zinc finger protein KIAA1473	314	4.00e-
	NP_006620.1	zinc finger protein 271	313	5.00e-8
	Q9P255	Hypothetical zinc finger protein KIAA1473	313	9.006-8
	BAB85542.1	KIAA1956 protein	313	5 9.00e-8
	XP_085836.1	similar to Hypothetical zinc finger protein KIAA1956	313	9.006-8
	XP_047550.1	similar to Hypothetical zinc finger protein KIAA1473	313	9.006-8
	NP_003406.1	zinc finger protein 268	312	1.006-8
	AAH36038.1	Unknown (protein for MGC:33240)	312	1.006-8
200	AAK69307.1	ZNF268B	312	1.00e-8
	S47071	finger protein HZF3, Krueppel-related - human (fragment)	312	4 2.00e-8
	NP_037512.1	zinc finger protein 228	312	2.00e-8
NM_007494 Mm.3217 F:(C-	F:(C-D) NP_446464.1	argininosuccinate synthetase		41
	TT	argininosuccinate synthetase	793	o o
	XP_094493.2	similar to argininosuccinate synthetase	612	612 1.00e-175

	601 1.00e-172	410 1.00e-114	305 9.00e-83	253 4.00e-67	arity to P09034	231 2.00e-60	34% Similarity to	218 2.00e-56	211 2.00e-54	none	se 2; KEX2-like	1247 0	1244 0	892 0		838 0	835 0	833 0	830	828 0	827 0	823 0	822 0	820 0	815 0	813 0	813 0	801	
similar to argininosuccinate synthetase	similar to argininosuccinate synthetase	similar to argininosuccinate synthetase	similar to argininosuccinate synthetase	similar to argininosuccinate synthetase	argininosuccinate synthase (citrulline-aspartate ligase); 84% Similarity to P09034	(NID:g114291)	similar to argininosuccinate synthase (citrulline-aspartate ligase); 84% Similarity to	P09034 (NID:g114291)	similar to argininosuccinate	proprotein convertase subtilisin/kexin type 2; subtilisin-like prohormone	convertases; prohormone convertase 2; neuroendocrine convertase 2; KEX2-like	endoprotease 2; proprotein convertase PC5	endoprotease	dJ531H16.1 (proprotein convertase subtilisin/kexin type 2 (NEC2))	tubulin, beta polypeptide		tubulin beta chain - human	tubulin, beta polypeptide	tubulin, beta, 2	Similar to tubulin, beta, 2	tubulin, beta, 2	Tubulin beta-5 chain	tubulin, beta 5	tubulin, beta, 5	Tubulin beta-1 chain	Tubulin beta-5 chain	tubulin beta	beta-tubulin - human (fragment)	
XP_167277.1	XP_062010.1	XP_094542.1	XP_172419.1	XP_095989.1	AAB96328.1		XP_070116.1		XP_070928.1	NP_002585.2			AAA60032.1	CAB89428.1	AAH01352.1	,	T08726	NP_001060.1	NP_006079.1	AAH24038.1	AAH29529.1	P05218	AAH20946.1	NP_006078.2	P07437	P04350	0808321A	138369	, , , , ,
										F:(C-D)	-2.35				F:(C-D)	-2.27													
			·		-					Mm.1247					Mm.20085	8													
						,				NM_008792	NP_032818.1				AK010786	BAB27182.1													

S

 $\ddot{-}$

끔

Ñ

			1013509	Trubulin beta-4 chain (Tubulin beta-III)	794	- 0
			NP 006077.1	tubulin, beta, 4	793	0
			XP_047083.4	similar to neu differentiation factor - human (fragment)	789	0
			BAB14016.1	unnamed protein product	785	0
			NP_115914.1	similar to chicken tubulin beta 5	785	0
			AAL32434.1	beta-tubulin 4Q	775	0
			0805287A	tubulin beta	770	0
			XP_047436.3	similar to tubulin, beta 3	156	0
			NP_064424.1	tubulin, beta polypeptide 4, member Q	731	0
			AAB48456.1	beta-tubulin	726	0
٠			AAH01678.1	Unknown (protein for IMAGE:2821278)	708	0
			NP_110400.1	beta tubulin 1, class VI	691	0
			XP_027577.1	similar to beta-tubulin 4Q	644	0
NM_012006	Mm.1978	F:(C-D)	XP_170752.1	similar to peroxisomal long-chain acyl-coA thioesterase; peroxisomal long-chain		<u>-</u> .
NP_036136.1		-2.24		acyl-coA thioesterase; putative protein	602	1.00e-172
			P49753	Peroxisomal acyl-coenzyme A thioester hydrolase 2 (Peroxisomal long-chain		
				acyl-coA thioesterase 2) (ZAP128)	009	1.00e-171
			AAH06500.1	Unknown (protein for MGC:2366)	009	1.00e-171
			NP_006812.2	peroxisomal long-chain acyl-coA thioesterase; peroxisomal long-chain acyl-coA		
				thioesterase; putative protein	599	1.00e-171
			BAA91989.1	unnamed protein product	298	1.00e-171
			NP_689544.1	hypothetical protein FLJ31235	494	1.00e-139
			AAC42007.1	ORF; putative	405	1.00e-113
			XP_090885.1	similar to Peroxisomal acyl-coenzyme A thioester hydrolase 2 (Peroxisomal		
			·	long-chain acyl-coA thioesterase 2) (ZAP128)	280	4.00e-75
AK006569	Mm.45980 F:(C-D)	F:(C-D)	NP_060301.1	hypothetical protein FLJ20456		
BAB24656.1		-2.18			254	6.00e-70
			AAH12021.1	Unknown (protein for MGC:21737)	245	5.00e-67
NM_010107	Mm.15675 F:(C-D)	F:(C-D)	NP_004419.1	ephrin A1 precursor; eph-related receptor tyrosine kinase ligand 1 (tumor necrosis		
NP_034237.1		-2.18		factor, alpha-induced protein 4)	353	2.00e-97
						•

Ŋ

્ન

Ō

S

Ü

			AAH32698.1	ephrin-A1	351	8.00e-97
NM_025754	Mm.20213	F:(C-D)	NP_000025.1	aldolase A; fructose-bisphosphate aldolase; Aldolase A, fructose-bisphosphatase		
NP_080030.1		-2.13			647	0
			229674	Chain , Aldolase A (E.C.4.1.2.13)	645	0
			CAA30979.1	aldolase A	636	0
			NP 005156.1	aldolase C, fructose-bisphosphate; Aldolase C, fructose-bisphosphatase	556	1.00e-158
			CAA30270.1	aldolase C	555	1.00e-158
NM 008303	Mm.19760 F:(C-D)	F:(C-D)	NP_002148.1	heat shock 10kDa protein 1 (chaperonin 10); heat shock 10kD protein 1		
NP 032329.1	1	-2.12		(chaperonin 10)	171	3.00e+43
NM 011300	Mm.5281	F:(C-D)	NP_001002.1	ribosomal protein S7; 40S ribosomal protein S7		
NP 035430.1		-2.11			376	1.00e-104
1			AAB00969.1	ribosomal protein	372	1.00e-103
			XP 012638.7	similar to bA271B5.1 (similar to ribosomal protein S7)	368	1.00e-102
			CAC17691.1	bA271B5.1 (similar to ribosomal protein S7)	368	1.00e-102
			XP 015717.4	similar to ribosomal protein S7	352	3.00e-97
			XP_056970.1	similar to ribosomal protein S7	341	5.00e-94
			XP_066966.1	similar to ribosomal protein S7	297	1.00e-80
	·		XP_068930.1	similar to ribosomal protein S7	290	2.00e-78
			XP_170827.1	similar to ribosomal protein S7	273	1.00e-73
			XP_117815.2	similar to ribosomal protein S7	236	2.00e-62
AK011896	Mm.27248 F:(C-D)	F:(C-D)	BAB14594.1	unnamed protein product		
BAB27902.1		-2.1			213	5.00e-55
			CAB66586.2	hypothetical protein	211	3.00e-54
NM_008322	Mm.2966	F:(C-D)	P48735	Isocitrate dehydrogenase [NADP], mitochondrial precursor (Oxalosuccinate		
NP_032348.1		-2.1		decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) (ICD-M)	820	0
			NP_002159.1	isocitrate dehydrogenase 2 (NADP+), mitochondrial; Isocitrate dehydrogenase,		-
				mitochondrial	845	0
			AAC50455.1	isocitrate dehydrogenase	734	0
	·		XP_028869.1	similar to isocitrate dehydrogenase 1 (NADP+), soluble	566	1.00e-161
			1 78827 J	isonitrate dehydronenses 1 (NADD+) soluble	200	566 1 000 161

			T46280	socitrate dehydrogenase (NADP) (EC 1.1.1.42), cytosolic [similarity]	565	565 1.00e-161
			XP_068996.1	similar to isocitrate dehydrogenase 1 (NADP+), soluble	436	1.00e-122
NM_011802	Mm.30088	F:(C-D)	NP_006651.2	ClpX caseinolytic protease X homolog; energy-dependent regulator of proteolysis;		<u> </u>
NP_035932.1		-2.08		ClpX (caseinolytic protease X, E. coli)	1041	-0
			CAB66856.1	hypothetical protein	856	0
AK004138	Mm.29364 F:(C-D)	F:(C-D)	CAA36480.1	ORFII		
BAB23187.1		-2.06			125	1.00e-65
•			NP_060110.1	hypothetical protein FLJ20048	243	8.00e-61
			AAC51269.1	putative p150	126	5.00e-52
			AAC51271.1	putative p150	129	3.006-51
			AAC51276.1	putative p150	127	3.00e-51
			AAA88037.1	unknown protein	127	3.00e-51
NM_008509	Mm.1514	F:(C-D)	NP_000228.1	lipoprotein lipase precursor		
NP_032535.1		-2.05,				
		F:(HI-D)				· · · · ·
		-2.42			838	
			AAH11353.1	Similar to lipoprotein lipase	836	
			AAC61679.1	lipoprotein lipase precursor	602	1.00e-170
			NP_006024.1	endothelial lipase precursor; endothelial cell-derived lipase	436	1.00e-120
			NP_000227.1	lipase C precursor	380	1.00e-103
			AAA59520.1	hepatic lipase precursor	379	1.00e-103
			A28997	triacylglycerol lipase (EC 3.1.1.3) precursor, hepatic	379	1.00e-103
NM_013541	Mm.426	F:(C-D)	5822569	Chain A, Crystal Structure Of Hgstp1-1[v104] Complexed With The Gsh Conjugate	377	1.00e-1
NP 038569.1		-2.05		Of (+)-Anti-Bpde		0.5
	-		2554839	Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1[v104]	377	1.00e-1
	•			Complexed With S-Hexylglutathione		0.4
			AAC13869.1	glutathione S-transferase-P1c	376	1.00e-1
						04
			NP_000843.1	glutathione transferase; deafness, X-linked 7; fatty acid ethyl ester synthase III	376	1.00e-1
						0.4

		4699783	Chain A, Human Glutathione S-Transferase P1-1 Y49f Mutant	375	1.00e-1
					0.4
		CAA30894.1	glutathione S-transferase	374	1.00e-1
		2981694	Chain A, Glutathione S-Transferase In Complex With Glutathione	374	1.006-1
		4139536	Chain A, Glutathione S-Transferase P1-1	374	04 1.00e-1
		2014220 +	Chain A History Of Prancforms Of A V4006 Milliant	27.7	0 4
		. 067+167	Orall A, numan Glucamione O-Fransierase PT-1 7 100 Mulant	າ ,	T-006-T
		23200508	Chain A, A Folding Mutant Of Human Class Pi Glutathione Transferase, Created By	372	1.00e-1
		100000	Mutating Glycine 146 Of The Wild-Type Protein To Alanine		03
		7/80951	Chain A, Giutathione S-Transterase In Complex With P-Bromobenzyigiutathione	372	1.006-1
		11514451	Chain A, Glutathione Transferase P1-1	371	1.00e-1
					03
-		23200510	Chain A, A Folding Mutant Of Human Class Pi Glutathione Transferase, Created By	371	1.00e-1
			Mutating Glycine 146 Of The Wild-Type Protein To Valine		0.3
		11514448	Chain A, Crystal Structure Of Pi Class Glutathione Transferase	370	1.00e-1
		4 4 4 4 7 7 7		(0 3
	-	//11/4	grudariiloile trafisierase (EC 2.3.1.10)/ Tatty-acyl-etryl-ester synthase (EC 3.1.1.0/)	χ ο ο	1.006-1
		20664358	Chain A, Crystal Structure Of A Recombinant Glutathione Transferase, Created By	360	1.00e-1
			Replacing The Last Seven Residues Of Each Subunit Of The Human Class Pi		00
			Isoenzyme With The Additional C-Terminal Helix Of Human Class Alpha		
			Isoenzyme		
		A60445	glutathione transferase (EC 2.5.1.18) pi - human	309	2.00e-8
NM_008756 Mm.4807	F:(C-D)	NP_002529.1 occludin	occludin		
NP_032782.1	-2.04			899	0

		AAH29886.1	occludin	897	0
NM_009349 Mm.299	F:(C-D)	AAD04723.1	thioether S-methyltransferase-like; similar to P40936 (PID:g731019)		<u> </u>
NP_033375.1	-2.04			271	8.00e-73
		092050	Indolethylamine N-methyltransferase (Aromatic alkylamine N-methyltransferase)		
	<u>.</u>		(Indolamine N-methyltransferase) (Arylamine N-methyltransferase) (Amine		
			N-methyltransferase)	267	7 2.00e-71
		NP_006765.3	indolethylamine N-methyltransferase; thioester S-methyltransferase-like	7 266	5.00e-71
		AAH33813.1	Unknown (protein for IMAGE:5209218)	266	5.00e-71
		NP_006160.1	nicotinamide N-methyltransferase	239	6.00e-63
NM_023850 Mm.38021	21 F:(C-D)	NP_003645.1	carbohydrate (keratan sulfate Gal-6) sulfotransferase 1; carbohydrate (chondroitin		
NP_076339.1	-2.03	,	6/keratan) sulfotransferase 1	778	3
		NP_004264.2	NP_004264.2 carbohydrate (chondroitin 6) sulfotransferase 3; chondroitin 6-sulfotransferase	305	5 1.00e-82
		BAA32576.1	chondroitin 6-sulfotransferase	303	3 7.00e-82
		NP_067628.1	carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6; macular dystrophy,		
			corneal, 1; carbohydate sulfotransferase 6; corneal N-acetylglucosamine		
,			6-sulfotransferase	214	t 4.00e-55
		NP_005760.1	carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4; N-acetylglucosamine		
			6-O-sulfotransferase	209	J 1.00e-53
		AAH35282.1	carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4	209	1.00e-53
		BAC11177.1	unnamed profein product	209	2.00e-53
NM_033146 Mm.4066	Mm.40667 F:(C-D)	Q9Y3B6	Protein CGI-112		
NP_149158.1	-2.03			393	1.00e-109
	-	NP 057133.1	CGI-112 protein	390	1.00e-108
		XP_033332.4	similar to Protein CGI-112	388	1.00e-108
NM_010324 Mm.19039	9 F:(C-D)	S29028	aspartate transaminase (EC 2.6.1.1) (clone 8C7)		
NP_034454.1	-2.01			810	0
•		S13035	aspartate transaminase (EC 2.6.1.1) - human	779	0
		NP_002070.1	aspartate aminotransferase 1; glutamic-oxaloacetic transaminase 1, soluble	779	0
-		AAH00525.1	glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2)	395	1 00e-109

0

7

 \sim

NM_016978	Mm.13694 F:(C-D)	F:(C-D)	NP 000265.1	NP_000265.1 ornithine aminotransferase predursor: Ornithine aminotransferase		
NP_058674.1		-2.01	l			
			AAB35211.1	ornithine aminotransferase, OAT [human, gyrate atrophy of the choroid and retina		<u> </u>
				(GACR) patient, Peptide Mutant, 439 aa]	780	
			3319072	Chain A, Human Ornithine Aminotransferase Complexed With The Neurotoxin		
			1	Gabaculine	727	
			XP_093015.1	ar to Ornithine aminotransferase, mitochondrial precursor (Ornithineoxo-acid	<u></u>	
				aminotransferase)	200	7
NM_011172	Mm.28456 F:(C-D)	F:(C-D)	NP_057419.2	proline dehydrogenase (oxidase) 1; proline oxidase 2; p53 induced protein		80L-
NF_055502.1		-5			889	-
			AAF21464.1	proline oxidase 2	888	
			AAD24775.1	proline dehydrogenase: PRODH		
			NP 005965.1	proline dehydrogenase, proline oxidase	778	5
			BAB3333 1	KIAA4663 sestein	821	0
			NP 067055 1		239	9.00e-63
NM_013809	Mm.10231	F:(C-D)	F:(C-D) NP 000757.2	cytochrome B450 subfamily IIA (at the tast is a subfamily IIA)	200	6.00e-51
NP_038837.1	2.	. 2		Statistics and substantial in (prierobal bital-inducible), polypeptide 13		
			016696	Cidochromo DAEO OAAO (OXIII A.O.)	563	1.00e-159
			Q45575	Gywdinolle r430 zA13 (CYPIIA13)	558	1.00e-158
			O4nOA0	coumarin /-hydroxylase (EC 1.14.14) cytochrome P450 2A6 -	555	1.00e-158
			NP_000753.2	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6; coumarin		
			-	7-hydroxylase; cytochrome P450, subfamily IIA (phenobarbital-inducible),		
				polypeptide 3; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	553	1 000 157
			P11509	Cytochrome P450 2A6 (CYPIIA6) (Coumarin 7-hydroxylase) (IIA3) (CYP2A3)	3	,
		·		(P450(I))	250	
			AAF13600.1	cytochrome P450-2A6	200	
			1609083A	Cytochrome P450IIA	ကိ	1.00e-15/
					551	1.00e-156
				Cytociniome P-450IIA (AA 1 - 489)	551	1.00e-156
				Cyrocin oine P450 ZA/ (CYPIIA7) (P450-IIA4)	543	1.00e-154
			7557	Cytochionie r450 ZA4 - numan	543	1.00e-154
) 7.55/000_141	cytochrome P450, subtamily IIA (phenobarbital-inducible), polypeptide 7 isoform 1	540	1.00e-153

540 1.00e-153		518 1.00e-146	· •	4 000-148		516 1.00e-146				514 1.00e-145	514 1.00e-145	514 1.00e-145		512 1.00e-145	512 1.00e-145	19;		511 1.006-144		511 1.00e-144	509 1.00e-144	509 1.00e-144	509 1.00e-144	509 1.00e-144			508 1.00e-144	507 1.00e-143	506 1.00e-143
sytochrome P450 - human	cytochrome P450 - human	P-450 IIA3 protein (1 is 3rd base in codon)	cytochrome P450, subfamily IIF, polypeptide 1; microsomal monooxygenase;	xenobiotic monooxygenase; flavoprotein-linked monooxygenase; siittiiai to	cytochrome P450, subramily IIF, polypeptide 1 (H. sapteris)	cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6	cytochrome P450, subtamily IIC, polypeptide 9, cytochrome P450, subtamily IIC	(mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase;	microsomał monooxygenase; xenobiotic monooxygenase; flavoprotein-linked	monooxygenase	cytochrome P-450	cytochrome P-450	Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase)	(P-450MP)	cytochrome P-450 S-mephenytoin 4-hydroxylase	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19;	mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic	monooxygenase; flavoprotein-linked monooxygenase	Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2)	(S-mephenytoin 4-hydroxylase)	Unknown (protein for MGC:22146)	cytochrome P450 2F1	cytochrome P450-2B6	cytochrome P450	cytochrome P450, subfamily IIC, polypeptide 8 isoform 1; mephenytoin	4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase;	flavoprotein-linked monooxygenase; P450 form 1	cytochrome P-450 S-mephenytoin 4-hydroxylase	cytochrome P450 2C8 - human
138965	138967	CAA32117.1	NP_000765.2			NP_000758.1	NP_000762.2				AAB23864.2	BAA00123.1	P11713	•	AAA52157.1	NP_000760.1			P10632		AAH20596.1	AAL'69652.1	AAF13602.1	1506290A	NP_000761.2			AAA52160.1	S66382
				•			4.																			-			
				-																									

1 A B 3 5 7 9 7 1	extrochrome P450 arachidonic acid enoxygenase isoform Gvo 2G8 [human kidney]		
	Pentide Partial 485 aal	506	1.00e-143
F38462	S-menhenytoin 4"-hydroxylase (FC 1 14 14 -) cytochrome P450 2C19 - human	506	
201021		3	
NP_000763.1	cytochrome P450, subtamily IIC (mephenytoin 4-hydroxylase), polypeptide 18;		
	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17;		•
	microsomal monooxygenase; flavoprotein-linked monooxygenase	505	1.00e-142
AAA52161.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	505	1.00e-142
P33260	ome P450 2C18 (CYPIIC18) (P450-6B/29C)	200	1.00e-141
P24903	Cytochrome P450 2F1 (CYPIIF1)	496	1.00e-140
152418	cytochrome P450 - human	475	1.00e-133
138966	cytochrome P450 - human	467	1.00e-131
NP_000764.1	cytochrome P450, subfamily IIE, polypeptide 1; microsomal monooxygenase;		
	xenobiotic monooxygenase; flavoprotein-linked monooxygenase; cytochrome P450,		
	subfamily IIE (ethanol-inducible)	464	1.00e-130
AAF13601.1	cytochrome P450-2E1	464	1.00e-130
AAD13753.1	cytochrome P450 2E1	460	1.00e-129
NP_085125.1	1 cytochrome P450, subfamily IIS, polypeptide 1; cytochrome P450 family member		
	predicted from ESTs; cytochrome P540, subfamily IIS, polypeptide 1	455	1.00e-127
BAB55227.1	unnamed protein product	451	1.00e-126
NP_085079.2	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7 isoform 2	445	1.00e-125
AAA52159.1	cytochrome P-450 S-mephenytoin 4-hydroxylase	418	1.00e-116
NP_110518.1	cytochrome P450, subfamily IIC, polypeptide 8 isoform 2; mephenytoin		
	4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase;		
	flavoprotein-linked monooxygenase; P450 form 1	406	1.00e-113
G38462	cytochrome P450 2C17 - human (fragment)	404	1.00e-112
AAA52143.1	cytochrome P450-IIB	389	1.00e-108
S21423	cytochrome P450 2C - human	382	1.00e-106
NP_000766.2	cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2;		
	microsomal monooxygenase; flavoprotein-linked monooxygenase; Cytochrome		
	P450, subfamily IIJ (arachidonic acid epoxygenase),	367	367 1.00e-101

		F			-
		pdb 4GTU	Glutathione S-Transferase; Chain: A, B, C, D, E, F, G, H; Ec: 2.5.1.18	325	4.00e-8 8
		NP_000842.2	glutathione S-transferase M5; glutathione S-transferase, Mu-5; glutathione S-alkyltransferase M5; glutathione S-alkyltransferase M5; S-(hydroxyalkyl)glutathione lyase M5; glutathione S-aralkyltransferase M5; GST class-mu 5	324	5.00e-8 8
	25	CAA48636.1	glutathione S-transferase	296	1.006-7
		AAH17836.1	Similar to glutathione S-transferase M2 (muscle)	289	2.00e-7
		pdb 3GTU	Glutathione S-Transferase; Chain: A, B, C, D; Ec: 2.5.1.18	288	3.00e-7
		XP_042722.1	similar to Glutathione S-transferase Mu 3 (GSTM3-3) (GST class-mu 3) (hGSTM3-3)	288	3.00e-7
		AAH08790.1	Unknown (protein for MGC:3704)	288	3.00e-7
		A35295	glutathione transferase (EC 2.5.1.18) class mu, GSTM3 - human	285	2.00e-7
		NP_671489.1	glutathione S-transferase M4 isoform 2; glutathione S-transferase, Mu-4; glutathione S-alkyltransferase M4; glutathione S-aryltransferase M4; S-(hydroxyalkyl)glutathione lyase M4; glutathione S-aralkyltransferase M4; GTS-Mu2; GST class-mu 4	283	2.00e-7
		XP_167023.1	similar to glutathione transferase M2 [Macaca fuscata]	257	7.006-6
		NP_666533.1	glutathione S-transferase M1 isoform 2; HB subunit 4; glutathione S-aryltransferase; S-alkyltransferase; glutathione S-transferase, Mu-1; glutathione S-aryltransferase; GST class-mu 1 S-(hydroxyalkyl)glutathione lyase; glutathione S-aralkyltransferase; GST class-mu 1	256	1.00e-6 7
AK003797 BAB23001.1	Mm.28252 F:(C-D)	CAD39140.1	hypothetical protein	319	2.00e-86

			NP_057364.1	NP_057364.1 carboxylesterase-related protein	434	434 1.00e-1
			·			20
AK014166 Mm.23082 F;(C-D) 076062	Mm.23082	F:(C-D)	076062	Delta(14)-sterol reductase (C-14 sterol reductase) (Sterol C14-reductase)		
BAB29187.1		-1.58		(Delta14-SR) (Transmembrane 7 superfamily member 2) (Another new gene 1)		
		-		(Putative sterol reductase SR-1)	536	536 1.00e-169
			AAH12857.1	.1 Similar to transmembrane 7 superfamily member 2	535	535 1.00e-169
			AAH09052.1	Similar to transmembrane 7 superfamily member 2	535	535 1.00e-169
			AAH38353.1	Similar to RIKEN cDNA 3110041O18 gene	469	469 1.00e-149
			NP_003264.1	NP_003264.1 transmembrane 7 superfamily member 2	514	514 1.00e-144
			XP_001795.5	XP_001795.5 similar to Lamin B receptor (Integral nuclear envelope inner membrane protein)		
				(LMN2R)	411	411 1.00e-116
			AAA59495.1	integral nuclear envelope inner membrane protein	411	411 1.00e-116
			NP 0022871	lamin B recentor.	407	407 1 00e-115

Master Table 1: Subtable 1B: Unfavorable Genes/Proteins

Main	Unigene	Behavior Human		Human Protein Name	Score E-Value	3-Value
			Protein			
NM_033373			BAA92054.1	unnamed protein product	598	1.0e-171
		U:(C-D)+				
NP_203537.1 Mm.20127 7.74	Mm.20127	7.74				
			NP_056330.3	keratin 23 isoform a; histone deacetylase inducible keratin 23;hyperacetylation-inducible type I	297	1.0e-170
				keratin; keratin, type I cytoskeletal 23; cytokeratin 23; type I intermediate filament		
				cytokeratin		
			AAH28356.1	type I intermediate filament cytokeratin	593	1.0e-169
			Q9C075	Keratin, type I cytoskeletal 23 (Cytokeratin 23) (K23) (CK 23).	591	1.0e-169
			T17294	hypothetical protein DKFZp434G032.1	322	7.0e-88
			NP_775320.1	keratin 23 isoform b; histone deacetylase inducible keratin 23; hyperacetylation-inducible type	321	2.0e-87
				I keratin; keratin, type I cytoskeletal 23; cytokeratin 23; type I intermediate filament		
				cytokeratin		
			S37780	keratin 20, type I-like, cytoskeletal	299	6.0e-81
			NP_061883.1	keratin 20; cytokeratin 20; keratin, type I cytoskeletal 20	299	8.0è-81
			P08727	Keratin, type I cytoskeletal 19 (Cytokeratin 19) (K19) (CK 19).	287	3.0e-77
			NP_002267.2	keratin 19; keratin, type I cytoskeletal 19; keratin, type I, 40-kd; cytokeratin 19; 40-kDa keratin	287	3.0e-77
				intermediate filament precursor gene		
			BAC04534.1	unnamed protein product	287	3.0e-77
			NP_000413.1	keratin 17	287	3.0e-77
	·		KRHU9	keratin 19, type I, cytoskeletal	586	7.0e-77
			NP_000214.1	keratin 12 (Meesmann corneal dystrophy); Keratin-12; keratin 12	283	3.0e-76
			NP_002266.2	keratin 15; keratin-15, basic; keratin-15, beta; type I cytoskeletal 15; cytokeratin 15	283	3.0e-76
			P19012	Keratin, type I cytoskeletal 15 (Cytokeratin 15) (K15) (CK 15).	283	3.0e-76
			NP_002265.1	keratin 13 isoform b; keratin, type I cytoskeletal 13; cytokeratin 13	281	2.0e-75
			NP 705694.1	keratin 13 isoform a; keratin, type I cytoskeletal 13; cytokeratin 13	281	2.0e-75

្ហហ

W	O	20	04/	092	416	•											٠							P	CT/	US:	200	4/01	1019	1
37.00	2.05-72	1.0e-74	2.0e-74	2.0e-74	2.0e-74	2.0e-74	2.0e-74	3.0e-70	3.0e-70	4.0e-70	3.0e-68	6.0e-68	8.0e-68	8.0e-68	8.0e-68	5.0e-67	8.0e-67	8.0e-67	2.0e-66	2.0e-66	3.0e-66	5.0e-66	7.0e-66	1.0e-65	2.0e-65	4.0e-65	5.0e-65	6.0e-65	1.0e-64	1.0e-64
100	707	278	278	278	277	277	277	264	264	263	257	256	256	256	256	253	252	252	251	251	250	249	249	. 248	248	247	246	246	245	245
Transfer 12 true T reductional true aution forms	Actault 13, type 1, cywaretetat, tuig aptice totill	keratin type 16	keratin 16; keratin, type I cytoskeletal 16; cytokeratin 16	keratin 16, type I, cytoskeletal	keratin 14, type I, cytoskeletal	Keratin 14	keratin 14; cytokeratin 14	type I hair keratin 6	Similar to keratin, hair, acidic, 6	cytokeratin 20		keratin 24	type I hair keratin 5	Keratin, type I cuticular HA5 (Hair keratin, type I HA5).	HHa5 hair keratin type I intermediate filament	simi	keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris)	Keratin, type I cytoskeletal	Keratin, type I cytoskeletal 10 (Cytokeratin 10) (K10) (CK 10).	type I hair keratin 3A; Ha-3I; hard keratin, type I,3I; keratin, hair, acidic,3A	keratin 10, type I, cytoskeletal	type I hair keratin 1; Ha-1; hard keratin, type I, 1; keratin, hair, acidic,1	Keratin, type I cuticular HA1 (Hair keratin, type I HA1).	Keratin, type I cuticular HA4 (Hair keratin, type I HA4).	type I hair keratin 3B; Ha-3II; hard keratin, type I, 3II; keratin, hair, acidic, 3B	keratin Ha1, type I, hair - human	hair keratin acidic 3-II	similar to keratin, hair, acidic, 4	type I hair keratin 4; hard keratin, type I, 4	type I hair keratin 2; Ha-2; hard keratin, type I, 2; keratin, hair, acidic, 2
7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	COTINI	AAA59460.1	NP_005548.2	JC4313	KRHUE	AAH02690.1	NP_000517.2	NP_003762.1	AAH43581.1	CAA51914.1	NP_002271.2	NP_061889.1	CAA76387.1	Q92764	CAA62286.1	XP_039921.3	AAH34697.1	P13645	NP 004129.2	076009	KRHU0	NP_002268.2	Q15323	O76011	NP_002270.1	S60034	CAA57956.1		NP_066293.2	NP 002269.2
			-																											

			1 ATT12020 1	المسامين فالمناف	240	0000
			AAH12079.1	Similar to molybdenum cofactor suiturase	319	Z.UUE-80
			NP_060417.1	molybdenum cofactor sulfurase	316	2.00e-85
S80191	,	F:(C-D)	AAH12418.1	Unknown (protein for MGC:9220)	828	0
AAB21335.1	-	-1.61				
			NP_001257.3	carboxylesterase 1 (monocyte/macrophage serine esterase 1); liver	824	0
				carboxylesterase; carboxylesterase 2 (liver)		_
			A48809	carboxylesterase - human	823	0
			BAA04650.1	carboxylesterase	823	0
			AAC60631.2	acyl coenzyme A:cholesterol acyltransferase	822	
			161085	carboxylesterase - human	822	0
			BAB85656.1	brain carboxylesterase hBr2	822	0
			AAD53175.1	egasyn	821	0
			P23141	Liver carboxylesterase precursor (Acyl coenzyme A:cholesterol acyltransferase)	821	0
			-	(ACAT) (Monocyte/macrophage serine esterase) (HMSE) (Serine esterase 1)		
				(Brain carboxylesterase hBr1)		
			NP_036254.1	carboxylesterase 3; brain carboxylesterase BR3	794	0
			157004	carboxylesterase - human (fragment).	734	0
			CAA37147.1	serine esterase N-terminal truncated (503 AA)	731	0
			AAA83932.1	carboxylesterase	631	1.00e-1
						79
			BAA84995.1	brain carboxylesterase hBr1	594	1.00e-1
		•				89
			NP_003860.1	carboxylesterase 2; intestinal carboxylesterase; liver carboxylesterase-2	463	1.00e-1 29
			AAH32095.1	Similar to carboxylesterase 2 (intestine, liver)	463	1.00e-1
						29
			AAB03611.1	carboxylesterase hCE-2	462	1.00e-1
						29
			CAD28531.1	hypothetical protein	449	1.00e-1
						25

			m 001//67	Of and a complete the second of the second o	244	2 0e-64 &
	,		XP_091605,5	similar to keratin complex-1, acidic, gene C23, kelatin complex-1, gene C23	117	2.00-01
			Q14532	Keratin, type I cuticular HA2 (Hair keratin, type I HA2).	244	2.0e-64
			CAA57179.1	hair type I acidic keratin	244	2.0e-64
			NP 000215.1	keratin 18	243	4.0e-64
			CAA82315.1	cytokeratin 9	243	7.0e-64
	·		CAA31377.1	cytokeratin 18 (424 AA)	243	7.0e-64
			NP 000217.1	keratin 9	243	7.0e-64
			137459	keratin Ha3-II, type I, hair	242	9.0e-64
			AAH00698.1	Keratin 18	242	1.0e-63
			AAA59468.1	keratin-10	239	6.0e-63
			CAA76389.3	type I hair keratin 7	236	5.0e-62
			NP 000412.1	keratin 10; Keratin-10	236	5.0e-62
			076015	Keratin, type I cuticular HA8 (Hair keratin, type I HA8).	. 236	6.0e-62
			NP 006762.3	type I hair keratin 8	236	6.0e-62
			AAH09754.1	Similar to keratin 18	233	4.0e-61
			NP 003761.2	type I hair keratin 7	232	9.0e-61
			BAC03847.1	unnamed protein product	216	9.0e-56
NM_010721	Mm.4846	n:(c-p)+	U:(C-D)+ NP_005564.1	lamin B1		~
NP_034851.1		7.08			878	0
			AAH12295.1	Similar to lamin B1	878	0
			Q03252	Lamin B2	530	1.0e-149
			NP_005563.1	lamin A/C isoform 2; 70 kDa lamin	522	1.0e-146
			P02545	Lamin A/C (70 kDa lamin)	522	1.0e-146
			CAA27173.1	put. lamin A precursor (aa 1-702)	525	1.0e-146
			AAH33088.1	Similar to lamin A/C	414	1.0e-114
			A45023	lamin B2 - human (fragment)	403	1.0e-111
			AAA36160.1	lamin A protein	385	1.0e-105
NM_026228	Mm.30239	n:(c-p)+	Mm.30239 U:(C-D)+ NP_071437.1	up-regulated by BCG-CWS		
NP_080504.1		4.88			788	0

			BAB55268.1	unnamed protein product	718	0
		·	BAA06685.1	KIAA0062	413	1.0e-114
			XP_046677.3	similar to KIAA0062	413	1.0e-114
			AAH15770.1	Unknown (protein for MGC:23235)	374	1.0e-102
			BAA96442.1	up-regulated by BCG-CWS	244	4.0e-63
NM_007702	Mm.449	U:(C-D)+	U:(C-D)+ AAC34987.1	cell death activator CIDE-A		
NP 031728.1		4.7	7.0		340	3.0e-92
	,		AAH31896.1	Similar to cell death-inducing DFFA-like effector a	319	5.0e-86
AK013885	Mm.15337		U:(C-D)+ NP_006759	BRCA1 associated protein	914	0
NP_082503.1	2	4.18				
			AAC24200	BRCA1-associated protein 2	857	0
			AAB88538	putative DDB p127-associated protein	410	1.0e-114
NM_011995			Q9Y6V0_2	[Segment 2 of 2] Piccolo protein (Aczonin).	4986	0
		U:(C-D)+		-		
NP_036125.2	Mm.40996	4.17				
			T00332.	hypothetical protein KIAA0559 - human	1918	0
			XP_168530	similar to KIAA0559 protein	1882	0
			Q9Y6V0_1	[Segment 1 of 2] Piccolo protein (Aczonin).	578	1.0e-163
			T00062	hypothetical protein KLAA0434 - human (fragment).	537	1.0e-151
	·		NP_003449	bassoon; zinc finger protein 231; neuronal double zinc finger protein	537	1.0e-151
			CAA77176	Bassoon protein	537	1.0e-151
	·		T00634	hypothetical protein H_DJ0897G10.1	512	1.0e-144
			CAB60727	aczonin	419	1.0e-116
NM_013623			NP_000598	orosomucoid 1 precursor; Orosomucoid-1 (alpha-1-acid glycoprotein-1); alpha-1-acid	165	4.0e-41
		U:(C-D)+		glycoprotein 1		
NP_038651.1	Mm.57239 4.05	4.05				
			AAH26238	orosomucoid 1	165	5.0e-41
			NP_000599	orosomucoid 2; alpha-1-acid glycoprotein, type 2	155	3.0e-38

 $\ddot{1}$

) | 20

25

0	0	0	1.0e-124	1.0e-124	1.0e-121	1.0e-121	1.0e-121	1.0e-119		1.0e-119	8.0e-86	1.0e-82	1.0e-82	1.0e-82	1.0e~82	1.0e-74
1806	1791	1776	446	446	434	434	434	428		428	317	306	306	306	306	280
Laminin beta-3 chain precursor (Laminin 5 beta 3) (Laminin Blk chain) (Kalinin B1 chain).	laminin B1½ chain precursor - human	S B3 chain	laminin, beta 2 precursor; laminin S	Laminin beta-2 chain precursor (S-laminin) (Laminin Bls chain).	laminin beta precursor; similar to AAB92586 (PID:g2708707)	laminin beta-2 chain precursor (version 1)	beta2/S laminin chain	laminin beta 1 related protein		laminin, beta 1 precursor	Similar to laminin, beta 1	laminin alpha5 chain precursor	laminin alpha 5; laminin alpha-5 chain	bA157P1.1.1 (laminin alpha 5)	Laminin alpha-5 chain precursor	Usher syndrome type IIa protein
013751	A53612	219	.1 NP_002283	.2 P55268	AD43183.	A55677	AA56130.	AF22284.		NP_002282	AH26018.	AM12527.	NP_005551 .3	AC22310.	015230	AF75819.
+(Q-	4.05	4	4		A 1	7	υ ₊	7	1	4	A 1	4 1	4	1 G	J	A 1
	Mm.4732 4												·			-
	NP 032510.1															·

NP_009054	Usherin	280	1.0e-74
AAG53651.	netrin 4 precursor	280	1.0e-74
AAC23748.	Usher syndrome type IIa protein	279	2.0e-74
NP_067052	netrin 4; beta-netrin	278	4.0e-74
BAB67800.	KIAA1907 protein	275	4.0e-73
AAH45172.	Similar to Laminin chain beta 2	264	6.0e-70
NP_002284	laminin, gamma 1 precursor; formerly LAMB2	251	7.0e-66
.2 P11047	Laminin gamma-1 chain precursor (Laminin B2 chain).	251	7.0e-66
XP_113963	similar to laminin alpha 3b chain	250	9.0e-66
NP_006050	laminin, gamma 3 precursor	234	5.0e-61
9N9X6O	Laminin gamma-3 chain precursor (Laminin 12 gamma 3).	234	5.0e-61
AAC51867.		230	1.0e-59
BAC11679.	unnamed protein product	226	1.0e-58
NP_004813	netrin 1; netrin 1, mouse, homolog of	213	1. 0. 45. 90.
CAA41418. 1	laminin A chain	203	1.0e-51
P25391	Laminin alpha-1 chain precursor (Laminin A chain).	202	3.0e-51

NM_026156 Mm.23739 U.(C-D)+ XP_048364.2 NP_080432.1 3.75 BAB15807.1 NP_080432.1 BAB84891.1 NM_013786 NP_064581.1 NM_013786 U.(C-D)+ NP_038814.1 Mm.26719 3.68 AAB88252 AAC39922 NP_038814.1 Mm.26719 3.68 AAB88252 AAC39922 NP_03699 NP_065762 Q92781	3.75 U:(C-D)+ ? B E E E E E E E E E E E E E E E E E E E		similar to Laminin alpha-1 chain precursor (Laminin A chain) Similar to PP3898 KIAA1177 protein HCNP protein; XPA-binding protein 2 Similar to HCNP protein; XPA-binding protein 2 FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; oxidoreductase; NAD+	1604 1603 1400 1318 607 473	3.0e-51 0 0 0 0 0 1.0e-172 1.0e-133
	(C-D)+ 775 F E E E E E E E E E E E E E E E E E E E		similar to PP3898 XAB2 KIAA1177 protein HCNP protein; XPA-binding protein 2 Similar to HCNP protein; XPA-binding protein 2 FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; NAD+	1604 1603 1400 1318 1147 607	0 0 0 0 1.0e-172
	(C-D)+ 75 FE FE		similar to PP3898 XAB2 KIAA1177 protein HCNP protein; XPA-binding protein 2 Similar to HCNP protein; XPA-binding protein 2 FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; oxidoreductase; NAD+	1604 1603 1400 1318 1147 607	0 0 0 0 1.0e-172 1.0e-133
Mm.26719	-(D)+		XAB2 KIAA1177 protein HCNP protein; XPA-binding protein 2 Similar to HCNP protein; XPA-binding protein 2 FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; NAD+	1604 1603 1400 1318 1147 607	0 0 0 0 1.0e-172 1.0e-133
Mm.26719	+(0-		XAB2 KIAA1177 protein HCNP protein; XPA-binding protein 2 Similar to HCNP protein; XPA-binding protein 2 FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; NAD+	1603 1400 1318 607 473	0 0 0 1.0e-172 1.0e-133
Mm.26719	+(0-		KIAA1177 protein HCNP protein; XPA-binding protein 2 Similar to HCNP protein; XPA-binding protein 2 FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; oxidoreductase; NAD+	1400 1318 1147 607 473	0 0 0 1.0e-172 1.0e-133
Mm.26719	+(0-		HCNP protein; XPA-binding protein 2 Similar to HCNP protein; XPA-binding protein 2 FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; oxidoreductase; NAD+	1318 1147 607 473	0 1.0e-172 1.0e-133
Mm.26719	-D)+		Similar to HCNP protein; XPA-binding protein 2 FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; oxidoreductase; NAD+	1147 607 473	1.0e-172
Mm.26719	-D)+		FLJ00081 protein 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; oxidoreductase; NAD+	607 473	1.0e-172 1.0e-133
Мт.26719	-D)+		3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; oxidoreductase; NAD+	473	1.0e-133
Mm.26719	:(C-D)+ 68		3(alpha->beta)-hydroxysteroid epimerase; retinol dehydrogenase; oxidoreductase; NAD+		
Мт.26719	-89				
			-dependent 3 alpha-hydroxysteroid dehydrogenase		
	1	AAB88252	oxidative 3 alpha hydroxysteroid dehydrogenase	442	1.0e-124
	1	AAC39922	sterol/retinol dehydrogenase	404	1.0e-112
	٦.	NP_003699	microsomal NAD+-dependent retinol dehydrogenase 4	399	1.0e-111
	1	NP_683695	orphan short-chain dehydrogenase / reductase; retinol dehydrogenase similar protein	312	6.0e-85
	I	NP_005762	NADP-dependent retinol dehydrogenase/reductase; 3-alpha hydroxysteroid dehydrogenase	300	3.0e-81
)]	Q92781	11-cis retinol dehydrogenase (11-cis RDH).	283	4.0e-76
	A	AAH28298	Similar to retinol dehydrogenase 5 (11-cis and 9-cis)	281	1.0e-75
	4	NP_002896	retinol dehydrogenase 5 (11-cis and 9-cis); retinol dehydrogenase 5 (11-cisand 9-cis)	272	1.0e-72
	4	AAD32458	retinol dehydrogenase homolog	267	2.0e-71
	4	AAF82748	retinol dehydrogenase homolog isoform-1	252	1.0e-66
NM_009345	F	P04053	DNA nucleotidylexotransferase (Terminal addition enzyme) (Terminal	771	0
); <u>n</u>	U:(C-D)+		deoxynucleotidyltransferase) (Terminal transferase).	_	
NP_033371.1 Mm.25620 3.66	99	·			
	d l	AAA53100	terminal DON'T	191	0
	Λ	WXHU	DNA nucleotidylexotransferase (EC 2.7.7.31)	765	0
	A	AAA61136	terminal deoxynucleotidyltransferase	369	1.0e-101

Ŋ

 $\ddot{\vdash}$

러

20

C)

WO 20	04/092416]	PCT/US2	004/010	191
1.0e-127	1.0e-124	1.0e-111	1.0e-107	1.0e-100	2.0e-96	1.0e-88	5.0e-83	3.0e-81	9.0e-72	3.0e-64	3.0e-64	3.0e-64	3.0e-64	3.0e-64
453	445	401	387	366	352	326	307	301	270	.245	245	245	245	245
glycoprotein 330	<pre>low density lipoprotein-related protein 1B (deleted in tumors); low density lipoprotein receptor related protein-deleted in tumor</pre>	candidate tumor suppressor protein	unnamed protein product	candidate tumor suppressor protein	Chain A, Crystal Structure Of The Ldl Receptor Ywtd-Egf Domain Pair.	MEGF7	low density lipoprotein-related protein 2 - human	similar to MEGF7	alpha-2 macroglobulin receptor	LDL receptor member LR3	low density lipoprotein receptor related protein - human	low density lipoprotein receptor-related protein 5; low density lipoprotein receptor-related protein 7; osteoporosis pseudoglioma syndrome		low density lipoprotein receptor-related protein 6; low density lipoprotein-related protein 6
AAB02882. 1	NP_061027 .1	AAL38109. 1	BAB70786. 1	AAL38108. 1	11JQA	BAA32468. 1	I38467	XP_035037	CAA38905. 1	AAC72791. 1	JE0372	NP_002326	AAK52433. 1	NP_002327
												·		
								-	·					
·														

1.0e-54		3.0e-54		2.0e-76	2			1.0e-170				1.0e-155	1.0e-150	1.0e-132	1.0e-132	1.0e-132	1.0e-131	1.0e-131	1.0e-131		1.0e-130	1.0e-126	1.0e-126	1.0e-113	1.0e-113	3.1e-69	8.1e-68	1.1e-67
213		212	T	285	2			603			1	554	375	330	330	330	327	327	327		327	312	312	414	252	167	166	. 166
20 day - 14.	epidermal growth factor (beta-urogastrone), urogastrone	candidate tumor suppressor protein			neurogiobin			CCR4 carbon catabolite repression 4-like (S. cerevisiae); CCR4-like (carbon catabolite	repression 4, S. cerevisiae)			nocturnin	pol protein	polymerase	Gaq-Pro-Pol protein	polymerase	pol/env ORF (bases 3878-8257) first start codon at 4172; Xxx; putative	polymerase	Endogenous retrovirus HERV-K10 putative pol polyprotein [Includes: Reverse	transcriptase; Endonuclease]	Gag-Pro-Pol-Env protein	Gag-Pro-Pol protein	pol protein	nocturnin	gag-pro-pol precursor protein	polymerase	polymerase	polymerase
	001954 1	AAL38107.			NP_067080			P_036250.1	,			AAG01389.1	AAM81188.1	AAK11553.1	AAD51797.1	AAD21097.1	AAA88033.1	AAK11554.1	P10266		AAD51793.1	AAD51796.1	AAL60056.1	AAG01388.1	AAG18012.1	AAC63294.1	AAC63291.1	AAC63292.1
	dN L	A -	4		Zi_	U:(C-D)+	3.28	Mm.86541 U:(C-D)+ NP_036250.1	3.08,	U:(HI-D)	2.08		\\		V	A	A	A	P		Y	A	¥	A	V	¥	V.	¥
		·				Mm.21511 U:(C-D)+		Mm.86541																				
					NM_022414		NP_071859.1	U70139	AAB62717.1																			

0

15

Ñ

D

*** •		04/0											_															
2.1e-67	3.1e-67	0		1.0e-169	1.0e-168	1.0e-168	1.0e-167	1.0e-167	1.0e-167	1.0e-167	1.0e-167			1.0e-107	1.0e-106	1.0e-101	3.0e-96	6.0e-96	6.0e-94		7.0e-94	7.0e-94	7.0e-94		8.0e-93	8.0e-93		1.0e-92
163	164	989		595	593	591	589	589	589	588	588			391	387	369	353	352	346		345	345	345		342	342		341
polymerase	polymerase	1	protein 14	GTP-binding protein alpha q subunit	GTP-binding protein alpha q	Guanine nucleotide-binding protein G(Y), alpha subunit (Alpha-11)	Guanine nucleotide-binding protein G(q), alpha subunit	GTP-binding protein alpha-q - human (fragment)	guanine nucleotide binding protein (G protein), alpha 11 (Gq class); Guanine	guanine nucleotide binding protein alpha 11 subunit	guanine nucleotide binding protein (G protein), q polypeptide; Guanine	nucleotide-binding protein (G protein), q; similar to guanine nucleotide binding protein	(G protein), q polypeptide (H. sapiens)	guanine nucleotide binding protein (G protein), alpha 15 (Gq class)		similar to Guanine nucleotide-binding protein, alpha-11 subunit (GL2)	Guanine nucleotide-binding protein G(O), alpha subunit 2	guanine nucleotide binding protein alpha oB	Guanine nucleotide-binding protein G(i), alpha-1 subunit (Adenylate cyclase-inhibiting	G alpha protein)	hypothetical protein	guanine nucleotide-binding regulatory protein alpha-inhibitory subunit	guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2;	Guanine nucleotide-binding protein (G protein), alpha-	guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O	Similar to guanine nucleotide binding protein (G protein), alpha inhibiting activity	polypeptide 2	guanine nucleotide-binding protein alpha-i subunit
AAC63293.1	AAC63290.1	U:(C-D)+ NP_004288.1		AAC50363.1	AAB64301.1	P29992	P50148	S71963	NP_002058.1	AAB64303.1	NP_002063.1			NP_002059.1	XP_009220.2	XP_095102.1	P29777	AAM12609.1	P04898		CAB43212.2	AAA52556.1	NP_002061.1		NP_066268.1	AAH14627.1		AAA52581.1
		U:(C-D)+	3.01																									
		Mm.22322	-																									
		NM_008137	NP_032163.1																									

			NP 002060.3	quanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1	341	2.0e-92
				guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3; 87U6	340	3.0e-92
			AAA52584.1	guanine nucleotide-binding protein	338	1.0e-91
			XP_170405.1	similar to Guanine nucleotide-binding protein G(T), alpha-3 subunit (Gustducin alpha-3 chain)	329	7.0e-89
AK009292	Mm.30487	U:(C-D)+	Mm.30487 U:(C-D)+ NP_005085.1	solute carrier family 27 (fatty acid transporter), member 4; fatty acid transport protein 4		
BAB26196.1		2.94,				
		U:(HI-D)			7. 7.0	1 06-158
		70.7	1 07070111	11.1.	707	1 00 138
			AAH04268.1	Unknown (protein for IMAGE:3613739)	492	1.06-130
			AAH09959.1	Unknown (protein for MGC:16752)	299	7.0e-80
			BAB55156.1	unnamed protein product	295	1.0e-78
			NP_077306.1	solute carrier family 27 member 3; fatty acid transport protein 3	295	1.0e-78
			NP_054750.1	very long-chain acyl-CoA synthetase homolog 1	286	6.0e-76
			NP_036386.1	solute carrier family 27 (fatty acid transporter), member 5; very long-chain acyl-CoA		
				synthetase homolog 2; very long-chain acyl-CoA synthetase-related protein; likely		
				ortholog of mouse solute carrier family 27 (fatty acid transporter), member 5	276	6.0e-73
			NP_003636.1	solute carrier family 27 (fatty acid transporter), member 2; very long-chain		
				fatty-acid-coenzyme A ligase 1; very-long-chain acyl-CoA synthetase	274	3.0e-72
			AAH03654.1	Similar to hypothetical protein MGC4365	249	8.0e-65
M12573	Mm.6388	U:(C-D)+	U:(C-D)+ NP_005336.2	heat shock 70kDa protein 1A; heat shock 70kD protein 1A; heat shock-induced		
AAA37863.1		2.94		protein; dnaK-type molecular chaperone HSP70-1	347	2.0e-94
			P08107	Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2)	347	2.0e-94
			NP_005337.1	heat shock 70kDa protein 1B; heat shock 70kD protein 1B	345	6.0e-94
			A29160	dnaK-type molecular chaperone HSPA1L	341	2.0e-92
			XP_175177.1	heat shock 70kD protein 1-like	312	6.0e-84
			NP_005518.1	heat shock 70kDa protein 1-like; Heat-shock 70kD protein-like-1	311	1.0e-83
			BAA32521.1	Heat shock protein 70 testis variant	310	3.0e-83
			XP_166348.1	similar to heat shock protein	310	3.0e-83

Ŋ

 $\ddot{}$

끔

 $\tilde{\sim}$

ம	
ത	
w	
⊣	

വ

W(20	04/	092	416	•																		PC	T/US2	:004/0	101	191	
1.0e-82	1.0e-80	1.0e-80	1.0e-80	1.0e-80	1.0e-80	1.0e-80	1.0e-80	1.0e-75	1.0e-75	1.0e-75		1.0e-75		1.0e-110		2.0e-76	2.0e-75	2.0e-75	2.09-75			2.0e-75		6.0e-75			3.0e-34	
308	301	301	301	301	300	300	300	285	285	285		285		401		284	281	281	281			281		280			142	
heat shock 70kD protein 1-like	Similar to heat shock cognate 71-kd protein	Unknown (protein for IMAGE:3906958)	Heat shock protein 70 testis variant	Similar to heat shock 70kD protein 8	heat shock 70kDa protein 2; heat shock 70kD protein 2; Heat-shock 70kD protein-2	Unknown (protein for MGC:33922)	heat shock protein	heat shock protein 70B' (AA 355-643)	similar to HEAT SHOCK 70 KD PROTEIN 6 (HEAT SHOCK 70 KD PROTEIN B)	heat shock 70kDa protein 6 (HSP70B')	heat shock 70kDa protein 6 (HSP70B'); heat shock 70kD protein 6 (HSP70B');	Heat-shock 70kD protein-6 (HSP70B')	Ras-related protein Rab-30			placental transforming growth factor-beta homolog	PLAB protein	prostate differentiation factor	prepro placental TGF-beta	Growth/differentiation factor 15 precursor (GDF-15) (Placental bone morphogenic	protein) (Placental TGF-beta) (Macrophage inhibitory cytokine-1) (MIC-1) (Prostate	differentiation factor) (NSAID-regulated protein 1) (NRG-1).	prostate differentiation factor; PTGF-beta; NSAID (nonsteroidal anti-inflammatory	drug)-activated protein 1			S100 calcium-binding protein A6; calcyclin; prolactin receptor-associated protein	
AAH34483.1	AAH07276.1	AAH15699.1	NP_006588.1	AAH08907.1	NP 068814.2	AAH36107.1	AAD11466.1	CAA36062.1	XP_084070.5	AAH35665.1	NP_002146.1		Q15771			JC5697	AAH00529	AAC24456	AAC39537			Q99988		NP_004855		6	NP_055439	
	-												Mm.26935 U:(C-D)+ Q15771	2.9	U:(C-D)+	2.8			-				-				7.7/	
													Mm.26935		Mm.3132	5						,	·			Mm.10014 U:(C-D)+	4	
													AK017185	BAB30625.1	389	Q9Z0J6			٠						NM_011313		NF_035443.1	

• •	•	-0"	 	 ٦

WO 2004		· -	1		0	0	10	۱0	ठ	12	121	2	12	12	18	j .	25	155	I‰		CT/\ 1	US20 1)04	/01 	019 L	1 1
	1.0e-30									1.0e-72	1.0e-72	1.0e-72	1.0e-72	1.0e-72	6.0e-62		8.0e-62	1.0e-55	9.0e-58	2.0e-55						
	131				898	846	846	845	845	273	273	273	273	273	237		236	229	223	216				736	734	723
	Major epididynus-specific protein E4 precursor (HE4) (Epididymal secretory protein E4) (WAP four-disulfide core domain protein 2				brain-derived neurotrophic factor receptor precursor, short splice form	neurotrophic tyrosine kinase, receptor, type 2	neurotrophin receptor tyrosine kinase type 2 truncated isoform	neurotrophin receptor tyrosine kinase type 2 truncated isoform	BDNF/NT-3 growth factors receptor precursor (TrkB tyrosine kinase) (GP145-TrkB) (Trk-B).	Unknown (protein for MGC:17113)	gene trkC protein	neurotrophic tyrosine kinase, receptor, type 3	TRKC	NT-3 growth factor receptor precursor (TrkC tyrosine kinase) (GP145-TrkC) (Trk-C	neurotrophic tyrosine kinase, receptor, type 1; Oncogene TRK	High affinity nerve growth factor receptor precursor (TRK1 transforming tyrosine kinase	protein) (p140-TrkA) (Trk-A).	nerve growth factor receptor precursor, high affinity	Chain X, Ligand Binding Domain Of Human Trkb Receptor	Chain X, Crystal Structure Of Trkb-D5 Bound To Neurotrophin-45			glucose-6-phosphatase, transport (glucose-6-phosphate) protein 1; Glucose-6-phosphate	transporter-1	glucose-6-phosphate transporter	glucose 6-phosphate translocase
	Q14508				173631	NP_006171	AAL67967.	AAL:67966	019910	AAH13693	173633	NP_002521	CAA12029	Q16288	NP_002520		P04629	TVHUTT	1WWBX	1HCFX			_	NP_001458.	AAD19898	CAA76898
U:(C-D)+ 2.7	(H.			U:(C-D)+	2.68									-									+(0-		7	
	U:(C Mm.27289 +2.7				Mm.3993												·					· · · ·		Mm.30087 2.68		
	AK005519 I49390		NM_008745		NP_032771.1																	NM_008063	_	NP_032089.1		

വ

20.

WC	20	04/0	092	416																	PC'	T/U	S20	04/	010	191	
1.0e-151		0			0		0	0		0	0		0	0		0		0	1.0e-112		1.0e-106		1.0e-105		1.0e-105		1.0e-105
533		1210			1207		918	781		780	780		889	647		647		647	404		382		381		380		380
PRO0685		metallocarboxypeptidase CPX-1 precursor	-		Potential carboxypeptidase X precursor (Metallocarboxypeptidase	CPX-1).	unnamed protein product	similar to Potential carboxypeptidase-like protein X2 precursor		Potential carboxypeptidase-like protein X2 precursor	Unknown (protein for IMAGE:5752707)		unnamed protein product	Similar to AE binding protein 1			protein 1; aortic carboxypeptidase-like protein	adipocyte transcription factor, AEBP1	Similar to carboxypeptidase X (M14 family)		Similar to carboxypeptidase Z		carboxypeptidase E precursor		CPZ gene product		carboxypeptidase E - human
AAF16691		NP_062555	۲.		Q96SM3		BAC11661.	XP 058409	.2	Q8N436	AAH36789.	1	BAC11672.	 AAH38588.	-	NP_001120	.2	JC5256	AAH32692.	1	AAH06393.		NP_001864	.1	NP_003643	τ.	S12461
			U:(C-D)+	5.66																-						-	
				Mm.22224																		,					
		NM_019696		NP_062670.1 Mm.22224 2.66																							

WO 20	004/09	2416														PC	r/US	S20	04/010	191	
1.0e-105	1.0e-103	5.0e-93	2.0e-92	2.0e-92	2.0e-92	5.0e-66	5.0e-66					1.0e-135		2.0e-89	2.0e-89	3.0e-68	_	ľ	6.0e-68	1.0e-67	
379	373	340	338	338	338	250	250				525	479		327	327	255			254	253	
carboxypeptidase E	carboxypeptidase N, polypeptide 1, 50kD precursor	similar to carboxypeptidase D	carboxypeptidase D	carboxypeptidase D precursor	Carboxypeptidase D precursor (gp180).	M (EC 3.4.17	carboxypeptidase M precursor				inositol(myo)-1(or 4)-monophosphatase 2	brain myo-inositol monophosphatase A2b; IMPase A2b	Chain A, Human Inositol Monophosphatase (E.C.3.1.3.25) Dimer Complex With Gadolinium	And Sulfate	inositol(myo)-1(or 4)-monophosphatase 1	hemoglobin alpha-1 globin chain			alpha 2 globin	alpha-2-globin	
BAA86053.	NP_001299	AAH45549.	AAC51775.	NP_001295	976370	D32619	NP 001865	ਜ਼			NP 055029	AAF07824		2HHMA	NP 005527	AAK37554.	· 		NP_000508	AAF72612.	1
										U:(C-D)+	63						U:(C-D)+	2.6			
						+	1			ר	Mm.34079 2.63						Mm.19611 U:(C-D)+	0	·		
									NM 053261	I	NP 444491.1					NM 008218		NP 032244.1			

Ŋ

٠	v	v	40	· • • • • • • • • • • • • • • • • • • •	U	 •	•

WO 2004 		416 		0	10	10	0	0	0	. 1	0		·	0	l	0	ı	0	1 1	PC	T/U	S2()04/ °	010)191
													i												
712	710			1748	1733	1332	1147	1046	842		2487			2487		2487		2482		1703	1098		186		
cytochrome P450, family 39, subfamily A, polypeptide 1; oxysterol 7alpha-hydroxylase;	oxysterol 7alpha-bydroxylase	1		Decorate communication Con	EAOCyst Computer Component Sees RTAA1699 protein		REC8	unnamed protein product	Similar to secretory protein SEC8		Multidrug resistance-associated protein 5 (Multi-specific	organic anion tranporter-C) (MOAT-C) (PABC11) (SMRP).		ATP-binding cassette, sub-family C, member 5; canalicular	multispecific organic anion transporter C	ABC protein		MRP5		multidrug resistance protein, short type	ATP-binding cassette, sub-family C, member 12 isoform e;	multidrug resistance-associated protein 9	ATP-binding cassette protein C11		
75750 EX	AAH10358			29 4 500	RAR21790	CAD39134	AAF66445	BAB14225	AAH26174		015440			NP_005679	н.	AAD37716.	, - 1	BAA76608.	g	JC5667	NP_150229	۲.	AAK58869.		-
+(Q.				U:(C-D)+	2.43							U:(C-D)+	2.45				-								
U:(C	MIII. 1 / 59 1				C760.IIIINI								Mm.20845												
NM_018887	INF_0015/3.1		NM_009148	1 121 CCO CT	NF_0551/4.1						NM_013790		NP_038818.1 Mm.20845 2.45			-									

Ŋ

WO 2004	<u> </u>		0	_	0			0		ि		0		ि		0		ि			ाट		S20 Tठ	-	_
	3																								
086	979		910		910			754		753		643		642		642		642			642		642		_
ATP-binding cassette, sub-family C, member 11 isoform a; multi-resistance protein 8; ATP-binding cassette transporter maps. ATP-hinding cassette protein C11	nding cassette transp	·	ATP-binding cassette protein C11 isoform A		ATP-binding cassette, sub-family C, member 11 isoform b;	multi-resistance protein 8; ATP-binding cassette transporter	MRP8; ATP-binding cassette protein Cll	ATP-binding cassette protein C12 isoform A		ATP-binding cassette, sub-family C, member 12 isoform a;	multidrug resistance-associated protein 9	multidrug resistance-associated protein		ABC transporter MOAT-B isoform		ATP-binding cassette, sub-family C, member 4; canalicular	multispecific organic anion transporter (ABC superfamily)	ATP-binding cassette, sub-family C, member 1 isoform 7;	multiple drug resistance-associated protein; multiple drug	resistance protein 1; multidrug resistance protein	multidrug resistance protein		ATP-binding cassette, sub-family C, member 1 isoform 1;	multiple drug resistance-associated protein; multiple drug	
NP_149163	AAK19755.		AAL99902.	<u>г</u> -1	NP_660187	, 단.		AAL79528.	r-1	NP_660188	۲.	AAL88745.	-	AAC27077.	7	NP_005836	۲.	NP_063957	г.		AAB83979.	-1	NP_004987	, H.	
		·				·																			
					·	٠													-						
		•					:																		

•	٦
С	۲
_	

vo	2004/	092	416	<u></u>	0	_	0	_	0	180	1	178	1	178	l	177	1	176	l	17,6	l		T/U)()-4/ 		/•/-
							i 			1.0e-180		1.0e-178		1.0e-178		1.0e-177		1.0e-176		1.0e-176		1.0e-17¢		1.0e-174		1.0e-17	_
642		640		639	635		634		633	632		624		624		621		619		617		610		610		019	
	multiple drug resistance-associated protein; multiple drug resistance protein 1; multidrug resistance protein	canalicular multispecific organic anion transporter		multidrug resistance protein (cell line H69AR)	ATP-binding cassette, sub-family C (CFTR/MRP), member 2;	canalicular multispecific organic anion transporter	ATP-binding cassette, sub-family C, member 9 isoform SUR2B;	sulfonylurea receptor 2A	multidrug resistance protein, canalicular	multidrug resistance protein 2 (MRP2)		ATP-binding cassette protein C12 isoform B		ATP-binding cassette, sub-family C, member 12 isoform b;	multidrug resistance-associated protein 9	ATP-binding cassette protein C4 splice variant A		bA46412.1 (ATP-binding cassette, sub-family C (CFTR/MRP),	member 4)	ATP-binding cassette, sub-family C, member 9 isoform SUR2A;	sulfonylurea receptor 2A	MRP3		ATP-binding cassette, sub-family C, member 3 isoform MRP3;	canicular multispecific organic anion transporter	multidrug resistance protein 3 (ABCC3)	
NP_063956	۲.	AAB09422.	T	DVHUAR	NP_000383	,г <u>.</u>	NP_064693	۲.	S71841	CAB45309.	н	AAL79529.	1	NP_660189	.1	AAN17334.	1	CAC36037.	7	NP_005682	Η.	AAD01430.		NP_003777	.2	CAA76658.	2
																											·
																,	.:				,				-		
-		-									_																
					-				-											,	1						

	BAA28146.	multidrug resistance-associated protein (MRP) -like protein-2	610	1.0e-174
	1	(MLP-2)		
, 4	JE0336	canalicular multispecific organic anion transporter	609	1.0e-173
	AA040749.	truncated ABCC12 protein	586	1.0e-166
	<u>H</u>			
	CAC69553.	multidrug resistance associated protein	583	1.0e-166
	Н			
	BAA92227.	FLJ00002 protein	579	1.0e-164
	Н.			
	NP_258261	ATP-binding cassette, sub-family C, member 10; multidrug	579	1.0e-164
	.2	resistance-associated protein 7		
	AAC36724.	sulfonylurea receptor 1	572	1.0e-162
	1			
	009428	Sulfonylurea receptor 1	572	1.0e-162
	AAB02278.	sulfonylurea receptor	571	1.0e-162
	, 1			
	AAB02418.	alternative splice (exon 17)	571	1.0e-162
	1			:
	AAK39642.	multidrug resistance-associated protein 7	269	1.0e-161
	1			
	NP_000343	ATP-binding cassette, sub-family C, member 8; Sulfonylurea	567	1.0e-161
	.1	receptor; sulfonylurea receptor (hyperinsulinemia)		
	NP_064694	ATP-binding cassette, sub-family C, member 9 isoform	555	1.0e-157
	.1	SUR2A-delta-14; sulfonylurea receptor 2A		
	AAB83983.	multidrug resistance protein	536	1.0e-152
	1			
	NP_063955	ATP-binding cassette, sub-family C, member 1 isoform 5;	536	1.0e-152
	.1	multiple drug resistance-associated protein; multiple drug		
	<u>,</u>	resistance protein 1; multidruq resistance protein		

WO 2	004/6	92416																	_ [CT	YU!	S20	04/0	101	191	
1.0e-150	1.0e-150		1.0e-150		1.0e-150			1.0e-143		1.0e-142	1.0e-129			1.0e-129		1.0e-114	1.0e-113		1.0e-106		1.0e-99		4.0e-87		3.0e-86	
531	531		530		530	•		509		206	461			461		411	410		386		363		322		319	
multidrug resistance protein	ATP-binding cassette, sub-family C, member 1 isoform 2;	multiple drug resistance-associated protein; multiple drug resistance protein	multidrug resistance protein		ATP-binding cassette, sub-family C, member 1	multiple drug resistance-associated protein; multiple drug	resistance protein 1; multidrug resistance protein	ATP-binding cassette, sub-family C, member 6; anthracycline	resistance-associated	multi-specific organic anion tranporter-E	ATP-binding cassette, sub-family C, member 1 isoform 4;	multiple drug resistance-associated protein; multiple drug	resistance protein 1; multidrug resistance protein	multidrug resistance protein		hypothetical protein DKFZp434L0827.1	FLJ00036 protein		multidrug resistance-associated protein homolog		Multiple drug resistance gene MRP1 (5' partial)		Multiple drug resistance gene MRP1 (partial)		Unknown (protein for IMAGE:2957862)	
AAB83981.	NP_063915	ਜ਼	AAB83980.	1	NP_063953	н.		NP_001162	.2	AAD51293.	NP_063954	۲.		AAB83982.	П	T43469	BAB15736.	<u>ਜ</u>	AAB71756.	1	AAC15784.	П	AAC05808.	1	AAH07229.	1
	_								•		 		<u>.</u>							-						
						-				,												•				·
												•														

WU	200	04/092	2416																		P	CI	/US	200	14/0
6.0e-84		1.0e-82	1.0e-80		2.0e-79			-		2.0e-79		5.0e-77		1.0e-72		1.0e-69		3.0e-63		1.0e-61		5.0e-61			
311		307	300		296					296		288		274		264		242		237		235			
Unknown (protein for IMAGE:3355848)		ATP-binding cassette, sub-family C, member 3 isoform MRP3A;	sulfonylurea receptor		cystic fibrosis transmembrane conductance regulator,	ATP-binding cassette (sub-family C, member 7); cystic fibrosis	transmembrane	conductance regulator; ATP-binding cassette, sub-family C	member 7; CFTR/MRP	Cystic fibrosis transmembrane conductance regulator (CFTR)	(cAMP-dependent chloride channel).	MRP3s1 protein		Similar to ATP-binding cassette, sub-family C (CFTR/MRP),	member 4	anthracycline resistance associated protein		Similar to hypothetical protein FLJ00002		cystic fibrosis transmembrane conductance regulator		ATP-binding cassette, subfamily B, member 4 isoform C; P	glycoprotein 3/multiple drug resistance 3;	P-glycoprotein-3/multiple drug resistance-3; multiple drug	resistance 3
AAH01636.	- 1	NP_064421	AAA99227.	Ä	NP_000483	2.				P13569		AAD38185.		AAH41560.	-	CAA65019.	~	AAH24103.	-	AAB46340.		NP_061338	٠.		
											-				·:-										•
				•				•			-		•												·

			NP 000434	ATP-binding cassette, subfamily B, member 4 isoform A; P	232	4.0e-60
				glycoprotein 3/multiple drug resistance 3;		
,	•			P-glycoprotein-3/multiple drug resistance-3; multiple drug		
				resistance 3	·	
			NP_000918	ATP-binding cassette, sub-family B (MDR/TAP), member 1; P	232	5.0e-60
			٠.	glycoprotein 1/multiple drug resistance 1;		
				P-glycoprotein-1/multiple drug resistance-1; multidrug		
				resistance 1		
			AAA59575.	P-glycoprotein	232	5.0e-60
			н			
			P08183	Multidrug resistance protein 1 (P-glycoprotein 1) (CD243	232	5.0e-60
				antigen).		
			AAB46341.	coded for by human cDNA M96936 (NID:g180293)	227	1.0e-58
			r- I			
			NP_061337	ATP-binding cassette, subfamily B, member 4 isoform B; P	226	3.0e-58
			۲.	glycoprotein 3/multiple drug resistance 3;		
	,			P-glycoprotein-3/multiple drug resistance-3; multiple drug		
				resistance 3		
			AAH39085.	Similar to ATP-binding cassette, sub-family C (CFTR/MRP),	215	6.0e-55
			1	member 11		
			T34527	hypothetical protein DKFZp434I2115.1	211	6.0e-54
			AAB46352.	transmembrane chloride conductor protein	210	1.0e-53
			н			
AK018132 M	Mm.41370 U:(C-D)+	:(C-D)+	AAH12375.1	Similar to KIAA1001 protein		
BAB31086.1	2.	2.44			903	0
			NP_055775.1	KiAA1001 protein	901	0
			AAB03341.1	arylsulfatase A	266	8.0e-70
			NP_000478.2	arylsulfatase A precursor	266	8.0e-70
			AAH14210.1	Similar to arylsulfatase A	266	1.0e-69

				And the Market A. Chain: D. Synopym: Cerebroside-3-Sulfate-Sulfatese; Ec: 3.1.6.8;	262	2.0e-68
			pdb 1E25	Alyisuiliatase A, Ohain: 1; Oynonym: Cerebroside-3-Sulfate-Sulfatase; Ec: 3.1.6.8;	261	3.0e-68
				Andenifetase A. Chain: P. Synonym: Cerebroside-3-Sulfate-Sulfatase; Ec. 3.1.6.8	261	3.0e-68
				Himan Ankinifatase A	261	4.0e-68
			\prod	Andsulfatase A: Chain: P: Synonym: Cerebroside-3-Sulfate-Sulfatase; Ec: 3.1.6.8	257	5.0e-67
			NP 000503.1	N-acetylgalactosamine-6-sulfatase precursor; Galactosamine (N-acetyl)-6-sulfate		
			1	Sulfatase: chondroitinase	251	3.0e-65
			A A H22389 1	Unknown (protein for MGC:24090)	237	5.0e-61
			NP 004033 1	an/sulfatase F	237	7.0e-61
		,	XP 035467 1	similar to arvisulatase F	235	2.0e-60
			A A H20729 1	Linknown (nrotein for MGC:31932)	233	1.0e-59
			NP 001660 1	andsulfatase Dinecursor, isoform a	230	7.0e-59
			1000100 TH	Tumor-associated calcium signal transducer 1 precursor (Major gastrointestinal		
NM 008532				tumor-associated protein GA733-2) (Epithelial cell surface antigen) (Epithelial glycoprotein)		
- Titl		U:(C-D)+		(EGP) (Adenocarcinoma-associated antigen) (KSA) (KS 1/4 antigen) (Cell surface		
NP 032558.1 Mm.4259	Mm.4259	2.41	P16422	glycoprotein Trop-1).	446	1.0e-125
				tumor-associated calcium signal transducer 1 precursor; membrane component, chromosome 4,		
				surface marker (35kD glycoprotein); MK-1 antigen; antigen identified by monoclonal antibody		1
	-		NP 002345	AUA1	446	1.0e-125
			AAA35723	enithelial glycoprotein (EGP) precursor	444	1.0e-124
			A48149	carcinoma-associated antigen GA733-1 precursor	265	2.0e-70
				tumor-associated calcium signal transducer 2 precursor; membrane component, chromosome 1,		
				surface marker 1 (40kD glycoprotein, identified by monoclonal antibody GA733); epithelial		
			NP 002344	glycoprotein-1	263	5.0e-7C
				Tumor-associated calcium signal transducer 2 precursor (Pancreatic carcinoma marker protein		
			P09758	GA733-1) (Cell surface glycoprotein Trop-2).	262	1.0e-69
AK004984	Mm.15875	U:(C-D)+	Mm.15875 U:(C-D)+ AAA53500.1	cytochrome P450 IID6		(
BAB23719.1	1	2.38			186	1.0e-45

WO 2004	1/09)24	16																ļ	PC	T/U	JS2	004	/01	019	1
1 0e-45	3 0e-45	0.00	3.0e-45		0	0	0	0	1.0e-150	1.0e-150	1.0e-150	1.0e-150	1.0e-150	1.0e-144	1.0e-144	1.0e-144	1.0e-144	1.0e-144			1.0e-154	1.0e-140	1.0e-140	1.0e-116	3.0e-91	4.0e-54
780	184	5 3	184		712	710	710	701	531	530	530	529	529	509	509	509	208	208			541	496	496	416	333	209
NP_000097.1 cytochrome P450, subfamily IID, polypeptide 6; debrisoquine 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked			cytochrome P450db1		Synapsin III	synapsin III isoform IIIa	synapsin III isoform IIIc	synapsin III isoform IIIb	synapsin IIb	synapsin II isoform Па	synapsin II isoform IIb	Synapsin II	synapsin IIb	synapsin I isoform Ib; brain protein 4.1	synapsin I isoform Ia; brain protein 4.1	synapsin I splice form a	Synapsin I (Brain protein 4.1).	synapsin To			ketohexokinase isoform b	ketohexokinase isoform a	ketohexokinase (fructokinase)	ketohexokinase	ketohexokinase	ketohexokinase
NP_000097.1		AAA35737.1	AAA36403.1		014994	NP 003481	NP 598344.	NP 598343	JC4940.	NP 598328	NP 003169	Q92777	AAC33789	NP_598006	NP_008881	A35363	P17600	AAC41931			NP_006479	NP_000212	AAH06233	CAA55346	CAA06409	CAA70516
				11·(C-D)+																U:(C-D)+	2.35					
				Mm 10364 [II:(C-D)+	5		·														Mm.22451	:				
				NM_013722	NP 038750.1	\top						-							NM_008439		NP_032465.1					

Ŋ.

 \vdash

15

20

WC	2004/	092	416																	PC	T/U:	S2 0	04/6	10	191
		0	0	2.0e-82		3.0e-82	2.0e-81			7.0e-99		2.0e-85	6.0e-85		2.0e-78	3.0e-78	7.0e-78		5.0e-61			-	0		0
		999	661	304		304	301			360		315	313		292	291	290		234	2091	<u>.</u>	-	1957		1955
		Adipophilin (Adipose differentiation-related protein) (ADRP).	adipose differentiation-related protein; adipophilin	cargo selection protein (mannose 6 phosphate receptor binding protein; placental protein 17	Cargo selection protein TIP47 (47 kDa mannose 6-phosphate receptor-binding protein) (47	kDa MPR-binding protein) (Placental protein 17).	placental protein 17b1; PP17b1			protein tyrosine phosphatase type IVA, member 1; Protein tyrosine phosphatase IVA1	protein tyrosine phosphatase type IVA, member 2 isoform 1; protein tyrosine phosphatase	IVA2; protein tyrosine phosphatase IVA; phosphatase of regenerating liver 2	ptp-IV1b, PTP-IV1 gene product	protein tyrosine phosphatase type IVA, member 3 isoform 1; potentially prenylated protein	tyrosine phosphatase	protein tyrosine phosphatase - human (fragment).	hPRL-3	protein tyrosine phosphatase type IVA, member 3 isoform 2; potentially prenylated protein	tyrosine phosphatase	adenylate cyclase 6 isoform a			KIAA0422		adenylate cyclase 6 isoform b
		Q99541	NP 001113	NP_005808		060664	AAD11622			NP_003454		NP_003470	AAB39331		NP_116000	168523	AAC29314		NP_009010	NP_056085	 H		BAA24852.	2	NP_066193
	U:(C-D)+	2.35							U:(C-D)+	2.3											U:(C-D)+	2.29			
	·	Mm.381								Mm.28909 2.3								-			Mm.15709 U:(C-D)+	1			
	NM_007408	NP_031434.1						NM_011200		NP_035330.1										NM_007405		NP_031431.1			

WO 2004/092416

cyclase). 106 adenylate cyclase 8; Adeny type VIII adenylyl cyclase 433 adenylate cyclase 2; ATP F cyclase; adenylyl cyclase AMP synthetase Adenylate cyclase, type II cyclase). 340 adenylate cyclase 4; adeny Adenylate cyclase 7 (Ca(2+)/calmodulin activat 105 adenylate cyclase 7 adenylate cyclase 3; adeny pyrophosphate-lyase 77. adenylyl cyclase type VI adenylyl cyclase type VI adenylate cyclase (EC 4.6. adenylate cyclase (EC 4.6. adenylate cyclase (EC 4.6. adenylate cyclase (EC 4.6. adenylate cyclase (EC 4.6. adenylate cyclase (EC 4.6.			095622	Adenylate cyclase, type V (ATP pyrophosphate-lyase) (Adenylyl	1290	0
type VIII adenylyl cyclase 8, Adenylyl cyclase-8, brain type VIII adenylyl cyclase - human type VIII adenylyl cyclase - human syclase; adenylyl cyclase 2; ATP pyrophosphate-lyase; type II adenylate cyclase; adenylyl cyclase 2; adenylate cyclase II; 3',5'-cyclic AMD synthetase Adenylate cyclase; type II (ATP pyrophosphate-lyase) (Adenylyl cyclase). denylate cyclase 4; adenylate cyclase type IV cyclase). denylate cyclase, type I (ATP pyrophosphate-lyase) (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). denylate cyclase 3; adenylyl cyclase, type III; ATP pyrophosphate-lyase 372 adenylate cyclase (EC 4.6.1.1), brain - human (fragment). adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylate cyclase adenylate cyclase adenylyl cyclase adenylyl cyclase adenylate cyclase adenylyl cyclase a		,		•		
type VIII adenylyl cyclase - human type VIII adenylyl cyclase - human cyclase; adenylate cyclase I; 3',5'-cyclic AMP synthetase Adenylate cyclase, type II (ATP pyrophosphate-lyase) (Adenylyl 624 cyclase). Adenylate cyclase 4; adenylate cyclase type IV Adenylate cyclase, type II (ATP pyrophosphate-lyase) (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase). (Ca(2+)/calmodulin activated adenylyl cyclase 3; adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 372 372 373 374 375 376 377 377 377 377 377 377	-		NP_001106	cyclase 8; Adenylyl cyclase-8,	713	0
type VIII adenylyl cyclase - human 133 adenylate cyclase 2; ATP pyrophosphate-lyase; type II adenylate 660 cyclase; adenylyl cyclase 2; adenylate cyclase II; 3',5'-cyclic AMP synthetase Adenylate cyclase, type II (ATP pyrophosphate-lyase) (Adenylyl 624 cyclase). 13. daenylate cyclase 4; adenylate cyclase type IV 616 13. unnamed protein product Adenylate cyclase, type I (ATP pyrophosphate-lyase) 601 (Ca(2+)/calmodulin activated adenylyl cyclase). 600 105 adenylate cyclase 3; adenylyl cyclase, type III; ATP 591 pyrophosphate-lyase 37. KIAA0511 protein pyrophosphate-lyase (EC 4.6.1.1), brain - human (fragment). 372 adenylate cyclase (EC 4.6.1.1), brain - human (fragment). 372 adenylate cyclase (EC 4.6.1.1) 312 312 313 3147 adenylyl cyclase (EC 4.6.1.1) 316			н <u>.</u>			
adenylate cyclase 2; ATP pyrophosphate-lyase; type II adenylate 660 cyclase; adenylyl cyclase 2; adenylate cyclase II; 3',5'-cyclic AMP synthetase Adenylate cyclase, type II (ATP pyrophosphate-lyase) (Adenylyl cyclase). 340 adenylate cyclase 4; adenylate cyclase type IV Adenylate cyclase, type I (ATP pyrophosphate-lyase) (Ca(2+)/calmodulin activated adenylyl cyclase). Adenylate cyclase 7 adenylate cyclase 3; adenylyl cyclase, type III; ATP pyrophosphate-lyase 372 Adenylate cyclase type VI adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 372 adenylate cyclase (EC 4.6.1.1), brain - human (fragment). 372 adenylate cyclase (EC 4.6.1.1) adenylate cyclase 376 377 adenylyl cyclase 377 378 Adenylyl cyclase 378 Adenylyl cyclase 379 Adenylyl cyclase 370 Adenylyl cyclase 371 Adenylyl cyclase 372 Adenylyl cyclase 374 Adenylyl cyclase	_		S48687	adenylyl cyclase -	713	0
cyclase; adenylyl cyclase 2; adenylate cyclase II; 3',5'-cyclic AMP synthetase Adenylate cyclase, type II (ATP pyrophosphate-lyase) (Adenylyl cyclase). 340 adenylate cyclase 4; adenylate cyclase type IV 616 13. unnamed protein product Adenylate cyclase, type I (ATP pyrophosphate-lyase) 601 602(2+)/calmodulin activated adenylyl cyclase). 602 603 604 606 607 608 608 609 609 609 609 600 600	-		NP_065433	cyclase 2; ATP pyrophosphate-lyase; type II	099	0
AMP synthetase Adenylate cyclase, type II (ATP pyrophosphate-lyase) (Adenylyl cyclase). 340 adenylate cyclase 4; adenylate cyclase type IV 616 13. unnamed protein product Adenylate cyclase, type I (ATP pyrophosphate-lyase) 601 (Ca(2+)/calmodulin activated adenylyl cyclase). 105 adenylate cyclase 3; adenylyl cyclase, type III; ATP 600 107 adenylate cyclase 3; adenylyl cyclase, type III; ATP 791 108 pyrophosphate-lyase 109 adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 109 adenylate cyclase (EC 4.6.1.1), brain - human (fragment). 110 adenylate cyclase (EC 4.6.1.1) 111 adenylyl cyclase (EC 4.6.1.1) 112 adenylate cyclase 113 adenylyl cyclase 114 adenylyl cyclase 115 adenylyl cyclase 116 adenylyl cyclase 117 adenylyl cyclase			٦.	adenylate cyclase II;		
Adenylate cyclase, type II (ATP pyrophosphate-lyase) (Adenylyl cyclase). 340 adenylate cyclase 4; adenylate cyclase type IV 616 13. unnamed protein product Adenylate cyclase, type I (ATP pyrophosphate-lyase) 601 (Ca(2+)/calmodulin activated adenylyl cyclase). 600 105 adenylate cyclase 3; adenylyl cyclase, type III; ATP 591 pyrophosphate-lyase 37. KIAA0511 protein 37. KIAA0511 protein 37. MAA0511 protein 37. MAA0511 product 37. MAA0511 product 37. MAA0511 product 37. MAA0511 product 37. MAA0511 product 38. Adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 372 38. Adenylate cyclase (EC 4.6.1.1) 38. Adenylate cyclase (EC 4.6.1.1) 39. Adenylate cyclase 30. Adenylate cyclase 30. Adenylyl cyclase				AMP synthetase		
adenylate cyclase 4; adenylate cyclase type IV unnamed protein product Adenylate cyclase, type I (ATP pyrophosphate-lyase) 601 (Ca(2+)/calmodulin activated adenylyl cyclase). 600 adenylate cyclase 3; adenylyl cyclase, type III; ATP 591 pyrophosphate-lyase KIAA0511 protein adenylyl cyclase (BC 4.6.1.1), brain - human (fragment). 372 unnamed protein product adenylate cyclase (BC 4.6.1.1) adenylate cyclase (BC 4.6.1.1) adenylate cyclase (BC 4.6.1.1) adenylate cyclase (BC 4.6.1.1)			Q08462	cyclase, type II (ATP pyrophosphate-lyase)	624	1.0e-178
adenylate cyclase 4; adenylate cyclase type IV unnamed protein product Adenylate cyclase, type I (ATP pyrophosphate-lyase). (Ca(2+)/calmodulin activated adenylyl cyclase). adenylate cyclase 3; adenylyl cyclase, type III; ATP pyrophosphate-lyase KIAA0511 protein adenylyl cyclase type VI adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 320 adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1)				cyclase).		
unnamed protein product Adenylate cyclase, type I (ATP pyrophosphate-lyase) 601 (Ca(2+)/calmodulin activated adenylyl cyclase). adenylate cyclase 3; adenylyl cyclase, type III; ATP 591 pyrophosphate-lyase KIAA0511 protein adenylyl cyclase type VI adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 372 unnamed protein product adenylate cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1)	-		NP_640340	cyclase 4; adenylate cyclase type	919	1.0e-176
unnamed protein product Adenylate cyclase, type I (ATP pyrophosphate-lyase) 601 (Ca(2+)/calmodulin activated adenylyl cyclase). adenylate cyclase 3; adenylyl cyclase, type III; ATP 600 adenylate cyclase 13; adenylyl cyclase, type III; ATP 691 pyrophosphate-lyase KIAA0511 protein adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 372 unnamed protein product 320 adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1)	-		.2			
Adenylate cyclase, type I (ATP pyrophosphate-lyase) (Ca(2+)/calmodulin activated adenylyl cyclase). adenylate cyclase 7 adenylate cyclase 3; adenylyl cyclase, type III; ATP pyrophosphate-lyase KIAA0511 protein adenylyl cyclase (BC 4.6.1.1), brain - human (fragment). adenylate cyclase (BC 4.6.1.1) adenylate cyclase (BC 4.6.1.1) adenylate cyclase (BC 4.6.1.1) adenylate cyclase (BC 4.6.1.1) adenylyl cyclase A 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9			CAD62613.	unnamed protein product	919	1.0e-176
Adenylate cyclase, type I (ATP pyrophosphate-lyase) (Ca(2+)/calmodulin activated adenylyl cyclase). adenylate cyclase 7 adenylate cyclase 3; adenylyl cyclase, type III; ATP 591 pyrophosphate-lyase KIAA0511 protein adenylyl cyclase type VI adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 372 unnamed protein product adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1) adenylyl cyclase			н			
adenylate cyclase 7 adenylate cyclase 3; adenylyl cyclase, type III; ATP 591 pyrophosphate-lyase KIAA0511 protein adenylyl cyclase type VI adenylyl cyclase (EC 4.6.1.1), brain - human (fragment). 372 unnamed protein product 3306 adenylyl cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1) 312 adenylyl cyclase (EC 4.6.1.1)			Q08828	type	601	1.0e-171
adenylate cyclase 7 adenylate cyclase 3; adenylyl cyclase, type III; ATP 591 pyrophosphate-lyase KIAA0511 protein adenylyl cyclase type VI adenylate cyclase (EC 4.6.1.1), brain - human (fragment). 372 unnamed protein product adenylate cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1) adenylyl cyclase (EC 4.6.1.1)				activated adenylyl		
adenylate cyclase 3; adenylyl cyclase, type III; ATP pyrophosphate-lyase KIAA0511 protein adenylyl cyclase type VI adenylate cyclase (EC 4.6.1.1), brain - human (fragment). adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylyl cyclase adenylyl cyclase	_		NP_001105		009	1.0e-171
adenylate cyclase 3; adenylyl cyclase, type III; ATP Pyrophosphate-lyase KIAA0511 protein adenylyl cyclase type VI adenylate cyclase (EC 4.6.1.1), brain - human (fragment). adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylyl cyclase adenylyl cyclase			.1			•
Pyrophosphate-lyase KIAA0511 protein adenylyl cyclase type VI adenylate cyclase (EC 4.6.1.1), brain - human (fragment). unnamed protein product adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylyl cyclase adenylyl cyclase			NP_004027	•-	591	1.0e-168
### RIAA0511 protein adenylyl cyclase type VI adenylate cyclase (EC 4.6.1.1), brain - human (fragment). unnamed protein product adenylate cyclase (EC 4.6.1.1) adenylate cyclase (EC 4.6.1.1) adenylyl cyclase adenylyl cyclase		-	.1	pyrophosphate-lyase		
adenylyl cyclase type VI adenylate cyclase (EC 4.6.1.1), brain - human (fragment). 372 1 unnamed protein product adenylate cyclase (EC 4.6.1.1) adenylyl cyclase adenylyl cyclase			BAA25437.	KIAA0511 protein	584	1.0e-166
adenylyl cyclase type VI adenylate cyclase (EC 4.6.1.1), brain - human (fragment). 372 1 unnamed protein product adenylate cyclase (EC 4.6.1.1) adenylyl cyclase adenylyl cyclase		٠.	1		-	
adenylate cyclase (EC 4.6.1.1), brain - human (fragment). 372 1 unnamed protein product adenylate cyclase (EC 4.6.1.1) adenylyl cyclase 306	-		AAF82479.	cyclase type	409	1.0e-113
adenylate cyclase (EC 4.6.1.1), brain - human (fragment). 372 1 unnamed protein product 320 adenylate cyclase (EC 4.6.1.1) 312 adenylyl cyclase 306			н			
adenylyl cyclase (EC 4.6.1.1) adenylyl cyclase 320 330			PQ0227	cyclase (EC 4.6.1.1), brain - human	372	1.0e-102
adenylate cyclase (EC 4.6.1.1) 312			BAB71270.	protein	320	2.0e-86
adenylate cyclase (EC 4.6.1.1) adenylyl cyclase 306			Н			
. adenylyl cyclase 306	_		137136	cyclase (EC	312	4.0e-84
1			AAC28647.	enyly1	306	3.0e-82
			Н			

വ

 Ξ

S

PCT/US2004/010191

WO 2		/092	416	5																P	CT/U	US2	004	/016	191
5.0e-77	4.0e-71		2.0e-53		2.0e-53		2.0e-53		2.0e-52		1.0e-151		1.0e-138		1.0e-107			1.0e-106	5.0e-95		5.0e-95	1.06-98	2 08-94		
288	269		210		210		210		207		531		489		384		•	384	358		358	357	343		
Similar to adenylate cyclase 7	unnamed protein product		KIAA0520 protein		adenylate cyclase 9		Adenylate cyclase, type IX (ATP pyrophosphate-lyase) (Adenylyl	cyclase).	adenylyl cyclase type IX		sulfotransferase family, cytosolic, 1C, member 1 isoform a;	sulfotransferase 1C1	sulfotransferase 1C1		sulfotransferase family, cytosolic, 1C, member 2;	sulfotransferase family, cytosolic, 1C, member C2;	sulfotransferase 1C2	Sulfotransferase 1C2 (SULTIC) (SULTIC#2).	thyroid hormone sulfotransferase	404044	OUNTIONII (PROCEIN IOF MGC:13356)	thyroid hormone sulfotransferase (EC 2.8.2) B2 -	Phenol-sulfating phenol sulfotransferase 1 (P-PST)	fotransferase) (Ts-	(ST1A3).
AAH39891. 1	BAC11613.		BAA25446.	2	NP_001107	.1	060503		CAB65084.	1	 U:(C-D)+ NP_001047	.1	AAF72802.	Į	NP_006579	.5		075897	AAB65154.	Z Z H 1 O R O K	Armicoso.	JC5885	P50225		
					·						U:(C-D)+	2.27													
												Mm.19320										-			
										,	AK007384	BAB25002.1	-												

		AAH00923.	Sulfotransferase family, cytosolic, 1A, phenol-preferring,	343	3.0e-94
		H	member 1, isoform a		
,		157945	phenol-sulfating phenol sulfotransferase	342	4.0e-94
		JC5248	aryl sulfotransferase (EC 2.8.2.1) HAST2	342	5.0e-94
		AAB31317.	aryl sulfotransferase ST1A3 [human, liver, Peptide, 295 aa].	342	5.0e-94
		H			
		JC2523	aryl sulfotransferase (EC 2.8.2.1) brain isoform	341	1.0e-93
	÷	S52399	aryl sulfotransferase (EC 2.8.2.1)	339	3.0e-93
		NP_001045	sulfotransferase family, cytosolic, 1A, phenol-preferring,	337	1.0e-92
	·•.,	г.	member 2; thermostable phenol sulfotransferase;		-
			phenolic-metabolizing (P) form of PST; arylamine		
			sulfotransferase; aryl sulfotransferase; phenol-preferring		
			phenol sulfotransferase2; phenol-sulfating phenol		
	· · · ·		sulfotransferase 2		
		NP_003157	sulfotransferase family, cytosolic, 1A, phenol-preferring,	334	1.0e-91
		۲.	member 3; thermolabile phenol sulfotransferase;		
			catecholamine-sulfating phenol sulfotransferase; aryl		
			sulfotransferase; thermolabile (monoamine, M form) phenol		
			sulfotransferase; monoamine-sulfating phenosulfotransferase;		
			placental estrogen sulfotransferase; monoamine-preferring		
			sulfotransferase		
,		P50226	Phenol-sulfating phenol sulfotransferase 2 (P-PST) (ST1A2).	334	1.0e-91
		S52791	aryl sulfotransferase (EC 2.8.2.1)	333	2.0e-91
		AAC51149.	arylamine sulfotransferase	333	2.0e-91
	·	H			
		AAC99987.	aryl sulfotransferase	330	3.0e-90
		1			:
	·	NP_005411	sulfotransferase, estrogen-preferring; estrogen	315	9.0e-86
	· ·	다.	sulfotransferase		

/O 2	004	1/092	416											•							P	C T	r/Us	S 2 0	04/0	010	191	
7.06-85	4 00 B)) •	6.0e~55		1.0e-54		1.0e-54		1.0e-54			1.0e-54		1.0e-54		1.0e-54		1.0e-54					0	0	1.0e-62	2.0e-62	3.0e-62	
313	312	3	212		211		211		211			211		211		211		211					657	654	238	238	237	İ
sulfotransierase, estrogen-preierring	Arian A Arratal Otumba Of Umman Detronen Calfornese	A, Liystai Stiucture of numan isstigen. Mutant In The Presence Of Paps	Chain A, Crystal Structure Of Human Dehydroepiandrosterone	Sulfotransferase In Complex With Substrate	dehydroepiandrosterone sulfotransferase		alcohol/hydroxysteroid sulfotransferase; hSTa		Alcohol sulfotransferase (Hydroxysteroid Sulfotransferase)	(HST) (Dehydroepiandrosterone sulfotransferase) (DHEA-ST) (ST2)	(ST2A3).	hydroxysteroid sulfotransferase SULT2Bla		hydroxysteroid sulfotransferase SULT2Bla		Chain A, Crystal Structure Of The Human Hydroxysteroid	Sulfotransferase In The Presence Of Pap.	hydroxysteroid sulfotransferase SULT2Blb					pleckstrin 2; pleckstrin 2 (mouse) homolog	pleckstrin 2 (mouse) homolog	pleckstrin; p47	Unknown (protein for MGC:17111)	protein kinase C substrate protein P47	
AAH27956. 1	4 5777 1	WC TUT	1J99A		AAA35758.	· Ĥ	AAB23169.	7	006520			AAC78553.	~ . ~	AAC78498.	- -	1ЕFНА	:	AAC78499.	~ 1				NP_057529	AAH08056	NP_002655	AAH18549	1408254A	
																·						U:(C-D)+	2.25					
																			-	٠.		Mm.10338 U:(C-D)+	,					
																					NM_013738	<u> </u>	NP_038766.1 0					

	~
•	_
•	`
•	

WO 20	04/09	241	6																PC	r/U	S2 00			91
0	0		0	1.0e-134		1.0e-117	36-00-0	0 . 0	37-90 6)	2 00-74	f 100.7	4 0e-74)	3.0e-64		3.0e-64		4.0e-64		4.06-64	4 00 b	, , ,	
1140	1136		842	477		421	000	007	205	ר ס א	270	6/2	278) 1	245		245		245	-	245	7 / 12	T # V	
synaptotagmin-like 4 (granuphilin-a)	ned protein product		bA524D16A.2.1 (novel protein similar to mouse granuphilin-a)	hassangs 2 2 (novel protein similar to mouse granuphilin-b)	4DION:2:4 DIOCET PROCESS	synaptotagmin-like 5		unnamed protein product		synaptotagmin-like 2 isoform b; chromosome 11 synaproragmin		KIAA1597 protein	7	synaptotagmin-like 2 isoform a; chromosome 11 synaptotagmin	Introve (protein for IMAGE:3942111)		hypothetical protein SB146		NADPH oxidase-related, C2 domain-containing protein		Similar to NADPH oxidase-related, C2 domain-containing protein		Similar to NADPH oxidase-related, C2 domain-concaining process	
NP_542775	200	BAC04287.	CAC16061.	1	CACION62.	NP_620135	Į.	BAB15030.	1	NP_115755	.2	BAB13423.	1	NP_116561	L. L. CCOOTIAN	ACM 0 2 6 2 3 .	AAK67636.	1	NP_116261	۲.	AAH15764.	. [AAH35725.	1
U:(C-D)+	2.22									·				-										
	Mm.38674		,																					
NM_013757	NP_038785.1 Mm.38674 2.22										-												w	

. 10

C	

VO 20)04/	092-	1 16	0		-			_				<u></u>	<u></u>		_		(0)	<u></u>	10			T/US				19
2.0e-54))	1.0e-154	1.0e-120	1.0e-119	1.0e-117	1.0e-81		4.0e-81	3.0e-65	7.0e-54	8.0e-50			1.0e-106	1.0e-106	1.0e-106		7.0e-85			5.0e-65	8.0e-64	
213				99/	762	542	432	427	422	302		301	248	210	197			387	387	386		315			246	242	
similar to synaptotagmin-like protein 3-a				transforming growth factor, beta 3	transforming growth factor-beta 3	Similar to transforming growth factor, beta 3	transforming growth factor, beta 2	transforming growth factor beta 2	transforming growth factor beta-2 precursor, long form	Transforming growth factor beta 1 precursor (TGF-beta 1).	transforming growth factor, beta 1 (Camurati-Engelmann disease); transforming growth factor,	beta 1; diaphyseal dysplasia 1, progressive (Camurati-Engelmann disease)	Human Transforming Growth Factor Beta 3, Crystallized From Peg 4000	Transforming Growth Factor Type Beta 2 (Tgf-B2).	Chain A, Solution Structure Of Tgf-B1, Nnn, Models 18-33 Of 33 Structures		general transcription factor IIF, polypeptide 1 (74kD subunit)		general transcription factor IIF, polypeptide 1 (74kD subunit)	RAP74	Transcription Initiation Factor IIf, Subunit; Chain: A, C, E, G; Fragment: Residues	2-119; Synonym: Transcription Initiation Factor Rap30	nlecketrin homology, like domain family A member 3. nlecketrin homology, like domain	procedum nominalgy-inco community by michigor by procedum nominalogy-inco comman,	family A, member 2	unnamed protein product	
XP_087804				NP_003230	CAA33024	AAH18503	NP_003229.	AAA50405	B31249	P01137		NP_000651	1TGK	1TFG.	1KLDA		U:(C-D)+ AAH00120.1		NP_002087.1	CAA45404.1	pdb 1F3U			,	NP_036528	BAC11454	
			U:(C-D)+	2.22													U:(C-D)+	2.21					11.(C-D)+		2.21		:
				Mm.1291				,																7,0,0	Mm.34346		
		NM_009368		NP_033394.1													AK013002	BAB28588.1			-		NM_013750	. 022000 CE	NP_038778.1		

വ

NP_032497.1 Mm.1012 2			Martin, Cypo i Cyconicai in Cyconicacini in Cyconicacini)	T:00:T
1017	U:(C-D)+			1.50	
	1	NP 002267	keratin 19; keratin, type I cytoskeletal 19; keratin, type I,	539	1.0e-153
		77.	40-kd; cytokeratin 19; 40-kDa keratin intermediate filament		
•			precursor gene		
		ККНОЭ	keratin 19, type I, cytoskeletal	539	1.0e-153
		NP_000413	keratin 17	453	1.0e-127
	· · ·	Н.			
		BAC04534.	unnamed protein product	453	1.0e-127
		1			
		KRHUE	keratin 14, type I, cytoskeletal	443	1.0e-124
		AAH02690.	Keratin 14	443	1.0e-124
. :		П		;	
		NP_000517	keratin 15; keratin-15, basic; keratin-15, beta; type I	443	1.0e-124
		.2	cytoskeletal 15; cytokeratin 15		
		NP_002266	keratin 15; keratin-15, basic; keratin-15; beta; type I	442	1.0e-124
		.2	cytoskeletal 15; cytokeratin 15		
-		P19012	Keratin, type I cytoskeletal 15 (Cytokeratin 15) (K15) (CK 15).	442	1.0e-124
-		NP_005548	keratin 16; keratin, type I cytoskeletal 16; cytokeratin 16	436	1.0e-122
		.2			
		JC4313	keratin 16, type I, cytoskeletal	436	1.0e-122
		NP_705694	keratin 13 isoform a; keratin, type I cytoskeletal 13;	433	1.0e-121
		۲.	cytokeratin13		
		KRHU3	keratin 13, type I, cytoskeletal, long splice form	433	1.0e-121
		NP_002265	keratin 13 isoform b; keratin, type I cytoskeletal 13;	432	1.0e-121
	,	.1	cytokeratin 13		
		AAA59460.	keratin type 16	431	1.0e-121
		н			

WO 20)04/	092416													PCT/U	S2004/		91
1.0e-114	1.0e-107	1.0e-107	1.0e-106	1.0e-105	1.0e-103		1.0e-101		T.0e~101	1.0e-99	3.0e-97	9.0e-97	9.0e-97	9.0e-97	1.0e-96	2.0e-96	4.0e-94	
409	386	386	384	380	374		365	1	365	361	353	352	352	352	351	350	343	
similar to keratin 17	Keratin, type I cytoskeletal 10 (Cytokeratin 10) (K10) (CK 10).	keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris)	keratin 10, type I, cytoskeletal	keratin 12 (Meesmann corneal dystrophy); Keratin-12; keratin 12	Kerstin 10. Kerstin-10	, , ,	Similar to keratin, hair, acidic, 6	-	type I hair keratin 6	keratin-10	type I hair keratin 5; Ha-5; hard keratin, type I, 5	type I hair keratin 5	Keratin, type I cuticular HA5 (Hair keratin, type I HA5).	HHa5 hair keratin type I intermediate filament	unnamed protein product	keratin 24	similar to keratin complex-1, acidic, gene C29; keratin	complex-1, gene C29
XP_039921	P13645	AAH34697.	KRHUO	NP_000214	T ND 000412	.1	AAH43581.	7	NP_003762	AAA59468. 1	NP_002271	CAA76387. 1.	092764	CAA62286. 1	BAC03847.	NP_061889	XP_091665	.3
							-							-	F ₂ , , , ,			
				·		-	Ü											

Ц

읔

വ

	NP 002268	type I hair keratin 1; Ha-1; hard keratin, type I, 1; keratin,	342	9.0e-94
	7	hair, acidic,1		
	Q15323	Keratin, type I cuticular HA1 (Hair keratin, type I HA1).	341	1.0e-93
	NP_002270	type I hair keratin 3B; Ha-3II; hard keratin, type I, 3II;	341	1.0e-93
	.1	keratin, hair, acidic,3B		
	NP_002269	type I hair keratin 2; Ha-2; hard keratin, type I, 2; keratin,	340	2.0e-93
	7	hair, acidic,2		
	NP_004129	type I hair keratin 3A; Ha-3I; hard keratin, type I,3I;	340	3.0e-93
	2.	keratin, hair, acidic, 3A		
	CAA57956.	hair keratin acidic 3-II	340	3.0e-93
	ᆏ			
	NP_061883	keratin 20; cytokeratin 20; keratin, type I cytoskeletal 20	340	3.0e-93
	т.			
	016009	Keratin, type I cuticular HA3-I (Hair keratin, type I HA3-I).	340	3.0e-93
	837780	keratin 20, type I-like, cytoskeletal - human	339	6.0e-93
	S60034	keratin Hal, type I, hair	337	2.0e-92
	AAH41070.	similar to keratin, hair, acidic, 4	337	2.0e-92
	1			
	014532	Keratin, type I cuticular HA2 (Hair keratin, type I HA2).	337	2.0e-92
	CAA57179.	hair type I acidic keratin	337	2.0e-92
	1			
	NP_066293	type I hair keratin 4; hard keratin, type I, 4	337	3.0e-92
,	.2			
	076011	Keratin, type I cuticular HA4 (Hair keratin, type I HA4).	334	1.0e-91
	I37459	keratin Ha3-II, type I, hair	332	5.0e-91
	NP_000217	keratin 9	325	9.0e-89
	.1			-
	CAA82315.	cytokeratin 9	325	9.0e-89

WO 20	004/092	416									1	PCT/US2	004/0	010191
4.0e-85	2.0e-83	5.0e-83	5.0e-83	5.0e-83	2.0e-82	2.0e-82	4.0e-82	1.0e-81	1.0e-81	7.0e-81	2.0e-79	6.0e-74	<u>`</u>	8.0e-74
313	307	306	306	306	304	304	303	301	301	299	294	276		275
keratin 19	gene product (clone 266) (266 AA)	keratin 18	Similar to keratin 18	cytokeratin 18 (424 AA)	keratin 10	Keratin 18	cytokeratin 20	Keratin, type I cuticular HA4 (Hair keratin, type I HA4).	type I hair keratin 8	type I hair keratin 7	type I hair keratin 7	keratin 23 isoform a; histone deacetylase inducible keratin 23; hyperacetylation-inducible type I keratin; keratin, type I cytokeratin 23. tyme I intermediate filement	cytokeratin	type I intermediate filamenț cytokeratin
BAA94607.	CAA29248. 1	NP_000215	AAH09754. 1	CAA31377. 1	AAA59199. 1	AAH00698. 1	CAA51914. 1	076015	NP_006762	CAA76389. 3	NP_003761	NP_056330		AAH28356. 1
										-				
			·					-			-			
														.

wo	200	4/09	9241	6	u·	-41*																	T/U	S2 0	04/	010		
2.0e-73	5.0e-73	5.0e-70		7.0e-65		1.0e-64		4.0e-63		1.0e-52		2 00.50)				133				- 77	8.Ue-47	0					٦
274	273	263		246		244		240		205	•	107	7		1		171	F			. 0	189	737					737
unnamed protein product	wittin time I cytoskeletal 23 (Cytokeratin 23) (K23) (CK 23).	to heartin 17	Similar to refacin 1/	similar to Keratin. type I cytoskeletal 18 (Cytokeratin 18)	147	(ALO) (ALO)	KEIGLIU		mutant keratin 9		Sratin, type i tytosketetai is tyjostetet	(K18) (CK 18)	Unknown (protein for IMAGE:5444378)					galectin 4; lectin galactoside-binding soluble 4	KIAA1879 protein				cytochrome P450, family 2, subfamily C, polypeptide 18;	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),	polypeptide 17; cytochrome P450, subfamily IIC (mephenytoin	4-hydroxylase), polypeptide 18; microsomal monooxygenase;	flavoprotein-linked monooxygenase	Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C).
BAA92054.	L		XP_209012	1. 100 av	##0T00 L	030000	AAB30058.	7	BAA19418.		XP_066374	.1	AAH33252.	H				NP 006140	Mm.15975 U:(C-D)+ BAB67772.1				NP_000763	다.				P33260
Щ			~		_		٠, ١	,	<u> </u>		- 1			<u> </u>			U:(C-D)+	2.2	U:(C-D)+	2.19,	U:(HI-D)	+2.62	Π			U:(C-D)+	2.18	
													_				Mm.21033 U:(C-D)+	9	Mm.15975	m							Mm.42101	
																NM 010707		NP_034837.1	AK007293	1	,				NM 010003	1	NP 034133.1 Mm.42101 2.18	

Ŋ

	NP 000760	cytochrome P450, family 2, subfamily C, polypeptide 19;	724	0
	н.	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),		
		polypeptide 19; mephenytoin 4'-hydroxylase; microsomal		-
		monooxygenase; xenobiotic monooxygenase; flavoprotein-linked		
		monooxygenase		
	AAB23864.	cytochrome P-450	719	0
-	7			
	BAA00123.	cytochrome P-450	719	
•	.ਜ			
	NP_000762	cytochrome P450, family 2, subfamily C, polypeptide 9;	719	0
	.2	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),	•	
		polypeptide 10; mephenytoin 4-hydroxylase; microsomal		
 -		monooxygenase; xenobiotic monooxygenase; flavoprotein-linked		
		monooxygenase; cytochrome P450, subfamily IIC (mephenytoin		
		4-hydroxylase), polypeptide 9		
	P10632	Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20)	717	0
		(P450 IIC2) (S-mephenytoin 4-hydroxylase).		-
	F38462	S-mephenytoin 4'-hydroxylase (BC 1.14.14) cytochrome P450	716	0
	•	2019		
-,	AAH20596.	Unknown (protein for MGC:22146)	716	0
	-			
	AAA52157.	cytochrome P-450 S-mephenytoin 4-hydroxylase	715	0
	1			
	1506290A	cytochrome P450	715	0
	P11713	Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin	715	0
	-	4-hydroxylase) (P-450MP).		

WO 2004/092416																	5200			<u></u>
0	0	0	0	0	1.0e-166	1.0e-163	1.0e-161					1.0e-157					1.0e-156		1.0e-155	1.0e-155
714	712	712	701	662	584	573	567					551					550		548	546
cytochrome P450, family 2, subfamily C, polypeptide 8 isoform 1; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase; P450 form 1	cytochrome P450 arachidonic acid epoxygenase isoform, Cyp 2C8 [human, kidney, Peptide Partial, 485 aa].	cytochrome P-450 S-mephenytoin 4-hydroxylase	cytochrome P-450 S-mephenytoin 4-hydroxylase.	cytochrome P450 - human	cytochrome P-450 S-mephenytoin 4-hydroxylase	cytochrome P450 2C17 - human	cytochrome P450, family 2, subfamily C, polypeptide 8 isoform	2; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),	polypeptide 8; mephenytoin 4-hydroxylase; microsomal	monooxygenase; xenobiotic monooxygenase; flavoprotein-linked	monooxygenase; P450 form 1	cytochrome P450, family 2, subfamily E, polypeptide 1;	cytochrome P450, subfamily IIE (ethanol-inducible), polypeptide	1; microsomal monooxygenase; xenobiotic monooxygenase;	flavoprotein-linked monooxygenase; cytochrome P450, subfamily	<pre>IIE (ethanol-inducible)</pre>	cytochrome P450-2E1		cytochrome P450 2C - human	cytochrome P450 2E1
NP_000761	AAB35292. 1	AAA52160. 1	AAA52161. 1	I52418	AAA52159. 1	G38462	NP_110518	г.				NP_000_4N	н.				AAF13601.	Ţ	S21423	AAD13753. 1
-													-							
											-									
· .								-												
								-												

VO 2004/092		m	10	101	10			١o	ıω					إس	, ພ	, w	1/U		(17-7 7)	11.	171
1.0e-137	1.0e-136	1.0e-133	1.0e-132	1.0e-132	1.0e-130			1.0e-129	1.0e-128					1.0e-128	1.0e-128	1.0e-128		1.0e-127		1.0e-127	
487	482	474	470	469	463			460	457					457	455	455		455		454	
cytochrome P450, family 2, subfamily F, polypeptide 1; cytochrome P450, subfamily IIF, polypeptide 1; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	cytochrome P450 2F1	cytochrome P450, family 2, subfamily B, polypeptide 6; cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6	Cytochrome P450 2F1 (CYPIIF1).	cytochrome P450-2B6	cytochrome P450, family 2, subfamily A, polypeptide 13;	cytochrome P450, subfamily IIA (phenobarbital-inducible),	polypeptide 13	Cytochrome P450 2A13 (CYPIIA13).	cytochrome P450, family 2, subfamily A, polypeptide 6; coumarin	7-hydroxylase; cytochrome P450, subfamily IIA	(phenobarbital-inducible), polypeptide 3; cytochrome P450,	<pre>subfamily IIA (phenobarbital-inducible), polypeptide 6;</pre>	xenobiotic monooxygenase; flavoprotein-linked monooxygenase	coumarin 7-hydroxylase (EC 1.14.14) cytochrome P450 2A6	cytochrome P450IIA	cytochrome P-450IIA (AA 1 - 489)		Cytochrome P450 2A6 (CYPIIA6) (Coumarin 7-hydroxylase) (IIA3)	(CYP2A3) (P450(I)).	cytochrome P450-2A6	
NP_000765	AAL69652.	NP_000758	P24903	AAF13602. 1	NP_000757	. 7.		016696	NP_000753	.2				04HUA6	1609083A	CAA32097.	1	P11509		AAF13600.	1
·																,		i			
											•										
									ı		•										

NP 000755	cytochrome P450, family 2, subfamily A, polypeptide 7 isoform	453	1.0e-127
.2	1; cytochrome P450, subfamily IIA (phenobarbital-inducible),		
	polypeptide 7		
P20853	Cytochrome P450 2A7 (CYPIIA7) (P450-IIA4).	452	1.0e-127
C34271	cytochrome P450 2A4 - human	451	1.0e-126
T38967	cytochrome P450 - human	446	1.0e-125
I38965 ·	cytochrome P450 - human	446	1.0e-125
CAA32117.	P-450 IIA3 protein (1 is 3rd base in codon)	423	1.0e-118
T			es.
NP_085125	cytochrome P450, family 2, subfamily S, polypeptide 1;	409	1.0e-114
Ħ.	cytochrome P450 family member predicted from ESTs; cytochrome		
	P540, subfamily IIS, polypeptide 1; cytochrome P450, subfamily		
	IIS, polypeptide 1		
AAD13466.	cytochrome P-450 2C	408	1.0e-113
1			
BAB55227.	unnamed protein product	405	1.0e-112
1			
138966	cytochrome P450 - human	389	1.0e-108
NP_085079	cytochrome P450, family 2, subfamily A, polypeptide 7 isoform	376	1.0e-104
.2	2; cytochrome P450, subfamily IIA (phenobarbital-inducible),		
	polypeptide 7		
NP_000766	cytochrome P450, family 2, subfamily J, polypeptide 2;	373	1.0e-103
7.	cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase)		
	polypeptide 2; microsomal monooxygenase; flavoprotein-linked		
	monooxygenase		
BAB85489.	cytochrome P450 2J2	373	1.0e-103
1			
AAA52143.	cytochrome P450-IIB	354	2.0e-97
1			

VO 2	004/092416						•			PCT/U	S2004/	01019
8.06-91	1.0e-90	2.0e-88	1.0e-85	3.0e-84	1.0e-74	1.0e-72	2.0e-72	6.0e-72	3.0e-70	5.0e-68	9.0e-63	3.0e-62
332	332	324	315	310	279	272	271	270	264	256	239	238
cytochrome P450 LID6	cytochrome P450, subfamily IID, polypeptide 6; debrisoquine 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase; cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing)-like 1	S-mephenytoin 4-hydroxylase	cytochrome P-450 HPH (120 AA)	Similar to hypothetical protein FLJ20359	debrisoquine 4-hydroxylase	hypothetical protein FLJ20359	cytochrome P450db1	cytochrome P450 epoxygenase	cytochrome P450 2A3, hepatic - human	cytochrome P-450 2C	similar to cytochrome P450, family 2, subfamily r, polypeptide 1; cytochrome P450, 2r1	cytochrome P450 CYP1B1
AAA53500. 1	NP_000097	AAL31348. 1	CAA35915.	AAH25761. 1	AAA35737. 1	NP_060251	AAA36403. 1	AAD30164.	O4HUPB	AAD13467. 1	XP_058459	AAC50809.
				-								
									_			
												
				,								**

3.0e-62		9.0e-60	4 2.0e-58	1 2.0e-57	0 4.0e-57	9 7.0e-57	7	4 0	0. 8	2 0	1.0e-137
238		229	224	221	220	219	1397	1294	1068	882	488
cytochrome P450, family 1, subfamily B, polypeptide 1; aryl hydrocarbon hydroxylase; cytochrome P450, subfamily I	<pre>injurocation mydrony rate (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile); microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase</pre>	Similar to cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 9	S-mephenytoin 4-hydroxylase	cytochrome P(1)-450	cytochrome P450, family 1, subfamily A, polypeptide 1; aryl hydrocarbon hydroxylase; cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1; flavoprotein-linked monooxygenase; cytochrome P1-450, dioxin-inducible; P450 form 6; xenobiotic monooxygenase; microsomal monooxygenase	cytochrome P-450-1	ATP-binding cassette, sub-family B, member 9 isoform 1	ATP-binding cassette, sub-family B, member 9 isoform 2	Similar to ATP-binding cassette, sub-family B (MDR/TAP), member 9	unnamed protein product	KIAA1520 protein
NP_000095		AAH20754.	AAL31347.	CAA26458.	NP_000490	AAA52139. 1	NP_062571	NP_062570	AAH17348. 1	BAC11171.	BAA96044.
	· · · · · · · · · · · · · · · · · · ·						U:(C-D)+				
	<u>-</u>	1					U Mm.41213 12			-	
		·							-	 	-
				-	.:		NM_019875				

WO 2	004/09:	2416					PCT/U	S2004/	010191
1.0e-132	1.0e-132	1.0e-132	1.0e-132	1.0e-132	.1.0e-131	1.0e-131 1.0e-131	1.0e-131	1.0e-131	1.0e-131
472	471	471	471	471	468	8 9 4 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8	467	466	466
ABC-transporter	таргв	peptide transporter	peptide transporter	transporter 2, ATP-binding cassette, sub-family B isoform 1; transporter 2, ABC (ATP binding cassette); ATP-binding cassette, sub-family B (MDR/TAP), member 3; antigen peptide transporter 2; peptide supply factor 2; peptide transporter PSF2; ABC transporter, MHC 2	peptide transporter	Antigen peptide transporter 1 (APT1) (Peptide transporter TAP1) (Peptide transporter PSF1) (Peptide supply factor 1) (PSF-1) (Peptide transporter involved in antigen processing 1). transporter 1, ATP-binding cassette, sub-family B; ATP-binding cassette, sub-family B (MDR/TAP), member 2; antigen peptide transporter 1; ATP-binding cassette, sub-family B, member 2; transporter, ATP-binding cassette, major histocompatibility		TAP2E	Antigen peptide transporter 2 (APT2) (Peptide transporter TAP2) (Peptide transporter PSF2) (Peptide supply factor 2) (PSF-2) (Peptide transporter involved in antigen processing 2).
BAB71769.	CAA80522.	AAC12903.	AAC12905.	NP_000535	AAC12906.	003518 NP_000584	AAA79901.	- CAA80523. 1	Q03519
	<u>.</u>								
				·			٠		

WO 20	104/092416					PCT	r/US20	04/010
1.0e-122	1.0e-122	1.0e-112	1.0e-110	1.0e-108	2.0e-99 6.0e-98	6.0e-98	4.0e-87	6.0e-87
437	437	403	397	392	362	357	321	320
transporter 2 isoform	transporter 2, ATP-binding cassette, sub-family B isoform 2; transporter 2, ABC (ATP binding cassette); ATP-binding cassette, sub-family B (MDR/TAP), member 3; antigen peptide transporter 2; peptide supply factor 2; peptide transporter, MHC 2	TAP2 protein	ATP-binding cassette, sub-	mono ATP-binding cassette protein unnamed protein product	unnamed protein product ATP-binding cassette, sub-family B, member 8; mitochondrial ABC protein	ATP-binding cassette, sub-family B, member 8, mitochondrial precursor (Mitochondrial ATP-binding cassette 1) (M-ABC1).	P-glycoprotein	hypothetical protein
AAD31384. 1	NP_061313	AAD23381. 1 AAD23601.	NP_036221	BAB20265. 1 BAA92038. 1	BAC04392. 1 NP_009119	Q9NUT2	AAA59575. 1	CAD38811. 1
,								
						·		

1	Ξ
	member 11
	/TAP)
	(MDR,
١	щ
	sub-family
	cassette.
	ND 000918 DTD-binding cassette, sub-family B (MDR/TAP), m
	0000
	O.M.
	1

	816000 dM	ATP-binding cassette, sub-family B (MDR/TAP), member 11; ABC	320	1.0e-86
	1.	member16, MDR/TAP subfamily; progressive familial intrahepatic		
		- 1		
	P08183	Multidrug resistance protein 1 (P-glycoprotein 1) (CD243	319	1.0e-86
		antigen).		
	NP_000434	ATP-binding cassette, subfamily B, member 4 isoform A; P	312	2.0e-84
	г.	glycoprotein 3/multiple drug resistance 3;		
		P-glycoprotein-3/multiple drug resistance-3; multiple drug		
		resistance 3		
	NP_061337	ATP-binding cassette, subfamily B, member 4 isoform B; P	312	2.0e-84
	<u>٠</u>	glycoprotein 3/multiple drug resistance 3;		
	-	P-glycoprotein-3/multiple drug resistance-3; multiple drug		
		resistance 3		
	NP_061338	ATP-binding cassette, subfamily B, member 4 isoform C; P	312	2.0e-84
-	۲.	glycoprotein 3/multiple drug resistance 3;		
		P-glycoprotein-3/multiple drug resistance-3; multiple drug		
		resistance 3		
	095342	Bile salt export pump (ATP-binding cassette, sub-family B,	311	3.0e-84
		member 11).		
	AAD28285.	bile salt export pump	311	3.0e-84
	Н			
	NP_003733	ATP-binding cassette, sub-family B (MDR/TAP), member 11; ABC	311	3.0e-84
	.2	member 16, MDR/TAP subfamily; progressive familial intrahepatic		
		cholestasis 2; bile salt export pump		
	AAD50509.	TAP2 protein	308	2.0e-83
	Н			
	CAA40740.	Y3	292	2.0e-78
	1			
	1703419A	MHC II Y3 gene	292	2.0e-78

WO 2 0	04/092	416													ı	PCT	r/U\$	S20 0	04/0)101	91	
7.0e-72	7.0e-67	6.0e-65	1.0e-59		1.0e-59	9 7 1 9 C	00.00	6.0e-58		3.0e-53	3.0e-53		7.0e-53		2.0e-52		2.0e-52		,	0		
270	254	247	229		229	200	0 7 7	224		208	208		207		206		206			1112		
P-glycoprotein	P-glycoprotein (431 AA)	Chain A, Crystal Structure Of The C-Terminal Atpase Domain Of Human Tapl	ATP-binding cassette, sub-family B (MDR/TAP), membe	member 16, MDR/TAP subfamily; progressive familial intrahepatic cholestasis 2; bile salt export pump	ATP-binding cassette, sub-family B, member 6	10 S	תווושוווכם לסופרוו לוסמתכר	ABC transporter		ATP-binding cassette, sub-family B (MDR/TAP), member 7	ATP-binding cassette, sub-family B, member 7, mitochondrial	<pre>precursor (AIP-binding cassette transporter // (ABC transporter 7 protein)</pre>	ABC transporter		ATP-binding cassette, sub-family B, member 7; ATP-binding	cassette 7	ABC transporter 7 protein			precursor polypeptide (AA 1-695)		
AAN76500. 1	CAA29547.	1JJ7 A	AAG33617.	н	NP_005680	יון יון יון יון יון יון יון יון יון יון	BAB/134/. 1	AAC28653.	1	ААН06323. 1	075027		AAD47141.	-	NP_004290	₽.	BAA28861.	1		CAA68374.	H	
											•	-									+(O-;	2.16
													·									Mm.15571
																				NM_007471		NP 031497.1 Mm.15571 2.16

۳	-
C	V
ċ	

₩ <u>Q</u> 20	004/	092	416		un 431	u .ar	witu		•												PC'	T/U	S20	04/	010	191
0	0	0	0			0		0		1.0e-132	1.0e-111		1.0e-111		1.0e-104	_	3.0e-96		3.0e-96		3.0e-96		7.0e-96		9.0e-96	
1111	886	736	736			736		735		469	400		400		379		351		351		351		350		349	
A4 amyloid protein precursor	beta amyloid peptide precursor	beta amyloid peptide precursor	amyloid beta (A4) precursor protein (protease nexin-II,	Alzheimer disease); Amyloid beta (A4) precursor protein;	amyloid beta-peptide	amyloid A4 protein		amyloid beta-protein precursor		beta-amyloid A4	amyloid-beta protein		APP protein		amyloid precursor protein		binding protein		Similar to amyloid beta		binding protein		Unknown (protein for MGC:10449)		amyloid precursor protein homolog HSD-2	
CAA31830. 1	1507304B	1507304A	NP_000475	+.		CAA30050.	.	AAA51722.	F	AAA51726. 1	AAB59501.	1	AAH04369.	1	AAA58727.		AAA35601.	1	AAH00373.	1	AAA36032.	н	AAH04371.	1	AAD47291.	1
																				,						
							-			٠.			٠				٠					<u>.</u> .	-			
			,	. , .													-									

	-			amyloid heta (A4) predursor-like profein 2: amyloid predursor	349	9.0e-96
			.1	10g HSD-2		
			AAA36130.	binding protein	349	9.0e-96
			н			
			AAA35526.	amyloid protein	347	4.0e-95
			-1			
			1907288A	amyloid precursor protein	344	3.0e-94
			1507304C	beta amyloid peptide precursor	278	2.0e-74
AF232828 Mm	.10379	Mm.10379 U:(C-D)+		neuro-oncological ventral antigen 1 isoform 1; Neurooncological ventral antigen 1;		
AAF35907.1 3		2.15	NP_002506	paraneoplastic Ri antigen	687	0
				neuro-oncological ventral antigen 1 isoform 2; Neurooncological ventral antigen 1;		
·			NP_006480	paraneoplastic Ri antigen	671	0
			NP_002507	neuro-oncological ventral antigen 2; neuro-oncological ventral antigen 3	402	1.0e-111
			AAB88661	astrocytic NOVA-like RNA-binding protein	401	1.0e-111
			AAD13116	RNA-binding protein Nova-2 [AA 29-492]; astrocytic NOVA-like RNA-binding protein	365	1.0e-100
-				neuro-oncological ventral antigen 1; Neurooncological ventral antigen 1; paraneoplastic Ri		
			NP_006482	antigen	273	9.0e-73
NM_008212						
		U:(C-D)+		Short chain 3-hydroxyacyl-CoA dehydrogenase, mitochondrial precursor (HCDH) (Medium		-
NP_032238.1 Mm	Mm.2491	2.15	Q16836	and short chain L-3-hydroxyacyl-coenzyme A dehydrogenase).	546	1.0e-155
				L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain; L-3-hydroxyacyl-CoA		
	-		NP_005318	dehydrogenase, short chain	544	1.0e-154
			AAB54009	3-hydroxyacyl-CoA dehydrogenase, isoform 2	535	1.0e-152
			AAB54008	3-hydroxyacyl-CoA dehydrogenase	535	1.0e-152
			1F0YA.	Chain A, L-3-Hydroxyacyl-Coa Dehydrogenase Complexed With Acetoacetyl-Coa And Nad+.	528	1.0e-150
				Chain A, X-Ray Crystal Structure Of The E170q Mutant Of Human L-3- Hydroxyacyl-Coa		
			1IL0A.	Dehydrogenase	527	1.0e-149

 \leftarrow

7

 \sim

526	oa. 525 1.0e-149	Short 506 1.0e-143	3		1075 0	550 1.0e-155	549 1.0e-155	548 1.0e-154	542 1.0e-152	541 1.0e-152				519 1.0e-147	334 2.0e-91				847 0	847 0	846 0	795 0		0 022		610 1.0e-174	r) 580 1.0e-165	A CONTRACTOR OF THE PERSON AND ADDRESS OF TH
Chain A, Biochemical Characterization And Structure Determination Of Hunan Heart Short	Chain L-3-Hydroxyacyr Coa Dong Control Complexed With 3-Hydroxybutyryl-Control Control	Chain A, L-3-Hydroxyacyl-Coa Dealy Construction Of Human Heart Short Chain A. Biochemical Characterization And Structure Determination Of Human Heart Short	Chain L.3-Hydroxyacyl Coa Dehydrogenase Provide Insight Into Catalytic Mechanism.		growth arrest-specific 6; AXL stimulatory factor		protein S (alpha); Protein S, alpha	Vitamin K-dependent protein S precursor	protein S alpha	protein S precursor	pre-protein S (AA -15 to 635)-tig start			Down syndrome critical region process;	Down syndrome critical protein A - number	hypothetical protein		Then affect the same of the safe flaving	Dimethylaniline monooxygenase [N-0x1ue 1011mbs] 2 (FMO form 2) (FMO II).	monooxygenase 3) (FMO 3) (Dimethylamline oxluase 3) (113x 12111)	Flavin containing monooxygenase 3	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.15.6)	dimethylaniline monooxygenase (N-oxide-forming) (EC 1.14.13.9), incpario	Putative dimethylaniline monooxygenase [N-oxide forming] o (Fravia-Contaming)	monooxygenase 6) (FMO 6) (Dimethylanline oxidase 0).	Dimethylaniline monooxygenase [N-oxide tornung] 2 (Funithary navm-comments)	monooxygenase 2) (FMO 2) (Umethylaniline oxtuase 2) (FMO 2) (PMO 2) (Petal liver)	The state of the s
	знара	1F12A	2HDHA		U:(C-D)+ NP 000811.1		NP 000304.1	P07225	AAA60180.1	AAA60181.1	CAA31383.1			NP 006043	JC5698	CAA05058				P31513	AAH32016	S51130	A38228		060774		099518	
	3				U:(C-D)+	2.14							U:(C-D)+	2.14					U:(C-D)+	2.14								
				1	Mm.3982									Mm.7472			1			Mm.2900			1					
					105010 Jun	-	THE COTON THE					NM 007834	I	NP 031860.1	_			NM 008030	}	132056 J	TOCOTO JAI							

 $\ddot{\sim}$

			Γ	famin containing monocovagenase 2. Flavin-containing monooxygenase 2 (adult liver)	561	1.0e-160
			IC+100_AN	Liavill Containing monocyferance of containing the containing		
				Umetnylamiine monooxygenase [iv-oxuce tottimg] o (tropany turing commendate of the condition on the condition of the conditio	546	1.0e-155
			P49326.	monooxygenase 5) (FMO 5) (Uniferry) aming oxidase 5).	5/15	1 0e-155
			NP_001452	flavin containing monooxygenase 5	2	1.00-155
			NP 002013	flavin containing monooxygenase 4	533	1.0e-151
			AAH35687	Similar to flavin containing monooxygenase 5	300	5.0e-81
			RAB13975	unnamed protein product	300	6.0e-81
			XP 060711	similar to dimethylanaline monooxygenase	205	2.0e-52
NM_009073						
•		U:(C-D)+			727	1 De. 118
NP_033099.1	Mm.679	2.13	NP_000318	retinal outer segment membrane protein 1; rod outer segment memorane protein 1	<u>+77</u> +	1.00-110
·			,			
NM_020568						
		U:(C-D)+			Č	
NP 065593.1	Mm.12966 2.12	2.12	BAB67774	KIAA1881 protein	1524	0
			XP 170901	similar to KIAA1881 protein	248	5.0e-65
NM_033327						
		U:(C-D)+		-		
NP 201584.1	Mm.23452 2.12	2.12	NP_055884	OLF-1/EBF associated zinc finger protein; Smad- and Olf-interacting zinc finger protein	2356	0
			NP_056276	early hematopoietic zinc finger	1563	0
			BAB84872	FLJ00107 protein	1561	0
			AAH32869	Similar to early hematopoietic zinc finger	1560	0
			CAD57322	early hematopoietic zinc finger	1553	0
			BAB13829	unnamed protein product	1030	0
			T17326	hypothetical protein DKFZp564D0764.1 - human (fragment).	887	0
			AAG49442	LYST-interacting protein LP3	275	5.0e-73
			NP 003421	zinc finger protein 91 (HPF7, HTF10)	253	2.0e-66
			NP 009084	zinc finger protein 208	233	2.0e-60

ហ

 $\vec{\vdash}$

15

20

ຸນ

ហ	
$^{\circ}$	
$^{\circ}$	

WC	20	04/092	416																		PC	T/U	JS2	004	/010)191	
4.0e-54			0	0	2.0e-79	2.0e-79	1.0e-72	2.0e-58			0	0	1.0e-167	1.0e-103	1.0e-103	4.0e-94		1.0e-93	3.0e-93	3.0e-93		2.0e-82	1.0e-68		1.0e-65		1.0e-65
212			904	870	295	295	273	225			0/9	299	586	374	374	343		342	341	341		305	259		249		249
Similar to zinc finger protein 268			nuclear factor (erythroid-derived 2)-like 2	transcription factor Nrf2	FLJ00380 protein	nuclear factor (erythroid-derived 2)-like 1; transcription factor 11 (basic leucine zipper type)	transcription factor Nrf1	transcription factor LCR-F1,			connective tissue growth factor	bA6918.1 (connective tissue growth factor)	connective tissue growth factor	nephroblastoma overexpressed gene	nov precursor	CYR61 protein	CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) (Insulin-like growth	factor-binding protein 10) (GIG1 protein).	CYR61 protein	Cyr61 protein	WNT1 inducible signaling pathway protein 1 isoform 1 precursor; wnt-1 signaling pathway	protein 1; Wnt1 signaling pathway protein 1; Wnt-1 inducible signaling pathway protein 1	tumor RMS cell line RD specific product	WNT1 inducible signaling pathway protein 3 isoform 2; wnt-1 signaling pathway protein 3;	Wnt1 signaling pathway protein 3; Wnt-1 inducible signaling pathway protein 3	WNT1 inducible signaling pathway protein 3 isoform 1; wnt-1 signaling pathway protein 3;	Wnt1 signaling pathway protein 3; Wnt-1 inducible signaling pathway protein 3
AAH07307			NP_006155	I59340	BAC03440	NP_003195	A49672	AAA20466			NP_001892.	CAC44023	AAA75378	AAH15028	NP_002505	AAG59863		000622	CAA72167	AAB84227		NP_003873	AAF21597		NP_569080		NP 003871
		U:(C-D)+	2.11							U:(C-D)+	2.1																
		2.4	Mm.1025								Mm.1810									-	-						-
		NM_010902	NP_035032.1						NM_010217		NP_034347.1																

 $\stackrel{\smile}{\dashv}$

15

20

WO 20)04/	リソス・	110																	,	rC.	r/U:	320	U#/(, , , ,	171
1.0e-50		0		-	0	·	0		1.0e-133		1.0e-133		1.0e-133		1.0e-131		1.0e-127	1.0e-102	•	1.0e-102	1.0e-102		1.0e-72		2.0e-72	
199		869			859		856		476		476		474		468		456	374		374	374		273		273	
WNT1 inducible signaling pathway protein 2 precursor; wnt-1 signaling pathway protein 2; connective tissue growth factor-like protein	10.00	fibulin 5 precursor; urine p50 protein; developmental arteries	and neural crest epidermal growth factor-like		UP50		unnamed protein product		fibulin-4		EGF-containing fibulin-like extracellular matrix protein 2	precursor (Fibulin-4) (FIBL-4) (UPH1 protein).	EGF-containing fibulin-like extracellular matrix protein 2;	fibulin 4	fibulin-like extracellular matrix protein		PH1	EGF-containing fibulin-like extracellular matrix protein 1	isoform a precursor; fibrillin-like	extracellular protein - human	EGF-containing fibulin-like extracellular matrix protein 1	isoform b; fibrillin-like	hypothetical protein		fibulin 2	
NP 003872	2000-111	NP_006320	.2		AAC62107.	1	CAD62618.	н_	CAA10791.	2	095967		NP_058634	۲.	AAG45245.	1	AAC62108.	NP_004096	.2	I38449	NP_061489	.1	CAB43267.	1	AAN05435.	
			U:(C-D)+	2.1						• ,				:												į
				Mm.25347 2.1																	÷					
		NM_011812	1 .	NP_035942.1						;																

£:		~	hart.				•
-	_	_		 	_	_	_

fibulin 2 273 3 fibulin 1 265 5 fibulin 1 isoform C precursor 265 5 unnamed protein product 242 4 fibulin 1 isoform D 242 5 fibulin 1 isoform B precursor 223 2 fibulin 1 isoform B precursor 223 2 fibulin 1 isoform A precursor 223 2 fibulin 1 isoform A precursor 233 2 vascular cell adhesion molecule 1, isoform b precursor; CD106 antigen 573 4 Vascular Cell Adhesion Molecule-1; Chain: A, B; Synonym: Vcam-D1, D 303 4 Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain 293 4 Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain 293 5 Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain 293 5 Fragment; Synonym: Vcam-1 Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To lgG, Hinge and Fc 290				NTD 001989	fibulin 2 precursor: Fibulin-2	273	3.0e-72
AAM05436. fibulin 2 1 AAH22497. fibulin 1 265 5 5 5 5 5 5 5 5 5				.1			
1 1 265 5				AAN05436.		273	3.0e-72
AAH22497. fibulin 1 265m 265 5 5 5 5 5 5 5 5 5				н			
1 1 265 5				AAH22497.	i	265	5.0e-70
NP_001987 fibulin 1 isofcom C precursor 265 5 5				П			
1.1 BAC11705. unnamed protein product 242 4				NP_001987	bulin 1 isoform C	265	5.0e-70
BAC11705. unnamed protein product 1	٠			г.			
NP_006477				BAC11705.		242	4.0e-63
NP_006477 fibulin 1 isoform D 242 5 5 2				г			
1 AAG17241. unknown 1 241 6 241 6 241 6 242 6 242 6 243 2 242 6 243 6 244 6				NP_006477		242	5.0e-63
AAG17241. unknown 1		-		۲.			
1 1 1 1 1 1 1 1 1 1				AAG17241.	uwouyun	241	6.0e-63
NP_006476				1			
NP_006478 fibulin 1 isoform A precursor 223 2				NP_006476		223	2.0e-57
NP_006478				.1		•	
Mm.1021 U:(C-D)+ NP_001069.1 vascular cell adhesion molecule 1, isoform a precursor; CD106 antigen 2.08 NP_542413.1 vascular cell adhesion molecule 1, isoform b precursor; CD106 antigen pdb 1VCA Human Vascular Cell Adhesion Molecule-1; Chain: A, B; Synonym: Vcam-D1, D2 (Integrin Binding Pdb 1I)9 Vascular Cell Adhesion Protein 1; Chain: A, B; Fragment: Vcam-D1, D2 (Integrin Binding Fragment); Synonym: Vcam-1 pdb 1VSC Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290				NP_006478	bulin 1 isoform A	223	2.0e-57
Mm.1021 U:(C-D)+ NP_001069.1 vascular cell adhesion molecule 1, isoform a precursor; CD106 antigen 2.08 NP_542413.1 vascular cell adhesion molecule 1, isoform b precursor; CD106 antigen pdb 1VCA Human Vascular Cell Adhesion Molecule-1; Chain: A, B; Synonym: Vcam-D1, 2 pdb 1JJ9 Vascular Cell Adhesion Protein 1; Chain: A, B; Fragment: N-Terminal Two-Domain pdb 1VSC Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290				.1			
Mm.1021 U:(C-D)+ NP_001069.1 vascular cell adhesion molecule 1, isoform a precursor; CD106 antigen 1132 1.08 NP_542413.1 vascular cell adhesion molecule 1, isoform b precursor; CD106 antigen 573 pdb 1VCA Human Vascular Cell Adhesion Molecule-1; Chain: A, B; Synonym: Vcam-1 303 pdb 1IJ9 Vascular Cell Adhesion Protein 1; Chain: A, B; Fragment: N-Terminal Two-Domain 293 pdb 1VSC Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain 293 Pdb 1VSC Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290							
NP_542413.1 vascular cell adhesion molecule 1, isoform b precursor; CD106 antigen 573 pdb 1VCA Human Vascular Cell Adhesion Molecule-1; Chain: A, B; Synonym: Vcam-D1, 2 303 pdb 1IJ9 Vascular Cell Adhesion Protein 1; Chain: A, Fragment: Vcam-D1, D2 (Integrin Binding Fragment); Synonym: Vcam-1 pdb 1VSC Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290	NM_011693	Mm.1021	U:(C-D)+	1.	vascular cell adhesion molecule 1, isoform a precursor; CD106 antigen		
 3.1 vascular cell adhesion molecule 1, isoform b precursor; CD106 antigen 573 Human Vascular Cell Adhesion Molecule-1; Chain: A, B; Synonym: Vcam-D1, 2 Vascular Cell Adhesion Protein 1; Chain: A; Fragment: Vcam-D1, D2 (Integrin Binding Pragment); Synonym: Vcam-1 Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290 	NP_035823.1	·	2.08			1132	0
Human Vascular Cell Adhesion Molecule-1; Chain: A, B; Synonym: Vcam-D1,2 Vascular Cell Adhesion Protein 1; Chain: A; Fragment: Vcam-D1, D2 (Integrin Binding Fragment); Synonym: Vcam-1 Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc				NP_542413.1	vascular cell adhesion molecule 1, isoform b precursor; CD106 antigen	573	1.0e-162
Vascular Cell Adhesion Protein 1; Chain: A; Fragment: Vcam-D1, D2 (Integrin Binding 293 Fragment); Synonym: Vcam-1 Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290				pdb 1VCA	Human Vascular Cell Adhesion Molecule-1; Chain: A, B; Synonym: Vcam-D1,2	303	7.0e-81
Fragment); Synonym: Vcam-1 Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290				pdb 1139	Vascular Cell Adhesion Protein 1; Chain: A; Fragment: Vcam-D1, D2 (Integrin Binding		
Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290					Fragment); Synonym: Vcam-1	293	1.0e-77
agment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details: brid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290				pdb 1VSC	Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain		
brid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc 290					Fragment; Synonym: Vcam-1; Engineered: Yes; Mutation: Y196D; Other_Details:		-
					Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge and Fc		8.0e-77

VO 200	· ista	0	0	1.0e-148	1.0e-148	1.0e-148		1.0e-101	1.0e-100	1.0e-100	T C	0.0e-73	4.0e-54		1.0e-147	1.0e-143		2.0e-66	T/US2		1.0e-113	9.0e-68	
636		636	632	525	525	525		366	365	363		780	211		521	208		251		966	409	257	
	Monocarboxylate transporter 2 (MC1 2). solute carrier family 16 (monocarboxylic acid transporters), member 7; monocarboxylate	transporter 2	monocarbovulate transnorter 2: MCT2	Illollocations) tate transporter to form 1	monocarooxytate transporter isotottar i	solute carrier family 10 (monocarooxy) in actor dampor cas), increases	nonocarobyyate transporter 1 - manner solute carrier family 16 (monocarboxylite acid transporters), member 3; monocarboxylate	transporter 3	Monocarhoxylate transnorter 3 (MCT 3).	solute carrier 16 (monocarhoxylic acid transporters), member 8; monocarboxylate transporter 3	solute carrier family 16 (monocarboxylic acid transporters), member 5; monocarboxylate	transporter 5	hypothetical protein FL J90193		6-11-0-1 Low D. Forbhood (Drosomhila)-like 6	IOTKIDEAU DOX FZ, IOTALICAU (E.I.OSOPHILL) TING C	forkhead box F1; forkhead (Drosophila)-like 5; Forkhead, drosophila, homolog-like 5;	forkhead-related activator 1	5' micleotidase ecto: Purine 5-Prime-Nucleotidase; 5' nucleotidase (CD73);	ecto-5'-nucleotidase	NTSE protein	ecto-5'-micleotidase	
	699090	CC7777	A A C70010	AAC/0919	CAD2//0/	NP_003042.	A55568	NP 004198	200500	092507 Am 027488	00+/C0_TAT	NP 004686	NP 699188		E .	NF 001443	7700204D	NP 001442		NP 002517	A A H1 5940	A A C 98672	7100000
-D)+															U:(C-D)+	2.08			+\(\(\frac{1}{2}\)-11	2.08			
	Mm.29161															Mm.6260				Mm.56948	200000000000000000000000000000000000000		
NM_011391	NP_035521.1 Mm.29161 2.08													NM_010225		NP 034355.1			NM_011851	O.C. No. 56948 2 08	1110/000 TNI		

10

Ŋ

ഗ

VO 2004/	092	416																		PC'	T/U	S20	04/	010	191	
1.0e-96	1.0e-96	5.0e-96		0	0		1.0e-178			1.0e-165			1.0e-163	1.0e-153	1.0e-104	1.0e-103	1.0e-102	1.0e-102	1.0e-101	1.0e-135			1.0e-113		1.0e-112	
352	352	349		1508	1382		629			584			579	544	380	377	375	374	373	479			406		403	
dermatopontin precursor - human	Dermatopontin precursor (Tyrosine-rich acidic matrix protein) (TRAMP).	dermatopontin	similar to Amyloid beta A4 precursor protein-binding family B member 2 (Fe65-like	protein)	Amyloid beta A4 precursor protein-binding family B member 2 (Fe65-like protein)	Similar to amyloid beta (A4) precursor protein-binding, family B, member 2 (Fe65-like	protein)	1	amyloid beta A4 precursor protein-binding, family B, member 1; stat-like protein;	adaptor protein FE65a2	+	beta A4 precursor protein-binding, family B, member 1; stat-like protein; adaptor	protein FE65a2	adaptor protein FE65a2	FE65-like protein 2 isoform a; amyloid precursor interacting protein	Similar to FE65-LIKE 2	FE65-like protein 2 isoform b; amyloid precursor interacting protein	FE65-like protein 2 isoform c; amyloid precursor interacting protein	FE65-like protein 2, isoform a; amyloid precursor interacting protein	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	member 9; protease inhibitor 9 (ovalbumin type)		Placental thrombin inhibitor (Cytoplasmic antiproteinase) (CAP)	(Protease inhibitor 6) (PI-6).	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	member 6; protease inhibitor 6 (placental thrombin inhibitor)
A47220	Q07507	AAH33736	U:(C-D)+ XP_051782.5		Q92870	AAH27946.1		NP_663722.1			NP_001155.1			AAL79526.1	NP_573420.1	AAH13158.1	NP_573419.1	NP_573418.1	NP_006042.2	NP_004146	۲.	, .	P35237		NP_004559	.3
-D)+			U:(C-D)+	2.06									-								U:(C-D)+	2.06				
U:(C			Mm.5159			τ,															Mm.19608 U:(C-D)+	3				
NM_019759			U70210	AAC53593.1																NM_011456		NP_035586.1				

<u>رم</u>

		NP_002631	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	391	e-108
		ਜ.	member 8; protease inhibitor 8 (ovalbumin type)		
		NP_109591	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	362	1.0e-99
		٦.	member 1; protease inhibitor 2		
			(anti-elastase), monocyte/neutrophil; protease inhibitor 2		
			(anti-elastase), monocyte/neutrophil derived		
		1BY7A	Chain A, Human Plasminogen Activator Inhibitor-2. Loop (66-98)	310	3.0e-84
			Deletion Mutant		
		NP_002965	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	306	6.0e-83
		г.	member 4; protease inhibitor (leucine-serpin); squamous cell		
		•	carcinoma antigen 2; leupin		
		I38202	leupin precursor - human	305	1.0e-82
		I38201	squamous cell carcinoma antigen 1 - human	303	5.0e-82
		NP_008850	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	302	1.0e-81
		т.	member 3; squamous cell carcinoma antigen 1		
		AAB20405.	squamous cell carcinoma antigen; SCC antigen	301	2.0e-81
		1			
		CAD56658.	squamous cell carcinoma antigen 1	300	3.0e-81
		1			
		NP_002566	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	300	6.0e-81
٠٠.		۲.	member 2; plasminogen activator inhibitor, type II		
			(arginine-serpin)		
		AAH12609.	Similar to serine (or cysteine) proteinase inhibitor, clade B	296	5.0e-80
		П	(ovalbumin), member 2		
		AAA36413.	plasminogen activator inhibitor	295	1.0e-79
		1			
		NP_005015	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	295	2.0e-79
		.1	member 10; protease inhibitor 10 (ovalbumin type, bomapin)		
	-	AA015303.	WSTP057	291	3.0e-78
	7,	1			

VO 20	04/0	0924	16																		F	PCI	r/U	S20	04/	010	191	
3.06-76	5.0e-74	5.0e-74		7.0e-74		3.0e-72		7.0e-71		6.0e-70		6.0e-70		8.0e-70	6.0e-63		2.0e-62		9.0e-61		1.0e-56		7.0e-56		9.0e-56	7.0e-55		
284	276	276		276		271		266		263		263		263	240		238		233		219		216		216	213		
SCCA2b	headpin serine proteinase inhibitor	hurpin		serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	member 13; hurpin; protease inhibitor 13 (hurpin, headpin)	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	member 12	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	member 5; protease inhibitor 5 (maspin)		member 11	serine proteinase inhibitor SERPINB11		Serpin B11	Similar to serine (or cysteine) proteinase inhibitor, clade B	(ovalbumin), member 8	SCCAlb		serine (or cysteine) proteinase inhibitor, clade B (ovalbumin),	member 7; mesangium predominant gene, megsin	hurpin		Chain A, Interactions Causing The Kinetic Trap In Serpin	Protein Folding	alphal antitrypsin	Chain A, A 2.1 Angstrom Structure Of An Uncleaved Alpha-1-	Antitrypsin Shows Variability Of The Reactive Center And Other	
BAB40773. 1	JC7118	CAA04937.	1	NP_036529	다.	NP_536722	۲.	NP_002630		NP_536723	ㅋ.	AAL16057.	-	Q96P15	AAH34528.		BAB40772.	⊢ 1	NP_003775	۲.	CAC03569.		1IZ2A		1313184B	1HP7A		
													•							- 					-			
																			-									
																												_

ហ

	1ATU	Uncleaved Alpha-1-Antitrypsin	212	2.0e-54
	1KCT	Alpha1-Antitrypsin	212	2.0e-54
	1012287A	antitrypsin alphal mutant	211	2.0e-54
	AAB60386.	protein C inhibitor	210	6.0e-54
		Chain A, Antithrombin Iii	209	8.0e-54
	1ATHB	Chain B, Antithrombin Iii	209	8.0e-54
	NP_000479	serine (or cysteine) proteinase inhibitor, clade C	209	8.0e-54
	·H	(antithrombin), member 1; antithrombin III		
	BAA06212.	antithrombin III variant	209	1.0e-53
•	Н			
	AAH15642.	Similar to serine (or cysteine) proteinase inhibitor, clade A	208	2.0e-53
:	н	(alpha-1 antiproteinase, antitrypsin), member 1		
	1PSI	Intact Recombined Alphal-Antitrypsin Mutant Phe 51 To Leu	208	2.0e-53
	P01009	Alpha-1-antitrypsin precursor (Alpha-1 protease inhibitor)	208	2.0e-53
		(Alpha-1-antiproteinase) (PRO0684/PRO2209).		
	1QLPA	Chain A, 2.0 Angstrom Structure Of Intact Alpha-1-Antitrypsin:	208	2.0e-53
		A Canonical Template For Active Serpins		
	NP_000286	serine (or cysteine) proteinase inhibitor, clade A (alpha-1	207	3.0e-53
· .	.2	antiproteinase, antitrypsin), member 1; Protease inhibitor		
		(alpha-1-antitrypsin); protease inhibitor 1 (anti-elastase),		
		alpha-1-antitrypsin		
	AAA51547.	alpha-1-antitrypsin precursor	207	5.0e-53
	ri			
	1DZHI	Chain I, P14-Fluorescein-N135q-S380c-Antithrombin-Iii	207	5.0e-53
	CAB45766.	hypothetical protein	207	5.0e-53
	п			

		NP_000615	serine (or cysteine) proteinase inhibitor, clade A (alpha-1	207	5.0e-53
		. 2	antiproteinase, antitrypsin), member 5; Protein C inhibitor		
			(plasminogen activator inhibitor-3); protein C inhibitor;		• • • •
	· ,		protein C inhibitor (plasminogen activator inhibitor III)		
		1DZGI	Chain I, N135q-S380c-Antithrombin-Iii	206	7.0e-53
		AAA51546.	alpha-1-antitrypsin	206	9.0e-53
		Н			
		AAB26244.	acrosomal serine protease inhibitor	506	9.0e-53
		7			
·	-	AAA51796.	antithrombin III	206	1.0e-52
		· [-]			
		AAF29581.	PRO0684	205	2.0e-52
		. 1			
		AAB59495.	alpha-1-antitrypsin	205	2.0e-52
		1			
:		AAA35688.	plasma serine protease inhibitor precursor	204	4.0e-52
		1			
		AAA51560.	alpha-1-antichymotrypsin precursor	1,97	3.0e-50
		1			
		P01011	Alpha-1-antichymotrypsin precursor (ACT).	197	3.0e-50
	-	AAD08810.	alpha-1-antichymotrypsin precursor	197	3.0e-50
		1			
		CAA48671.	alphal-antichymotrypsin	197	3.0e-50
		1.			
-		AAH34554.	serine (or cysteine) proteinase inhibitor, clade A (alpha-1	197	4.0e-50
		1	antiproteinase, antitrypsin), member 3		
		1LQ8A	Chain A, Crystal Structure Of Cleaved Protein C Inhibitor	196	7.0e-50
		1QMNA	Chain A, Alphal-Antichymotrypsin Serpin In The Delta	196	9.0e-50
			Conformation (Partial Loop Insertion).		
			7.7	1	

Ŋ

	7	7APIA	Chain A, Modified Alphal-Antitrypsin (Modified Alphal-Proteinase Inhibitor) (Tetragonal Form 1).	196	y.ue-50
	-	1D5SA	Chain A, Crystal Structure Of Cleaved Antitrypsin Polymer	196	9.0e-50
		-			
NM_008880 .	U:(C-D)+				
NP 032906.1 Mm.10306 2.06	ì	NP 066928	phospholipid scramblase 1	428	1.0e-119
$\overline{}$		NP 065092	phospholipid scramblase 2	357	2.0e-98
	2	NP 065086	phospholipid scramblase 4	263	4.0e-70
	Ą	AAH28354	phospholipid scramblase 4	263	6.0e-70
		Q9NRY6	Phospholipid scramblase 3 (PL scramblase 3) (Ca(2+)-dependent phospholipid scramblase 3).	258	1.0e-68
	Ш	BAC11458	unnamed protein product	258	1.0e-68
	A	AAH11735	Similar to phospholipid scramblase 3	257	3.0e-68
961800_MN	.4s,				
<u>.</u>	U:(C-D)+	-	Phosphatidylcholine transfer protein (PC-TP) (StAR-related lipid transfer protein 2) (StARD2)		
NP_032822.1 Mm.5062 2.05		Q9UKL6	(START domain-containing protein 2).	361	1.0e-100
	4	NP_067036	phosphatidylcholine transfer protein; START domain containing 2	359	3.0e-99
	4	AAF08345	phosphatidylcholine transfer protein	356	2.0e-98
			Chain A, Crystal Structure Of Human Phosphatidylcholine Transfer Protein In Complex With		-
	<u></u>	1LN2A.	Dilinoleoylphosphatidylcholine (Seleno-Met Protein).	352	2.0e-97
	4	AAH05112	Unknown (protein for IMAGE:4026343)	295	5.0e-80
Mm.27744	(C-D)+	VP_005139.1	unc119 (C.elegans) homolog, isoform a; unc119 (C.elegans) homolog; retinal protein 4		700
NP_035806.1	2.04			- Sc	001-90.1
	I	NP_473376.1	unc119 (C.elegans) homolog, isoform b; unc119 (C.elegans) homolog; retinal protein 4	317	2.0e-85
NM_011717					
n'	+(Q-;				,
NP_035847.1 Mm.20878 2.04		AAD19818	Human homolog of Mus musculus wizL protein [AA 4-1561]	1444	0
	7	A A D 10817	Human homolog of Mus musculus wiz protein [A A 64.034]	1443	C

വ

		AAC97985	Human homolog of Mus musculus wizS protein [AA 171-934]	1223	0
1		Г	widely-interspaced zinc finger motifs	1223	0
		: BAB55234	unnamed protein product	758	0
		AAH07551	WIZ protein	562	1.0e-159
		T51885	hypothetical protein DKFZp547M136.1 - human (fragment).	215	3.0e-55
		AAH02329	Unknown (protein for IMAGE:3532992)	210	1.0e-53
•	U:(C-D)+	1	solute carrier family 16 (monocarboxylic acid transporters), member 2; X-Imked		
Mm.5045	2.04	NP_006508	PEST-containing transporter	814	5
		AAB60374	X-linked PEST-containing transporter	814	0
			solute carrier family 16 (monocarboxylic acid transporters), member 10; T-type amino acid		
		NP 061063	transporter 1	453	1.0e-126
	-	AAF71072	PRO0813	200	1.0e-40
		AAH17968	hypothetical protein PRO0813	199	3.0e-50
	U:(C-D)+				
Mm.5728	2.04	CAB65088	poly-(ADP-ribose) polymerase II	987	0
			Poly [ADP-ribose] polymerase-2 (PARP-2) (NAD(+) ADP-ribosyltransferase-2)		
		Q9UGNS	(Poly[ADP-ribose] synthetase-2) (pADPRT-2) (hPARP-2).	982	0
		CAB41505	poly(ADP-ribosyl) polymerase-2	942	0
			poly (ADP-ribosyl) transferase-like 2; ADP-ribosyltransferase (NAD+; poly (ADP-ribose)		
	-	NP_005475	polymerase)-like 2; poly(ADP-ribose) synthetase	939	0
		BAA92017	unnamed protein product	877	0
		AAA51599	poly(ADP-ribose) polymerase	382	1.0e-106
		AAB59447	poly(ADP-ribose) synthetase.	381	1.0e-105
			Poly [ADP-ribose] polymerase-1 (PARP-1) (ADPRT) (NAD(+) ADP-ribosyltransferase-1)		
		P09874	(Poly[ADP-ribose] synthetase-1).	381	1.0e-105
		AAA60137	poly(ADP-ribose) polymerase	381	1.0e-105

ψÇ	20	04/	092	416	ં કરી લ	etter ter	ili enil	at wh.	orlins														PC'	T/U	S20)04/	010	191
1.0e-105	1.0e-105	2.0e-73	· 2.0e-73		9.0e-73	8.0e-68			0	1.0e-178	1.0e-144	1.0e-141	1.0e-118	1.0e-109	2.0e-80	0			0		0		0		0		1.0e-176	
380	379	274	274		272	256			788	628	516	504	430	396	303	1484			1483		1482		983		799		618	
ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)	poly(ADP-ribosyl)transferase; ADP-ribosyltransferase NAD(+); poly(ADP-ribose) synthetase	Unknown (protein for MGC:20611)	poly (ADP-ribose) polymerase 3	poly (ADP-ribosyl) transferase-like 3; ADP-ribosyltransferase (NAD+; poly (ADP-ribose)	polymerase)-like 2; poly(ADP-ribose) synthetase	NAD+ ADP-ribosyltransferase homolog DKFZp566G0224.1		Unknown (protein for MGC:16590)		Unknown (protein for IMAGE:3029289)	FLJ00103 protein	simile	Unknown (protein for MGC:20519)		unnamed protein product	matriptase; suppression of tumorigenicity 14 (colon carcinoma);	membrane-type serine protease; serine protease TADG-15; tumor	associated differentially expressed gene 15 protein	prostamin		serine protease TADG15		Similar to suppression o		ST14 protein		serine protease SNC19	
AAH37545	NP 001609	AAH14260	AAM95460		NP 005476	T08713		Mm.35241 U:(C-D)+ AAH23549.1		AAH07570.1	BAB84871.1	XP 036104.4	AAH12332.1	BAB47492.1	BAB71400.1	NP_068813	٦.	,	BAB20376.	н	AAG15395.	T	AAH05826.	H	AAH18146.	т.	AAG13949.	1
								U:(C-D)+	2.03								U:(C-D)+	2.03										,
								Mm.35241										Mm.37947										
								AF241249	AAG02285.1							NM_011176		NP_035306.2 Mm.37947		,								

S

 $\vec{\vdash}$

	1EAWA	Chain A, Crystal Structure Of The Mtspl (Matriptase)-Bpti	448	1.0e-125
		(Aprotinin) Complex		
	NP_705837	nsmembi	418	1.0e-116
	.1	serine proteinase matriptase-2		
	CAC85953.	matriptase-2	417	1.0e-116
	NP_002763	enterokinase precursor; proenterokinase; enteropeptidase	233	1.0e-60
			233	09-00
	BAA95557.	enterokinase	T C 7)))
	H			
	NP_054777	DESC1 protein	220	1.0e-56
	г.			
	Q9Y5Q5	Atrial natriuteric peptide-converting enzyme	214	1.0e-54
•		(pro-ANP-converting enzyme) (Corin) (Heart specific serine		
		proteinase ATC2).		
	AAK53559.	epitheliasin	206	3.0e-52
	Н			
	AAK29280.	androgen-regulated serine protease TMPRSS2 precursor	206	3.0e-52
	П			
	NP_005647	transmembrane protease, serine 2; epitheliasin	206	3.0e-52
	.2			
	AAC51784.	serine protease	204	1.0e-51
	Н			
NM_008797				
	U:(C-D)+			
NP 032823.1 Mm.1845 2	2.03 NP_000911	pyruvate carboxylase precursor	2115	0
	P11498	Pyruvate carboxylase, mitochondrial precursor (Pyruvic carboxylase) (PCB).	2114	0
	AAB31500	pyruvate carboxylase; pyruvate:carbon dioxide ligase	2093	0
	NP 000273	Propionyl-Coenzyme A carboxylase, alpha polypeptide precursor	362	2.0e-99

Ľ

2

ກ

w(20	04/09	24	16			_						_]	PC	r/U	S20	04/	010	191	
2.0e-99	2.0e-99	2 0e-99	100	1.0e-98	1.0e-52	2.0e-52			0	0			1.0e-139			7.0e-93			6.0e-87	1.0e-86		0	1.0e-137	1.0e-123	1.0e-123	1.0e-123	1.0e-112	3.0e-98
362	362	298	3 6	329	207	206			783	770			498			343	-		323	323		934	490	445	444	443	409	362
propionyl-CoA carboxylase alpha subunit	3-methylcrotonyl-CoA carboxylase biotin-containing subunit	methylcrotonoyl-Coenzyme A carboxylase 1 (alpha); 3-methylcrotonyl-CoA carboxylase	biotin-containing subunit	3-methylcrotonyl-CoA carboxylase biotin-containing subunit	acetyl-CoA carboxylase (EC 6.4.1.2)	acetyl-Coenzyme A carboxylase alpha	FK506-binding protein 5; 51 kDa FK506-binding protein 5; 54 kDa progesterone	receptor-associated immunophilin; T-cell FK506-binding protein; peptidylprolyl	cis-trans isomerase; rotamase; FF1 antigen; HSP90-binding immunophilin	FKBP54	1	protein, 59kD; p59 protein; HSP binding immunophilin; peptidylprolyl cis-trans	isomerase; rotamase; FK506 binding protein 4 (59kD)	_	(Rotamase) (p59 protein) (HSP binding immunophilin) (HBI) (FKBP52 protein) (52 kDa	FK506 binding protein) (FKBP59)	similar to FK506-binding protein 4 (Possible peptidyl-prolyl cis-trans isomerase	FKBP4) (PPiase) (Rotamase) (p59 protein) (HSP binding immunophilin) (HBI)	(FKBP52 protein) (52 kDa FK506 binding protein) (FKBP59)	Similar to FK506-binding protein 4 (59kD)	glypican 1 precursor		glypican 6 precursor	_		glypican-4	GPC4 (glypican 4)	similar to Glypican-2 precursor (Cerebroglycan) (HSPG M13)
AAL.66189	BAA99407		NF_064551	AAK67986	S41121	NP 000655	Mm.15439 U:(C-D)+ NP_004108.1			AAA86245.1	NP_002005.1			XP_095921.1			XP_172777.1	-		AAH02887.1	U:(C-D)+ NP_002072.1		NP_005699.1	NP_001439.2	075487	AAC69991.1	CAB39178.1	XP_168232.2
							U:(C-D)+	2.02													U:(C-D)+	2.02						
							Mm.15439	0				·									Mm.24193							
							NM_010220	NP_034350.1	1		11.2										NM_016696	NP_057905.1						

C	
r	η
C	V

WO 200)4/0	924																<u>. </u>				PC			004	/01	0191
1 00 148	1.0e-145	70 00	9.0e-90	9.0e-96	1.0e-75	1.0e-50	1.0e-50	3.0e-50	3.0e-50			0	0	3.0e-69		0			0	0	1.0e-179		4.0e-63	1.0e-61	,	•	0
	217	3	349	349	282	199	199	198	198	7		742	723	265		929	679		629	650	629		244	240			1024
	NSP-like 1	RIN2-B	RTN2-C	reticulon 2	Similar to reticulon 2	reticulon 1; neuroendocrine-specific protein	nueroendocrine-specific protein B	neuroendocrine-specific protein C - human	Similar to reticulon 1		TGFB inducible early growth response		EGR alpha transcription factor - human	1	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial);		1	${}^{-}$	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1	hydroxymethylglutaryl-CoA synthase (EC 4.1.3.5), cytosolic, fibroblast isoform		1 sim	(관		1 solute carrier family 5 (sodium/glucose cotransporter), member 1; Human Na+/glucose	cotransporter 1 mRNA, complete cds; solute carrier family 5 (sodium/glucose	transporter), member 1
	AAC14910	AAC32543	AAC32544	NP 005610	AAH14244	NP 066959	AAA59951	160904	AAH00314		U:(C-D)+ NP_005646.1		A57531	NP 003588.1	Mm.10633 U:(C-D)+ NP 005509.1	1 -	AAA92674.1	NP_002121.1		S27197	BAC04559.1	XP_060842.1	l 	AAA92673.1	U:(C-D)+ NP_000334.1		
U:(C-D)+		•									U:(C-D)+	2.01			U:(C-D)+	. 2										2	
	Mm.24142 2.02										Mm.4292				Mm.10633										Mm.25237		
NM_013648	NP_038676.1										NM 013692	NP 038720.1			AK004865	BAB23626.1									NM 019810	NP_062784.1	

WO 2004/	092	416					manen														PC	T/U	S2 0	04/	010	191	
0	0		,	0		1.0e-165		1.0e-162	1.0e-162	1.0e-152		1.0e-143	1.0e-143			1.0e-143	1.0e-110		0	0	1.0e-83		1.0e-83	1.0e-83	2.0e-81	2.0e-77	2.0e-69
856	709		709	200		583		575	574	540		512	511			510	399		1091	1081	313		313	312	305	291	265
solute carrier family 5 (low affinity glucose cotransporter), member 4; solute carrier family 5 (neutral amino acid transporters, system A), member 4; low affinity sodium glucose cotransporter,	Na glucose cotransporter	solute carrier family 5 (sodium/glucose cotransporter), member 2; solute carrier family	5 (sodium/glucose transporter), member 2	sodium/glucose cotransporter	dJ1024N4.1 (novel Sodium:solute symporter family member similar to SLC5A1	(SGLT1))	NP_443176.2 sodium/myo-inositol cotransporter 2; putative sodium-coupled cotransporter RKST1;	homolog of rabbit KST1	putative sodium-coupled cotransporter RKST1	ilar to 597 aa protein related to Na/glucose cotransporters	fF65B7.1 (solute carrier family 5 (sodium/glucose cotransporter), member 1 (SGLT1,	High Affinity Sodium-Glucose Cotransporter))	Sodium/myo-inositol cotransporter (Na(+)/myo-inositol cotransporter)	solute carrier family 5 (inositol transporters), member 3; solute carrier family 5 (inositol	transporter), member 3; human solute carrier family 5, member 3, Sodium/myo-inositol	cotransporter; sodium/myo-inositol cotransporter 1	-		transmembrane protein 9 superfamily member 1	Transmembrane 9 superfamily protein member 1 precursor (hMP70)	SM-11044 binding protein	similar to Transmembrane 9 superfamily protein member 3 precursor (SM-11044	binding protein) (EP70-P-iso)	transmembrane protein TM9SF3	unnamed protein product	KIAA0255 gene product	endomembrane protein emp70 precursor isolog
NP_055042.1 solut fami	1909123A	NP 003032.1	I	AAL66409.1	CAC00574.1		NP 443176.2		AAK97053.1	XP 064487.3	CAB06090.2		P53794	NP_008864.1			NP_689564.1	Mm.29649 U:(C-D)+ NP_006396.2		015321	AAF21983.1	XP_050993.1		AAF98159.1	BAB55369.1	NP_055557.1	NP_064508.1
																		U:(C-D)+	2								
														-				Mm.29649									
											-				-			NM_028780	NP_083056.1								

ស

protein 9 superfamily member 2
unnamed protein product
unnamed protein product
alpha2(I) collagen
alpha 2 type
Collagen of
collagen alpha
pro-alpha 2(I)
Collagen alpha
procollagen
type I collagen
alpha 1 type II
alpha-1 polypeptide; cartilage collagen; chondrocalcin,
included; COL11A3,
Collagen
alpha 1 type II
polypeptide; cartilage collagen; chondrocalcin, included;
COL11A3, formerly
collagen
collagen
Collagen
pro alpha 1(I)

PCT/US2004/010191

C	V
<	ľ
C	V

		970000 dN	alpha 1 type I collagen preproprotein; Collagen I, alpha-1	442	1.0e-123
		.1	lypeptide;		<u> </u>
			tendon and bone, alpha-1 chain		
		AAA51995.	alpha 1 (I) chain propeptide	441	1.0e-123
		H			-
		AAH36531.	Unknown (protein for MGC:33668)	439	1.0e-122
		r.			
		AAA51997.	collagen alpha-1(II)	417	1.0e-116
		н			
		NP_000081	alpha 1 type III collagen; Collagen III, alpha-1	394	1.0e-109
		۲.	polypeptide;collagen, fetal		
		CGHU7L	collagen alpha 1(III) chain precursor	393	1.0e-109
		CAA29886.	alpha1 (III) collagen	384	1.0e-106
		н			
		CAA28454.	pro- alpha (V)collagen (AA 1099)	359	2.0e-98
		н-			
		NP_000384	alpha 2 type V collagen preproprotein; Collagen V, alpha-2	359	2.0e-98
		т.	polypeptide; AB collagen; collagen, fetal membrane, A		
			polypeptide		
		AAL13166.	type V preprocollagen alpha 2 chain	357	7.0e-98
		П			1
		AAH28178.	Similar to collagen, type III, alpha 1 (Ehlers-Danlos syndrome	352	2.0e-96
			type IV, autosomal dominant)		
	· -	CAA29604.	pro-alpha 1 (II) collagen (313 AA; AA 975-271c)	337	8.0e-92
		П			
		AAH43613.	Similar to collagen, type V, alpha 2	336	2.0e-91
-		러			
		AAH07252.	Unknown (protein for MGC:15506)	335	4.0e-91
		Н			

Ŋ

WO 20	04/092	2416										PC'	T/US2(004/010	191
1.0e-90	5.0e-83	1.0e-81	9.0e-80	4.0e-78	7.0e-67	3.0e-66	1.0e-54	1.0e-54	1.0e-54	1.0e-54	1.0e-54	1.0e-54	1.0e-54	1.0e-54	2.0e-52
333	308	303	297	291	254	252	214	214	213	213	213	213	213	213	206
pro alpha 1(II) collagen	. alpha-1 type III collagen	. type I collagen pro alpha 1(I) chain propeptide	. carboxy-propeptide of alpha 1 (III) procollagen	. C-terminal propeptide domain	3. alpha-2 type V collagen). prepro-alpha-2 chain	Collagen alpha 1(XI) chain precursor	collagen alpha 1(XI) chain precursor	. collagen type XI alpha-a isoform B	alpha 1 type XI collagen isoform B preproprotein; collagen XI, alpha-1 polypeptide	collagen type XI alpha-1	alpha 1 type XI collagen isoform C preproprotein; collagen XI, alpha-1 polypeptide	collagen type XI alpha-1 isoform A	alpha 1 type XI collagen isoform A preproprotein; collagen XI, alpha-1 polypeptide	
CAA26223.	AAA52002 1	AAB27856.	CAA25879	CAA29605	AAA52058 1	CAA68709 1	P12107	CGHUIE	AAF04726	NP_542196	AAF04724 1	NP_542197	AAF04725 1	NP_001845	NP_000084
								,					-		

Ŋ

WO 20)U4/	092: —	416	· 					 															004 			
2.0e-52	2.0e-52	3.0e-52				-	1.0e-58	1.0e-58			3.0e-69	1.0e-54		0	0	1.0e-180	1.0e-179	1.0e-167	1.0e-166	1.0e-166	1.0e-166	1.0e-166	1.0e-160	1.0e-160	1.0e-160	1.0e-160	1.0e-159
206	206	206					229	229			264	216	-	635	635	633	628	288	586	586	286	282	292	292	292	595	564
COL5Al protein	Collagen alpha 1(V) chain precursor	collagen alpha 1(V) chain precursor		1 chromosome 11 open reading frame 24				1 chromosome 11 open reading frame 24		1 inducible T-cell co-stimulator; activation-inducible lymphocyte immunomediatory	molecule; inducible costimulator	1 Similar to inducible T-cell co-stimulator	2 heat shock 70kDa protein 1A; heat shock 70kD protein 1A; heat shock-induced	protein; dnaK-type molecular chaperone HSP70-1	Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2)	Τ.	dnaK-type molecular chaperone HSPA1L		1 Heat shock protein 70 testis variant	1 heat shock 70kDa protein 1-like; Heat-shock 70kD protein-like-1	1 similar to heat shock protein	1 heat shock 70kD protein 1-like	2 heat shock 70kDa protein 2; heat shock 70kD protein 2; Heat-shock 70kD protein-2	1 Unknown (protein for MGC:33922)	Heat shock protein 70 testis variant	1 Similar to heat shock cognate 71-kd protein	1 heat shock protein
AAH08760. 1	P20908	CGHU1V		NP_071733.1				AAH11765.1		U:(C-HI) NP_036224.1	٠.	AAH28006.1	NP_005336.2		P08107	NP_005337.1	A29160	XP_175177.1	BAA32521.1	NP_005518.1	XP_166348.1	AAH34483.1	NP_068814.2	AAH36107.1	NP_06588.1	AAH07276.1	AAD11466.1
				U:(C-HI)	+3.19	U:(C-D)+	2.42			U:(C-HI)	+6.6		U:(C-HI)	+3.58													
·							Mm.23780 2.42			Mm.42044			Mm.19655	6								·					
		-				AK007868	BAB25319.1			NM_017480	NP_059508.1		M12571	AAA57234.1													

H

20

Ö

W(20	04/	092	416																			PC'	T/U	S2 0	04/	010	191
1.0e-157		1.0e-156				0	0	0		0	8.0e-91	8.0e-91		2.0e-79			2.0e-79	2.0e-79	2.0e-78	2.0e-77	1.0e-76		1.0e-76		1.0e-76		1.0e-76	1.0e-74
555		552				654	653	653		641	332	335		297			297	297	294	291	288		288		287		286	281
heat shock 70kDa protein 6 (HSP70B')	_		annexin A2; annexin II; lipocortin II; Annexin II (lipocortin I); calpactin I, heavy	polypeptide (p36); annexin II (lipocortin II; calpactin I, heavy polypeptide); annexin II	(lipocortin II)		annexin A2	annexin A2	bA255A11.8 (novel protein similar to annexin A2 (ANXA2) (lipocortin II, calpactin I	heavy chain, chromobindin 8, PAP-IV))	annexin I; annexin I (lipocortin I); lipocortin I	Annexin I	annexin IV; annexin IV (placental anticoagulant protein II); placental anticoagulant	protein II	Annexin A4 (Annexin IV) (Lipocortin IV) (Endonexin I) (Chromobindin 4) (Protein II)	(P32.5) (Placental anticoagulant protein II) (PAP-II) (PP4-X) (35-beta calcimedin)	(Carbohydrate-binding protein P33/P41) (P33/41)	protein PP4-X	annexin A11; annexin XI; autoantigen, 56-kD; calcyclin-associated annexin 50	annexin VI isoform 2; annexin VI (p68); calcium-binding protein p68; calphobindin II;	protein p68 (1 - 673)	Annexin Vi; Chain: A; Synonym: Lipocortin Vi, P68, P70, Protein III, Chromobindin 20,	67 Kda Calelectrin, Calphobindin-II, Cpb- II	annexin VI isoform 1; annexin VI (p68); calcium-binding protein p68; calphobindin II;	calelectrin F498	Annexin VI (Lipocortin VI) (P68) (P70) (Protein III) (Chromobindin 20) (67 kDa	calelectrin) (Calphobindin-II) (CPB-II)	Annexin III
AAH35665.1	NP_002146.1		NP_004030.1				AAH09564.1	AAH23990.1	CAB99342.1	,	NP_000691.1	pdb 1AIN	NP_001144.1		P09525			AAC41689.1	NP_001148.1	NP_004024.1	CAA68286.1	I6M1 dbq	-	NP_001146.1		P08133		pdb/1AXN
			U:(C-HI)	+3.49,	U.(C-D)	4.83													-									
	-		Mm.584					-																				
			NM_007585	NP_031611.1								•																

W			19241																					JS2		/010
	1 0e-74	2001	2.0e-72	2.0e-72	2.0e-72			4.0e-72	5.0e-72		5.0e-72	1.0e-71	1.0e-71		1.0e-71	1.0e-71	1.0e-69	4.0e-69	9.0e-69	1.0e-68	3.0e-67	9.0e-66	2.0e-64	1.0e-63	1.0e-63	
	281	103	274	274	274			273	273		273	271	271		271	27.1	265	263	262	261	257	252	248	245	245	
annexin A3: Annexin III (lipocortin III); annexin III (lipocortin III,		calcimedin 35-alpha); calcimedin 35-alpha	Annexin V (Lipocortin V, Endonexin II, Placental Anticoagulant Protein) (Calcium lons	annexin V. endonexin II. anchorin CII. lipocortin V: placental anticoagulant protein I	Annexin V	Annexin V (Lipocortin V, Endonexin II, Placental Anticoagulant Protein) Mutant With	Glu 17 Replaced By Gly, Glu 78 Replaced By Gln (E17G, E78Q) Complexed With	Calcium	annexin A5	Annexin V (Lipocortin V, Endonexin II, Placental Anticoagulant Protein) (Calcium Ions	Are Visible) Mutant With Glu 78 Replaced By Gln (E78Q) (Second Crystal Form)	annexin VIII - human	annexin VIII; Annexin VII	Annexin V; Chain: Null; Engineered: Yes; Mutation: P13, P87, P119, P163, and P248	Substituted With Thioproline (Prs); Biological_Unit: Monomer	similar to annexin A8	anexin VIII	annexin VII isoform 2; annexin VII (synexin); synexin	annexin VII isoform 1; annexin VII (synexin); synexin	similar to annexin A8	annexin A13 isoform b	annexin A13; annexin XIII; annexin, intestine-specific	Unknown (protein for MGC:1925)	keratinocyte annexin-like protein	annexin 31; annexin XXXI	
NP 005130 1			pdb 1HVD	NP 001145 1	ndbl1ANW	pdb 1HVF	•		AAH18671.1	pdb 1HVG		LUHU8	NP 001621.1	pdb 1SAV		XP 036593.2	AAB46383.1	NP 004025.1	NP 001147.1	XP 054475.4	CAC34622.1	NP 004297.1	AAH05830.1	AAG16780.1	NP_003559.1	
		•																								
										-																
																					-					
1			1	I	ı	1			i	1		i	1	ı		ı	1	1	ł	ı	I	ı	ı	ŀ	1	ıJ

, rV

 $\stackrel{\smile}{\dashv}$

12

WO 2004	2.0e-56	7.0e-56			0	0	0	2.0e-64	<u>.</u>			2.0e-64	9.0e-64	2.0e-59			2.0e-59	4.0e-59	9.0e-29	2.0e-58	6.0e-58		6.0e-58	6.0e-58	6.0e-58	2.0e-57
_	219	218			710	709	706	248				248	246	231			231	230	229	228	226		226	226	526	224
Mm.28398 U.(C-HI) NP_000125.1 intestinal fatty acid binding protein 2; Fatty acid-binding protein, intestinal; I-FABP; fatty +3.49, acid binding protein 2, intestinal		Intestinal Fatty Acid Binding Protein; Chain: A; Synonym: I-Fabp	U:(C-HI) NP_000093.1 cytochrome P450, subfamily XVII polypeptide; steroid 17-alpha-monooxygenase;	steroid 17-aigina-liyaioxyiaxer 17,20 iyaxe, cytociii olid p-100 XX ii i		cytochrome P450c17	steroid 17-alpha-hydroxylase	cytochrome P(1)-450		flavoprotein-linked monooxygenase; cytochrome P1-450, dioxin-inducible; aryl	hydrocarbon hydroxylase; P450 form 6; xenobiotic monooxygenase; microsomal	monooxygenase	cytochrome P-450-1	cytochrome P-450-1		dioxin-inducible P3-450; P450 form 4; microsomal monooxygenase; xenobiotic	monooxygenase; aryl hydrocarbon hydroxylase; flavoprotein-linked monooxygenase	cytochrome P450-1A2	cytochrome P450 4	Cytochrome P450 XXIB (Steroid 21-hydroxylase) (P450-C21B)	CYP21B protein	cytochrome P450, subfamily XXIA polypeptide 2; steroid 21-monooxygenase; steroid	21-hydroxylase	21-hydroxylase B	mutant 21-hydroxylase B	steroid 21-monooxygenase
NP_000125.1		pdb 3IFB	NP_000093.1			AAA59984.1	AAA52140.1	CAA26458.1	NP_000490.1	-			AAA52139.1	AAK25728.I	NP_000752.1			AAF13599.1	AAA35738.1	P08686	AAA52063.1	NP_000491.2		AAA52064.1	AAA52065.1	CAA41709.1
U:(C-HI) +3.49,	2.22		U.(C-HI)	+3.41,	3.69												,									
Mm.28398			Mm.1262															-								
NM_007980 NP_032006.1			NM_007809	NF_031855.1													ı						_	-		

		A A C 50809 1	Cytochrome P450 CYP1B1	224	3.0e-57
			cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1; aryl hydrocarbon		20
			hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase;		
			flavoprotein-linked monooxygenase	224	3.0e-57
		AAB59440.1	steroid 21-hydroxylase	224	3.0e-57
	U:(C-HI)	Mm.23780 U:(C-HI) NP_071733.1	chromosome 11 open reading frame 24		· · ·
<u> </u>	3.19,				
	U:(C-D)				,
• •	2.42			229	1.0e-58
		AAH11765.1	chromosome 11 open reading frame 24	229	1.0e-58
듬	Mm.18170 U:(C-HI)	015492	Regulator of G-protein signaling 16 (RGS16) (Retinally abundant regulator of G-protein		
<u> </u>	3.17		signaling) (RGS-R) (A28-RGS14P)	323	2.0e-87
\vdash		NP 002919.1	regulator of G-protein signalling 16; Regulator of G protein signaling-16	320	2.0e-86
3	Mm.19143 U:(C-HI)	NP_000679.1	aminolevulinate, delta-, synthase 1		
	3.05			833	0
\vdash		CAA68506.1	5-aminolevulinate synthase precursor	808	0
\vdash		CAB06076.1	5-aminolevulinic acid synthase	645	0
\vdash		P22557	5-aminolevulinic acid synthase, erythroid-specific, mitochondrial precursor		
			(Delta-aminolevulinate synthase) (Delta-ALA synthetase) (ALAS-E)	645	0
1		CAA39795.1	delta-aminolevulinate synthase (erythroid)	644	0
		NP_000023.1	aminolevulinate, delta-, synthase 2; Aminolevulinate, delta-, synthase-2	644	0
		AAH30230.1	Similar to aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)	642	0
		AAG35538.1	PRO2399	350	3.0e-95
Mm.4210	U:(C-HI)	U:(C-HI) XP_045060.2	similar to fatty aldehyde dehydrogenase		
_	3.02			751	0
Г		NP_000373.1	aldehyde dehydrogenase 3A2; aldehyde dehydrogenase 10; aldehyde dehydrogenase		
			3 family, member A2; fatty aldehyde dehydrogenase	751	0
_		NP_000682.3	aldehyde dehydrogenase 3 family, member A1; aldehyde dehydrogenase, dimeric		
			NADP-preferring; acetaldehyde dehydrogenase; ALDH, stomach type	572	1.0e-162
		P30838	Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH class 3) (ALDHIII)	572	1.0e-162

ស

2

 \vec{s}

WC	20	04/0	092	416																	F	'C1	T/US	520	04/0)101
1.0e-162	1.0e-162	1.0e-132		1.0e-126	1.0e-119		1.0e-107	1.0e-107	1.0e-107				1.0e-168	1.0e-147	2.0e-78		2.0e-55	1.0e-54				5.0e-64	1.0e-63		1.0e-56	3.0e-55
572	572	473		453	431		392	391	330				592	525	295		218	216				245	244		220	216
aldehyde dehydrogenase [NAD(P)] (EC 1.2.1.5) 3 -	aldehyde dehydrogenase 3	unnamed protein product	aldehyde dehydrogenase 3B1; aldehyde dehydrogenase 7; aldehyde dehydrogenase 3	family, member B1	Similar to aldehyde dehydrogenase 3 family, member B1	aldehyde dehydrogenase 3B2; aldehyde dehydrogenase 8; aldehyde dehydrogenase 3	family, member B2	Similar to aldehyde dehydrogenase 3 family, member B2	unnamed protein product	homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain	member 1; MMS-inducible gene			unknown	unknown	Similar to homocysteine-inducible, endoplasmic reticulum stress-inducible,	ubiquitin-like domain member 1	hypothetical protein FLJ22313					chimeric cDNA from Myxoid liposarcoma	DNA-damage-inducible transcript 3; C/EBP homologous protein; growth arrest- and	DNA damage-inducible	DNA-damage-inducible protein GADD153 - human
A42584	AAH04370.1	BAC04239.1	NP_000685.1		AAH33099.1	NP_000686.1		AAH07685.1	BAC03897.1	NP_055500.1 hom			est i	AAC09357.1	AAG17233.1	AAH09739.1		NP_071768.2	U:(C-HI) AAB27103.1				CAA63088.1	NP_004074.2		JC1169
										_	3.00,	U:(C-D)	2.29						U:(C-HI)	2.98,	U:(C-D)	2.16				
										Mm.29151 U:(C-HI)							,		Mm.7549							
										NM 022331	NP_071726.1								NM_007837	NP_031863.1						

WO 2 004	/092-	416																		I	PC]	r/U	S2 0	04/	010	191
	1.0e-115	1.0e-113	4.0e-52		e-104				1.0e-179	1.0e-178	2.0e-53	2.0e-50				0	0	0	0	1.09-144	1.0e-131	1.0e-131	1.0e-130	1.0e-130	1.0e-129	1.0e-113
	417	409	207		379				628	626	213	202				1151	1139	1124	1117	514	470	470	468	468	465	409
Type I iodothyronine deiodinase (Type-I 5'deiodinase) (DIOI) (Type 1 DI) (5DI)		thyroxine deiodinase type 1; 5Dl; thyroxine deiodinase type I (selenoprotein)	Similar to deiodinase, iodothyronine, type I	Mm.35083 U:(C-HI) NP_077016.1 hypothetical protein MGC4504		sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3	synthase); ganglioside G(M3) Synthase			CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase	sialyltransferase 6 (N-acetyllacosaminide alpha 2,3-sialyltransferase)	Gal beta 1,3(4) GlcNAc alpha 2,3-sialyltransferase	carnitine acetyltransferase precursor, isoform 1				Carnitine O-acetyltransferase (Carnitine acetylase) (CAT)	carnitine acetyltransferase	carnitine acetyltransferase isoform 2	carnitine acetyltransferase precursor, isoform 3	Choline O-acetyltransferase (CHOACTase) (Choline acetylase) (ChAT)	choline acetyltransferase isoform S	choline acetyltransferase isoform 2; acetyl CoA:choline O-acetyltransferase	choline acetyltransferase isoform R	choline acetyltransferase isoform 1; acetyl CoA:choline O-acetyltransferase	choline acetyltransferase - human (fragment).
P49895		NP 000783.2	AAH17955.1	NP_077016.1		Mm.38248 U:(C-HI) NP_003887.1				AAD14634.1	NP 006270.1	AAL14347.1	NP_000746.2				P43155	CAA55359.1	NP_003994.2	NP_659006.1	P28329	AAK08951.1	NP_065574.1	AAK08952.1	NP_066266.1	T01786
U.(C-HI) 2.84,	U:(C-D) 2.06			U:(C-HI)	2.77	U:(C-HI)	2.65,	U:(C-D)	2.16				U:(C-HI)	2.57,	U:(C-D)	2.16										
Mm.2774	-			Mm.35083		Mm.38248							Mm.20396 U:(C-HI)										`			
NM_007860 Mm.2774 U.(C-HI) P49895 NP_031886.1 2.84,				AK007378	BAB24997.1	NM_011375	NP_035505.1						NM_007760	NP_031786.1												

D.

 $\overline{\mathbf{H}}$

15

•
L
(

WO 2	004/	092	416																			PC	T/	US2		/01		1
1.0e-117				1.0e-156	1.0e-100	1.0e-100	·	3.0e-69	1.0e-67		3.0e-60	2.0e-58	3.0e-58	4.0e-54		0	0	0	1.0e-172	-	1.0e+170	1.0e-163	1.0e-163		1.0e-163	1.0e-162	1.0e-162	1.0e-161
422				554	369	367		262	259		233	228	227	213		842	726	717	605		598	575	575		575	572	572	220
Mm.14376 U:(C-HI) NP_005422.1 X-ray repair cross complementing protein 2; X-ray repair, complementing defective,	elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2				dJ483K16.1.1 (novel protein (isoform 1))	homolog of yeast long chain polyunsaturated fatty acid elongation	elor	Stargardt disease 3 (autosomal dominant)	dJ92C4.1 (novel protein, partly predicted by Fgenesh and Genscan)	CD3Z antigen, zeta polypeptide (TiT3 complex)		T-cell surface glycoprotein CD3 zeta chain precursor (T-cell receptor T3 zeta chain)	—	1	fatty acid desaturase 2; delta-6 fatty acid desaturase; linoleoyl-CoA desaturase	(delta-6-desaturase)-like 2	fatty acid desaturase 2	p5327	probable delta-6 fatty acid desaturase (EC 1.14.99) - human (fragment).	fatty acid desaturase 3; delta-6 fatty acid desaturase; linoleoyl-CoA desaturase	(delta-6-desaturase)-like 3	unnamed protein product	unnamed protein product	fatty acid desaturase 1; linoleoyl-CoA desaturase (delta-6-desaturase)-like 1; delta-5	desaturase; delta-5 fatty acid desaturase	fatty acid desaturase 1	delta-5 fatty acid desaturase	unnamed protein product
NP_005422.1	NP_060240.1				CAB89418.1	NP 068586.1	NP 073563.1	l	CAC19496.1	U:(C-HI) AAH25703.1		P20963	NP 000725.1	AAF34793.1	NP_004256.1	4, °4	AAH09011.1	AAG43192.1	T08765	NP_068373.1		BAC11182.1	BAB55103.1	NP_037534.2		AAH07846.1	AAF70457.1	BAC11229.1
U:(C-HI)	Ē	2.53,	U:(C-D)	2.08						U:(C-HI)	2.49					2.46												
Mm.14376	Mm.2567									Mm.1224					Mm.38901 U:(C-HI)													
NM_020570	NM_019423	NP_062296.1								NM 031162	NP 112439.1				NM 019699	NP 062673.1									,			

വ

W	20	04/	092	416																		PC	170	52U	/U4/ 	010	ועוי 	l
1.0e-161	1.0e-161	1.0e-106	3.0e-88				0	0	1.0e-87	1.0e-87	8.0e-82	5.0e-81	2.0e-66	5.0e-66	7.0e-54			1 0e-107		2.0e-79		1.0e-178		0	1e-17-	1.0e-166	1.0e-166	1.0e-166
570	569	315	327				761	260	326	326	306	304	256	254	214			301		298		624		919	009	288	282	286
delta-5 desaturase		BC269730_1	1	VDUP1				2 Ithioredoxin interacting protein; upregulated by 1,25-dihydroxyvitamin D-3	2 similar to RIKEN cDNA 2410003C09 gene	Unknown (protein for IMAGE:4838787)	KIAA1376 protein	2 similar to hypothetical protein CLONE24945	1 hypothetical protein CLONE24945	Unknown (protein for MGC:26574)	Unknown	1 DnaJ (Hsp40) homolog, subfamily B, member 9; microvascular endothelial	differentiation gene 1; DKFZP564F1862 protein; endoplasmic reticulum DnaJ homolog	4	similar to putative microvascular endothelial differentiation gene 1; similar to X98993		1 Kruppel-like factor 15; KKLF protein; kidney-enriched Kruppel-like factor	·	2 zinc finger protein 93 homolog; zinc finger protein homologous to mouse Zfp93; zinc	finger protein homologous to Zfp93 in mouse; zinc finger protein 93 homolog (mouse)	Hypothetical zinc finger-like protein	zinc finger protein 226	Zinc finger protein 226	1 zinc finger protein 226; Kruppel-associated box protein
AAF29378.1	BAB55173.1	AAC23396.1	BAB55167.1	BAB18859.1	-			NP_006463.2	XP_041721.2	AAH28704.1	BAA92614.1	XP_033042.2	NP_056498.1	AAH22516.1	AAD20053.1	NP_036460.1			AAD08848.1		Mm.41389 U:(C-HI) NP_054798.1		Mm.10375 U:(C-HI) NP_004225.2		AAF88107.1	AAF88103.1	91.KN6Ò	NP_057528.1
				U:(C-HI)	2.36,	U:(C-D)	2.42									U:(C-HI)	2.34,	U:(C-D)			U:(C-HI)	2.34	U:(C-HI)	2.32				
				Mm.77432 U:(C-HI)												Mm.27432					Mm.41389		Mm.10375	0				
				NM_023719	NP_076208.1											NM_013760	NP_038788.1				NM_023184	NP_075673.1	NM_018791	NP_061261.1				

2

2

20

C.

		IZinc finger protein ZNF45	9/6	1.0e-163
	NP_003416.1	zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide); Zinc		
		finger protein-45 (a Kruppel-associated box (KRAB) domain	573	1.0e-162
	XP_091906.2	similar to Zinc finger protein 229	548	1.0e-155
	AAD12728.1	zinc finger protein	541	1.0e-152
	AAF76875.1	zinc finger protein	533	1.0e-150
	NP_037530.1	zinc finger protein 224	518	1.0e-146
	NP_037512.1	zinc finger protein 228	517	1.0e-145
	XP_009363.3	similar to ZNF228 protein	515	1.0e-145
	AAG23968.1	ZNF228 protein	515	1.0e-145
	AAF88104.1	ZNF234	512	1.0e-144
	XP_044207.1	similar to Zinc finger protein 234 (Zinc finger protein HZF4)	512	1.0e-144
	137570	zinc finger protein - human (fragment)	511	1.0e-143
	Q14588	Zinc finger protein 234 (Zinc finger protein HZF4)	511	1.0e-143
	AAF24967.1	ZNF225	507	1.0e-142
	NP_653290.2	hypothetical protein FLJ32191	501	1.0e-140
	NP_037494.1	zinc finger protein 225	501	1.0e-140
AK007864 Mm.27338 U:(0	Mm.27338 U:(C-HI) XP_084735.2	similar to RIKEN cDNA 1810054O13		
BAB25316.1 2.31			384	1.0e-105
	AAH17073	Similar to RIKEN cDNA 1810054O13 gene	346	7.0e-94
NM_019545 Mm.20413 U:((Mm.20413 U:(C-HI) NP_057612.1	hydroxyacid oxidase 3; medium-chain 2-hydroxy acid oxidase HAOX3;	-	
NP_062418.1	-	(S)-2-hydroxy-acid oxidase; glycolate oxidase	645	0
	NP_057611.1	hydroxyacid oxidase 2; long-chain L-2-hydroxy acid oxidase; (S)-2-hydroxy-acid		
		oxidase; glycolate oxidase	474	1.0e-132
	AAF14000.1	long-chain L-2-hydroxy acid oxidase	461	1.0e-128
-	NP_060015.1	hydroxyacid oxidase 1; (S)-2-hydroxy-acid oxidase; glycolate oxidase	300	3.0e-80
	BAA82872.1	a liver-specific gene similar to the plant glycolate oxidase	299	8.0e-80
NM_011058 Mm.2924 U:(0	U:(C-HI) NP_006197.1	platelet-derived growth factor receptor alpha precursor		
NP_035188.1			1905	0

			NT 002600 1	platelet, derived arough factor recentor heta preciusor; heta platelet-derived growth		
			1.00200- IV	practice deliver grown racio receptor being produced practice acres grown	828	
				ומנות ופנפטוסו	020)
		·	AAA36427.1	platelet-derived growth factor receptor	825	0
			AAH32224.1	platelet-derived growth factor receptor, beta polypeptide	825	0
			AAC50969.1	KIT protein	523	1.0e-146
			NP_000213.1	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog precursor	523	1.0e-146
			NP_005202.1	colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms)		
				oncogene homolog	485	1.0e-135
			P07333	Macrophage colony stimulating factor I receptor precursor (CSF-1-R) (Fms		
•				proto-oncogene) (c-fms) (CD115 antigen)	485	1.0e-135
			CAA81393.1	FLT3 receptor tyrosine kinase	414	1.0e-113
		·	NP_004110.1	fms-related tyrosine kinase 3	411	1.0e-113
			A36873	protein-tyrosine kinase (EC 2.7.1.112) STK-1 precursor - human	405	1.0e-111
			AAH15186.1	Unknown (protein for MGC:14519)	363	2.0e-98
		٠	AAC16449.1	vascular endothelial growth factor receptor	352	3.0e-95
	٠		NP_002010.1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability		
		-		factor receptor)	352	3.0e-95
		۔	NP_002011.1	fms-related tyrosine kinase 4; fms-related tyrosine kinase-4 (vascular endothelial		
				growth factor receptor 3)	344	1.0e-92
			CAA48290.1	FTL4	343	2.0e-92
			P35916	Vascular endothelial growth factor receptor 3 precursor (VEGFR-3) (Tyrosine-protein		
	٠			kinase receptor FLT4)	343	2.0e-92
			AAC16450.1	vascular endothelial growth factor receptor 2	341	7.0e-92
			NP_002244.1	kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert		
				domain receptor	341	7.0e-92
			JC1402	protein-tyrosine kinase (EC 2.7.1.112) KDR - human	340	1.0e-91
	·		158357	receptor tyrosine kinase - human (fragment).	340	1.0e-91
NM_010565	Mm.2594	U:(C-HI)	U:(C-HI) NP_005529.1	inhibin beta C chain preproprotein; activin beta-C chain		
NP_034695.1		2.28			503	1.0e+141
			NP_113667.1	activin beta E	202	1.0e-52

വ

Н

12

 \sim

WO 2	:00	4/0	924	116]	PC	T/U	S20)04,	/010	191
C			5	0	0		1.0e-155	1.0e-143			1.0e-124	1.0e-124	1.0e-112	-	0		0	0	0	0	1.0e-55		0	0	1.0e-155	8.0e-76		3.0e-47
1253	42,42	2 0	976	925	925		549	510			448	446	406		1213		1210	1205	1125	975	220		779	270	220	286		188
adrenoleukodystrophy related protein	ON IN A 1 III ON TO THE PROPERTY OF THE PROPERTY III OF THE PROPER	ATP-binding cassette, sub-tamily D, member Z; adrenoleukodysuopily-like 1, lincup.	ATP-binding cassette, sub-family D (ALD), member 1; adrenoleukodystrophy protein	adrenoleukodystrophy protein	Adrenoleukodystrophy protein (ALDP)	70-kd peroxisomal membrance protein homolog {internal fragment} [human, Peptide	Partial, 386 aa]	adrenoleukodystrophy related protein	ATP-binding cassette, sub-family D, member 3; Peroxisomal membrane protein-1	(70kD); peroxisomal membrane protein 1 (70kD, Zellweger syndrome); peroxisomal	membrane protein-1	peroxisomal membrane protein, 70K - human	70kD peroxisomal integral membrane protein	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a-like 1;	HepA-related protein; SMARCA-like protein 1	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily	a-like 1	HepA-related protein HARP	hypothetical protein DKFZp434B1050.1 - human (fragment)	unnamed protein product	unnamed protein product	Similar to RIKEN cDNA 1700018O18 gene		unnamed protein product	Similar to RIKEN cDNA 1700018018 gene	similar to F16H11.1.p	dynein, cytoplasmic, light polypeptide; Dynein, cytoplasmic, light chain (protein inhibitor	of neuronal NOS); protein inhibitor of neuronal nitric oxide synthase
JC5712		NP_005155.1	NP_000024.2	1908394A	P33897	AAB27045.1		AAB00541.1	NP_002849.1			S20313	CAA58470.1	NP_054859:2		AAH16482.1		AAF24984.1	T34557	BAA90955.1	BAC04536.1	AAH11587.1		BAC04100.1	AAH06353.1	XP 065744.2	Mm.29908 U:(C-HI) NP_003737.1	
U:(C-HI) JC5712	2.27					-				,				Mm.36676 U:(C-HI)	2.27							Mm.38305 U:(C-HI)	2.24				U:(C-HI)	2.24
Mm.4817				-										Mm.36676								Mm.38305					Mm.29908	
	NP_036124.1													NM 018817	NP 061287.1							AK006096	BAB24407.1				NM_019682	NP_062656.1

ហ

wo	2004	1/09	24	16																		PC'	T/U	S20		0101		_
-	-	0	C	D- 0	0	0		=	1.0e-131	1.0e-103		6.06-70	2.0e-69				0				0		-		0	•)	
		1993	1243	2 9	1243	949		-	471	376		266	237	·			979				957				952	1	797	736
	domain (TM) and short cytoplasmic domain, (semaphorin) 5A; semaphorin F; sema	domain (TM) and short extension domain. 5A		KIAA1445 protein	similar to KIAA1445 protein	semaphorin F	_			HOVE of relimin	_		+	_		factor, RNA polymerase II, E, 70/85kD; transcription initiation factor TFIID 70 kD	subunit	TBP-associated factor 6 isoform gamma; TAF6 RNA polymerase II, TATA box binding		factor, RNA polymerase II, E, 70/85kD; transcription initiation factor TFIID 70 kD	subunit	1 TBP-associated factor 6 isoform delta; TAF6 RNA polymerase II, TATA box binding		factor, RNA polymerase II, E, 70/85kD; transcription initiation factor TFIID 70 kD	subunit	serine/threonine protein kinase sgk		1 serum/glucocorticoid regulated kinase
U.(C-HI) NP_003957.1		_		BAA95969.1	XP 032249.3	AAC14668.1	Mm.19596 U:(C-HI) NP_115680.1			1 02012214 4	AAN01230.1	NF_005517.1	D A D 70014 1	U-(C-HI) NP 005632.1				NP 620834.1	ı			NP 620835.1	1			AAD41091.1		NP 005618.1
U.(C-HI)	2.23	-					U.(C-HI)	2.22,	U:(C-D)	2.15				U(C-HI)	2.2				٠								2.2	
Mm.24733							Mm.19596		`					Mm 1994												Mm.28405 U:(C-HI)		
NM 009154	NP_033180.1						AK005274	BAB23924.1						NIM 009315	NP 033341 1					. —						NM_011361	NP 035491.1	

WO 2004/092416	PCT/US2004/010191

			AAH15326.1	Unknown (protein for MGC:21163)	532	1.0e-149
			1	protein kinase	532	1.0e-149
			2	serum/glucocorticoid regulated kinase-like; cytokine-independent survival kinase	527	1.0e-148
			AAF12757.2	protein kinase	206	1.0e-142
			12	serum/glucocorticoid regulated kinase 2 isoform beta	506	1.0e-142
			7	v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma); protein		
				kinase B	327	4.0e-88
NM_011844	Mm.19479 U:(C-HI)	_	NP_009214.1	monoglyceride lipase; lysophospholipase-like; likely ortholog of mouse monoglyceride		
NP 035974.1	5 2.19	တ		lipase	538	1.0e-151
			CAC43316.1	monoglyceride lipase	528	1.0e-148
NM_018861	Mm.6379 U:(U:(C-HI)	AAA19438.1	neutral amino acid transporter		
NP_061349.1	2.18	<u></u>			929	0
			NP_003029.2	solute carrier family 1 (glutamate/neutral amino acid transporter), member 4; Solute		
		٠,		carrier family 1 (glutamate/neutral amino acid transporter),	9/9	0
			155389	neutral amino acid transporter - human	673	0
			BAA94861.1	IASCT1	670	0
			A47131	Na+-dependent neutral amino acid transporter SATT	630	1.0e-179
			NP_005619.1	solute carrier family 1 (neutral amino acid transporter), member 5; baboon M7 virus		
				receptor; RD114 virus receptor; neutral amino acid transporter B	365	2.0e-99
			AAD09814.1	neutral amino acid transporter	365	2.0e-99
			AAH00062.1	solute carrier family 1 (neutral amino acid transporter), member 5	365	2.0e-99
			AAK77026.1	sodium-dependent neutral amino acid transporter type 2 truncated isoform	365	2.0e-99
			AAC50629.1	neutral amino acid transporter B	365	3.0e-99
			AAD09812.1	RD114/simian type D retrovirus receptor	361	5.0e-98
AF213258	Mm.14976 U:(C-HI)	1	NP_690864.1	membrane-associated guanylate kinase-related 3		
AAG43836	0 2.17,	. ,				
	<u>;</u>	U:(C-D)				
	2.34	34			1995	0
			XP_032749.	similar to membrane-associated guanylate kinase MAGI3		1
			2		1989	0

Ŋ

wo	2004/0	092416
----	--------	--------

			AAG24545.1	membrane-associated quanylate kinase MAGI3	1972	0
		-	_	AA1634 protein	1590	0
			1	dJ730K3.2 (similar to BAI1-associated protein)	1163	0
			NP 036433.	atrophin-1 interacting protein 1; activin receptor interacting p; KIAA0705 gene product		
			I —		696	0
			AAK94066.1	MAGI-1C beta	853	0
			AAK94064.1	MAGI-1B alpha beta	847	0
			NP_004733.	BAI1-associated protein 1; WW domain-containing protein 3		
			-		843	0
		*.	JE0209	brain-specific angiogenesis inhibitor-associated protein 1 - human	839	0
			80.1	KIAA0705 protein	827	0
			_	MAGI-1A	689	0
			CAC36032.1	bA473L1.1 (novel protein similar to BAI1-associated protein 1 (BAIAP1))	282	1.0e-166
			BAB15479.1	unnamed protein product	300	1.0e-162
-			AAC04844.1 m	membrane associated guanylate kinase 1	450	1.0e-125
NM_008382	Mm.3510	U:(C-HI)	U:(C-HI) NP_113667.1	activin beta E		
NP_032408.1		2.13			537	1.0e-151
			NP_005529.1	inhibin beta C chain preproprotein; activin beta-C chain	243	1.0e-62
NM_007679	Mm.4639	U:(C-HI)	NP_005186.1	U.(C-HI) NP_005186.1 CCAAT/enhancer binding protein (C/EBP), delta		
NP_031705.1		2.11			343	3.0e-93
			A40225	transcription activator NF-IL6 beta - human	340	4.0e-92
			XP_171180.1	similar to CCAAT/enhancer binding protein delta (C/EBP delta) (Nuclear factor		
				NF-IL6-beta) (NF-IL6-beta)	340	4.0e-92
NM_030887	Mm.10356	U:(C-HI)	Mm.10356 U:(C-HI) NP_569736.1	Jun dimerization protein		
NP 112149.1 0	0	2.07			244	3.0e+63

Ŋ

 \ddot{a}

금

VO 2004/092416			E	14111													F	CT	7US	S2 0	04/0	10	191	
7.0e-54	2.0e-53						1.0e-130		0	0		0				0	0	0		1.0e-84	1.0e-78	4.0e-71	4.0e-71	4.0e-71
213	211						465		1795	1792		1792		1023		1022	944	662		316	296	271	271	271
transforming growth factor beta-stimulated protein TSC-22	cerebral protein-2	BCR downstream signaling 1						Solute carrier family 12 member 3 (Thiazide-sensitive sodium-chloride cotransporter)	(Na-Cl symporter)	NaCl electroneutral Thiazide-sensitive cotransporter	solute carrier family 12 (sodium/chloride transporters), member 3; Solute carrier family	12 (sodium/potassium/chloride transporters),	solute carrier family 12 (sodium/potassium/chloride transporters), member 2; Solute	carrier family 12 (sodium/potassium/chloride transporters),	sodium potassium chloride cotransporter 2; Solute carrier family 12	(sodium/potassium/chloride transporters),	lar to solute carrier family 12 (sodium/potassium/chloride transporters), member 2	thiazide-sensitive sodium-chloride cotransporter - human (fragment)	solute carrier family 12 (potassium/chloride transporters), member 7;	potassium/chloride transporter KCC4	sodium-potassium-chloride cotransporter	KIAA1176 protein	electroneutral potassium-chloride cotransporter KCC2	solute carrier family 12, (potassium-chloride transporter) member 5
Mm.20927 U:(C-HI) NP_006013.1 trar 2.06, U:(C-D) 2.89, U:(HI-D) 2.64	BAB46917.1	NP_036240.1		.e	٠.			P55017		G01202	NP_000330.1	·	NP_001037.1		NP_000329.1		AAH33003.1	PC4180	NP_006589.1		AAL32454.1	BAA86490.1	AAG43493.1	NP 065759.1
U:(C-HI) 2.06, U:(C-D) 2.89, U:(HI-D) 2.64		U:(C-HI)	2.06,	U:(C-D)	2.23,	U:(HI-D)	2.12	U.(C-HI)	2.06															
Mm.20927		Mm.38392 U:(C-HI)						Mm.18290 U:(C-HI) P55017	5															·
NM_009366		NM_019992	NP_064376.1					NM_019415	NP_062288.1															

wo	2004/092410	6

WO 2	004	/092	241	6																	_				004	/010		
1.0e-145	1.0e-83	1.0e-83	4.0e-76	1.0e-67	1.0e-62	1.0e-52		1.0e-93		2.0e-92	8.0e-76	•	2		0	0		0	1.0e-136	5.0e-89	5.0e-89	2.0e-74	2.0e-74	3.0e-70				8.0e-70
516	311	311	286	258	241	208		343		340	285	1	920		648	648		645	486	330	330	281	281	268				266
diacylglycerol O-acyltransferase 2 like 1; diacylglycerol acyltransferase 2-like	horothatical protein	Thypoxicaca process	diacylolycerol O-acyltransferase homolog 2; GS1999full	hA351K33 5 (novel profein)	broothotical profein El 100644	similar to predicted proteins AAB54240 (PID:g2088822) and S67138 (PID:g2132925	_		Ubiquitin-Conjugating Enzyme E2 H10; Chain: A, B; Synonym: Ubiquitin-Conjugating	Enzyme Ubch10; Ec: 6.3.2.19;	dJ447F3.2.4 (ubiquitin-conjugating enzyme E2 H10 (isoform 4))	CYR61 protein		CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) (Insulin-like growth	factor-binding protein 10) (GIG1 protein)	CYR61 protein	NP 001545.1 cysteine-rich, angiogenic inducer, 61; cysteine-rich heparin-binding protein 61;	cysteine-rich, anigogenic inducer, 61	tumor RMS cell line RD specific product	bA6918.1 (connective tissue growth factor)	connective tissue growth factor	1	1	con	_		pathway protein 1; connective tissue growth factor related protein WISP-1; Wnt-1	induced secreted protein 1
Mm.41325 U:(C-HI) NP_477513.1 diacyl	7 1738061 1	A A H15234 1	115053 1	112/02/14	CAUI3472.1	A AD45832 1	Mm.89830 U:(C-HI) NP 008950.1	- 1	pdb 117K		CAC36108.1	U:(C-HI) AAG59863.1	,	000622		CAA72167.1	NP 001545.1	· .	AAF21597.1	CAC44023.1	NP 001892.1	AAH15028.1	NP 002505.1	AAA75378.1	NP 003873.1	· ·		
J.(C-HI)	4.04						U:(C-HI)	2.04].			U:(C-HI)	2.04															
Mm.41325	1						Mm.89830					Mm.1231																
	BAB22288.1						AK003722	BAB22959.1				NM_010516	NP 034646.1															

,	W _a	Ģ	2004/092416	r
		_	2	

•	PCT/U	S2004/	010191
	90	69	0

, i	-		NP_569080.1 W	WNT1 inducible signaling pathway protein 3, isoform 2; Wnt1 signaling pathway		n r
				protein 3; lost in inflammatory breast cancer tumor suppressor protein; connective		'trr
				tissue growth factor like protein; connective tissue growth factor related protein		
				WISP-3	216	7.0e-55
			NP_003871.1	WNT1 inducible signaling pathway protein 3, isoform 1; Wnt1 signaling pathway		
				protein 3; lost in inflammatory breast cancer tumor suppressor protein; connective		
		-		tissue growth factor like protein; connective tissue growth factor related protein		
				WISP-3	211	2.0e-53
NM_010354	Mm.21109 U:(C-HI)	U:(C-HI)	NP_000168.1	gelsolin (amyloidosis, Finnish type); Gelsolin		
NP_034484.1		2.03	-		1422	0
			Q9Y6U3	Adseverin (Scinderin)	904	0
			BAC11416.1	unnamed protein product	904	0
			AAK60494.1	scinderin	899	0
			NP_009058.1	villin 1; Villin-1	672	0
			AAD15423.1	similar to mouse adseverin(D5); similar to PID:g2218019	999	0
			BAB67798.1	KIAA1905 protein	999	0
	-		pdb/1DB0	Carboxy-Terminal Half Of Gelsolin (G4-G6) Bound To Actin	643	0
			NP_006567.2	advillin	640	0
		,	075366	Advillin (p92)	638	0
			NP_149119.1	scinderin; adseverin; KIAA1905 protein	588	1.0e-167
			AAH17491.1	Similar to gelsolin (amyloidosis, Finnish type)	542	1.0e-153
	•		BAC11465.1	unnamed protein product	497	1.0e-139
			AAH04134.1	Similar to advillin	464	1.0e-129
			pdb/1JHW	Macrophage Capping Protein; Chain: A; Synonym: Actin-Regulatory Protein Cap-G;		
6				Engineered	389	1.0e-106
AK002717	Mm.46241 U:(C-HI)	U:(C-HI)	NP_005692.1	RNA, U transporter 1; snurportin-1; snuportin-1		
XP_134867	· ·	2.02			424	1.0e-169
AK004600	Mm.34514 U:(C-HI)	U:(C-HI)	NP_062455.1	Rho guanine nucleotide exchange factor 3; RhoGEF protein; 59.8 kDA protein		
BAB23401.1	·	2.02			941	0
			BAB14891.1	unnamed protein product	782	0

WC	, Z()	04/0	リソス・	410																			PC'	1/0		U-4/1	,101
1.0e-167	1.0e-156		1.0e-156	1.0e-140		1.0e-120	1.0e-120	1.0e-120		3.0e-69		2.0e-67	7.0e-66	2.0e-49		0		0		0		0		5.0e-94	1.0e-89		1.0e-110
290	553		553	200		432	432	432		263		257	252	197		826		825		824	*	823		346	332		402
Similar to Rho guanine nucleotide exchange factor (GEF) 3	guanine nucleotide-exchange factor	intersectin 1 (SH3 domain protein); intersectin (SH3 domain protein 1A); SH3 domain	protein-1A; human intersectin-SH3 domain-containing protein SH3P17	guanine nucleotide regulatory protein	3-hydroxy-3-methylglutaryl-Coenzyme A reductase		Hmg-Coa Reductase; Chain: A, B, C, D; Fragment: Catalytic Portion; Ec: 1.1.1.34	Similar to 3-hydroxy-3-methylglutaryl-Coenzyme A reductase	DnaJ (Hsp40) homolog, subfamily B, member 6 isoform b; Heat shock protein J2		similar to DnaJ (Hsp40) homolog, subfamily B, member 6 isoform b; Heat shock	protein J2	DnaJ (Hsp40) homolog, subfamily B, member 6 isoform a; Heat shock protein J2	similar to DnaJ homolog subfamily B member 8 (mDJ6)	p67phox-like protein		Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa	neutrophil oxidase factor) (p67-phox)	neutrophil cytosolic factor 2; neutrophil cytosolic factor 2 (65kD, chronic granulomatous	disease, autosomal 2); p67phox	Similar to neutrophil cytosolic factor 2 (65kD, chronic granulomatous disease,	autosomal 2)	Neutrophil Cytosol Factor 2; Chain: A; Fragment: N-Terminal Domain Residues 1 -	213	Neutrophil Cytosol Factor 2 (Ncf-2) Tpr Domain, Residues 1-203	TERA protein	
AAH22249.1	CAA08974.1	-		G01210	Mm.2226 U:(C-HI) NP 000850.1	•	pdb/1DQ8	AAH33692.1	U:(C-HI) NP_005485.1	-	XP_052862.4		NP 490647.1	XP_093388.1	Mm.10729 U:(C-HI) AAM89263.1	!	P19878		NP_000424.1		AAH01606.1		pdb 1HH8		pdb 1E96	Mm.18637 U:(C-HI) NP_067061.1	
					U:(C-HI)	2.02			U:(C-HI)	2.02					U:(C-HI)	2.02					·				-	U:(C-HI)	2.02
					Mm.2226				Mm.3075					·	Mm.10729											Mm.18637	
					M62766	AAA37819.1			NM_008299	NP_032325.1					NM_010877	NP_035007.1								•		NM_019643	NP_062617.1

W	200	04/09	241	6												-						PCT/US2	2004/		
		0	0	0	0	0	1.0e-179	1.0e-177	1.0e-169	1.0e-169	1.0e-148	1.0e-68		1.0e-71	1.0e-71			3.0e-75		3.0e-75	3.0e-74	3.0e-82		8.0e-82	
	 ·	779	779	773	662	259	632	625	269	596	526	263		271	271			282		282	279	306		305	
methyl-CpG binding protein 1			methyl CnG hinding domain protein 1 isoform 1	methyl-CnG binding protein solice variant 1	methyl-CnG binding domain protein 1 isoform 2	methyl-CnG binding protein splice variant 2	methyl-CpG binding domain protein 1 isoform PCM1	methyl-CpG binding protein	methyl-CpG binding domain protein 1	methyl-CpG binding domain protein 1 isoform 3	methyl-CpG binding domain protein 1 isoform 4	Unknown (protein for MGC:21089)	hypothetical protein MGC17791		similar to RIKEN cDNA 2600017J23		five-lipoxygenase activating protein (FLAP)		arachidonate 5-lipoxygenase-activating protein; five-lipoxygenase activating protein;	MK-886-binding protein	lipoxygenase activating protein	similar to Krueppel-like factor 13 (Transcription factor BTEB3) (Basic transcription element binding protein 3) (BTE-binding protein 3) (RANTES factor of late activated T lymphocytes-1) (RFLAT-1) (Transcription factor NSLP1) (Novel Sp1-like zinc fi		transcription factor; RANTES factor of late activated 1 lymphocytes-1; basic	וומוזארווו מפווומוו חווחווו לו איסיפווו ס
Mm.22522 U:(C-HI) AAD50371.1			C 163530 EN	A A D 51442 1	NP 056670.2	A A D 51443 1	NP 056723.2	CAA71735.1	AAH33242.1	NP 056669.1	NP 002375.1	AAH12487.1	U:(C-HI) NP_689575.1		XP 059012.1		Mm.19844 U:(C-HI) CAA36441.1		NP_001620.2		1603359A	Mm.41170 U:(C-HI) XP_096904.4	NP_057079.1		
J:(C-HI)	2.01,	U:(C-D)	C1.7										U:(C-HI)	2			U:(C-HI)	2				U:(C-HI) 2			
Mm.22522 L	_ (N		1										Mm.2312				Mm.19844					Mm.41170			
NM 013594													NM 025566	NP 079842.1			AK004002	BAB23117.1				NM_021366 NP_067341.1			

1 0 1 5 1 5

WO 2	004/	ロソス・	110																PC	1/(32	!)(J+,	/010	0191	
1 0e-71	1.0e-71			0	0	0	0	4.0e-84	1.1e-138	1.0e-138	1.0e-138		1.0e-135	1.0e-134	1.0e-131	1.0e-128	1.0e-122	1.0e-121	1.0e-121	1.0e-118	1.0e-118	1.0e-118	6.0e-83		6.0e-83
27.1	271			822	815	812	763	311	497	494	493		482	481	471	461	439	438	437	426	426	426	310		310
	similar to RIKEN cDNA 2600017123			p10-binding protein	p10-binding protein	unnamed protein product	p10-binding protein BITE splice variant	Similar to p10-binding protein	alpha1-antichymotrypsin	similar to Alpha-1-antichymotrypsin precursor (ACT)	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),	member 3	alpha-1-antichymotrypsin precursor - human	alpha-1-antichymotrypsin precursor	alpha-1-antichymotrypsin precursor	alpha - 1-Antichymotrypsin	chymotrypsin inhibitor	alpha1 Antichymotrypsin	alpha-1-antichymotrypsin, precursor; alpha-1-antichymotrypsin; antichymotrypsin	Cleaved Antichymotrypsin A347R	Cleaved Antichymotrypsin A349R	Cleaved Antichymotrypsin T345R	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),	member 4; protease inhibitor 4 (kallistatin)	Kallistatin precursor (Kallikrein inhibitor) (Protease inhibitor 4)
1 3E3007 CE	NP 089575.1 XP 059012.1			AAH30598	NP 077817	BAB14403	AAG35791	AAH16050	Mm.22650 U:(C-D)+ CAA48671.1	XP 028322.1	AAH34554.1		ITHUC	AAD08810.1	AAA51560.1	pdb 1QMN	1313184C	pdb 2ACH	NP_001076.1	pdb 3CAA	pdb 1AS4	pdb/4CAA	NP_006206.2		P29622
(C-HI)	7+			U:(C-D)+ 1.9					U:(C-D)+ 1.77							-									-
	Mm.2312			Mm.18879					Mm.22650															,	
NM_025566	NP_0/9842.1		NM_023873	NP 076362.1					NM_009252 NP_033278.1																

LC

 Ξ

7.2

~

S

member 5: Profein C inhibitor (plasminoden activator inhibitor-3); protein C inhibitor,
protein C inhibitor (plasminogen activator inhibitor III)
hypothetical protein DKFZp434P131.1
plasma serine protease inhibitor precursor
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),
member 1; Protease inhibitor (alpha-1-antitrypsin); protease inhibitor 1 (anti-elastase),
Similar to serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase,
acrosomal serine protease inhibitor
Alpha-1-antitrypsin precursor (Alpha-1 protease inhibitor) (Alpha-1-antiproteinase)
11 11 12 C manage of all finterlastics of recentary like d
toll-like receptor 1; Toll/interleukin-1 receptor-like
Toll protein-like receptor DKFZp547I0610.1 - human
Chain A, Crystal Structure Of The C713s Mutant Of The Tir Domain Of Human Tlr2

 $\stackrel{\smile}{\dashv}$

幵

 $\tilde{\kappa}$

, WO	20 <u>04</u>	/092	416	
_				_

98
Ñ

	O 2	004	<u>/0</u> 92416) ,.																		PC'
9.0e-91	4.0e-70		1.0e-110								0	0	0	0	0	0	0	1.0e-169	1.0e-105	1.0e-105	1.0e-92	•
266	264		401								795	793	793	657	639	638	635	269	382	382	342	
2.												,										
Chain A Crystal Structure Of P681h Mutant Of Tir Domain Of Human Tir2	Chain A. Crystal Structure Of The Tir Domain Of Human Th2.		Ras-related protein Rab-30		vanin 1 precursor; Vannin 1; pantetheinase							Tiff66	dJ55C23.1 (vanin 1)	vanin 3 isoform 1 precursor; VNN3 protein; pantetheinase	dJ55C23.2 (vanin 2)	vanin 2, isoform 1 precursor; Vannin 2; pantetheinase	VNN2 protein	vanin 2, isoform 2; Vannin 2; pantetheinase	Biotinidase precursor	biotinidase precursor	dJ55C23.5.1 (vanin 3, isoform 1)	
1FVXA	1FYWA		015771		NP_004657.1 van							AAF21453.1	CAB40075.1	NP_060869.1	CAB40076.1	NP_004656.2	CAA10569.1	NP_511043.1	P43251	NP_000051.1	CAC33872.1	
			<u>(</u>		D	(C-HI)+4	.37, U	(C-D)	3.14, U	(HI-D)	2.37											
			U:(C		Mm.27154																	
			AK017185 BAB30625.1		NM_011704	NP_035834.1					_											

	200					1.0e-120	1.0e-119	1.0e-119	1.0e-118	1.0e-117	2.0e-73						1.0e-110		1.0e-110	9.0e-80	5.0e-51	2.0e-50	2.0e-50		2.0e-50	3.0e-20
						432	431	428	426	422	277					-	399		399	299	203	201	201		201	101
Apolipoprotein A-IV precursor (Apo-AIV)							apolipoprotein A-IV precursor	\top	T	T		D-site-binding protein (Albumin D box-binding protein) (TAXREB302)						D site of albumin promoter (albumin D-box) binding protein; D site of albumin promoter	<u>ā</u> :	Т	1_	Т	thyrotroph embryonic factor - human	dJ979N1.5 (thyrotrophic embryonic factor (orthlog of chicken vitellogenin gene-binding	protein VBP beta/beta isoform) (isoform 2))	П
P06727							CAA31955.1		1	18.1								NP 001343.1	l	BAA05833.1	NP 002117.1	010587	B55558	97.1		NP 003207.1
	(C-HI)+2	.98, U	(c-p)	2.42, ∪	(HI-D)	2.16	T					U (C-HI) Q10586	2.79, U	(c-D)	4.24, U	(HI-D	2.47									
Mm.4533			-									Mm.3459	,													
NM 007468	NP 031494.1											NM 016974	NP 058670.1	ı												

.00-139 .00-139	1.0e-139	1.0e-139	1.0e-138	1.0e-125		1.0e-78		7.0e-41		1.0e-115		1.0e-91		3.0e-91		0	0	0	0	1.0e-166	1.0e-164	1.0e-164	1.0e-163	1.0e-163	1.0e-162	1.0e-162
497	496	495	494	450		295		167		415		337		336		1778	1741	1723	1721	587	582	582	578	576	575	573
transmembrane 4 superfamily member 2; membrane component, x chromosome, surface marker 1; T-cell acute lymphoblastic leukemia associated antigen 1; transmembrane protein A15; tetraspanin protein; cell surface glycoprotein A15; CD231	tetraspanin protein	T-cell acute lymphoblastic leukemia associated antigen 1 - human	Unknown (protein for MGC:26217)	TALLA-1	transmembrane 4 superfamily member 6; tetraspan TM4SF; A15 homolog; tetraspanin	TM4-D; tetraspanin 6	matrix Gla protein		SRY (sex determining region Y)-box 11; SRY (sex-determining region Y)-box 11		HEAT-SHOCK 20 KD LIKE-PROTEIN		crystallin, alpha B; crystallin, alpha-2; Rosenthal fiber component; heat-shock 20 kD	like-protein			VLA-3 alpha subunit	Integrin alpha-3 precursor (Galactoprotein B3) (GAPB3) (VLA-3 alpha chain) (CD49c)	I integrin alpha 3 isoform b, precursor	integrin alpha6 subunit	I integrin alpha chain, alpha 6	Ť	integrin alpha-6 chain precursor, splice form A [validated]	integrin alpha 7 chain		integrin alpha 7
Mm.18590 U.(HI-D) NP_004606.2 2.86	CAB65594.1	139368	AAH18036.1	AAF44123.1	NP_003261.1		NP_000891.1		U:(HI-D) NP_003099.1		043416		NP_001876.1		Mm.57035 U:(HI-D) NP_002195.1		BAA00845.1	P26006	NP_005492.1	CAA42099.1	NP_000201.1	AAD48469.1	B36429	CAB41534.1	NP_002197.1	AAC18968.1
U:(HI-D) 2.86							U:(HI-D)	2.36	U:(HI-D)	2.36	U:(HI-D) 043416	2.06			U:(HI-D)	2.05										
Mm.18590							Mm.19345 U:(HI-D)	6	Mm.6238		Mm.178				Mm.57035	×.										
NM_019634 NP_062608.1							NM_008597	NP_032623.1	NM_009234	NP_033260.1	NM_009964	NP_034094.1			NM_013565	NP_038593.1										

ហ

 $\stackrel{\smile}{\vdash}$

H

(2)

S

WO 2004/092416

PCT/US2004/010191

Master Table 1: Subtable 1C: Mixed Genes/Proteins

270

Mouse Gene	Unigene	Behavior Human		Human Protein Name	Score E-Value	5-Value
Protein			Protein	it.		
NM_016875	Mm.29286	(G-IH):U	NP_057066.1	Mm.29286 U:(HI-D) NP_057066.1 germ cell specific Y-box binding protein; contrin		
NP_058571.1		2.73				
		F:(C-D)				
,		-4.72			285	1.00e-75
			AAH33800.1	germ cell specific Y-box binding protein	285	1.00e-75
AF001293		(G-IH):0	XP_012694.8	U:(HI-D) XP_012694.8 similar to zinc finger protein, subfamily 1A, 3 (Aiolos)		
AAB58795.1	Mm.37444 2.59	2.59				
,.		F:(C-D)				
		-3.71			920	0
			NP_036613.1	zinc finger protein, subfamily 1A, 3 (Aiolos)	911	0
·			CAC80429.1	AlOlos isoform four	822	0
		·	CAC80427.1	AIOLOS isoform two	753	0
			CAC80428.1	AIOLOS isoform three	735	0
			CAC80431.1	AIOLOS isoform six	548	1.00e-145
			CAC80430.1	AIOLOS isoform five	516	1.00e-145
			NP_006051.1	zinc finger protein, subfamily 1A, 1 (Ikaros); Ikaros (zinc finger protein)	909	1.00e-142
			AAB50683.1	hlk1	493	1.00e-138
			NP_057344.1	zinc finger protein, subfamily 1A, 2 (Helios); zinc finger DNA binding protein Helios	466	1.00e-130
·			AAH18349.1	Unknown (protein for MGC:17055)	448	1.00e-124
			AAH28936.1	Similar to zinc finger protein, subfamily 1A, 2 (Helios)	417	1.00e-115
			BAB47411.1	KIAA1782 protein	406	1.00e-112
			NP_071910.1	zinc finger protein, subfamily 1A, 4 (Eos); zinc finger transcription factor Eos	403	1.00e-111

Ŋ

10

15

Email	WO 200-	1.00e-131	1.00e-127			1.00e-127			-	0			,	1.00e-156				6.00e-57		2.00e-56	1.00e-54			1.00e-104	
,		469	456			456	-			1219				552		_		223		221	215			379	
	U:(HI-D) NP_659508.1 cytokine-inducible SH2-containing protein isoform 2; cytokine-inducible SH2-containing 2.45	signaling	cytokine-inducible inhibitor of signalling type 1b	NP_037456.4 cytokine-inducible SH2-containing protein isoform 1; cytokine-inducible SH2-containing	protein; cytokine-inducible inhibitor of signaling type 1B; suppressor of cytokine	signaling	Mm.10490 U;(HI-D) NP_063946.1 N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2; N-acylsphingosine	amidohydrolase 2; mitochondrial ceramidase; N-acylsphingosine amidohydrolase (acid	ceramidase) 2		1 ankyrin repeat and SOCS box-containing 8				ITIM-containing receptor MAFA-L				killer cell lectin-like receptor subfamily G, member 1; mast cell function-associated	antigen (ITIM-containing)		1 pleckstrin homology-like domain, family A, member 1; PQ-rich protein			
	NP_659508.1		AAF97410.1	NP_037456.4			NP_063946.1				NP_077000.1		•		AAC32200.1				NP_005801.2		AAC34731.1	U:(HI-D) NP_031376.1			
	U:(HI-D) 2.45	F:(C-D) -2.25		1			(G-IH):N	2.42	F:(C-D)	-2.62	(a-iH):U	2.35	F:(C-D)	-2.5	(a-1H):0	2.13	F:(C-D)	-2.74				(a-ih):u	2.1	F:(C-D) -3.91	
	Mm.4592						Mm.10490	0			Mm.20076 U:(HI-D)	9			Mm.20434							Mm.3117			4
	NM_009895 NP_034025.1						NM_018830	NP_061300.1			AF398969	AAK97491.1			NM_016970	NP_058666.1						NM_009344	NP_033370.1		

Ŋ

10

15

V
_

wo 2	2004/ <u>0</u> 9	241	6																			PCT	yus	S20 (<u>)4/0</u>	10191	····
0		0	0	4 006-83	0000	4.00e-83	4.00e-83		4.00e-83	e e	4.00e-83	1.00e-82	1.00e-82	2.00e-82	3.00e-82	2.00e-81	2.00e-81		7.00e-63	5.00e-62	1.00e-55					3.00e-81	5.00e-80
691		684	682	310	215	310	310		310		310	308	308	308	307	305	305		243	240	216					301	298
similar to tropomyosin, fibroblast - human		Gia derived nexin precursor (GDN) (Protease nexin I) (PN-1) (Protease inhibitor 7)	In derived neurite promoting factor precursor	glia delived il cuite promong tack produce.	Piasminogen Activator innibitor- i	plasminogen activator inhibitor	Plasminogen Activator Inhibitor-1; Chain: A; Synonym: Pai-1, Endothelial Plasminogen	Activator Inhibitor, Pai	serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor	type 1), member 1; plasminogen activator inhibitor, type I	prebeta-migrating plasminogen activator inhibitor	plasminogen activator inhibitor 1	Cleaved Substrate Variant Of Plasminogen Activator Inhibitor-1	Human Plasminogen Activator Inhibitor Type-1 In Complex With A Pentapeptide	Plasminogen Activator Inhibitor-1	Active Form Of Human Pai-1		serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1; protease	inhibitor 12 (neuroserpin)	serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1	protease inhibitor 14; pancpin	fibroblast growth factor 21					fibroblast growth factor 21 precursor
U:(HI-D) XP_059422.1 similar		P07003	A 26061	110001	pdb 1DB2	CAA28444.1	pdb 1LJ5		NP_000593.1		AAA60008.1	AAA60009.1	pdb 9PAI	pdb 1A7C	pdb/1B3K	pdb 1DVM	CAA31208.1	NP_005016.1		AAH18043.1	NP 006208.1						NP_061986.1
U:(HI-D)	2.01 F:(C-D)	-2.61																				U:(C-HI)	6.00,	U:(C-D)	5.03,	F:(HI-D) -3.06	Г
Mm.3093																			•			Mm.14373	9				
	NP_033281.1																					NM_020013	NP_064397.1				

10 10 20 20

w	20	04/092																			_	<u>CT</u>	<u>YUS</u>			101	
	·		. 0	0	0					•	0	0	1.00e-140	1.00e-138	1.00e-137	1.00e-137			1.00e-136	1.00e-136	1.00e-136	1.00e-136	1.00e-136	1.00e-135	1.00e-135	1.00e-135	1.00e-134
			1711	1315	1276						671	665	499	494	489	489			487	486	486	486	485	485	484	483	480
	antigen identified by monoclonal antibody Ki-67; Proliferation-related Ki-67 antigen			antigen of the monoclonal antibody Ki-67	cell proliferation antigen Ki-67, short form - human	cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6						cytochrome P450-2B6	NP_000757.2 cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 13	Cytochrome P450 2A13 (CYPIIA13)	coumarin 7-hydroxylase (EC 1.14.14) cytochrome P450 2A6 - human		NP_000753.2 cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6; coumarin	7-hydroxylase; cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide	3; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	cytochrome P-450IIA (AA 1 - 489)	cytochrome P450IIA	Cytochrome P450 2A6 (CYPIIA6) (Coumarin 7-hydroxylase) (IIA3) (CYP2A3) (P450(I))	cytochrome P450-2A6	cytochrome P450 2A4 - human	Cytochrome P450 2A7 (CYPIIA7) (P450-IIA4)		cytochrome P450 - human
	U:(C-HI) NP_002408.2			CAA46520.1	B48666	U:(C-HI) NP_000758.1 cytoch						AAF13602.1	NP_000757.2	016696	O4HUA6	CAA32117.1	NP_000753.2			CAA32097.1	1609083A	P11509	AAF13600.1	C34271	P20853	NP 000755.2	138965
	U.(C-HI)	4.07, F·(HI-D)	-4.25	Ī		U:(C-HI)	34.21,	(C-D)	8.32,	F:(HI-D)	-3.81																
	Mm.4078					Mm.876																					
	X82786	CAA58026.1					NP_034130.1																				

Ŋ

 $\ddot{}$

러

oylochrome P450-IIB oylochrome P450-IIB oylochrome P450-IIB oylochrome P450-IIB Unknown (protein for MGC:22146) Unknown (protein for MGC:22146) Oylochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2) (S-mephenytoin 4-hydroxylase) oylochrome P450, subfamily IIF, polypeptide 1; microsomal monooxygenase; similar to cylochrome P450, subfamily IIF, polypeptide 1 oylochrome P450, subfamily IIC, polypeptide 8 isoform 1; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase; P450 form 1 oylochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; oylochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase oylochrome P450 S-mephenytoin 4-hydroxylase oylochrome P450 S-mephenytoin 6-hydroxylase oylochrome P450 S-mephenytoin 6-hydroxylase oylochrome P450 S-mephenytoin 6-hydroxylase oylochrome P450 C2C8 - human oylochrome P450 C2C8 - human oylochrome P450 C2C8 - human oylochrome P450 C2C8 - human oylochrome P450 C2C8 (CYPIIC18) (P450-6B/29C) oylochrome P450 C2C8 (CYPIIC18) (P450-6B/29C) oylochrome P450 cytochrome P450 cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC, polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase; cytochrome P450 CC10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) oylochrome P450 CC10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) oylochrome P450 CC10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase)	W(_	/09:	2410	<u> </u>	<u> </u>		<u></u>	~			<u>~ 1</u>			_				$\overline{}$		ധ	اي		PCT	17U:	\$200 ശ I)4/0	1019 က [ေ	91 ကါ
143.1 Gytochrome P450-IIB cytochrome P450-IIB cytochrome P450 C28 (CYPIIC8) (P450 form 1) (P450 MP-12IMP-20) (P450 IIC2) (S-mephenytoin 4-hydroxylase) (S-mephenytoin 4-hydroxylase) (S-mephenytoin 4-hydroxylase) 1161.1 Cytochrome P450, subfamily IIF, polypeptide 1; microsomal monooxygenase; similar to cytochrome P450, subfamily IIF, polypeptide 8 isoform 1; mephenytoin 4-hydroxylase; nicrosomal monooxygenase; Aavobiotic monooxygenase; P450, subfamily IIC, polypeptide 8 isoform 1; mephenytoin 4-hydroxylase; nicrosomal monooxygenase; Ravoprotein-linked monooxygenase; P450 form 1 microsomal monooxygenase; Ravoprotein-linked monooxygenase cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; Ravoprotein-linked monooxygenase 1501.1 cytochrome P450 subfamily IIC (mephenytoin 4-hydroxylase) cytochrome P450 subfamily IIC, polypeptide 9; cytochrome P450 subfamily IIC, polypeptide 9; cytochrome P450 zc18 (CYPIIC18) (P450-6B/29C) Cytochrome P450 subfamily IIC, polypeptide 9; cytochrome P450, subfa	1.00e-134	1.00e-131	1.00e-129	-	1.00e-129			007	1.00e-12E	1.00e-128			1.00e-128		-	1.00e-127	1.00e-127	1.00e-127		1.00e-12	1.00e-127	1.00e-126	1.00e-125			1.00e-125	1.00e-125		1.00e-12	1.00e-12.
596.1 6 596.1 1 0765.2 1 0761.2 1 0763.1 1 160.1 1 160.1 1 160.1 1 162.1 1 163.1 1 163	478	471	462		462			,	461	461			459		-	458	458	458		458	456	455	449			449	449		445	445
AAA52143. 138967 AAH20596. P10632 P10632 NP_000765. NP_000761 NP_000761 S66382 AAB35292. AAB35292. BAA00123 NP_000762	г		1	7	(S-menhenytoin 4-hydroxylase)			xenobiotic monooxygenase; flavoprotein-linked monooxygenase; similar to cytociil oille	P450, subfamily IIF, polypeptide 1	Т			monooxygenase; P450 form 1	7		microsomal monooxygenase; flavoprotein-linked monooxygenase	1	Т			Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)		1	_		monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	1	ठि	(P-450MP)	.1 cytochrome P-450 S-mephenytoin 4-hydroxylase
	AAA52143.1	138967	A A H20506 1	D10637	70007	, 37,000 and	7.co/000_4vi			AAA52161.1	NP 000761.	· .		NP 000763.	l		AAA52160.	S66382	AAB35292.1		P33260	AAL 69652.1	BAA00123.	NP 000762.	ì		AAB23864.	P11713		AAA52157.1
		-			 =		-					_																		
				1		$\frac{1}{1}$				_				_				_	L				_	-						

Ŋ

ц	ı
1	
0	V

444 1.00e-123
258 6.00e-68
258 1.00e-67
245 5.00e-64
ZZU Z.UUE-50
577 1.00e-163
393 1.00e-108
390 1.00e-107
389 1.00e-107
387 1.00e-106
387 1.00e-106
387 1.00e-106
387 1.00e-106
382 1.00e-105
327 2.00e-88

3.00e-88		Z.00e-87 ₹)92-		2.00e-86	2.00e-86	2.00e-86						0		0	0	0	0	0	1.00e-139	1.00e-139	1.00e-139	РСТ	1.00e-139	1.00e-139	1.00e-138	1.00e-137
326	700	324			320	320	320						780		777	765	761	746	736	499	499	499	_	497	497	495	489
protein kinase (EC 2.7.1.37) cdc2-related PCTAIRE-2 - human	PCTA	cdc2-related PCTAIRE-2	Cdk5-P25(Nck5A) Complex - Protein Kinase II Catalytic Subunit, Cdk5 - Cdk5	Activator 1, Cyclin-Dependent Kinase 5 Regulatory Subunit 1, Protein Kinase II 23	Kda Subunit, Tpkii Regulatory Subunit, P23, P25, P35	cyclin-dependent kinase 5	cyclin-dependent kinase 5 (EC 2.7) - human	U:(C-HI) NP_000769.1 cytochrome P450, subfamily IVA, polypeptide 11; fatty acid omega-hydroxylase;	P450HL-omega; alkane-1 monooxygenase; lauric acid omega-hydroxylase					Cytochrome P450 4A11 precursor (CYPIVA11) (Fatty acid omega-hydroxylase) (P-450	HK omega) (Lauric acid omega-hydroxylase) (CYP4AII) (P450-HL-omega)	fatty acid omega-hydroxylase (EC 1.14.15) cytochrome P450 4A11 - human	fatty acid omega-hydroxylase	fatty acid omega-hydroxylase CYP4A11	dJ18D14.4 (cytochrome P450, subfamily IVA, polypeptide 11)	cytochrome P450 4B1 - human	cytochrome P450	AAM09532.1 cytochrome P450	cytochrome P450, subfamily IVB, polypeptide 1; cytochrome P450, subfamily IVB,	member 1; microsomal monooxygenase	cytochrome P450	Unknown (protein for MGC:22150)	Unknown (protein for MGC:40051)
823384	586.1		pdb 1H4L			NP 004926.1	JE0374	√P_000769.1						Q02928		165981	BAA02864.1	AAF76722.1	CAB72105.1	O4HUB1	AAL57720.1	I	NP_000770.1		AAL57721.1	AAH17758.1	AAH28102.1
								U:(C-HI)	24.5,	F:(C-D)	-5.06,	F:(HI-D)	-7.06											-			
								Mm.7459																			
								NM 007822	NP 031848.1																		

rU

ĺ

 \exists

15 Ŋ

	v
-	_
	V

wo	200	4/09																					PC]	r/U					
				1.00e-125	1.00e-124	1.00e-123	2.00e-96	2.00e-96	7.00e-96	5.00e-52	3.00e-51	3.00e-51				1.00e-152		1.00e-151	1.00e-149				0	1.00e-174	1.00e-163	1.00e-156	1.00e-125	. 1.00e-118	1.00e-116
		803	770	451	448	445	562	356	354	208	206	206		_		540		535	528				725	612	278	553	451	428	420
U:(C-HI) NP_000868.1 Interleukin 1 receptor, type I				Interleukin-1 Receptor Antagonist; Chain: X; Synonym: II1Ra	Type-1 Interleukin-1 Receptor Complexed With Interleukin-1 Beta	II-1 Receptor Type 1 Complexed With Antagonist Peptide Af10847		IL-1Rrp2	interleukin 1 receptor-like 2		interleukin 1 receptor accessory protein-like 2	X-linked interleukin-1 receptor accessory protein-like 2	unknown				aldehyde reductase (aldose reductase) like 6; similar to mouse aldehyde reductase 6	(renal); myo-inositol oxygenase; kidney-specific protein 32	kidney-specific protein 32	Indian hedgehog protein precursor (IHH) (HHG-2)				Indian hedgehog protein	similar to Indian hedgehog protein precursor (IHH) (HHG-2)	Indian hedgehog gene	sonic hedgehog preproprotein	desert hedgehog preproprotein	Sonic hedgehog gene
NP_000868.1				pdb 1IRA			5.3			I .	NP 059112.1	•	AAF25204.1				NP_060054.2		AAK00766.1			-		AAA62178.1		2117287B	NP 000184.1		2117287A
U:(C-HI)	2.59,	F:(HI-D)	-2.22									٠	U:(C-HI)	2.51	F:(C-D)	-2.15				U:(C-HI) Q14623	2.45,	F:(HI-D)	-2.47						
Mm.896		<u> </u>											Mm.15820 U:(C-HI)							Mm.2543									
NM_008362	NP_032388.1												NM_019977	NP_064361.1						NM_010544	NP_034674.1								

ហ

10

ä

σ
~
$^{\circ}$

- WO 2004/092416

AAB67604.1 Sonic Hedgehog; associated with holoprosencephaly in humans and segment polarity
defects in Drosophila
JC5697 placental transforming growth factor-beta homolog - human
AAC39537.1 prepro placental TGF-beta
XP_038098.1 similar to Growth/differentiation factor 15 precursor (GDF-15) (Placental bone
(Prostate differentiation factor) (NSAID-regulated protein 1) (NRG-1)
AAC24456.1 prostate differentiation factor
protein) (Placental TGF-beta) (Macrophage inhibitory cytokine-1) (MIC-1) (Prostate
differentiation factor) (NSAID-regulated protein 1) (NRG-1)
NP_004855.1 ate differentiation factor; PTGF-beta
Mm.28479 U.(C-HI) NP_005554.1 stathmin 1; metablastin; prosolin; oncoprotein 18; phosphoprotein 19; stathmin;
leukemia-associated phosphoprotein p18
AAH14353.1 Similar to stathmin 1/oncoprotein 18
Mm.23375 U.(C-HI) Q9NZJ5 Eukaryotic translation initiation factor 2-alpha kinase 3 precursor (PRKR-like
endoplasmic reticulum kinase) (Pancreatic eIF2-alpha kinase) (HsPEK)
NP_004827.2 eukaryotic translation initiation factor 2-alpha kinase 3; eukaryotic translation initiation
factor 2 alpha kinase 3

PCT/US2004/010191

Ŋ

WO 2004/092416	•	PCT/US2004/010191

WO 200	4/0924	116																	P		<u>US</u>	<u>200</u> 4
	4.00e-60			3.00e-85		3.00e-85	2.00e-79	2.00e-60	2.00e-57	2.00e-54			C	٦	00 00 1	4.00e-99	2.00e-96	2.00e-96	1.00e-79	5.00e-63	3.00e-62	1.00e-54
	233			316		316	296	233	223	214			7	5)		364	355	355	299	244	241	216
hypothetical protein R30953_1		pre-serum amyloid P component			serum amyloid P component precursor; amyloid P component, serum;	pentaxin-related; 9.5S alpha-1-glycoprotein	Serum Amyloid P Component (Sap)	similar to C-reactive protein precursor	C-Reactive Protein; Chain: A, B, C, D, E, F, G, H, I, J	C-reactive protein, pentraxin-related; C-reactive protein	U:(C-HI) NP_000697.1 arginine vasopressin receptor 1A; V1a vasopressin receptor; vascular/hepatic-type	arginine vasopressin receptor; antidiuretic hormone receptor 1A			argi	hormone receptor 1B; vasopressin V1B receptor; pituitary vasopressin receptor 3	oxytocin receptor		oxytocin receptor	т	vas	vasopressin receptor type 2
Mm.15793 U.(C-HI) NP_062558.1 2.13		U:(C-HI) AAA60302.1			NP 001630.1	i	pdb 1SAC	XP 049673.1	odb/11LJ7	NP 000558.1	NP_000697.1				NP_000698.1		NP_000907.1	1808301A	CAA56562.1	NP 000045.1	1913493A	AAB87678.1
U:(C-HI) 2.13	F:(C-D) -2.1	U:(C-HI)	2.03,	F:(HI-D)							U:(C-HI)	2.02,	F:(HI-D)	-2.03								
Mm.15793		Mm.2165									Mm.4351											
NM_011579 NP_035709.1		NM_011318	NP_035448.1								NM 016847	NP_058543.1	J									

•	7
a	Э
c	V

<u>wo</u>	200	04/0	92	116	.ji., 1].	ااستاه	n 730	ndh.]	PC1	7US	52 0	04/0	101
	•	•	2.00e-99		2.00e-99	6.00e-95					٠	0	0.	-	0	0	1.00e-180	1.00e-179		3.00e-55							
-			236		236	236						748	899		652	646	631	630		217						344	342
KIAA0432				CDC5-like; CDC5 (cell division cycle 5, S. pombe, homolog)-like; Cell division cycle 5,	S. pombe, homolog-like; Cdc5-related protein	dJ319D22.1 (CDC5-like protein)	U:(C-D) NP_005387.1 pancreatic lipase-related protein 2						pancreatic lipase	Lipase (E.C. 3.1.1.3) Complexed With Colipase and Inhibited By Undecane	Phosphonate Methyl Ester	lipase	pancreatic lipase-related protein 1	pancreatic lipase-related protein 1	dA149D17.1 (PLRP2 (PNLIPRP2, Pancreatic Lipase Related Protein 2 Precursor, EC	3.1.1.3) LIKE protein)	NP_150285.1 winged helix/forkhead transcription factor						HNF-3/forkhead-like protein 1
Mm.28270 U:(C-D) BAA24862.2 KIAA0432				NP_001244.1 CDC		CAC08557.1	NP_005387.1			-			NP_000927.1	pdb/11LPB		1604419A	NP_006220.1	AAH25784.1	CAA22264.1		NP_150285.1	,					AAK00639.1
U:(C-D)	2.97	F:(C-D)	-2.87				U:(C-D)	2.35,	U:(HI-D)	2.73	F:(C-D)	-2.85										2.23,	U:(HI-D)	2.15	F:(C-D)	-2.79	
Mm.28270						·	Mm.1230														Mm.44235 U:(C-D)					•	
C76314	NP_690023.1						NM_011128	NP_035258.1													NM_008239	NP_032265.2					

•	V
C	О
_	V

	ert• er	11. H	,					_									_	PC1	Γ/U:	S20		_	_	_
0	0	0	0	0	0	0			0	1.00e-143	1.00e-143	1.00e-109	7.00e-85	7.00e-85	3.00e-78	1.00e-70	1.00e-70				0	0	1.00e-180	1.00e-111
1875	1875	833	728	726	969	969			688	510	510	398	317	317	295	270	270				999	999	633	403
NP_055370.1 Itransient receptor potential cation channel, subfamily M, member 5; MLSN1 and TRP-related TRP-related; MLSN1- and TRP-related	LTRPC5 protein	transient receptor potential cation channel, subfamily M, member 4	TRP-related cation influx channel	unnamed protein product	transient receptor potential-related channel 7, a novel putative Ca2+ channel protein	transient receptor potential cation channel, subfamily M, member 2; transient receptor	potential-related channel 7, a novel putative Ca2+ channel protein; transient receptor	potential channel 7	putative TRP cation channel	LTRPC6	transient receptor potential cation channel, subfamily M, member 8	transient receptor potential cation channel, subfamily M, member 6	channel-kinase 1	similar to LTRPC7	unnamed protein product	melastatin 1		cartilage associated protein				cartilage associated protein; cartilage-associated protein	unnamed protein product	nucleolar protein No55
NP_055370.1	CAB66342.1	NP_060106.2	AAL02142.1	BAA90907.1	BAA95563.1	NP 003298.1			CAD01139.1	BAB86335.1	NP_076985.3	NP_060132.3	AAK19738.2	XP_030709.6	BAB15429.1	AAC80000.1	NP_002411.2	AAH08745.1				NP_006362.1	BAC03743.1	CAC16786.1
																			2.05	F:(C-D)	-2.29			
Mm.14374 U:(C-D) 7 2.05, U:(HI-D) 2.32 F:(C-D)																	-	Mm.20904 U:(C-D)		-				
NM_020277 NP_064673.1																		NM_019922	NP_064306.1					

Ŋ 20

<u>wo</u>	2004/0	<u>92416</u>	1)11	11																<u>P</u>) 4/ ()	101		
1.00e-1/11			0			0		, 0	0			0	0	0	0			0	0		0	0	0		0	0	0
402		704	704			683		681	089			629	629	629	629			678	229		229	229	929		674	674	674
nucleolar autoantigen (55kD) similar to rat synaptonemal complex	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17;	microsomal monooxygenase; flavoprotein-linked monooxygenase	Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)	NP_000760.1 cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19;	mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic	monooxygenase; flavoprotein-linked monooxygenase	Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2)	(S-mephenytoin 4-hydroxylase)	Unknown (protein for MGC:22146)	cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC	(mephenytoin 4-hydroxylase), polypeptide 10; mephenytoin 4-hydroxylase; microsomal	monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase	cytochrome P-450 [Homo sapiens]	cytochrome P-450 S-mephenytoin 4-hydroxylase	cytochrome P-450 [Homo sapiens]		microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked	monooxygenase; P450 form 1	cytochrome P450 2C8 - human.	cytochrome P450 arachidonic acid epoxygenase isoform, Cyp 2C8 [human, kidney,	Peptide Partial, 485 aa]	cytochrome P-450 S-mephenytoin 4-hydroxylase	S-mephenytoin 4'-hydroxylase (EC 1.14.14) cytochrome P450 2C19	Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase)	(P-450MP)	cytochrome P-450 S-mephenytoin 4-hydroxylase	cytochrome P450
NP_006446.1	Mm.42100 F:(HI-D) NP_000763.1 -2.06		P33260	NP_000760.1			P10632		AAH20596.1	NP_000762.2			AAB23864.2	AAA52161.1	BAA00123.1	NP_000761.2			S66382	AAB35292.1		AAA52160.1	F38462	P11713	-	AAA52157.1	1506290A
	F:(HI-D) -2.06	U:(C-D) 2.35																							•		
	Mm.42100																										
	AF047725 AAD13720.1					,											-										

Ŋ

10

0	20	04 /\	())	110	<u> 11:, 11:</u> ,	₩	8	8	47	47				0	0	Γ	35				0	0	PC'	0	0
						2.00e-48	4.00e-48	4.00e-48	1.00e-47	1.00e-47							5.00e-85				•				
640						190	189	189	188	188				640	640		313				1493	1488	1487	1476	790
cytochrome P450 - human	2 N-acetyltransferase 8; kidney- and liver-specific gene product; kidney- and	liver-specific gene					1 putative N-acetyltransferase Camello 2		kidney- and liver-specific gene		oxysterol 7alpha-hydroxylase				1 cytochrome P450, subfamily VIIB, polypeptide 1; oxysterol 7alpha-hydroxylase	Cytochrome P450 7A1 (Cholesterol 7-alpha-monooxygenase) (CYPVII) (Cholesterol	7-alpha-hydroxylase)	Lipin 1				1 lipin 1	Similar to lipin 1	-	1 lipin 2
152418	NP_003951.2				-		NP_057431.1	BAA71643.1	AAH12626.1	T44342	AAC95426.1			-	NP_004811.1	P22680		Q14693				NP_663731.1	AAH30537.1	XP_041136.4	NP 055461.1
	1	-7.8,	F:(C-D)	-2.61,	U:(HI-D)	2.99					F:(C-HI)	-6.41,	U:(HI-D)	5.83				F:(C-HI)	-3.7,	U:(C-D)	3.14				
	Mm.46315 F:(C-HI)										Mm.4781							Mm.28548							
	AK007530	BAB25091.1									NM_007825	NP_031851.1						NM_015763	NP_056578.1						

10 10 15

u	Į
α	Э
C	V

$\mathbf{w}\mathbf{o}$	20	04/0	924	116																				<u> </u>		04/	<u>010</u>	<u> 191</u>	
		•		-	2.00e-72		4.00e-72	4.00e-72		2.00e-71	2.00e-71	1.00e-70	6.00e-68	1.00e-52	1.00e-52				0	0	0	0	0		0		0		0
	<u>. </u>				268		267	267		265	265	261	253	202	202			_	952	946	941	939	939		927		925	_	924
F:(C-HI) CAA50586.1 cytochrome P450						cytochrome P450, subfamily IVA, polypeptide 11; fatty acid omega-hydroxylase;	P450HL-omega; alkane-1 monooxygenase; lauric acid omega-hydroxylase	fatty acid omega-hydroxylase (EC 1.14.15) cytochrome P450 4A11 - human	Cytochrome P450 4A11 precursor (CYPIVA11) (Fatty acid omega-hydroxylase) (P-450	HK omega) (Lauric acid omega-hydroxylase) (CYP4AII) (P450-HL-omega)	fatty acid omega-hydroxylase	fatty acid omega-hydroxylase CYP4A11	dJ18D14.4 (cytochrome P450, subfamily IVA, polypeptide 11)	unnamed protein product	Unknown (protein for MGC:40051)	amylase, alpha 2A; pancreatic; Amylase, pancreatic, alpha-2A				amylase, alpha 2B; pancreatic; Amylase, pancreatic, alpha-2B	similar to Alpha-amylase, salivary precursor (1,4-alpha-D-glucan glucanohydrolase)	alpha-amylase (EC 3.2.1.1) precursor, salivary - human	amylase, alpha 1A; salivary; Amylase, salivary, alpha-1A	Chain A, Structure Of Human Pancreatic Alpha-Amylase In Complex With The	Carbohydrate Inhibitor Acarbose	Chain , Mol_id: 1; Molecule: Human Pancreatic Alpha-Amylase; Chain: Null; Ec:	3.2.1.1	Chain A, Three Dimensional Structure Analysis Of The R195q Variant Of Human	Pancreatic Alpha Amylase
CAA50586.1						NP_000769.1		165981	002928		BAA02864.1	AAF76722.1	CAB72105.1	BAC03751.1	AAH28102.1	NP_000690.1	,			NP_066188.1	XP_086988.1	99£29	NP_004029.1	7245760		1421331	,	18655894	
F:(C-HI)	-3.57,	F:(C-D)	-2.54,	(G-IH):N	2.82											F:(C-HI)	-3.13	U:(C-D)	3.23										
																Mm.324													
X71479	CAA50585.1															699600 MN	NP_033799.1				•				-				

١	٥)
¢	χ	
(`	J

VO.	20	04/	092	416	11,.	r,	0		0	Ι-	0	Γ		0	0	0	.0	ဖ္	Γ				F	CT.	<u>/us</u>	200	4/0	101
																		1.00e-146								•		
	924		923				923		923		923			922	919	914	904	515						798		796	791	780
Chain A, Three Dimensional Structure Analysis Of The R337q Variant Of Human	Pancreatic Alpha-Mylase	Chain A, Subsite Mapping Of The Active Site Of Human Pancreatic Alpha-Amylase	Using Substrates, The Pharmacological Inhibitor Acarbose, And An Active Site Variant	Chain A, Mechanistic Analyses Of Catalysis In Human Pancreatic Alpha- Amylase:	Defailed Kinetic And Structural Studies Of Mutants Of Three Conserved Carboxvlic	Detailed Miletic Aria of detailed County of Miletics Of Miletics Of County o	Acids	Chain A, Three Dimensional Structure Analysis Of The R195a Variant Of Human	Pancreatic Alpha Amylase	Chain A, Three Dimensional Structure Analysis Of The R337a Variant Of Human	Pancreatic Alpha-Amylase	Chain A, Mechanistic Analyses Of Catalysis In Human Pancreatic Alpha- Amylase:	Detailed Kinetic And Structural Studies Of Mutants Of Three Conserved Carboxylic	Acids	Chain , Human Salivary Amylase	Chain A, Role Of Mobile Loop In The Mechanism Of Human Salivary Amylase	Chain A, Role Of Ethe Mobile Loop In The Mehanism Of Human Salivary Amylase	alpha-amylase	Platelet glycoprotein IV (GPIV) (GPIIIB) (CD36 antigen) (PAS IV) (PAS-4 protein)						CD36 antigen (collagen type I receptor, thrombospondin receptor); CD36 antigen	(collagen type I)	cell adhesion receptor CD36	CD36 antigen (collagen type I receptor, thrombospondin receptor)
18655893		14719496		20664071				20664068		18655892		20664074	-		1633119	15988375	15988376	AAA57345.1	P16671					-	NP_000063.1		159613	AAM14636.1
													· · · · · ·							-3.03,	U:(C-D)	2.05,	U:(HI-D)	3.33				
																			Mm.18628 F:(C-HI)							-		
																			NM_007643	NP_031669.1								

 $\vec{\exists}$

c	ſ
ι,	١

WO 2	004/	092																				<u>C</u>			04/0)10	191	
	3.00e-72	3.00e-72		2.00e-67	2.00e-66				1.00e-125	1.00e-120	3.00e-86				1.00e-95	1.00e-95	4.00e-94	1.00e-93	1.00e-93	5.00e-93	5.00e-93	1:00e-92	1.00e-92	3,00e-92	4.00e-92	2.00e-91	2.00e-91	4.00e-91
	271	271	·	255	252		-		447	428	316				347	347	342	340	340	338	338	337	337	335	335	333	333	332
NP_005497.1 scavenger receptor class B, member 2; CD36 antigen (collagen type I receptor, thrombospondin receptor) -: CD36 antigen (collagen type I receptor, thrombospondin	receptor)-like 2 (lysosomal integral membrane protein II)	lysosomal integral membrane protein II - human	scavenger receptor class B, member 1; CD36 antigen-like 1; scavenger receptor class	B type 1; CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 1	membrane glycoprotein CLA-1 protein long form precursor - human	similar to uridine phosphorylase; similar to Q16831 (PID:g2494059)				similar to Uridine phosphorylase (UDRPase)	uridine phosphorylase	MHC class II histocompatibility antigen DQw1-beta chain precursor				cell surface glycoprotein - human	MHC class II HLA-DQ-beta-1	I major histocompatibility complex, class II, DQ beta 1 precursor	MHC class II HLA-DQ-beta-1	HLA class II histocompatibility antigen, DQ(W3) beta chain precursor	MHC class II HLA-DQ	HLA class II histocompatibility antigen, DQ(3) beta chain precursor (Clone II-102)		MHC HLA-DQ-beta cell surface glycoprotein - human	MHC class II HLA-DQ-beta-1	MHC class II antigen	MHC class II HLA-DQ-beta-1	MHC class II HLA-DQ-beta-1
NP_005497.1		A56525	NP_005496.2		A48528	AAD12227.1				XP_087230.2	NP_003355.1	154432			•	167725	AAA92332.1	NP_002114.1	AAA92331.1	P05537	AAB41231.1	P01920	AAA59768.1	155996	AAC41966.1	AAF28315.1	AAC41964.1	AAC41965.1
						F:(C-HI)	-2.95,	U:(HI-D)	2.34			F:(C-HI)	-2.87,	U:(HI-D)	2.37													
						Mm.20037 F:(C-HI)	<u> </u>					Mm.6716	•															
						AK007264	BAB24924.1					NM_010379	NP_034509.1															

 \Box

 $\stackrel{\sim}{\sim}$

wc	20																					P		_	200	04/0	101	
	6.00e-91	3.00e-90	4.00e-90	4.00e-90	4.00e-90	7.00e-90	7.00e-90	9.00e-90						1.00e-59		1.00e-59	1.00e-59		1.00e-56				1.00e-133	1.00e-133				2.00e-69
	331	329	328	328	328	328	328	327						228		228	228		218				474	474				259
HLA class II histocompatibility antigen, DQB1*0602 beta chain precursor (DQ(5))	(DC-1)	lymphocyte antigen	MHC class II histocompatibility antigen DQ-beta chain precursor - human	MHC class II histocompatibility antigen HLA-DQ beta chain (DQ4) precursor - human	HLA class II histocompatibility antigen, DX beta chain precursor	human leukocyte antigen-DQ beta chain	MHC class II HLA-DQ-beta-1	MHC class II HLA-DQ-beta-1	hydroxysteroid sulfotransferase SULT2B1a						sulfotransferase family, cytosolic, 2B, member 1; sulfotransferase family 2B, member		hydroxysteroid sulfotransferase SULT2B1b	Chain A, Crystal Structure Of Human Dehydroepiandrosterone Sulfotransferase In	Complex With Substrate	P2Y purinoceptor 1				G protein-coupled receptor 91	beta-galactosidase binding lectin precursor; Lectin, galactose-binding, soluble, 1;	galectin		
P03992		AAA59772.1	817891	B37044	P05538	CAA65280.1	AAC41973.1	AAC41974.1	AAC78553.1						NP_004596.1 sulfotr		AAC78499.1	21465697		AAL95690.1				NP_149039.1	NP_002296.1 beta-c			
									F:(C-HI)	-2.84,	F:(C-D)	-2.36,	U:(HI-D)	2.6						F:(C-HI)	-2.79,	U:(HI-D)	3.03		F:(C-HI)	-2.65,	U:(C-D)	2.32
									Mm.6562					i						Mm.12511 F:(C-HI)	0				Mm.43831			
									NM_020564	NP_065589.1										NM_032400	NP_115776.1				NM_008495	NP_032521.1		·

0

വ

C	,	١
C	Ľ)
C	`	į

<u> </u>	20	04/0	リソス	+10			,	~						_	_						<u> </u>	0	
6.00e-69						8.00e-64		3.00e-63						0									
257					-	241		239		**				1479	811							808	908
beta galactoside soluble lectin	Unknown (protein for IMAGE:2819455)		-				translocase of inner mitochondrial membrane 17 homolog A (yeast); preprotein	translocase	TJ6 protein						ATPase, H+ transporting, lysosomal V0 subunit a isoform 1	NP_005168.2 ATPase, H+ transporting, lysosomal, non-catalytic accessory protein 1A, 110/116 kDa	subunit; ATPase, H+ transporting, lysosomal non-catalytic accessory protein 1	(110/116kD); vacuolar proton pump, subunit 1; clathrin-coated vesicle/synaptic vesicle	proton pump 116 kDa subunit; vacuolar proton translocating ATPase 116 kDa subunit	A isoform 1; vacuolar adenosine triphosphatase subunit Ac116; H(+)-transporting	two-sector ATPase, 116 kDa accessory protein A1; vacuolar-type H(+)-ATPase 115	kDa subunit	vacuolar-type H(+)-ATPase 115 kDa subunit
1713410A	AAH00294.1						NP_006326.1		F:(C-HI) NP_036595.1						AAH32398.1	NP_005168.2							CAA96077.1
	F:(C-HI)	-2.51,	F:(C-D)	-3.41,	U:(HI-D)	3.46			F:(C-HI)	-2.51,	F:(C-D)	-2.34,	U:(HI-D)	4.16									
	Mm.2368								Mm.1158														
	AK003129	BAB22589.1							NM_011596	NP_035726.1													

PCT/US2004/010191

C	⊃
C	n
c	V

WO 2004/092416								PCT/US	200		1019
0				0	0	0	1.00e-174		1.00e-142	1.00e-142	7.00e-75
787		992		764	757	640	609		505	504	280
NP_065683.1 ATPase, H+ transporting, lysosomal V0 subunit a isoform 4; vacuolar proton pump 116 kDa accessory subunit; vacuolar proton pump, subunit 2; H(+)-transporting two-sector ATPase, noncatalytic accessory protein 1B; ATPase, H+ transporting, lysosomal (vacuolar proton pump) non-catalytic accessory protein 1B; renal tubular acidosis; ATPase, H+ transporting, lysosomal (vacuolar proton pump) non-catalytic accessory protein 2 (38kD)	T-cell, immune regulator 1, isoform a; ATPase, H+ transporting, 116kD; vacuolar proton translocating ATPase 116 kDa subunit A isoform 3; V-ATPase 116-kDa isoform a3; osteoclastic proton pump 116 kDa subunit; T cell immune response cDNA7 protein; specific 116-kDa vacuolar proton pump subunit; T-cell, immune regulator 1;	infantile malignant osteopetrosis	vacuolar proton translocating ATFase TTO KDa suburiit ATSOIOTTI 3 (V-ATFase 116-kDa isoform a3) (Osteoclastic proton pump 116 kDa subunit) (OC-116 KDa) (OC116) (T-cell immune regulator 1) (T cell immune response cDNA7 protein)	(TIRC7)	specific 116-kDa vacuolar proton pump subunit	Unknown (protein for MGC:22527)	T-cell, immune regulator 1, isoform b; ATPase, H+ transporting, 116kD; vacuolar proton translocating ATPase 116 kDa subunit A isoform 3; V-ATPase 116-kDa isoform a3; osteoclastic proton pump 116 kDa subunit; T cell immune response cDNA7 protein; specific 116-kDa vacuolar proton pump subunit; T-cell, immune regulator 1; infantile malignant osteopetrosis	similar to Homeobox protein Hox-C13 (Hox-3G)		homeo box C13	unnamed protein product
NP_065683.1	NP_006010.2	013400	Q13488		AAA97878.1	AAH22300.1	NP_006044.1	XP_006804.2		NP_059106.1	BAB14786.1
								F:(C-HI) -2.33, U:(HI-D)	3.03		
								Mm.20706 F:(C-HI) 2 -2.33, U:(HI-D)			
								AF193796 AAL09298.1			

<u>V</u>	VQ.	200	1/(92	416			.02	7521								, -							PC'	r/U			010	191	
		-		0	0	0	0	1.00e-110	1.00e-109				1.00e-143	1.00e-143	2.00e-62	3.00e-62	5.00e-59	1.00e-58	1.00e-58	1.00e-57				6.00e-84	6.00e-83	8.00e-83	2.00e-82	1.00e-81	2.00e-81	2.00e-81
				1249	1246	916	760	397	394				206	504	237	237	226	224	224	221				309	306	305	304	301	301	301
			. •		. ,																						,			
	Complement component o precursor				complement C6 precursor [validated]	similar to Complement component C6 precursor	complement component C6	complement component 7, precursor	complement C7	deoxyribonuclease I-like 3		-		DNase gamma	deoxyribonuclease I precursor	deoxyribonuclease I	deoxyribonuclease I-like 2	deoxyribonuclease I-like 1	DNL1L gene product	DNase I	Fc-gamma-RIIb2		:		Fc-gamma-RIIb2	precursor polypeptide (AA -42 to 249)	lgG Fc fragment receptor precursor	lgG Fc receptor beta-Fc-gamma-RII	IgG Fc receptor	Fc-gamma-RIIb1
	NP_000056.1 Comp				A34372	XP_170508.1	AAB59433.1	NP_000578.1	CAA60121.1	NP_004935.1	,			AAC23652.1	BAA11841.1	NP_005214.2	NP_001365.1	NP_006721.1	AAB00496.1	AAB00495.1	AAD00638.1				AAD00641.1	CAA36713.1	AAA35842.1	AAA36051.1	CAA35644.1	AAD00639.1
		-2.26,	U:(HI-D)	3.29						F:(C-HI)	-2.2,	(G-IH):N	2.24								F:(C-HI)	-2.18,	U:(HI-D)	2.55						
	Mm.20247 F:(C-HI)	•	<u>~</u>							Mm.10287											Mm.10809									
- E		NP_057913.1								NM_007870	NP_031896.1										NM_010187	NP_034317.1								

ស

0

5

 $\tilde{\mathbf{z}}$

wc	20	04/0	92-	416	ta tan	1 pg:58112	<u>د ۱</u> ۰۰ دو	mu:															PC	T/U	S20	04/0	101	191
2.00e-81	3.00e-80		3.00e-80		4.00e-80	1.00e-80				1.00e-140	1.00e-139		1.00e-139	1.00e-137	7.00e-79	8.00e-74	2.00e-62	1.00e-60	9.00e-60	3.00e-59	7.00e-59	7.00e-59	1.00e-57	3.00e-57	3.00e-57	4.00e-57	4.00e-57	5.00e-56
301	297	-00	297		296	296				496	495		495	488	293	276	238	233	230	228	227	227	223	221	221	221	221	218
Fc-gamma-Rllb1	Fc-gamma-Rlib1	Low affinity immunoglobulin gamma FC region receptor II-B precursor (FC-gamma	RII-B) (FCRII-B) (IGG FC receptor II-B) (FC-gamma-RIIB) (CD32) (CDW32)	NP_003992.2 Fc fragment of IgG, low affinity Ilb, receptor for (CD32); Fc fragment of IgG, low affinity	II, receptor for (CD32)	Fc gamma (IgG) receptor IIb precursor - human	uterine water channel - human				aquaporin 1 (channel-forming integral protein, 28kD)	aquaporin 1; aquaporin 1 (channel-forming integral protein, 28kDa); Aquaporin-1	(channel-forming integral protein, 28kDa); Colton blood group	aquaporin 1	channel-like integral membrane protein	aquaporin	putative alternative lens membrane intrinsic protein	major intrinsic protein of lens fiber; aquaporin	aquaporin 2; Aquaporin-2 (collecting duct)	hAQP-CD=collecting duct aquaporin [human, kidney, Peptide, 271 aa]	water-channel aquaporin 2 - human	water-channel aquaporin 2 - human	aquaporin (water channel protein)	aquaporin 4 C2 isoform; mercurial-insensitive water channel	aquaporin 4 isoform a; mercurial-insensitive water channel	mercurial-insensitive water channel - human	aquaporin 4, long splice form - human	aquaporin 5; Aquaporin-5
AAD00637.1	AAD00640.1	P31994		NP_003992.2		Л.0119	152366				AAH22486.1	NP 000376.1		AAL87136.1	AAC50649.1	AAC23788.1	AAC03168.1	NP_036196.1	NP_000477.1	AAB30268.1	I51877	164818	AAC16481.1	NP_004019.1	NP_001641.1	139177	139178	NP_001642.1
							1	-2.17,	(G-IH):N	2.38																		
							Mm.18625 F:(C-HI)																					
			_ _				NM_007472	NP_031498.1																				

20 10 20 20

wo	2004	/0924	116
----	------	-------	-----

WO 2004/092416																	P	CT	/US	520 0) 4/ 0	101	91	
	1.00e-141	1.00e-141	1.00e-140	1.00e-112				0	2.00e-98	4.00e-95	4.00e-93	4.00e-93	4.00e-93	8.00e-92	1.00e-89	1.00e-89	2.00e-87	4.00e-75		2.00e-74	5.00e-74	8.00e-74	4.00e-73	4.00e-73
8833	502	502	498	402				934	359	348	341	341	341	337	330	330	322	281		280	278	277	275	275
Mm. 19987 F:(C-HI) NP_001913.2 dopachrome tautomerase (dopachrome delta-isomerase, tyrosinase-related protein 2); -2.14, F:(C-D) -2.01, U:(HI-D) 2.28	pre propeptide (AA -24 to 503)	tyrosinase-related protein 1	bA3L8.1 (tyrosinase-related protein 1).	tyrosinase (oculocutaneous albinism IA); Tyrosinase	EGF-TM7-latrophilin-related protein				KIAA0768 protein	lectomedin-3	lectomedin-1 beta	latrophilin 1; KIAA0786 protein; lectomedin-1; latrophilin	lectomedin-1 alpha	KIAA0786 protein	lectomedin-2	lectomedin-2; KIAA0821 protein	Unknown (protein for IMAGE:3162852)	egf-like module containing, mucin-like, hormone receptor-like sequence, 2 isoform b	CD97 antigen, isoform 2 precursor; leukocyte antigen CD97; seven-span	transmembrane protein	egf-like module-containing mucin-like receptor 3 isoform a	EGF-like module EMR2	egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform a	seven fransmembrane helix receptor
NP_001913.2	CAA35785.1	NP_000541.1	CAD13328.1	NP_000363.1	NP_071442.1				BAA34488.1	NP_056051.1 lector	AAD54676.1	NP_036434.1	AAD54675.1	BAA34506.1	AAG27461.1	NP_055736.1	AAH07587.1	NP_690880.1	NP_001775.2		NP_115960.1	AAF21974.1	NP_038475.2	BAC06146.1
F:(C-H) -2.14, F:(C-D) -2.01, U:(HI-D)						-2.04,	U:(HI-D)	2.02							ì							7		
Mm.19987					Mm.27242 F:(C-HI)																			
NM_010024 NP_034154.1					AF385682	AAK62363.1																		

ហ

(ፓ
(`

wc	2004/	092	416																		P	CT/	US:	200	4/01	019
4.00e-73	3.00e-70	3.00e-70	3.00e-70	1.00e-68	1.00e-68		2.00e-68	7.00e-67	09- 0 00'9	6.00e-60	6.00e-60	6.00e-60	4.00e-58	_			· 1.00e-101	1.00e-101	1.00e-100	1.00e-100	1.00e-97		8.00e-64	6.00e-64	6.00e-64	7.00e-64
275	265	265	265	260	260		259	254	231	231	231	231	225			•	367	365	364	363	355		308	243	243	242
leucocyte antigen CD97	.1 CD97 antigen, isoform 1 precursor; leukocyte antigen CD97; seven-span transmembrane protein	1	1 seven transmembrane helix receptor	1 seven transmembrane helix receptor	Leucocyte antigen CD97 precursor	l-Jbe	module containing, mucin-like, hormone receptor-like	.1 egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform c	.1 egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform e	.1 egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform d	.1 egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform g	.1 egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform f	.1 R29368_2	.1 decay accelerating factor for complement (CD55, Cromer blood group system);	Decay-accelerating factor of complement			Complement decay-accelerating factor precursor (CD55 antigen)	.1 decay-accelerating factor precursor	.1 decay-acceleration factor	decay-accelerating factor, splice form 1 precursor - human	Chain R, Structural Model Of Human Decay-Accelerating Factor Bound To Echovirus	7 From Cryo-Electron Microscopy	1 decay-accelerating factor 1 ab	1 decay-accelerating factor 4ab	1 decay-accelerating factor 3
137225	NP_510966.1	AAB36682.1	BAC06178.1	BAC06133.1-	P48960	NP_001965.1		NP_690881.1	NP_690883.1	NP_690882.1	NP_690885.1	NP_690884.1	AAC05172.1	NP_000565.1				P08174	AAA52167.1	AAB48622.1	A26359	23200413		AAL25833.1	AAL25835.1	AAL25834.1
	-			·											-2.04,	U:(HI-D)	2.14						•			
														Mm.20236 F:(C-HI)												
							•							NM_010016	NP_034146.1											

.WO 2004/092416 tto the	ratte		rullm															PC1	r/U	S20	04/0	101	91
0	0	1.00e-148	1.00e-127		-		0	0	1.00e-91	7.00e-81				1.00e-106	1.00e-105	1.00e-105	2.00e-65	1.00e-110				1.00e-109	1.00e-109
648	638	523	452				1337	1330	335	300				381	380	379	246	395				394	394
	Similar to RIKEN cDNA 1500015N03 gene		hypothetical protein MGC2993	B-cell lymphoma 6 protein; B-cell CLL/lymphoma-6; cys-his2 zinc finger transcription	factor BCL5; zinc finger protein 51; lymphoma-associated zinc finger gene on	chromosome 3		B-cell CLL/lymphoma 6 (BCL6) protein	BAZF		hematopoietically expressed homeobox; proline-rich homeodomain-containing	transcription factor			homeobox protein HEX - human	Similar to hematopoietically expressed homeobox	homeobox related protein	XP_002155.1 similar to Glutathione S-transferase Mu 1 (GSTM1-1) (HB subunit 4) (GTH4)	(GSTM1a-1a) (GSTM1b-1b) (GST class-mu 1)			Chain A, Ligand-Free Human Glutathione S-Transferase M1a-1a	glutathione transferase M1
Mm.20387 F:(C-HI) AAG23766.1 PP3 -1.7, F:(C-D) -2.35, U:(HI-D) 2.52	AAH08074.1	AAH33157.1	NP_115703.1	NP_001697.2				A48752	BAC00962.1	XP_171849.1	NP_002720.1				7970NI	AAH14336.1	CAA79730.1	XP_002155.1				4388890	AAA59203.1
F:(C-HI) -1.7, F:(C-D) -2.35, U:(HI-D) 2.52				F:(C-D)	-4.15,	U:(HI-D)	2.11		-		F:(C-D)	-2.62,	U:(HI-D)	2.05				F:(C-D)	-2.27	U:(C-D)	2.17		
Mm.20387				Mm.15811 F:(C-D)							Mm.33896 F:(C-D)							Mm.14601 F:(C-D)					
NM_023740 NP_076229.1				NM_009744	NP_033874.1						NM_008245	NP_032271.1						NM_008183	NP_032209.1				

ហ

10

 $\ddot{\sim}$

•	ι
	J
C	٠.

WO 2004/092	416					•													 I	PC1	r/U:	520	04/0) 101	191
1.00e-105	1.00e-105	1.00e-105			1.00e-104			1.00e-104	1.00e-104		1:00e-104	1.00e-104		1.00e-103		8.00e-97	2.00e-93	<u> </u>		7.00e-93	3.00e-90	3.00e-90	3.00e-90		3.00e-89
379	379	378			377			377	377		376	376		373		351	340			338	329	329	329		326
glutathione S-transferase M2; glutathione S-transferase 4; GST, muscle; GST class-mu 2; glutathione S-transferase Mu 2; glutathione S-alkyltransferase M2; glutathione S-aryltransferase M2; S-(hydroxyalkyl)glutathione lyase M2; glutathione S-aralkyltransferase M2	Glutathione S-transferase Mu 5 (GSTM5-5) (GST class-Mu 5)	glutathione S-transferase M5; glutathione S-transferase, Mu-5; glutathione	S-alkyltransferase M5, glutathione S-aryltransferase M5, S-(hydroxyalkyl)glutathione	lyase M5; glutathione S-aralkyltransferase M5; GST class-mu 5	glutathione S-transferase M4 isoform 1; glutathione S-transferase, Mu-4; glutathione	S-alkyltransferase M4; glutathione S-aryltransferase M4; S-(hydroxyalkyl)glutathione	lyase M4; glutathione S-aralkyltransferase M4; GTS-Mu2; GST class-mu 4	glutathione transferase (EC 2.5.1.18) class mu, GSTM4 (version 2) - human	ain A, Ligand-Free Human Glutathione S-Transferase M2-2 (E.C.2.5.1.18), Monoclinic	Crystal Form	glutathione transferase M4	Chain A, Ligand-Free Homodimeric Human Glutathione S-Transferase M4- 4	(E.C.2.5.1.18)	Chain , Glutathione S-Transferase (Human, Class Mu) (Gstm2-2) Form A	(E.C.2.5.1.18) Mutant With Trp 214 Replaced By Phe (W214f)	glutathione S-transferase	glutathione S-transferase M4 isoform 2; glutathione S-transferase, Mu-4; glutathione	S-alkyltransferase M4; glutathione S-aryltransferase M4; S-(hydroxyalkyl)glutathione	lyase M4; glutathione S-aralkyltransferase M4; GTS-Mu2; GST class-mu 4	Similar to glutathione S-transferase M2 (muscle)	similar to Glutathione S-transferase Mu 3 (GSTM3-3) (GST class-mu 3) (hGSTM3-3)	Unknown (protein for MGC:3704)	Chain B, Ligand-Free Heterodimeric Human Glutathione S-Transferase M2-3 (Ec	2.5.1.18), Monoclinic Crystal Form	glutathione transferase (EC 2.5.1.18) class mu, GSTM3 - human
NP_000839.1 glutath class-r glutath glutath S-aralk	P46439	NP_000842.2			NP_000841.1			S32425	4557966		AAA57346.1	6980588		494185		CAA48636.1	NP_671489.1			AAH17836.1	XP_042722.1	AAH08790.1	5822511		106129
														_											

Ŋ

WO 2004	/092416
1.00e-83	
308	
NP_666533.1 glutathione S-transferase M1 isoform 2; HB subunit 4; glutathione S-alkyltransferase; 3.08 1.00e-83 S glutathione S-transferase Mu-1; glutathione S-aralkyltransferase; GST class-mu	

Master Table 2: Subtable 2A Classes of Favorable Genes/Proteins

വ

Mouse Gene	Већачлог	Human Protein Class
Protein		
NM_007630	F:(HI-D)	
NP_031656.1	-5.28	Cyclin
		Subclass: cyclin B2
		Subclass: cyclin B1; G2/mitotic-specific cyclin B1
NM 007913	F:(HI-D)	
NP 031939.1	-2.66	Early growth response
		Subclass: early growth response 1; G0S30
		Subclass: early growth response 3
AF127033	F:(HI-D)	fatty acid synthase; FAS [Homo sapiens]
AAG02285.1	-2.1	
NM_011169	F:(HI-D)	prolactin receptor
NP_035299.1	-2.08	
		Subclass: prolactin receptor
		Subclass: prolactin receptor isoform delta S1 precursor
		Subclass: prolactin receptor short isoform 1a
		Subclass: intermediate prolactin receptor isoform
NM_013490	F:(HI-D)	choline kinase
NP_038518.1	-2.04	
		Subclass: choline kinase
		Subclass: choline/ethanolamine kinase isoform a
NM_013888	F:(HI-D)	J domain containing protein 1
NP_038916.1	-2.04	
NM_019499	F:(HI-D)	MAD2-like 1; MAD2 (mitotic arrest deficient, yeast, homolog)-like 1; mitotic arrest deficient, yeast, homolog-like 1
NP_062372.1	-2.04	

NM_011850 NP_035980.1	F:(HI-D) -2.03	short heterodimer partner; orphan nuclear receptor SHP; small heterodimer partner; nuclear receptor subfamily 0, group B, member 2
AF213393	F:(HI-D)	
AAF31432.1	-2.02	ATP-binding cassette, sub-family A
		Subclass: ATP-binding cassette, sub-family A member 8
		Subclass: ATP-binding cassette, sub-family A (ABC1), member 9
		Subclass: ATP-binding cassette, sub-family A (ABC1), member 10
		Subclass: ATP-binding cassette, sub-family A (ABC1), member 6
NM_013646	F:(HI-D)	
NP_038674.1 -2.02	-2.02	RAR-related orphan receptor
		Subclass: RAR-related orphan receptor A, isoform a; RAR-related orphan receptor alpha; retinoic acid receptor-related orphan
		receptor alpha; transcription factor RZR-alpha; ROR-alpha
		Subclass: RAR-related orphan receptor A, isoform c; RAR-related orphan receptor alpha; retinoic acid receptor-related orphan
		receptor alpha; transcription factor RZR-alpha; ROR-alpha
		Subclass: RAR-related orphan receptor A, isoform b; RAR-related orphan receptor alpha; retinoic acid receptor-related orphan
		receptor alpha; transcription factor RZR-alpha; ROR-alpha
		Subclass: RAR-related orphan receptor A, isoform d; RAR-related orphan receptor alpha; retinoic acid receptor-related orphan
		receptor alpha; transcription factor RZR-alpha; ROR-alpha
		Subclass: RAR-related orphan receptor B; RAR-related orphan receptor beta; retinoic acid-binding receptor beta; nuclear
		receptor RZR-beta
NM_009425 NP_033451.1	F:(HI-D) -10.21	tumor necrosis factor (ligand) superfamily, member 10; Apo-2 ligand; TNF-related apoptosis inducing ligand TRAIL
AK018485	F:(C-HI)-2.4	
2204249A	5	hypothetical protein FL J90165

NM_008182		
	F:(C-HI)	glutathione transferase
NP_032208.1 -9.17,	-9.17,	
	F:(C-D) -5 68	
		Subclass: glutathione S-transferase A1; GST, class alpha, 1; glutathione S-alkyltransferase A1; glutathione S-aryltransferase
		A1; S-(hydroxyalkyi)glutathione lyase A1; glutathione S-aralkyltransferase A1; GST-epsilon; glutathione S-transferase 2
		Subclass: TPA: glutathione transferase A5
		Subclass: Chain A, Glutathione S-Transferase A1-1 (E.C.2.5.1.18)
		Subclass: Glutathione S-transferase A3-3 (GST class-alpha)
		Subclass: glutathione S-transferase A3
		Subclass: glutathione transferase (EC 2.5.1.18) alpha-2 (clone GTH2) - human
NM_028089	F:(C-HI)	cytochrome P-450
NP_082365.1	-4.31,	
	F:(C-D)	
	-5.26	
		Subclass: cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC
		(mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
		polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked
		monooxygenase
		Subclass: Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) (P-450MP)
		Subclass: cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4'-hydroxylase;
		microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase
		Subclass: Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2) (S-mephenytoin 4-hydroxylase)
		Subclass: cytochrome P450 2C17

NM 007818	F:(C-HI)	cytochrome P450
NP 031844.1 -4.29,	-4.29,	
1	F:(C-D)	
	-8.15	
		Subclass: Cytochrome P450 3A4 (Quinine 3-monooxygenase) (CYPIIIA4) (Nifedipine oxidase) (NF-25) (P450-PCN1)
		Subclass: cytochrome P450, subfamily IIIA, polypeptide 4; nifedipine oxidase; P450-III, steroid inducible;
		glucocorticoid-inducible P450; cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3
		Subclass: cytochrome P450, subfamily IIIA, polypeptide 5; niphedipine oxidase; aryl hydrocarbon hydroxylase; xenobiotic
		monooxygenase; microsomal monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, subfamily IIIA, polypeptide 7; aryl hydrocarbon hydroxylase; microsomal monooxygenase;
	·	xenobiotic monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450 polypeptide 43 isoform 2; cytochrome P450 polypeptide 43
		Subclass: cytochrome P450 polypeptide 43 isoform 1; cytochrome P450 polypeptide 43
		Subclass: cytochrome P450 polypeptide 43 isoform 3; cytochrome P450 polypeptide 43
NM_025429	F:(C-HI)	
NP_079705.1 -3.51,	-3.51,	
	F:(C-D)	
	-3.01	serine (or cysteine) proteinase inhibitor
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1; protease inhibitor 2 (anti-elastase),
		monocyte/neutrophil; protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; protease inhibitor 9 (ovalbumin type)
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 10; protease inhibitor 10 (ovalbumin type,
		bomapin)
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8; protease inhibitor 8 (ovalbumin type)
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6; protease inhibitor 6 (placental thrombin
		inhibitor)

NM_008341	F:(C-HI)	insulin-like growth factor binding protein 1
NP_032367.1 -3.37,	-3.37,	
	F:(C-D)	
	-3.47,	
	F:(HI-D)	
	-2.03	
U38940	F:(C-HI)	asparagine synthetase; glutamine-dependent asparagine synthetase; TS11 cell cycle control protein
AAA85125.1 -3.11,	-3.11,	
	F:(C-D)	
	-2.11	
103953	F:(C-HI)	Chain A, ligand-free Glutathione S-Transferase
AAA37748.1	-3.03	
		Subclass: Chain A, ligand-free, Glutathione S-transferase Mu 1 (GSTM1-1) (HB subunit 4) (GTH4) (GSTM1a-1a)
•		(GSTM1b-1b) (GST class-mu 1)
		Subclass: Chain A, Ligand-Free Homodimeric Human Glutathione S-Transferase Mu 4
		Subclass: Chain A, glutathione S-transferase M2; glutathione S-transferase 4; GST, muscle; GST class-mu 2; glutathione
		S-transferase Mu 2; glutathione S-alkyltransferase M2; glutathione S-aryltransferase M2; S-(hydroxyalkyl)glutathione lyase M2;
		glutathione S-aralkyltransferase M2
		Subclass: Glutathione S-transferase Mu 5 (GSTM5-5) (GST class-Mu 5)
		Subclass: Similar to Glutathione S-transferase Mu 3 (GSTM3-3) (GST class-mu 3) (hGSTM3-3)
NM_013459	F:(C-HI)	
NP_038487.1	-2.94	Complement factor D
		Subclass: Complement factor D precursor (C3 convertase activator) (Properdin factor D) (Adipsin)
		Subclass: Chain, Mutant Of Factor D With Enhanced Catalytic Activity
		Subclass: Chain, Human Complement Factor D In Complex With Isatoic Anhydride Inhibitor

NM 016810	F:(C-HI)	golgi SNAP receptor complex member 1; Golgi SNARE 28 kDa
	-2.86	
AK006128	F:(C-HI)	ATP-binding cassette
BAB24422.1	-2.71	
		Subclass: ATP-binding cassette, sub-family C, member 3 isoform MRP3; canicular multispecific organic anion transporter
		Subclass: multidrug resistance-associated protein(MRP)-like protein-2 (MLP-2)
		Subclass: ATP-binding cassette, sub-family C, member 1, isoform 4; multiple drug resistance protein 1; multidrug resistance
		protein; multiple drug resistance-associated protein
		Subclass: ATP-binding cassette, sub-family C, member 1, isoform 3; multiple drug resistance protein 1; multidrug resistance
		protein; multiple drug resistance-associated protein
		Subclass: ATP-binding cassette, sub-family C, member 1, isoform 1; multiple drug resistance protein 1; multidrug resistance
		protein; multiple drug resistance-associated protein
		Subclass: ATP-binding cassette, sub-family C, member 1, isoform 2; multiple drug resistance protein 1; multidrug resistance
		protein; multiple drug resistance-associated protein
		Subclass: ATP-binding cassette, sub-family C, member 1, isoform 7; multiple drug resistance protein 1; multidrug resistance
		protein; multiple drug resistance-associated protein
		Subclass: ATP-binding cassette, sub-family C, member 1, isoform 6; multiple drug resistance protein 1; multidrug resistance
		protein; multiple drug resistance-associated protein
NM_008742	F:(C-HI)	neurotrophin 3
NP_032768.1	-2.68	
NM_008361	F:(C-HI)	interleukin 1, beta
NP_032387.1 -2.65,	-2.65,	
	F:(C-D) -2.03	

AF294617	F:(C-HI)	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
AAG02118.1	-2.63	
NM_009998	F:(C-HI)	cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6
NP_034128.1 -2.61,	-2.61,	
	F:(C-D)	
	-2.33	
NM_008988	F:(C-HI)	putative neuronal cell adhesion molecule (punc)
NP_033014.1	-2.6	
		Subclass: putative neuronal cell adhesion molecule (punc)
		Subclass: similar to punc
NM_010166	F:(C-HI)	Eyes absent homolog
NP_034296.1	-2.57	
		Subclass: Eyes absent homolog 3 (EYA3)
		Subclass: eyes absent homolog 4 (Drosophila);
		Subclass: eyes absent 1 isoform b; Eyes absent, Drosophila, homolog of, 1; Melnick-Fraser syndrome
		Subclass: EYA1A
		Subclass: Eyes absent homolog 2
		Subclass: EYA1D
AK002480	F:(C-HI)	cystathionase isoform 1; cystathionine gamma-lyase; homoserine deaminase; homoserine dehydratase; cysteine
NP_666065.1 -2.55,	-2.55,	desulfhydrase
	F:(C-D)	
	-2.57	

AK018226	F.(C-H)	serine (or cysteine) proteinase inhibitor, clade B (ovalbumin)
XP_110043.1 -2.53,	-2.53,	
	F:(C-D) -2.4	
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1; protease inhibitor 2 (anti-elastase),
		monocyte/neutrophil; protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; protease inhibitor 9 (ovalbumin type)
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8; protease inhibitor 8 (ovalbumin type)
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 10; protease inhibitor 10 (ovalbumin type,
		bomapin)
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6; protease inhibitor 6 (placental thrombin
		inhibitor)
NM_010361	F:(C-H)	glutathione S-transferase
NP_034491.1 -2.46,	-2.46,	
	F:(C-D)	
	-2.25	
		Subclass: glutathione S-transferase theta 2
		Subclass: glutathione S-transferase theta 1
AK018485	F:(C-HI)	similar to data source: SPTR, source key: Q60928, evidence: ISS~putative~similar to GAMMA-GLUTAMYLTRANSPEPTIDASE
BAB31233.1	-2.46	PRECURSOR (EC 2.3.2.2) (GAMMA- GLUTAMYLTRANSFERASE) (GGT)
		Alternate: hypothetical protein FLJ90165
NM_010924	F:(C-HI)	nicotinamide N-methyltransferase
NP_035054.1 -2.45,	-2.45,	
	F:(C-D)	
	-2.19	
NM_021307	F:(C-HI)	Zinc finger protein
NP_067282.1	-2.44	

		Subclass: zinc finger protein 228
		Subclass: similar to ZNF228 protein
	-	Subclass: Zinc finger protein 226
		Subclass: zinc finger protein 93 homolog; zinc finger protein homologous to mouse Zfp93; zinc finger protein homologous to
		Zfp93 in mouse; zinc finger protein 93 homolog (mouse)
		Subclass: Hypothetical zinc finger-like protein
		Subclass: similar to Zinc finger protein 229
		Subclass: Zinc finger protein ZNF45
NM_008295	F:(C-HI)	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1; Hydroxy-delta-5-steroid dehydrogenase, 3 beta-
NP_032321.1 -2.43,	-2.43,	and steroid
	F:(C-D)	
	-5.64,	
	F:(HI-D)	
	-2.32	
NM_010001	F:(C-HI)	cytochrome P450
NP_034131.1 -2.43,	-2.43,	
	F:(C-D)	
	-2.56	
		Subclass: Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)
		Subclass: cytochrome P450 2C19
		Subclass: cytochrome P450 2C9
		Subclass: cytochrome P450 2C10
		Subclass: cytochrome P450 2C8

AK012213	F:(C-HI)	aldehyde dehydrogenase 1 family
BAB28101.1	-2.39,	
	F:(C-D)	
	-2.05	
		Subclass: aldehyde dehydrogenase 1 family, member B1; aldehyde dehydrogenase 5
		Subclass: Aldehyde dehydrogenase X, mitochondrial precursor (ALDH class 2)
		Subclass: Aldehyde dehydrogenase 1A2 (Retinaldehyde-specific dehydrogenase type 2) (RALDH(II)) (RALDH-2)
		Subclass: Aldehyde dehydrogenase 1A1; aldehyde dehydrogenase 1, soluble; aldehyde dehydrogenase, liver cytosolic; ALDH
		class 1; acetaldehyde dehydrogenase 1; retinal dehydrogenase 1
		Subclass: Aldehyde dehydrogenase 1A3; aldehyde dehydrogenase 6
NM_023154	F:(C-HI)	Similar to RIKEN cDNA 0610025L15 gene product
NP_075643.1	-2.39,	
	F:(C-D)	
	-2.48	
NM_010401	F:(C-HI)	histidine ammonia-lyase; Histidine ammonia-lyase (histidase)
NP_034531.1 -2.39,	-2.39,	
	F:(C-D)	
	-2.21	
NM_023455	F:(C-HI)	putative N-acetyltransferase Camello 2
NP_075944.1 -2.39,	-2.39,	
	F:(C-D)	
	-2.04	
		Alternate: N-acetyltransferase 8; kidney- and liver-specific gene product; kidney- and liver-specific gene
		Alternate: GLA
		Alternate: kidney- and liver-specific gene product
		Alternate: hypothetical protein TSC501

ហ

 $^{\circ}$

15

NM 018779	F:(C-HI)	phosphodiesterase
NP_061249.1 -2.35,	-2.35,	
	F:(C-D)	
	24.3	Subclass: phosphodiesterase 3A, cGMP-inhibited
		Subclass: phosphodiesterase 3B, cGMP-inhibited
		ı
AK009563	F:(C-HI)	similar to RIKEN cDNA 2310032D16
BAB26361.1	-2.33	
		Alternate: KIAA1434 protein
NM_009466	F:(C-HI)	UDP-glucose dehydrogenase (uridine diphosphoglucose dehydrogenase)
NP_033492.1 -2.32,	-2.32,	
	F:(C-D)	
	-2.00	
NM_013584	F:(C-HI)	leukemia inhibitory factor receptor, LIF receptor [human, placenta, Peptide, 1078 aa]
NP_038612.1 -2.31,	-2.31,	
	F:(C-D)	
	-2.46	
NM_008061	F:(C-HI)	glucose-6-phosphatase, catalytic
NP_032087.1 -2.28,	-2.28,	
	F:(C-D)	
	-2.14	

NM 025631	F:(C-HI)	hypothetical protein dJ726C3.2
	-2.25,	
	F:(C-D)	
	-2.16	
	F:(C-HI)	
	-2.25,	
NM_025631	F:(C-D)	
NP_079907.1	-2.16	hypothetical protein dJ726C3.2
NM_025404	F:(C-H)	ADP-ribosylation factor
NP_079680.1	-2.24,	
	F:(C-D)	
	-2.03	
		Subclass: ADP-ribosylation factor 4-like; ADP-ribosylation factor-like 6
		Subclass: similar to ADP-ribosylation-like 4
		Subclass: ADP-ribosylation factor-like 7
		Subclass: ADP ribosylation factor-like protein
NM_008615	F:(C-HI)	NADP-dependent malic enzyme
NP 032641.1 -2.22	-2.22	
		Subclass: cytosolic malic enzyme 1; malic enzyme, cytoplasmic; malic enzyme 1, soluble; NADP-dependent malic enzyme;
		malate dehydrogenase; pyruvic-malic carboxylase
		Subclass: malic enzyme 3, NADP(+)-dependent, mitochondrial; malic enzyme, NADP+-dependent, mitochondrial;
		pyruvic-malic carboxylase; malate dehydrogenase; NADP-ME
		Subclass: malic enzyme 2, NAD(+)-dependent, mitochondrial; Malic enzyme, mitochondrial; malic enzyme 2, mitochondrial;
		pyruvic-malic carboxylase; malate dehydrogenase

и о <u>и</u>

NM 026104	F(C-H)	Similar to RIKEN cDNA 1700095E04 gene product
	-2.22	
		Alternate: unnamed protein product
NM_008792	F:(C-HI)	
NP_032818.1 -2.19	-2.19	proprotein convertase
		Subclass: proprotein convertase subtilisin/kexin type 2; subtilisin-like prohormone convertases; prohormone convertase 2;
		neuroendocrine convertase 2; KEX2-like endoprotease 2; proprotein convertase PC5
		Subclass: proprotein convertase subtilisin/kexin type 1 preproprotein; prohormone convertase 3; prohormone convertase 1;
		neuroendocrine convertase 1; proprotein convertase 1
NM_013743	F:(C-HI)	
NP_038771.1	-2.19	pyruvate dehydrogenase kinase
		Subclass: pyruvate dehydrogenase kinase, isoenzyme 4
		Subclass: pyruvate dehydrogenase kinase, isoenzyme 1
		Subclass: pyruvate dehydrogenase kinase, isoenzyme 2
		Subclass: pyruvate dehydrogenase kinase, isoenzyme 3
NM_010357	F:(C-HI)	
NP_034487.1 -2.17,	-2.17,	
	F:(C-D)	
	-2.93	Glutathione S-transferase
		Subclass: Glutathione S-transferase A3-3 (GST class-alpha)
		Subclass: glutathione S-transferase A3
		Subclass: glutathione S-transferase A1; GST, class alpha, 1; glutathione S-alkyltransferase A1; glutathione S-aryltransferase
		A1; S-(hydroxyalkyl)glutathione lyase A1; glutathione S-aralkyltransferase A1; GST-epsilon; glutathione S-transferase 2
		Subclass: glutathione S-transferase A2; glutathione S-transferase 2; GST, class alpha, 2; liver GST2; glutathione
		S-alkyltransferase A2; glutathione S-aryltransferase A2; S-(hydroxyalkyl)glutathione lyase A2; glutathione S-aralkyltransferase
		A2; GST-gamma; HA subunit 2
		Subclass: Chain A, Glutathione Transferase A1-1 Complexed With An Ethacrynic Acid Glutathione Conjugate (Mutant R15k)
		Subclass: TPA: glutathione transferase A5

		Subclass: glutathione S-transferase A4: glutathione S-alkyltransferase A4: glutathione S-aryltransferase A4:
		glutathione S-transferase, alpha 4
NM_011146	F:(C-HI)	
NP_035276.1	-2.17	peroxisome proliferative activated receptor gamma
		peroxisome proliferative activated receptor gamma, isoform 2; PPAR-gamma; peroxisome proliferator activated receptor
		gamma
		peroxisome proliferative activated receptor gamma, isoform 1; PPAR-gamma; peroxisome proliferator activated receptor
		gamma
NM 007395	F:(C-HI)	
NP_031421.1	-2.16	activin A type IB receptor
		Subclass: activin A type IB receptor precursor; serine(threonine) protein kinase
		Subclass: activin A type IB receptor, isoform b precursor; serine(threonine) protein kinase
		Subclass: activin type I receptor SKR2, splice form 2
		Subclass: activin A type IB receptor, isoform c precursor; serine(threonine) protein kinase
		Subclass: activin type I receptor SKR2 splice form 3
		Subclass: transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kDa); transforming growth factor
		beta receptor I (activin A receptor type II-like kinase, 53kD)
NM_009127	F:(C-HI)	Acyl-CoA desaturase (Stearoyl-CoA desaturase) (Fatty acid desaturase) (Delta(9)-desaturase)
NP_033153.1 -2.15,	-2.15,	
	F:(C-D)	
	-3.29,	
	F:(HI-D)	
	-2.11	

 \subseteq

7)

NM 007824 [F-(C-HI)	F-(C-H)	
NP 031850.1 -2.14.	-2.14.	
	F:(C-D)	
	-3.09	Cytochrome P450
		Subclass: Cytochrome P450 7A1 (Cholesterol 7-alpha-monooxygenase) (CYPVII) (Cholesterol 7-alpha-hydroxylase)
		Subclass: cytochrome P450, subfamily VIIIB, polypeptide 1; 7 alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase; sterol
		12-alpha-
		Subclass: sterol 12-alpha hydroxylase CYP8B1
AK002979	F:(C-HI)	calcyon
BAB22492.1	-2.14,	
	F:(C-D)	
	-2.15	
	F:(C-HI)	
	-2.14,	
AK002979	F:(C-D)	
BAB22492.1	-2.15	calcyon
NM_011817	F:(C-HI)	growth arrest and DNA damage inducible protein gamma (GADD45-gamma)
NP_035947.1	-2.13	
NM_027000	F:(C-HI)	similar to Nucleolar GTP-binding protein 1 (Chronic renal failure gene protein) (GTP-binding protein NGB)
NP_081276.1	-2.13	
		Alternate: G protein-binding protein CRFG; GTP-binding protein
		Alternate: G protein-binding protein CRFG
		Alternate: putative G-binding protein
		Alternate: unnamed protein product

 $\ddot{}$

 \sim

NM_007815	F:(C-HI)	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
NP_031841.1 -2.11,	-2.11,	
	F:(C-D)	
	-2.78	
		Subclass: Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)
		Subclass: cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4'-hydroxylase;
		microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
		polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked
		monooxygenase
		Subclass: cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 17
		Subclass: cytochrome P450, subfamily IIC, polypeptide 8 isoform 1; mephenytoin 4-hydroxylase; microsomal monooxygenase
		xenobiotic monooxygenase; flavoprotein-linked monooxygenase; P450 form 1
		Subclass: Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) (P-450MP)
AK006487	F:(C-HI)	hypothetical protein BC015148
BAB24612.1	-2.1	
NM_008587	F:(C-HI)	c-mer proto-oncogene tyrosine kinase
NP_032613.1	-2.1	
NM_007912	F:(C-HI)	Epidermal growth factor receptor
NP_031938.1 -2.09,	-2.09,	
	F:(C-D)	
	-2.69	
		Subclass: epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); epidermal
		growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog); Epidermal growth factor receptor
		Subclass: p110 epidermal growth factor receptor
		Subclass: v-erb-a erythroblastic leukemia viral oncogene homolog 4; avian erythroblastic leukemia viral (v-erb-b2) oncogene
		homolog 4; v-erb-a avian erythroblastic leukemia viral oncogene homolog-like 4

Ŋ

 $\ddot{\dashv}$

Ξi.

		Subclass: v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); Transformation gene ERBB-3; v-erb-b2 avian
	·	Subclass: Receptor protein-tyrosine kinase erbB-3 (c-erbB3) (Tyrosine kinase-type cell surface receptor HER3)
		Subclass: v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; Avian
		erythroblastic leukemia viral (v-erb-b2) oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
		(neuro/glioblastoma derived oncogene homolog)
		Subclass: Similar to v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
		Subclass: herstatin
NM_010145	F:(C-HI)	epoxide hydrolase 1, microsomal (xenobiotic); Epoxide hydroxylase 1, microsomal (xenobiotic)
NP_034275.1 -2.09,	-2.09,	
	F:(C-D)	
	-2.09	
919600 MN	F:(C-HI)	aldehyde oxidase 1
NP_033806.1	-2.08	
NM_010012	F:(C-HI)	cytochrome P450, subfamily VIIIB, polypeptide 1 (CYP8B1); 7 alpha-hydroxy-4-cholesten-3-one 12-alpha-hydroxylase; sterol
NP_034142.1	-2.08	12-alpha-hydroxylase
NM_011921	F:(C-HI)	aldehyde dehydrogenase 1
NP_036051.1	-2.08	
		Subclass: aldehyde dehydrogenase 1A1; aldehyde dehydrogenase 1, soluble; aldehyde dehydrogenase, liver cytosolic; ALDH
		class 1; acetaldehyde dehydrogenase 1; retinal dehydrogenase 1
		Subclass: aldehyde dehydrogenase 1 family, member A2; retinaldehyde dehydrogenase 2
		Subclass: aldehyde dehydrogenase 1A3; aldehyde dehydrogenase 6
		Subclass: aldehyde dehydrogenase 1 family, member B1; aldehyde dehydrogenase 5

ហ

ATA 010776	E-(0 LI)	
	(11-2)	
NP_061246.1	-2.07,	
	F:(C-D)	
	-2.11	cytokine receptor related protein
		Subclass: cytokine receptor related protein 4
		Subclass: cytokine receptor-like factor 3
		Subclass: cytokine receptor-like molecule 9
NM_007474	F:(C-HI)	aquaporin 8
NP_031500.1	-2.07	
NM_023737 NP_076226.1	F:(C-HI) -2.07	enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase
AK005535	F:(C-HI)	solute carrier family 39 (zinc transporter), member 4
BAB24106.1	-2.06,	
	F:(C-D)	
	-2.16	
NM_009864	F:(C-HI)	Cadherin
NP_033994.1	-2.05	
		Subclass: cadherin 1, type 1 preproprotein; calcium-dependent adhesion protein, epithelial; cadherin 1, E-cadherin (epithelial);
		uvomorulin; cell-CAM 120/80; Arc-1
		Subclass: E-cadherin
		Subclass: cadherin 3, type 1 preproprotein; P-cadherin; placental cadherin; cadherin 3, P-cadherin (placental);
		calcium-dependent adhesion protein, placental
		Subclass: cadherin 2, type 1 preproprotein; N-cadherin 1; cadherin 2, N-cadherin (neuronal); neural cadherin;
		calcium-dependent adhesion protein, neuronal
		Subclass: cadherin 4, type 1 preproprotein; cadherin 4, R-cadherin (retinal); R-cadherin; retinal cadherin
		Subclass: Cadherin-4 precursor (Retinal-cadherin) (R-cadherin) (R-CAD)

ហ

		Alternate: uvomorulin
NM_023341	F:(C-HI)	chaperone
NP 075830.1	-2.05	
		Subclass: chaperone-ABC1-like
		Subclass: chaperone, ABC1 activity of bc1 complex like
		Alternate: unnamed protein product
AF071068	F:(C-HI)	
AAC25566.1	-2.04,	
	-2.29	decarboxylase
		Subclass: dopa decarboxylase (aromatic L-amino acid decarboxylase); aromatic L-amino acid decarboxylase
		Subclass: Histidine decarboxylase (HDC)
NM_009263	F:(C-HI)	Osteopontin
NP_033289.1	-2.04	
		Subclass: Osteopontin precursor (Bone sialoprotein 1) (Urinary stone protein) (Secreted phosphoprotein 1) (SPP-1)
		(Nephropontin)
	٠	Subclass: OPN-a
		Subclass: OPN-b
		Subclass: OPN-c
NM_053200	F:(C-HI)	carboxylesterase
NP_444430.1	-2.04	
		Subclass: carboxylesterase 3; brain carboxylesterase BR3
		Subclass: brain carboxylesterase hBr2
		Subclass: carboxylesterase 1 (monocyte/macrophage serine esterase 1); liver carboxylesterase; carboxylesterase 2 (liver)

		Subclass: Liver carboxylesterase precilisor (Acyl coepzyme Archolesteral acyltransferase) (ACAT) (Monocyte/macrophage	le/marronhage
		serine esterase) (HMSE) (Serine esterase 1) (Brain carboxylesterase hBr1)	
		Subclass: serine esterase N-terminal truncated (503 AA)	
		Subclass: brain carboxylesterase hBr1	* .
		Subclass: Alternate: acyl coenzyme A:cholesterol acyltransferase	
			, de
AK007964	F:(C-HI)	cholinephosphotransferase 1	
BAB25375.1	-2.03,		
	F:(C-D)		
	-2.36		
NM_009748	F:(C-HI)	Golgi vesicular membrane trafficking protein p18; Bet1 (S. cerevisiae) homolog; Bet1p homolog	
NP_033878.1 -2.03,	-2.03,		. ·
	F:(C-D)		-
:	-2.15		·
NM_019811	F:(C-HI)	acetyl-CoA synthetase	
NP_062785.1 -2.03,	-2.03,		
	F:(C-D)		
	-2.11		· .
		Subclass: acetyl-CoA synthetase isoform a; cytoplasmic acetyl-coenzyme A synthetase; acetate-CoA ligase; acyl-activating	acyl-activating
		enzyme; acetate thiokinase; acetyl-CoA synthetase	
		Subclass: acetyl-CoA synthetase isoform b; cytoplasmic acetyl-coenzyme A synthetase; acetate-CoA ligase; acyl-activating	acyl-activating
		enzyme; acetate thiokinase; acetyl-CoA synthetase	
NM_011834	F:(C-HI)	L-kynurenine/alpha-aminoadipate aminotransferase; kynurenine aminotransferase II	
NP_035964.1 -2.03	-2.03		
		Alternate: Similar to L-kynurenine/alpha-aminoadipate aminotransferase	

NM 009221	F:(C-HI)	alpha-svnuclein isoform NACP140: non A4 component of amyloid precursor
	-2.02	
NM_011125	F:(C-HI)	phospholipid transfer protein
NP_035255.1 -2.01	-2.01	
		Alternate: Similar to phospholipid transfer protein
NM_010062	F:(C-HI)	deoxyribonuclease
NP_034192.1	-2.00,	
	F:(C-D) -2.4	
		Subclass: deoxyribonuclease II, lysosomal; DNase II, lysosomal
		Subclass: deoxyribonuclease II beta, isoform 1 precursor; DNase II-like acid DNase; endonuclease DLAD
NM_007811	F:(C-HI)	Cytochrome P450 26 (Retinoic acid-metabolizing cytochrome) (P450RAI) (hP450RAI) (Retinoic acid 4-hydroxylase)
NP_031837.1 -17.03,	-17.03,	
	F:(C-D)	
	-3.81	
NM_053215	F:(C-HI)	UDP glycosyltransferase; UDP-glucuronyltransferase
NP_444445.1	-1.98,	
	F:(C-D)	
	-3.23	
		Subclass: UDP glycosyltransferase 2 family, polypeptide B17; UDP-glucuronyltransferase, family 2, beta-17
		Subclass: similar to UDP-glucuronosyltransferase 2B15 precursor, microsomal (UDPGT) (UDPGTH-3) (HLUG4)
		Subclass: UDP glycosyltransferase 2 family, polypeptide B15; UDP-glucuronyltransferase, family 2, beta-15
		Subclass: UDP glycosyltransferase 2 family, polypeptide B4; UDP-glucuronyltransferase, family 2, beta-4
		Subclass: similar to UDP-glucuronosyltransferase 2B4 precursor, microsomal (UDPGT) (Hyodeoxycholic acid) (HLUG25)
		(UDPGTH-1)
•		Subclass: UDP glycosyltransferase 2 family, polypeptide B7; UDP-glucuronyltransferase, family 2, beta-7

		Subclass: UDP alvoosyltransferase 2 family, polypeptide A1: UDP alucuronosyltransferase 2 family, polypeptide A1
		Subclass: UDP glycosyltransferase 2 family, polypeptide B11
,		Subclass: UDP glycosyltransferase 2 family, polypeptide B10
		Subclass: UDP glycosyltransferase 2 family, polypeptide B28
NM_022411		
NP_071856. F:(C-D)-5.5	F:(C-D)-5.5	
1	9	transporter protein
		Subclass: sodium/sulfate symporter/sodium/sulphate symporter
		Subclass: solute carrier family 13 (sodium/sulfate symporters), member 1; solute carrier family 13 (sodium/sulphate
		symporters), member 1
		Subclass: solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2; sodium-coupled citrate
		transporter
		Subclass: Solute carrier family 13, member 3 (Sodium-dependent high-affinity dicarboxylate transporter 2).
		(Na(+)/dicarboxylate cotransporter 3) (NaDC-3) (hNaDC3).
		Subclass: Solute carrier family 13, member 4 (Na+/sulfate cotransporter SUT-1).
		Subclass: Na+-coupled citrate transporter protein
NM_018866		
NP_061354. F:(C-D)-3.5	F:(C-D)-3.5	
1	2	chemokine
		Subclass: chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant); B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1);small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cell chemoattractant)
NM_009270		
NP_033296. F:(C-D)-3.4	F:(C-D)-3.4	
1	4	Enzymes involved in hepatic cholesterol synthesis

NIM_017379 NP_059075. F:(C-D)-3.1 tubulin Subclass: tubulin, alpha, ubiquitous Subclass: tubulin, alpha 1; testis-specific alpha tubulin; tubulin alpha-1 chain Subclass: tubulin, alpha 1; testis-specific alpha tubulin; tubulin alpha-1 chain Subclass: tubulin, alpha 2 isoform 1 Subclass: tubulin, alpha 2 isoform 1 Subclass: tubulin, alpha 2 isoform 1 Subclass: tubulin alpha 2 isoform 1 Subclass: tubulin alpha 8 Subclass: tubulin beta 6 Subclass: tubulin beta 6 Subclass: tubulin beta 6 Subclass: tubulin beta 1 chain Subclass: tubulin beta 1 chain Subclass: tubulin beta 4 chain (Tubulin) (Gamma-tubulin complex component 1) (GCP-1). Subclass: tubulin gamma 2 Subclass: tubulin gamma 2 Subclass: tubulin gamma 2 Subclass: tubulin pesilon Subclass: tubulin epsilon Subclass: tubulin epsilon 1; epsilon-tubulin	
F:(C-D)-3.1	
F:(C-D)-3.1	
F:(C-D)-3.1	
F:(C-D)-3.1	
F:(C-D)-2.8	
F:(C-D)-2.8	
F:(C-D)-2.8	
F:(C-D)-2.8	ր, tubulin alpha-1 chain
F:(C-D)-2.8	
F:(C-D)-2.8	
F:(C-D)-2.8	
F:(C-D)-2.8	ic; hum-a-tub1; hum-a-tub2
F:(C-D)-2.8	
F:(C-D)-2.8) (Gamma-tubulin complex_component 1) (GCP-1).
F:(C-D)-2.8	
F:(C-D)-2.8	
F:(C-D)-2.8	
AK005060	
P29758 F:(C-HI)-2.6 alanine-glyoxylate aminotransferase	
Subclass: alanine-glyoxylate aminotransferase 2-like 1	

വ

2

1

ñ

C.1

		Subclass: alanine-glyoxylate aminotransferase 2 precursor; beta-alanine-pyruvate aminotransferase; beta-ALAAT II
NM_021475		
NP 067450. F:(C-D)-2.7	F:(C-D)-2.7	
1	4	metalloproteinase
		Subclass: disintegrin and metalloproteinase
		Subclass: a disintegrin and metalloproteinase domain 28 isoform 1 preproprotein
		Subclass: a disintegrin and metalloproteinase domain 28 isoform 2 preproprotein
		Subclass: a disintegrin and metalloproteinase domain 28 isoform 3 preproprotein
		Subclass: ADAM 7 precursor (A disintegrin and metalloproteinase domain 7) (Sperm maturation-related glycoprotein GP-83).
		Subclass: a disintegrin and metalloproteinase domain 8 precursor
		Subclass: a disintegrin and metalloproteinase domain 9 preproprotein; meltrin gamma
		Subclass: a disintegrin and metalloproteinase domain 33 isoform beta preproprotein; disintegrin and reprolysin
		metalloproteinase family protein; metalloprotease disintegrin
		Subclass: a disintegrin and metalloproteinase domain 33 isoform alpha preproprotein; disintegrin and reprolysin
		metalloproteinase family protein; metalloprotease disintegrin
		Subclass: disintegrin protease; ADAM-like protein decysin 1
NM_007703		
NP_031729. F:(C-D)-2.7	F:(C-D)-2.7	
1	~	Enzymes that elongate long chain fatty acids
		Subclass: elongation of very long chain fatty acids like 3
		Subclass: CIG30
		Subclass: ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast); long-chain
	,	fatty-acyl elongase

	•	
NM_013878		
NP_038906.	F:(C-D)-2.6	
<u></u>	က	calcium binding protein
		Subclass: calcium binding protein 2
		Subclass: calcium binding protein 2 isoform 1; CaBP2
		Subclass: calcium binding protein 2 isoform 2; CaBP2
		Subclass: calcium binding protein 1
		Subclass: calcium binding protein 1 isoform 1; calbrain; calcium binding protein 5; calcium binding protein 1; calbrain
		Subclass: calcium binding protein 1 isoform 2; calbrain; calcium binding protein 5; calcium binding protein 1; calbrain
		Subclass: calcium binding protein 4
		Subclass: calcium binding protein 5
NM_011087		
NP 035217 E-(C-D)-2 4	E-(0-0)-3	
1	9	Receptor
		Subclass: leucocyte immunoglobulin-like receptor
		Subclass: leucocyte immunoglobulin-like receptor-3; LIR-3
		Subclass: leukocyte immunoglobulin-like receptor, subfamily A
		Subclass: leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1; leukocyte immunoglobulin-like
		receptor 6
		Subclass: leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2; leukocyte immunoglobulin-like
•		receptor 7
		Subclass: leukocyte immunoglobulin-like receptor, subfamily A, member 5; immunoglobulin-like transcript 10
		Subclass: leukocyte immunoglobulin-like receptor, subfamily B
		Subclass: leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 5
		Subclass: leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2; leukocyte
		immunoglobulin-like receptor 2

		Subclass: leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 6; immunoglobulin-like
		transcript 8
		Subclass: leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1; leukocyte
		immunoglobulin-like receptor 1; CD85 antigen
		Subclass: leukocyte immunoglobulin-like receptor 1
		Subclass: leukocyte immunoglobulin-like receptor-2
		Subclass: leucocyte immunoglobulin-like receptor-4; LIR-4
		Subclass: immunoglobulin-like transcript 5 protein, ILT5
		Subclass: immunoglobulin-like transcript 6
		Subclass: immunoglobulin-like transcript 7; ILT7
		Subclass: killer cell inhibitory receptor p91 precursor
		Subclass: monocyte inhibitory receptor precursor
NM_010849		
NP_034979.	F:(C-D)-2.4	v-myc myelocytomatosis viral oncogene homolog; Avian myelocytomatosis viral (v-myc) oncogene homolog; C-MYC; v-myc
2	2	avian myelocytomatosis viral oncogene homolog
NM_009414		
NP_033440. F:(C-D)-2.4	F:(C-D)-2.4	
<u> </u>	2	hydroxylase
		Subclass: tryptophan hydroxylase
		Subclass: tryptophan hydroxylase 1 (tryptophan 5-monooxygenase); tryptophan hydroxylase (tryptophan 5-monooxygenase)
		Subclass: neuronal tryptophan hydroxylase
		Subclass: phenylalanine hydroxylase
		Subclass: tyrosine hydroxylase
		Subclass: hydroxylase 2,Tyr
	·	Subclass: hydroxylase 3,Tyr

NM_008039		
NID 032065		
1 - 00000	F:(C-D)-2.4	Receptor
	1-	Subclass: formyl peptide receptor
		Subclass: formyl peptide receptor-like 1; lipoxin A4 receptor (formyl peptide receptor related)
		Subclass: formyl peptide receptor-like 2
		Subclass: fMet-Leu-Phe receptor (fMLP receptor) (N-formyl peptide receptor)(FPR) (N-formylpeptide chemoattractant
		receptor).
		Subclass: N-formyl peptide receptor
		Subclass: N-formylpeptide receptor fMLP-R98
		Subclass: orphan G-protein coupled receptor Dez isoform a
		Subclass: chemokine-like receptor
		Subclass: Chemokine receptor-like 1 (G-protein coupled receptor DEZ) (G protein-coupled receptor ChemR23).
NM_023142		
NP_075631.		
	6	actin related protein
		Subclass: actin related protein 2/3 complex subunit 1A; actin binding protein (Schizosaccharomyces pombe sop2-like); SOP2-like protein
·		Subclass: actin related protein 2/3 complex subunit 1B; ARP2/3 protein complex subunit p41; actin related protein 2/3 complex subunit 1A (41 kD)
NM_007864		
NP_031890. F:(C-D)-2.3	F:(C-D)-2.3	
-	8	Presynaptic protein
		Subclass: Presynaptic protein SAP97 (Synapse-associated protein 97) (Discs, large homolog 1) (hDlg).

		O. Laboration of the second 40. Above in 440.
		Subciass, daige fibrilloug 4, diapsyiller of
		Subclass: discs, large, homolog 3; neuroendocrine-dig
		Subclass: discs, large (Drosophila) homolog 4
		Subclass: KIAA1232 protein
		Subclass: Tax interaction protein 15
		Subclass: post-synaptic density 95
NM_010098		
NP 034228. F:	F:(C-D)-2.3	
		extraretinal photoreceptor
		Subclass: Opsin (encephalopsin, panopsin)
		Subclass: opsin 3 (encephalopsin, panopsin); opsin 3 (encephalopsin)
		Subclass: encephalopsin splice variant 1-2-5-6
NM_010206		
NP_034336. F:	F:(C-D)-2.3	
1 5		Receptor
		Subclass: Receptor tyrosine kinase
		Subclass: Growth Factor Receptor tyrosine kinase
		Subclass: fibroblast growth factor receptor
		Subclass: fibroblast growth factor receptor 1
		Subclass: fibroblast growth factor receptor 1 isoform 1 precursor; fms-related tyrosine kinase-2; heparin-binding growth factor
		receptor; FMS-like tyrosine kinase 2; basic fibroblast growth factor receptor 1; N-sam tyrosine kinase; FLG protein;
		protein-tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein kinase
		Subclass: fibroblast growth factor receptor 1 isoform 2 precursor; fms-related tyrosine kinase-2; heparin-binding growth factor
		receptor; FMS-like tyrosine kinase 2; basic fibroblast growth factor receptor 1; N-sam tyrosine kinase; FLG protein;
		protein-tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein kinase
,		Subclass: similar to fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)

	Subclass: fibroblast growth factor receptor 1 isoform 3 precursor; fms-related tyrosine kinase-2; heparin-binding growth factor	ng growth factor
	receptor; FMS-like tyrosine kinase 2; basic fibroblast growth factor receptor 1; N-sam tyrosine kinase; FLG protein;	otein;
	protein-tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 1 isoform 4 precursor; fms-related tyrosine kinase-2; heparin-binding growth factor	ng growth factor
	receptor; FMS-like tyrosine kinase 2; basic fibroblast growth factor receptor 1; N-sam tyrosine kinase; FLG protein;	otein;
	protein-tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 1 isoform 5 precursor; fms-related tyrosine kinase-2; heparin-binding growth factor	ng growth factor
	receptor; FMS-like tyrosine kinase 2; basic fibroblast growth factor receptor 1; N-sam tyrosine kinase; FLG protein;	otein;
_	protein-tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 1 isoform 6 precursor;fms-related tyrosine kinase-2; heparin-binding growth factor	ng growth factor
	receptor; FMS-like tyrosine kinase 2; basic fibroblast growth factor receptor 1; N-sam tyrosine kinase; FLG protein;	otein;
	protein-tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 1 isoform 7 precursor; fms-related tyrosine kinase-2; heparin-binding growth factor	ing growth factor
	receptor; FMS-like tyrosine kinase 2; basic fibroblast growth factor receptor 1; N-sam tyrosine kinase; FLG protein;	otein;
	protein-tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 1 isoform 9 precursor; fms-related tyrosine kinase-2; heparin-binding growth factor	ng growth factor
	receptor; FMS-like tyrosine kinase 2; basic fibroblast growth factor receptor 1; N-sam tyrosine kinase; FLG protein;	otein;
	protein-tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2	·
	Subclass: fibroblast growth factor receptor 2 isoform 1 precursor; keratinocyte growth factor receptor, K-sam protein; protein	protein; protein
	tyrosine kinase, receptor like 14; FGF receptor, bacteria-expressed kinase, fibroblast growth factor receptor BEK; tyrosylprotein	3EK; tyrosylproteir
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 2 precursor; keratinocyte growth factor receptor; K-sam protein; protein	protein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein	3EK; tyrosylprotein
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 3 precursor; keratinocyte growth factor receptor; K-sam protein; protein	protein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein	3EK; tyrosylprotein
	kinase; hydroxyaryl-protein kinase	

	Subclass: fibroblast growth factor receptor 2 isoform 4 precursor; keratinocyte growth factor receptor; K-sam protein; protein	otein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein	K; tyrosylproteir
	kinase; hydroxyaryl-protein kinase	
	Subclass: ibroblast growth factor receptor 2 isoform 5 precursor; keratinocyte growth factor receptor; K-sam protein; protein	tein; protein
.	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylproteir	K; tyrosylproteir
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 6 precursor; keratinocyte growth factor receptor; K-sam protein; protein	otein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylproteir	K; tyrosylproteir
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 7 precursor; keratinocyte growth factor receptor; K-sam protein; protein	otein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylproteir	K; tyrosylprotein
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 8 precursor; keratinocyte growth factor receptor; K-sam protein; protein	otein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylproteir	K; tyrosylproteir
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 9 precursor; keratinocyte growth factor receptor; K-sam protein; protein	otein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein	K; tyrosylproteir
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 10 precursor; keratinocyte growth factor receptor; K-sam protein; protein	rotein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein	K; tyrosylprotein
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 11 precursor; keratinocyte growth factor receptor; K-sam protein; protein	rotein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein	K; tyrosylproteir
	kinase; hydroxyaryl-protein kinase	
	Subclass: fibroblast growth factor receptor 2 isoform 12 precursor; keratinocyte growth factor receptor; K-sam protein; protein	rotein; protein
	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylproteir	K; tyrosylproteir
	kinase; hydroxyaryl-protein kinase	

Subone Su	SUBCIASS: HIDTODIAST GLOWIN FACION FECEPTION 2 ISOLOTHING PRECUISON, NETACH FACEPTION, INSTALL PROCESS AND PROCESS.
tyros kinas Subc Subc	
kinas Subc Subc	tyrosine kinase, receptor like 14; FGF receptor; bacteria-expressed kinase; fibroblast growth factor receptor BEK; tyrosylprotein
ogns ogns	kinase; hydroxyaryl-protein kinase
odus .	Subclass: fibroblast growth factor receptor 3
Subc	Subclass: fibroblast growth factor receptor 3 isoform 1 precursor; hydroxyaryl-protein kinase; tyrosine kinase JTK4
	Subclass: fibroblast growth factor receptor 3 isoform 2 precursor; hydroxyaryl-protein kinase; tyrosine kinase JTK4
ogns	Subclass: fibroblast growth factor 4
Saba	Subclass: fibroblast growth factor receptor 4 isoform 1 precursor; tyrosine kinase related to fibroblast growth factor receptor;
tyros	tyrosylprotein kinase; protein-tyrosine kinase; hydroxyaryl-protein kinase
SqnS	Subclass: fibroblast growth factor receptor 4 isoform 2 precursor; tyrosine kinase related to fibroblast growth factor receptor;
tyros	tyrosylprotein kinase; protein-tyrosine kinase; hydroxyaryl-protein kinase
oqnS	Subclass: fibroblast growth factor receptor 4, soluble-form splice variant
Subs	Subclass: keratinocyte growth factor receptor
Subs	Subclass: keratinocyte growth factor receptor 2 isoform K-sam-IIC3
Subs	Subclass: keratinocyte growth factor receptor 2 isoform KGFR
SqnS	Subclass: keratinocyte growth factor receptor 2 isoform BEK
Saus	Subclass: heparin-binding growth factor receptor
Subs	Subclass: heparin-binding growth factor receptor variant alpha-a2
Sans	Subclass: heparin-binding growth factor receptor K-sam precursor
ogns	Subclass: RET tyrosine kinase receptor
ogns	Subclass: ret proto-oncogene isoform c; RET transforming sequence; hydroxyaryl-protein kinase; cadherin family member 12;
ono	oncogene RET
ogns	Subclass: ret proto-oncogene (multiple endocrine neoplasia MEN2A, MEN2B and medullary thyroid carcinoma 1, Hirschsprung
disease)	ase)
odus	Subclass: ret proto-oncogene isoform b; RET transforming sequence; hydroxyaryl-protein kinase; cadherin family member 12;
oouo	oncogene RET
ogns	Subclass: ret proto-oncogene isoform a; RET transforming sequence; hydroxyaryl-protein kinase; cadherin family member 12;
onco	oncogene RET
Subc	Subclass: vascular endothelial growth factor receptor
Sabs	Subclass: vascular endothelial growth factor receptor 2

. 10

Ŋ

വ

 \tilde{a}

		Subclass: TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)
		Subclass: insulin-like growth factor I receptor, IGF-IR [human, Peptide, 1367 aa].
NM_011781		metalloprotease/disintegrin-like protein (ADAM)
NP_035911. F:(C-D)-2.3	F:(C-D)-2.3	
-	ဗ	
		Subclass: ADAM 2 precursor (A disintegrin and metalloproteinase domain 2)(Fertilin beta subunit) (PH-30) (PH30).
		Subclass: ADAM 7 precursor (A disintegrin and metalloproteinase domain 7) (Sperm maturation-related glycoprotein GP-83).
		Subclass: a disintegrin and metalloproteinase domain 8 precursor
		Subclass: disintegrin/metalloproteinase domain 9 short protein precursor
		Subclass: ADAM 11 precursor (A disintegrin and metalloproteinase domain 11) (Metalloproteinase-like, disintegrin-like, and
		cysteine-rich protein) (MDC).
		Subclass: a disintegrin and metalloprotease domain 11 isoform 1 preproprotein; metalloproteinase-like, disintegrin-like,
		cysteine-rich protein
	-	Subclass: a disintegrin and metalloprotease domain 11 isoform 2 preproprotein; metalloproteinase-like, disintegrin-like,
		cysteine-rich protein
		Subclass: a disintegrin and metalloprotease domain 12 isoform 1 preproprotein; A disintegrin and metalloproteinase domain
		12 (Meltrin-alpha, mouse, homolog of); meltrin alpha
		Subclass: a disintegrin and metalloprotease domain 12 isoform 2 preproprotein; A disintegrin and metalloproteinase domain 12
		(Meltrin-alpha, mouse, homolog of); meltrin alpha
		Subclass: disintegrin-like metalloproteinase MDC15
		Subclass: a disintegrin and metalloproteinase domain 18 proprotein
		Subclass: ADAM 19 precursor (A disintegrin and metalloproteinase domain 19) (Meltrin beta) (Metalloprotease and disintegrin
-	·	dentritic antigen marker) (MADDAM).
		Subclass: a disintegrin and metalloproteinase domain 19 isoform 1 preproprotein; meltrin beta
		Subclass: a disintegrin and metalloproteinase domain 19 isoform 2 preproprotein; meltrin beta
	·	Subclass: ADAM 20 precursor (A disintegrin and metalloproteinase domain 20).
		Subclass: ADAM 21; testis-specific metalloprotease-like membrane protein
		Subclass: a disintegrin and metalloproteinase domain 22

	Subclass: a disintegrin and metalloproteinase domain 22 isoform 1 proprotein; MDC2 delta
	Subclass: a disintegrin and metalloproteinase domain 22 isoform 2 proprotein; MDC2 delta
·	Subclass: a disintegrin and metalloproteinase domain 22 isoform 3 proprotein; MDC2 delta
	Subclass: a disintegrin and metalloproteinase domain 22 isoform 4 proprotein; MDC2 delta
	Subclass: a disintegrin and metalloproteinase domain 22 isoform 5 proprotein; MDC2 delta
	Subclass: a disintegrin and metalloproteinase domain 23 preproprotein
	Subclass: a disintegrin and metalloproteinase domain 28
	Subclass: a disintegrin and metalloproteinase domain 28 isoform 1 preproprotein
	Subclass: a disintegrin and metalloproteinase domain 28 isoform 2 preproprotein
	Subclass: a disintegrin and metalloproteinase domain 28 isoform 3 preproprotein
	Subclass: ADAM 29 precursor (A disintegrin and metalloproteinase domain 29).
	Subclass: a disintegrin and metalloproteinase domain 29 isoform 1 preproprotein
	Subclass: a disintegrin and metalloproteinase domain 29 isoform 2 preproprotein
	Subclass: a disintegrin and metalloproteinase domain 29 isoform 3 preproprotein
	Subclass: ADAM 30 precursor (A disintegrin and metalloproteinase domain 30).
	Subclass: a disintegrin and metalloprotease domain 33
	Subclass: a disintegrin and metalloproteinase domain 33 isoform alpha preproprotein; disintegrin and reprolysin
	metalloproteinase family protein; metalloprotease disintegrin
A CARLO MANAGEMENT OF THE PROPERTY OF THE PROP	Subclass: a disintegrin and metalloproteinase domain 33 isoform beta preproprotein; disintegrin and reprolysin
The state of the s	metalloproteinase family protein; metalloprotease disintegrin
	Subclass: fertilin beta
NM_011461	
NP_035591. F:(C-D)-2.3	hypothetical protein MGC40611

NM_009021			
NP_033047.	NP_033047. F:(C-D)-2.2		-
I —		retinoic-acid induced protein	
		Subclass: retinoic-acid induced protein 1	
		Subclass: retinoic acid induced 1 isoform 1	
		Subclass: retinoic acid induced 1 isoform 2	
		Subclass: retinoic acid induced 1 isoform 3	
		Subclass: KIAA1820 protein	
		Subclass: hypothetical protein DKFZp434A139.1 - human	
NM_021468			
NP_067443.	NP_067443. F:(C-D)-2.1		
ı 	8	UNC13 (C. elegans)-like; homolog of rat Munc13 (diacylglycerol-binding)	
		Alternate: KIAA1032 protein	
X03796			
CAA27422.1	4		
		Subclass: aldolase B, fructose-bisphosphate; Aldolase B, fructose-bisphosphatase	
		Subclass: aldolase C, fructose-bisphosphate; Aldolase C, fructose-bisphosphatase	
NM_007489			•
NP_031515.	F:(C-D)-2.1		
~ ~	3	Nuclear transcription factor	
		Subclass: aryl hydrocarbon receptor nuclear translocator; Arnt	
		Subclass: aryl hydrocarbon receptor nuclear translocator isoform 1; dioxin receptor, nuclear translocator; hypoxia-inducible	/poxia-inducible
		factor 1, beta subunit	

L		Subclass: aryl-hydrocarbon receptor nuclear translocator 2; aryl hydrocarbon receptor nuclear translocator 2
<u>L., </u>		Subclass: BMAL1 protein (Brain and muscle ARNT-like 1) (Member of PAS protein 3) (Basic-helix-loop-helix-PAS orphan
		MOP3) (BHLH-PAS protein JAP3).
		Subclass: brain and muscle Ah receptor nuclear translocator-like protein, BMAL1b Subclass: BMAL1c
		Subclass: brain and muscle Ah receptor nuclear translocator-like protein, BMAL1d
		_
		Subclass: transcription factor BMAL2
		Subclass: brain-muscle-ARNT-like transcription factor 2a
		Subclass: brain-muscle-ARNT-like transcription factor 2b
		Subclass: brain-muscle-ARNT-like transcription factor 2c
		Subclass: brain-muscle-ARNT-like transcription factor 2d
		Subclass: bHLH-PAS transcription factor MOP9
		Subclass: bHLH-PAS transcription factor MOP9
		Subclass: PAS protein 3
		Subclass: cycle-like factor CLIF
NM_013533		
	. 1	
NP_038561. I	F:(C-D)-Z.1	\V. cictore
	0	Subclass: protein 'A' isoform 1; protein 'A'
		Subclass: protein A-3
NM_013598		
NP_038626. F:(C-D)-2.1	F:(C-D)-2.1	
1	7	Gubdass: mast cell growth factor
		OUDCIASS. Hast cen growin racioi

		Subclass: mast cell growth factor, isoform b	
		Subclass: stem cell growth factor	
NM_007753		Carboxypeptidase	
NP_031779.	F:(C-D)-2.0		
	8		
		Subclass: Carboxypeptidase A	
		Subclass: Pancreatic carboxypeptidase A1	_
		Subclass: Carboxypeptidase A2	_
		Subclass: carboxypeptidase A4; carboxypeptidase A3	-
		Subclass: carboxypeptidase A5	
		Subclass: metallocarboxypeptidase A6	
		Subclass: TPA: carboxypeptidase A-6; CPA6	
		Subclass: Mast cell carboxypeptidase A3 precursor	
		Subclass: mast cell carboxypeptidase A; MC-CPA	
		Subclass: carboxypeptidase B	
		Subclass: plasma carboxypeptidase B2 isoform b; carboxypeptidase U; thrombin-activatable fibrinolysis inhibitor;	
		carboxypeptidase B-like protein; thrombin-activable fibrinolysis inhibitor	
		Subclass: plasma carboxypeptidase B2 isoform a preproprotein; carboxypeptidase U; thrombin-activatable fibrinolysis inhibitor;	
		carboxypeptidase B-like protein; thrombin-activable fibrinolysis inhibitor	
		Subclass: carboxypeptidase O	
		Subclass: TPA: carboxypeptidase O; CPO	 -
NM_019952			
NP_064336.	F:(C-D)-2.0		
-	7	cardiotrophin-like cytokine	
		Subclass: cardiotrophin-like cytokine; neurotrophin-1/B-cell stimulating factor-3	

ហ

NM_031390		
NP_113567.	NP_113567. F:(C-D)-2.0	preferentially expressed antigen in melanoma; melanoma antigen preferentially expressed in tumors; Opa-interacting protein OIP4; preferentially expressed antigen of melanoma
NM_016851		
NP 058547. F:(C-D)-2.0	F:(C-D)-2.0	
! -		interferon regulatory factor
		Subclass: Interferon regulatory factor 4 (IRF-4) (Lymphocyte specific interferon regulatory racion / (17) Emby (marker)
		myeloma oncogene 1).
		Subclass: interferon regulatory factor 5
		Subclass: interferon regulatory factor 5 isoform a
		Subclass; interferon regulatory factor 5 isoform b
		Subclass: interferon regulatory factor 6; Popliteala pteryglum syndrome
		Subclass: interferon consensus sequence binding protein 1; H-ICSBP; interferon regulatory lactor o
		Subclass: ICSAT transcription factor
NM_009988		
NP 034118	NP 034118 (F-(C-D)-2.0	
	. 9	homophilic adhesion molecule
		Subclass: coxsackie and adenovirus receptor protein
		Subclass: coxsackie virus and adenovirus receptor; 46 KD coxsackievilus and adenovirus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 46 KD coxsackievilus and adenovirus receptor; 47 KD coxsackievilus and adenovirus receptor; 47 KD coxsackievilus receptor; 47 KD coxsackievilus receptor; 47 KD coxsackievilus receptor; 47 KD coxsackievilus receptor; 47 KD coxsackievilus receptor; 47 KD coxsackievilus receptor; 47 KD coxsackievilus receptor; 47 KD coxsackievilus receptor; 48
		Subclass: coxsackie-adenovirus-receptor isoform CAR4/7
		Subclass: coxsackie-adenovirus-receptor isotorm CAR3//

25

20

NM_025436		
NP_079712. F:(C-D)-2.0	F:(C-D)-2.0	sterol-C4-methyd oxidase-like: C.4 methyl sterol
	-	
NM_019871		
NP_063924.	F:(C-D)-2.0	
1	4	condensing enzyme
		Subclass: acyl-malonyl condensing enzyme
		Subclass: hypothetical protein FLJ40154
NM_009770		
NP_033900. F:(C-D)-2.0	F:(C-D)-2.0	
1	2	B-cell translocation gene 3; abundant in neuroepithelium area
NM_009993	F:(C-D)	cytochrome P450
NP_034123.1	-3.27	
		Subclass: cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 2; dioxin-inducible P3-450; P450 form 4; microsomal monooxygenase; xenobiotic monooxygenase; aryl hydrocarbon hydroxylase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1; flavoprotein-linked monooxygenase,
		oytoonisti 1-1-oo, aloonitiitaaside, alyi iyarooalboli iyarooyjase, 1-4oo loliil o, xenoblolic monooxygenase, microsomal monooxygenase ¯
		Subclass: cytochrome P450 CYP1B1
902200 MN	F:(C-D)	suppressor of cytokíne signaling-2; STAT induced STAT inhibitor-2; cytokine-inducible SH2 protein 2
NP_031732.1	-2.51	
NM_009396 NP_033422.1	F:(C-D) -2.5	F:(C-D) -2.5 tumor necrosis factor, alpha-induced protein 2

20

	Subclass:	Subclass: zinc finger protein 268
	Similar to	Similar to zinc finger protein 208
	Subclass:	Subclass: Zinc finger protein ZNF45
	Subclass:	Subclass: zinc finger protein 16 (KOX 9)
	Subclass:	Subclass: similar to Zinc finger protein 85
	Subclass:	Subclass: zinc finger protein 43 (HTF6)
	Subclass:	Subclass: similar to Zinc finger protein 35 (Zfp-35)
	Subclass:	Subclass: zinc finger protein 228
	Subclass:	Subclass: similar to Zinc finger protein 20 (Zinc finger protein KOX13) (DKFZp572P0920)
	Subclass:	Subclass: similar to Zinc finger protein 184
	Subclass:	Subclass: zinc finger protein 177
	Subclass:	Subclass: bB479F17.3 (zinc finger protein 41)
	Subclass:	Subclass: similar to Zinc finger protein 41
	Subclass:	Subclass: zinc finger protein 287
	Subclass:	Subclass: zinc finger protein 331; zinc finger protein 463; C2H2-like zinc finger protein
	Subclass:	Subclass: zinc finger protein 271
	Subclass:	Subclass: Hypothetical zinc finger protein KIAA1473
	Subclass:	Subclass: similar to Hypothetical zinc finger protein KIAA1473
	Subclass:	Subclass: similar to Hypothetical zinc finger protein KIAA1956
٠	Subclass:	Subclass: KRAB zinc finger protein
	Subclass:	Subclass: KIAA1956 protein
	Subclass:	TRAF6-inhibitory zinc finger protein; TRAF6-binding zinc finger protein
	Alternate:	Alternate: hypothetical protein
	Subclass:	Subclass: FLJ40981
	Subclass:	Subclass: similar to hypothetical protein FLJ40981
	Subclass:	Subclass: hypothetical protein FLJ21628
	Subclass:	Subclass: hypothetical protein FLJ32191
	Subclass:	Subclass: hypothetical protein DKFZp572C163.1
	Subclass:	Subclass: hypothetical protein FLJ30932
] Subclass:	Subclass: hypothetical protein FLJ14345

Subclass: hypothetical protein FLJ90396 Subclass: hypothetical protein DKFZp572P0920.1	argininosuccinate synthetase	Subclass: argininosuccinate synthetase Subclass: similar to argininosuccinate synthetase	proprotein convertase subtilisin/kexin type 2; subtilisin-like prohormone convertases; prohormone convertase 2; neuroendocrine convertase 2; KEX2-like endoprotease 2; proprotein convertase PC5	tubulin, beta polypeptide	Subclass: tubulin, beta, 2	Subclass: tubulin, beta, 4 (tubulin beta-III)	Subclass: tubulin, beta, 5	Subclass: tubulin beta-1	Subclass: similar to tubulin, beta 3	Subclass: tubulin, beta polypeptide 4, member Q	Subclass: beta tubulin 1, class VI	Subclass: similar to beta-tubulin 4Q	Alternative: similar to neu differentiation factor - human (fragment)		S-transf	Subclass: similar to Glutathione S-transferase Mu 1 (GSTM1-1) (HB subunit 4) (GTH4) (GSTM1a-1a) (GSTM1b-1b) (GST III)	class-mu 1)	Subclass: glutathione transferase M1
	F:(C-D)		F:(C-D) -2.35	F:(C-D)										F:(C-D)	-2.27			
	NM_007494		NM_008792 NP_032818.1	AK010786 BAB27182.1										NM_008183	NP_032209.1			

NM_012006 NP_036136.1	F:(C-D) F:(C-D)	Subclass: glutathione S-transferase M2; glutathione S-transferase M2; S-(Inydroxyalky))glutathione yase M2; glutathione S-araikyltransferase M3; glutathione S-araikyltransferase M3; glutathione S-araikyltransferase M3; glutathione S-araikyltransferase M5; glutathione S-araikyltransferase M5; glutathione S-araikyltransferase M5; glutathione S-araikyltransferase M5; glutathione S-araikyltransferase M5; GST class-mu 5 Subclass: glutathione S-transferase M4; glutathione B-araikyltransferase M5; GST class-mu 5 Subclass: glutathione S-transferase M4; glutathione S-araikyltransferase M4; GST class-mu 4 Subclass: glutathione S-transferase M4; S-(hydroxyalky))glutathione B-transferase, Mu-4; glutathione S-araikyltransferase M4; GST class-mu 4 Subclass: similar to glutathione S-transferase M2 (muscle) Subclass: similar to glutathione S-transferase M3 (GST class-mu 3) (hGSTM3-3) (GST class-mu 4 Subclass: similar to glutathione S-transferase M3 (GST class-mu 3) (hGSTM3-3) Subclass: similar to glutathione S-transferase M3 (GST class-mu 3) (hGSTM3-3) Subclass: similar to glutathione S-transferase M3 (GST class-mu 3) (hGSTM3-3) Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9 Subclass: glutathione S-transferase (EC 2.5.1.18) class-mu 9
BAB24656.1		Alternative: Unknown (protein for MGC:21737)
NM_010107 NP_034237.1	F:(C-D) 1 -2.18	ephrin-A1

 $\ddot{\vdash}$

 $\stackrel{\circ}{\circ}$

aldolase Subclass: Aldolase A; fructose-bisphosphate aldolase; Aldolase A, fructose-bisphosphatase Subclass: aldolase C, fructose-bisphosphate; Aldolase C, fructose-bisphosphatase	heat shock 10kDa protein 1 (chaperonin 10); heat shock 10kD protein 1 (chaperonin 10)	ribosomal protein	Subclass: ribosomal protein S7; 40S ribosomal protein S7 Subclass: similar to ribosomal protein S7	F:(C-D) -2.1 unnamed protein product		isocitrate dehydrogenase 2 (NADP+), mitochondrial; Isocitrate dehydrogenase, mitochondrial	CipX caseinolytic protease X homolog; energy-dependent regulator of proteolysis; ClpX (caseinolytic protease X, E. coli)	ORFII	Alternative: hypothetical protein FLJ20048 Alternative: putative p150	lipoprotein lipase
F:(C-D) -2.13	F:(C-D) -2.12	F:(C-D) -2.11		F:(C-D) -2.1		F:(C-D) -2.1	F:(C-D) -2.08	F:(C-D) -2.06		F:(C-D) -2.05, F:(HI-D) -2.42
NM_025754 NP_080030.1	NM_008303 NP_032329.1	NM_011300 NP 035430.1		AK011896	BAB27902.1	NM_008322 NP_032348.1	NM_011802 NP_035932.1	AK004138 BAB23187.1		NM_008509 F:(C-I NP_032535.1 -2.05, F:(HI-

		Subclass: Similar to lipoprotein lipase
		Subclass: lipoprotein lipase
NM_013541	F:(C-D)	glutathione S-transferase
NP_038569.1	-2.05	
		Subclass: glutathione transferase pi
		Subclass: glutathione S-transferase-P1c
		Subclass: Chain A, Glutathione S-Transferase P1-1
		Subclass: glutathione transferase; deafness, X-linked 7; fatty acid ethyl ester synthase III
NM_008756	F:(C-D)	occludin
ſ	-2.04	
NM_009349	F:(C-D)	Methyltransferase
NP_033375.1	-2.04	
		Subclass: Indolethylamine N-methyltransferase (Aromatic alkylamine N-methyltransferase) (Indolamine N-methyltransferase)
	•	(Arylamine N-methyltransferase) (Amine N-methyltransferase)
		Subclass: indolethylamine N-methyltransferase; thioester S-methyltransferase-like
		Subclass: thioether S-methyltransferase-like; similar to P40936 (PID:g731019)
		Subclass: nicotinamide N-methyltransferase
NM_023850	F:(C-D)	
NP_076339.1	-2.03	carbohydrate sulfotransferase
		Subclass: carbohydrate (keratan sulfate Gal-6) sulfotransferase 1; carbohydrate (chondroitin 6/keratan) sulfotransferase 1
		Subclass: carbohydrate (chondroitin 6) sulfotransferase 3; chondroitin 6-sulfotransferase
		Subclass: carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6; macular dystrophy, corneal, 1; carbohydate
		sulfotransferase 6; corneal N-acetylglucosamine 6-sulfotransferase
		Subclass: carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4; N-acetylglucosamine 6-O-sulfotransferase

Protein CGI-112	Alternate: similar to Protein CGI-112	aspartate aminotransferase	Subclass: aspartate aminotransferase 1; glutamic-oxaloacetic transaminase 1, soluble	Subclass: glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2)	Ornithine aminotransferase		proline dehydrogenase (oxidase) 1; proline oxidase 2; p53 induced protein		cytochrome P450	Subclass: Cytochrome P450 2A13 (CYPIIA13)	Subclass: coumarin 7-hydroxylase (EC 1.14.14) cytochrome P450 2A6 -	Subclass: Cytochrome P450 2A7 (CYPIIA7) (P450-IIA4)	Subclass: cytochrome P450 2A4 - human	Subclass: P-450 IIA3 protein (1 is 3rd base in codon)	Subclass: cytochrome P450, subfamily IIF, polypeptide 1; microsomal monooxygenase; xenobiotic monooxygenase;	flavoprotein-linked monooxygenase; similar to cytochrome P450, subfamily IIF, polypeptide 1 (H. sapiens)	Subclass: cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6	Subclass: cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),	polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked	monooxygenase	Subclass: Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) (P-450MP)
F:(C-D) -2.03		F:(C-D)			F:(C-D)	-2.01	F:(C-D) -2		F:(C-D) -2												
NM_033146 NP_149158.1		NM_010324 NP_034454.1			NM_016978	NP_058674.1	NM 011172	NP_035302.1	NM_013809 NP_038837.1												

		Subclass: cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4-hydroxylase;
		microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase
		Subclass: Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2) (S-mephenytoin 4-hydroxylase)
		Subclass: cytochrome P450, subfamily IIE, polypeptide 1; microsomal monooxygenase; xenobiotic monooxygenase;
		flavoprotein-linked monooxygenase; cytochrome P450, subfamily IIE (ethanol-inducible)
		Subclass: cytochrome P450, subfamily IIS, polypeptide 1; cytochrome P450 family member predicted from ESTs; cytochrome
		P540, subfamily IIS, polypeptide 1
		Subclass: cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2; microsomal monooxygenase;
		flavoprotein-linked monooxygenase; Cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase),
		Subclass: cytochrome P450, subfamily IID, polypeptide 6; debrisoquine 4-hydroxylase; microsomal monooxygenase;
		xenobiotic monooxygenase; flavoprotein-linked monooxygenase
		Subclass: Cytochrome P450 2C17
		Subclass: Cytochrome P450 2C18 (CYPIIC18) (P450-6B/29C)
NM_008184	F:(C-D)	glutathione transferase
NP_032210.1	-1.78	
		Subclass: Glutathione S-transferase Mu 1 (GSTM1-1) (HB subunit 4) (GTH4) (GSTM1a-1a) (GSTM1b-1b) (GST class-mu 1)
		Subclass: glutathione S-transferase M2; glutathione S-transferase 4; GST, muscle; GST class-mu 2; glutathione S-transferase
		Mu 2; glutathione S-alkyltransferase M2; glutathione S-aryltransferase M2; S-(hydroxyalkyl)glutathione lyase M2; glutathione
		S-aralkyltransferase M2
		Subclass: glutathione S-transferase M4 isoform 1; glutathione S-transferase, Mu-4; glutathione S-alkyltransferase M4;
		glutathione S-aryltransferase M4; S-(hydroxyalkyl)glutathione lyase M4; glutathione S-aralkyltransferase M4; GTS-Mu2; GST
		class-mu 4
		Subclass: glutathione S-transferase M5; glutathione S-transferase, Mu-5; glutathione S-alkyltransferase M5; glutathione
		S-aryltransferase M5; S-(hydroxyalkyl)glutathione lyase M5; glutathione S-aralkyltransferase M5; GST class-mu 5
		Subclass: glutathione transferase (EC 2.5.1.18) class mu, GSTM3 - human
AK003797	F:(C-D)	molybdenum cofactor sulfurase
BAB23001.1	-1.71	
		Alternate: Similar to molybdenum cofactor sulfurase

S80191	F:(C-D)	Unknown (protein for MGC:9220)
AAB21335.1 -1.61	-1.61	
		Alternate: carboxylesterase
		Subclass: carboxylesterase 1(monocyte/macrophage serine esterase 1); liver carboxylesterase; carboxylesterase 2 (liver)
		Subclass: acyl coenzyme A:cholesterol acyltransferase
		Subclass: brain carboxylesterase hBr1
		Subclass: brain carboxylesterase hBr2
		Subclass: egasyn
		Subclass: Liver carboxylesterase precursor (Acyl coenzyme A.cholesterol acyltransferase) (ACAT) (Monocyte/macrophage
		serine esterase) (HMSE) (Serine esterase 1) (Brain carboxylesterase hBr1)
		Subclass: carboxylesterase 3; brain carboxylesterase BR3
		Subclass: serine esterase N-terminal truncated (503 AA)
		Subclass: carboxylesterase 2; intestinal carboxylesterase; liver carboxylesterase-2
		Subclass: Similar to carboxylesterase 2 (intestine, liver)
AK014166	F:(C-D)	Delta(14)-sterol reductase (C-14 sterol reductase) (Sterol C14-reductase) (Delta14-SR) (Transmembrane 7 superfamily
BAB29187.1	-1.58	member 2) (Another new gene 1) (Putative sterol reductase SR-1)
		Alternate: Similar to transmembrane 7 superfamily member 2
		Alternate: Iamin B receptor
		Alternate: similar to Lamin B receptor (Integral nuclear envelope inner membrane protein) (LMN2R)
		Alternate: integers aniclose inner mambrana arrivain

Master Table 2: Subtable 2B Classes of Unfavorable Genes/Proteins

Mam	Већауло	Behāvio Human Protein Name
	ı	
NM_033373	U:(C-D) Keratin	Keratin
NP_203537.1	+7.74	
		Subclass: Keratin, type I cytoskeletal
		Subclass: Keratin, type I cytoskeletal 23 (Cytokeratin 23) (K23) (CK 23).
		Subclass: Keratin 23 isoform a; histone deacetylase inducible keratin 23;hyperacetylation-inducible type I keratin; keratin, type I cytoskeletal
		23; cytokeratin 23; type I intermediate filament
		cytokeratin
		Subclass: keratin 23 isoform b; histone deacetylase inducible keratin 23; hyperacetylation-inducible type I keratin; keratin, type I cytoskeletal
		23; cytokeratin 23; type I intermediate filament cytokeratin
		Subclass: cytokeratin 9
		Subclass: Keratin, type I cytoskeletal 10 (Cytokeratin 10) (K10) (CK 10).
		Subclass: keratin 12 (Meesmann corneal dystrophy); Keratin-12; keratin 12
		Subclass: keratin 13 isoform a; keratin, type I cytoskeletal 13; cytokeratin 13
		Subclass: keratin 13 isoform b; keratin, type I cytoskeletal 13; cytokeratin 13
		Subclass: keratin 14, type I, cytoskeletal
		Subclass: keratin 15; keratin-15, basic; keratin-15, beta; type I cytoskeletal 15; cytokeratin 15, (Cytokeratin 15) (K15) (CK 15)
		Subclass: keratin 16; keratin, type I cytoskeletal 16; cytokeratin 16
		Subclass: keratin 17
		Subclass: cytokeratin 18
		Subclass: Keratin, type I cytoskeletal 19 (Cytokeratin 19) (K19) (CK 19), 40-kd; cytokeratin 19; 40-kDa keratin intermediate filament
		precursor gene
		Subclass: keratin 20; cytokeratin 20; keratin, type I cytoskeletal 20
		Subclass: keratin 24
		Subclass: Keratin, type I cuticular HA1 (Hair keratin, type I HA1).
		Subclass: type I hair keratin 2; Ha-2; hard keratin, type I, 2; keratin, hair, acidic, 2

. كا

		Subclass: type I hair keratin 3A; Ha-3I; hard keratin, type I,3I; keratin, hair, acidic,3A
·		Subclass: type I hair keratin 3B; Ha-3II; hard keratin, type I, 3II; keratin, hair, acidic, 3B
		Subclass: Keratin, type I cuticular HA4 (Hair keratin, type I HA4).
		Subclass: type I hair keratin 5; Ha-5; hard keratin, type I, 5
		Subclass: type I hair keratin 6
		Subclass: type I hair ketatin, 7
		Subclass: Keratin, type I cuticular HA8 (Hair keratin, type I HA8).
		Subclass: type I intermediate, filament cytokeratin
NM_007702	U:(C-D)	U:(C-D) cell death activator CIDE-A
NP_031728.1	+4.7	
		Alternate: Similar to cell death-inducing DFFA-like effector a
AK013885	(C-D)	BRCA1 associated protein
NP 082503.1	+4.18	
		Subclass: BRCA1-associated protein 2
		Subclass: putative DDB p127-associated protein
	Ω:(C-D)	
NP 036125.2	+4.17	presynaptic cytomatrix protein
		Subclass: Piccolo protein (Aczonin).
		Alternate: Zinc finger protein
NM_013623	U:(C-D)	
NP_038651.1	+4.05	Glycoprotein
		Subclass: Orosomucoid-1 (alpha-1-acid glycoprotein-1); alpha-1-acid glycoprotein 1
		Subclass: orosomucoid 2; alpha-1-acid glycoprotein, type 2
NM_008484	(a-ɔ):n	
NP_032510.1	+4.05	Laminin
		Subclass: Laminin beta chain

	Subclass: Jaminin, beta 1
	Subclass: beta2/S laminin chain
	Subclass: Laminin beta-2 chain (S-laminin) (Laminin B1s chain).
	Subclass: Laminin beta-3 chain (Laminin 5 beta 3) (Laminin B1k chain) (Kalinin B1 chain).
	Subclass: laminin S B3 chain
	Subclass: Laminin alpha chain
	Subclass: Laminin alpha-1 chain precursor (Laminin A chain).
	Subclass: laminin alpha 3b chain
	Subclass: laminin alpha 5; laminin alpha-5 chain
	Subclass: Laminin gamma chain
	Subclass: Laminin gamma-3 chain (Laminin 12 gamma 3).
	Alternate: Usher syndrome type IIa protein
	Alternate: netrin
	Subclass: netrin 4; beta-netrin
	Subclass: netrin 1; netrin 1, mouse, homolog of
NM_013786 U:(C-D)	-D) sterol/retinol dehydrogenase
NP_038814.1 +3.68	
	Subclass: 3-hydroxysteroid epimerase; oxidative 3-alpha-hydroxysteroid-dehydrogenase; 3(alpha->beta)-hydroxysteroid epimerase; retinol
	dehydrogenase; oxidoreductase; NAD+ -dependent 3 alpha-hydroxysteroid dehydrogenase
	Subclass: nicrosomal NAD+-dependent retinol dehydrogenase 4
	Subclass: orphan short-chain dehydrogenase / reductase; retinol dehydrogenase similar protein
	Subclass: 11-cis retinol dehydrogenase (11-cis RDH).
	Subclass: retinol dehydrogenase 5 (11-cis and 9-cis); retinol dehydrogenase 5 (11-cisand 9-cis)
	Subclass: retinol dehydrogenase homolog isoform-1
NM_009345 U:(C-D)	·D
NP 033371.1 +3.66	6 DNA synthesizing/modifying enzymes
	Subclass: DNA nucleotidylexotransferase (Terminal addition enzyme) (Terminal deoxynucleotidyltransferase) (Terminal transferase).
	Subclass: polymerase (DNA directed), mu; polymerase (DNA-directed), mu; pol iota

S

10

15

7

NM_013703	U:(C-D)	U:(C-D) Lipoprotein Receptor
NP 038731.1	+3.61	
		Subclass: very low density lipoprotein receptor
		Subclass: low density lipoprotein receptor; LDL receptor; LDLR precursor
		Subclass: apolipoprotein E receptor 2 isoform 1 precursor; apolipoprotein E receptor 2
		Subclass: apolipoprotein E receptor 2 isoform 2 precursor; apolipoprotein E receptor 2
		Subclass: apolipoprotein E receptor 2 isoform 3 precursor; apolipoprotein E receptor 2
		Subclass: low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)
		Subclass: 1ow density lipoprotein-related protein 2; megalin
1000		Subclass: low density lipoprotein-related protein 1B (deleted in tumors); low density lipoprotein receptor related protein-deleted in tumor
		Subclass: LDL receptor member LR3
		ISubclass: ow density lipoprotein receptor-related protein 5; low density lipoprotein receptor-related protein 7; osteoporosis pseudoglioma
		syndrome
		Subclass: low density lipoprotein receptor-related protein 6; low density lipoprotein-related protein 6
		Subclass: apolipoprotein E receptor 2 906
		Subclass: glycoprotein 330
		Subclass: MEGF7
		Subclass: similar to MEGF7
NM_022414	U:(C-D)	
NP_071859.1	+3.28	oxygen-binding respiratory protein
		Subclass: neuroglobin
NM_011313	U:(C-D)	
NP 035443.1	+2.77	Calcium-binding protein
		Subclass: S100 calcium-binding protein A6; calcyclin; prolactin receptor-associated protein

	U:(C-D)	
	+2.7	
AK005519	U:(C-HI	
149390)+2.7	Major epididymis-specific protein E4 precursor (HE4) (Epididymal secretory protein E4) (WAP four-disultide core domain protein 2)
	U:(C-D)	
NP 032771.1	+2.68	l yrosine Kinase Keceptor
		Subclass: brain-derived neurotrophic factor receptor precursor, short splice form
		Subclass: neurotrophic tyrosine kinase, receptor, type 2
	٠	Subclass: BDNF/NT-3 growth factors receptor precursor (TrkB tyrosine kinase) (GP145-TrkB) (Trk-B).
		Subclass: NT-3 growth factor receptor precursor (TrkC tyrosine kinase) (GP145-TrkC) (Trk-C
1		Subclass: neurotrophic tyrosine kinase, receptor, type 3
	-	Subclass: neurotrophic tyrosine kinase, receptor, type 1; Oncogene TRK
NM_008063	U:(C-D)	
NP 032089.1	+2.68	glucose-6-phosphate transporter
		Subclass: glucose-6-phosphatase, transport (glucose-6-phosphate) protein 1; Glucose-6-phosphate transporter-1
NM_019696	U:(C-D)	
NP_062670.1	+2.66	carboxypeptidase
		Subclass: adipocyte enhancer binding protein 1 precursor; AE-binding protein 1; adipocyte transcription factor, AEBP1; aortic
		carboxypeptidase-like protein
		Subclass: metallocarboxypeptidase CPX-1 precursor
		Subclass: Potential carboxypeptidase X precursor (Metallocarboxypeptidase CPX-1).
		Subclass: carboxypeptidase D
		Subclass: carboxypeptidase E
		Subclass: carboxypeptidase M
·		Subclass: carboxypeptidase N, polypeptide 1
		Subclass: Similar to carboxypeptidase X (M14 family)

		0.1.1. 0.11. 1
		Subclass: Sumilar to Carooxypepudase & Subclass: similar to Potential carboxmentidase like arotein X2 arequeor
		Subclass: Potential carboxynentidase-like nrotein X2 nrecursor
NM_053261	U:(C-D)	
NP_444491.1	+2.63	inositol monophosphatase
		Subclass: inositol(myo)-1(or 4)-monophosphatase 1
		Subclass: inositol(myo)-1(or 4)-monophosphatase 2
		Subclass: brain myo-inositol monophosphatase A2b; IMPase A2b
	·	Subclass: Chain A, Human Inositol Monophosphatase (E.C.3.1.3.25) Dimer Complex With Gadolinium And Sulfate
NM_008218	(C-D)	U.(C-D) Hemoglobin
NP_032244.1	+2.6	
		Subclass: hemoglobin alpha-1 globin chain
	·	Subclass: hemoglobin alpha-2
NM_018887	U:(C-D)	
NP_061375.1	+2.54	Cyytochrome P450
		Subclass: cytochrome P450, family 39, subfamily A, polypeptide 1; oxysterol 7alpha-hydroxylase; cytochrome P450, subfamily XXXIX
		(oxysterol 7 alpha-hydroxylase), polypeptide 1
NM_009148	U:(C-D)	
NP_033174.1	+2.45	Exocyst complex component
		Subclass: Exocyst complex component Sec8
NM_013790	U:(C-D)	
NP_038818.1	+2.45	Multidrug resistance-associated protein (Multi-specific organic anion tranporter; ATP-binding cassette
		Subclass: Multidrug resistance-associated protein 5 (Multi-specific organic anion tranporter-C) (MOAT-C) (pABC11) (SMRP).
		Subclass: ATP-binding cassette, sub-family C, member 5; canalicular multispecific organic anion transporter C
		Subclass: ATP-binding cassette protein C11

	Subclass: ATP-binding cassette, sub-family C, member 11 isoform a; multi-resistance protein 8; ATP-binding cassette transporter MRP8;
	ATP-binding cassette protein C11
	Subclass: ATP-binding cassette, sub-family C, member 11 isoform b; multi-resistance protein 8; ATP-binding cassette transporter MRP8;
	ATP-binding cassette protein C11
	Subclass: ATP-binding cassette, sub-family C, member 12 isoform a; multidrug resistance-associated protein 9
	Subclass: ATP-binding cassette, sub-family C, member 12 isoform b; multidrug resistance-associated protein 9
	Subclass: ATP-binding cassette, sub-family C, member 12 isoform e; multidrug resistance-associated protein 9
	Subclass: ATP-binding cassette, sub-family C, member 1 isoform 1; multiple drug resistance-associated protein; multiple drug resistance
	protein 1; multidrug resistance protein
	Subclass: ATP-binding cassette, sub-family C, member 1 isoform 2; multiple drug resistance-associated protein; multiple drug resistance
	protein 1; multidrug resistance protein
	Subclass: ATP-binding cassette, sub-family C, member 1 isoform 3; multiple drug resistance-associated protein; multiple drug resistance
	protein 1; multidrug resistance protein
	Subclass: ATP-binding cassette, sub-family C, member 1 isoform 4; multiple drug resistance-associated protein; multiple drug resistance
	protein 1; multidrug resistance protein
	Subclass: ATP-binding cassette, sub-family C, member 1 isoform 5; multiple drug resistance-associated protein; multiple drug resistance
	protein 1; multidrug resistance protein
	Subclass: ATP-binding cassette, sub-family C, member 1 isoform 6; multiple drug resistance-associated protein; multiple drug resistance
	protein 1; multidrug resistance protein
	Subclass: ATP-binding cassette, sub-family C, member 1 isoform 7; multiple drug resistance-associated protein; multiple drug resistance
	protein 1; multidrug resistance protein
	Subclass: ATP-binding cassette, sub-family C (CFTR/MRP), member 2; canalicular multispecific organic anion transporter
,	Subclass: ATP-binding cassette, sub-family C, member 9 isoform SUR2B; sulfonylurea receptor 2A
	Subclass: ATP-binding cassette, sub-family C, member 3 isoform MRP3A; canicular multispecific organic anion transporter
	Subclass: ATP-binding cassette, sub-family C, member 4; canalicular multispecific organic anion transporter (ABC superfamily)
·	Subclass: ATP-binding cassette, subfamily B, member 4 isoform A; P glycoprotein 3/multiple drug resistance 3; P-glycoprotein-3/multiple
	drug resistance-3; multiple drug resistance 3
	Subclass: ATP-binding cassette, subfamily B, member 4 isoform B; P glycoprotein 3/multiple drug resistance 3; P-glycoprotein-3/multiple
	drug resistance-3; multiple drug resistance 3

'n

		Subclass: ATP-binding cassette, subfamily B, member 4 isoform C; P glycoprotein 3/multiple drug resistance 3; P-glycoprotein-3/multiple
		drug resistance-3; multiple drug resistance 3
		Subclass: ATP-binding cassette, sub-family C, member 6; anthracycline resistance-associated
		Subclass: cystic fibrosis transmembrane conductance regulator, ATP-binding cassette (sub-family C, member 7); cystic fibrosis transmembrane
		conductance regulator; ATP-binding cassette, sub-family C member 7; CFTR/MRP
		Subclass: ATP-binding cassette, sub-family C, member 8; Sulfonylurea receptor; sulfonylurea receptor (hyperinsulinemia)
		Subclass: ATP-binding cassette, sub-family C, member 9 isoform SUR2A-delta-14; sulfonylurea receptor 2A
		Subclass: ATP-binding cassette, sub-family C, member 10; multidrug resistance-associated protein 7
		Subclass: ATP-binding cassette, sub-family B (MDR/TAP), member 1; P glycoprotein 1/multiple drug resistance 1; P-glycoprotein-1/multiple
		drug resistance-1; multidrug resistance 1
		Subclass: Cystic fibrosis transmembrane conductance regulator (CFTR) (cAMP-dependent chloride channel).
	Ŀ	
NM_008532	U:(C-D)	
NP_032558.1	+2.41	Membrane glycoprotein
		Subclass: Cell-surface receptor
		Subclass: Tumor-associated calcium signal transducer 1 precursor (Major gastrointestinal tumor-associated protein GA733-2) (Epithelial cell
		surface antigen) (Epithelial glycoprotein) (EGP) (Adenocarcinoma-associated antigen) (KSA) (KS 1/4 antigen) (Cell surface glycoprotein
		Trop-1).
		Subclass: tumor-associated calcium signal transducer 1 precursor; membrane component, chromosome 4, surface marker (35kD glycoprotein);
		MK-1 antigen; antigen identified by monoclonal antibody AUA1
		Subclass: tumor-associated calcium signal transducer 2 precursor; membrane component, chromosome 1, surface marker 1 (40kD glycoprotein
	;	identified by monoclonal antibody GA733); epithelial glycoprotein-1
		Subclass: Tumor-associated calcium signal transducer 2 precursor (Pancreatic carcinoma marker protein GA733-1) (Cell surface glycoprotein
		Trop-2).
NM_013722	U:(C-D)	
NP_038750.1	+2.35	Regulator of neurotransmitter release
		Subclass: Synapsins
		Subclass: Synapsin III
		Subclass: synapsin III isoform IIIa

		Subclass: synapsin III isoform IIIc
		Subclass: synapsin III isoform IIIb
		Subclass: Synapsin II
		Subclass: synapsin II isoform IIa
		Subclass: synapsin II isoform IIb
		Subclass: Synapsin I (Brain protein 4.1).
		Subclass: synapsin I isoform Ia; brain protein 4.1
		Subclass: synapsin I isoform Ib; brain protein 4.1
NM_008439	U:(C-D)	
NP 032465.1	+2.35	Fructose metabolizing enzymes
		Subclass: ketohexokinase
		Subclass: ketohexokinase isoform a
		Subclass: ketohexokinase isoform b
NM_007408	U:(C-D)	
NP_031434.1	+2.35	Lipid storage proteins
		Subclass: Adipophilin (Adipose differentiation-related protein) (ADRP).
		Subclass: Cargo selection protein TP47 (47 kDa mannose 6-phosphate receptor-binding protein) (47 kDa MPR-binding protein) (Placental
		protein 17).
NM_011200	(C-D):N	
NP_035330.1	+2.3	protein tyrosine phosphatase
		Subclass: protein tyrosine phosphatase type IV
		Subclass: protein tyrosine phosphatase type IVA, member 1; Protein tyrosine phosphatase IVA1
		Subclass: protein tyrosine phosphatase type IVA, member 2 isoform 1; protein tyrosine phosphatase IVA2; protein tyrosine phosphatase IVA;
		phosphatase of regenerating liver 2
		Subclass: ptp-IV1b, PTP-IV1 gene product
		Subclass: protein tyrosine phosphatase type IVA, member 3 isoform 1; potentially prenylated protein tyrosine phosphatase
		Subclass: protein tyrosine phosphatase type IVA, member 3 isoform 2; potentially prenylated protein tyrosine phosphatase

NM_007405	U:(C-D)	
NP_031431.1	+2.29	Adenylate cyclase
		Subclass: Adenylate cyclase, type I (ATP pyrophosphate-lyase) (Ca(2+)/calmodulin activated adenylyl cyclase).
		Subclass: adenylate cyclase 2; ATP pyrophosphate-lyase; type II adenylate cyclase; adenylyl cyclase 2; adenylate cyclase II; 3,5'-cyclic AMP
		synthetase
		Subclass: adenylate cyclase 3; adenylyl cyclase, type III; ATP pyrophosphate-lyase
ŕ		Subclass: adenylate cyclase 4; adenylate cyclase type IV
	·	Subclass: Adenylate cyclase, type V (ATP pyrophosphate-lyase) (Adenylyl cyclase).
		Subclass: adenylyl cyclase type VI
	,	Subclass: adenylate cyclase 6 isoform a
		Subclass: adenylate cyclase 6 isoform b
		Subclass: adenylate cyclase 7
		Subclass: adenylate cyclase 8; Adenylyl cyclase-8, brain
		Subclass: Adenylate cyclase, type IX (ATP pyrophosphate-lyase) (Adenylyl cyclase).
AK007384	U:(C-D)	sulfotransferase
BAB25002.1	+2.27	
		Subclass: sulfotransferase family, cytosolic, 1C, member 1 isoform a; sulfotransferase 1C1
		Subclass: sulfotransferase family, cytosolic, 1C, member 2; sulfotransferase family, cytosolic, 1C, member C2; sulfotransferase 1C2
		Subclass: Phenol-sulfating phenol sulfotransferase 1 (P-PST) (Thermostable phenol sulfotransferase) (Ts-PST) (HAST1/HAST2) (ST1A3).
		Subclass: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2; thermostable phenol sulfotransferase; phenolic-metabolizing (P)
	,	form of PST; arylamine sulfotransferase; aryl sulfotransferase; phenol-preferring phenol sulfotransferase2; phenol-sulfating phenol
		sulfotransferase 2
	,	Subclass: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3; thermolabile phenol sulfotransferase; catecholamine-sulfating
		phenol sulfotransferase; aryl sulfotransferase; thermolabile (monoamine, M form) phenol sulfotransferase; monoamine-sulfating
		phenosulfotransferase; placental estrogen sulfotransferase; monoamine-preferring sulfotransferase
	 	Subclass: Alcohol sulfotransferase (Hydroxysteroid Sulfotransferase) (HST) (Dehydroepiandrosterone sulfotransferase) (DHEA-ST) (ST2)
		(ST2A3).
		Subclass: hydroxysteroid sulfotransferase SULT2B1a

Subclass: hydroxysteroid sulfotransferase SULT2B1b Subclass: thyroid hormone sulfotransferase	Subclass: pleckstrin 2; pleckstrin 2 (mouse) homolog	synaptotagmin-like proteins Subclass: synaptotagmin-like 4 (granuphilin-a) Subclass: bA524D16A.2.1 (novel protein similar to mouse granuphilin-a) Subclass: bA524D16A.2.2 (novel protein similar to mouse granuphilin-b) Subclass: synaptotagmin-like 5 Subclass: synaptotagmin-like 2 isoform b; chromosome 11 synaptotagmin Subclass: synaptotagmin-like 2 isoform a; chromosome 11 synaptotagmin	Subclass: Transforming growth factor Subclass: Transforming growth factor beta Subclass: Transforming growth factor beta 1 (TGF-beta 1). Subclass: transforming growth factor beta 2 Subclass: transforming growth factor beta 2 Subclass: transforming growth factor-beta 3	Protein containing pleckstrin homology-like domain Subclass: pleckstrin homology-like domain, family A, member 3; pleckstrin homology-like domain, family A, member 2
Ø Ø	U:(C-D) +2.25 Pi Si Si	U:(C-D) +2.22 sy Sy Sy Sy Sy Sy Sy Sy Sy Sy Sy Sy Sy Sy		U:(C-D) +2.21 Pr
	NM_013738 NP_038766.1	NM_013757 NP_038785.1		NM_013750 NP_038778.1

008471	U:(C-D) Keratin	Keratin
NF 05497.1	17:71	Subclass: cytokeratin 9
		Subclass: Keratin, type I cytoskeletal 10 (Cytokeratin 10) (K10) (CK 10).
		Subclass: Keratin-12
		Subclass: keratin 13, type I, cytoskeletal
		Subclass: keratin 14, type I, cytoskeletal
		Subclass: keratin 15; keratin-15, basic; keratin-15, beta; type I cytoskeletal 15; cytokeratin 15
		Subclass: keratin 16, type I, cytoskeletal
		Subclass: keratin 17
		Subclass: keratin 18
		Subclass: keratin 19; keratin, type I cytoskeletal 19; keratin, type I, 40-kd; cytokeratin 19; 40-kDa keratin intermediate manicul procusor gong
		Subclass: keratin 20; cytokeratin 20; keratin, type I cytoskeletal 20
		Subclass: Keratin, type I cytoskeletal 23 (Cytokeratin 23) (K23) (CK 23).
	-	Subclass: keratin 24
		Subclass: type I hair keratin 1; Ha-1; hard keratin, type I, 1; keratin, hair, acidic, I
		Subclass: type I hair keratin 2; Ha-2; hard keratin, type I, 2; keratin, hair, acidic, 2
		Subclass: Keratin, type I cuticular HA3-I (Hair keratin, type I HA3-I).
	٠	Subclass: type I hair keratin 3A; Ha-3I; hard keratin, type I,3I; keratin, hair, acidic,3A
10年10年		Subclass: type I hair keratin 3B; Ha-3II; hard keratin, type I, 3II; keratin, hair, acidic, 3B
		Subclass: hair keratin acidic 3-II
		Subclass: Keratin, type I cuticular HA4 (Hair keratin, type I HA4).
n.d		Subclass: Keratin, type I cuticular HA5 (Hair keratin, type I HA5).
		Subclass: type I hair keratin 6
		Subclass: type I hair keratin 7
		Subclass: type I hair keratin 8
NM_010707	U:(C-D)	
NP_034837.1	+2.2	galectin
		Subclass: galectin 4; lectin galactoside-binding soluble 4
	-	

NM_010003	U:(C-D)	
NP_034133.1	+2.18	cytochrome P450
		Subclass: cytochrome P450, family 2
		Subclass: cytochrome P450, family 2, subfamily C
		Subclass: cytochrome P450, family 2, subfamily C, polypeptide 18; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
		polypeptide 17; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; microsomal monooxygenase;
		flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, family 2, subfamily C, polypeptide 19; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
		polypeptide 19; mephenytoin 4'-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450 arachidonic acid epoxygenase isoform, Cyp 2C8 [human, kidney, Peptide Partial, 485 aa].
		Subclass: cytochrome P450, family 2, subfamily C, polypeptide 8 isoform 1; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
		polypeptide 8; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase;
		P450 form 1
		Subclass: cytochrome P450, family 2, subfamily C, polypeptide 8 isoform 2; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
•		polypeptide 8; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase;
		P450 form 1
		Subclass: cytochrome P450, family 2, subfamily C, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide
		10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase; cytochrome
		P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 9
		Subclass: Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) (P-450MP).
		Subclass: cytochrome P450, family 2, subfamily A
		Subclass: cytochrome P450, family 2, subfamily A, polypeptide 6; coumarin 7-hydroxylase; cytochrome P450, subfamily IIA
		(phenobarbital-inducible), polypeptide 3; cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6; xenobiotic
		monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, family 2, subfamily A, polypeptide 7 isoform 1; cytochrome P450, subfamily IIA (phenobarbital-inducible),
		polypeptide 7
		Subclass: cytochrome P450, family 2, subfamily A, polypeptide 13; cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 13
		Subclass: cytochrome P450 family 2 subfamily B
		Subclass: Mochrome PASO family 2 subfamily B notimentide 6: outschrome DASO subfamily ITB (nhenohorbited industible) notimentide 6
		oucciass: you must resu, taimiy 2, suotaimiy b, polypeptide o; cytochrome resu, suotaimiy 11b (phenobarottal-inducible), polypeptide o

		Cit. C. Corre
		Subclass: cytochrome P450, subtarnily IID
		Subclass: cytochrome P450, subfamily IID, polypeptide 6; debrisoquine 4-hydroxylase; microsomal monooxygenase; xenobiotic
		monooxygenase;
		flavoprotein-linked monooxygenase; cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing)-like 1
		Subclass: cytochrome P450, family 2, subfamily E
		Subclass: cytochrome P450, family 2, subfamily E, polypeptide 1; cytochrome P450, subfamily IIE (ethanol-inducible), polypeptide 1;
		microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase; cytochrome P450, subfamily IIE
	-	(ethanol-inducible)
		Subclass: cytochrome P450, family 2, subfamily F
	, .	Subclass: cytochrome P450, family 2, subfamily F, polypeptide 1; cytochrome P450, subfamily IIF, polypeptide 1; microsomal
		monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, family 2, subfamily J
		Subclass: cytochrome P450, family 2, subfamily J, polypeptide 2; cytochrome P450, subfamily IIJ (arachidonic acid epoxygenase) polypeptide
		2; microsomal monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, family 2, subfamily S
		Subclass: cytochrome P450, family 2, subfamily S, polypeptide 1; cytochrome P450 family member predicted from ESTs; cytochrome P540,
		subfamily IIS, polypeptide 1; cytochrome P450, subfamily IIS, polypeptide 1
		Subclass: cytochrome P450, family 1
		Subclass: cytochrome P450, family 1, subfamily A
		Subclass: cytochrome P450, family 1, subfamily A, polypeptide 1; aryl hydrocarbon hydroxylase; cytochrome P450, subfamily I (aromatic
	.=	compound-inducible), polypeptide 1; flavoprotein-linked monooxygenase; cytochrome P1-450, dioxin-inducible; P450 form 6; xenobiotic
		monooxygenase; microsomal monooxygenase
		Subclass: cytochrome P450, family 1, subfamily B
		Subclass: cytochrome P450, family 1, subfamily B, polypeptide 1; aryl hydrocarbon hydroxylase; cytochrome P450, subfamily I
	,	(dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile); microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked
		топоохуденаѕе
NM_019875	U:(C-D)	U:(C-D) ABC-transporter; peptide transporter; ATP-binding cassette
NP_063928.1	+2.17	
		Subclass: ATP-binding cassette, sub-family B, member 9 isoform 1

	Subclass: ATP-binding cassette, sub-family B, member 9 isoform 2
·	Subclass: transporter 2, ATP-binding cassette, sub-family B isoform 1; transporter 2, ABC (ATP binding cassette); ATP-binding cassette, sub-family B (MDR/TAP), member 3; antigen peptide transporter 2; peptide transporter PSF2; ABC transporter, MHC
	Subclass: transporter 1, ATP-binding cassette, sub-family B; ATP-binding cassette, sub-family B (MDR/TAP), member 2; antigen peptide
	transporter 1; ATP-binding cassette, sub-family B, member 2; transporter, ATP-binding cassette, major histocompatibility complex, 1; ABC
	transporter, MHC 1; peptide supply factor 1 Substant Antion neartide frommorter 1 (ADT1) (Partide frommorter DAT1) (Partide from 1) (DAT 1)
	Substance in a supplied in antigen processing 1).
	Subclass: Antigen peptide transporter 2 (APT2) (Peptide transporter TAP2) (Peptide transporter PSF2) (Peptide supply factor 2)
	(PSF-2)(Peptide transporter involved in antigen processing 2).
	Subclass: transporter 2, ATP-binding cassette, sub-family B isoform 2; transporter 2, ABC (ATP binding cassette); ATP-binding cassette,
	sub-family B (MDR/TAP), member 3; antigen peptide transporter 2; peptide supply factor 2; peptide transporter PSF2; ABC transporter,
	MHC 2
	Subclass: ATP-binding cassette, subfamily B, member 4 isoform A; P glycoprotein 3/multiple drug resistance 3; P-glycoprotein-3/multiple
	drug resistance-3; multiple drug resistance 3
	Subclass: ATP-binding cassette, subfamily B, member 4 isoform B; P glycoprotein 3/multiple drug resistance 3; P-glycoprotein-3/multiple
	drug resistance-3; multiple drug resistance 3
	Subclass: ATP-binding cassette, subfamily B, member 4 isoform C; P glycoprotein 3/multiple drug resistance 3; P-glycoprotein-3/multiple
	drug resistance-3; multiple drug resistance 3
	Subclass: ATP-binding cassette, sub-family B, member 6
	Subclass: ATP-binding cassette, sub-family B, member 7, mitochondrial precursor (ATP-binding cassette transporter 7) (ABC transporter 7
·	protein).
	Subclass: ATP-binding cassette, sub-family B, member 8, mitochondrial precursor (Mitochondrial ATP-binding cassette 1) (M-ABC1).
	Subclass: ATP-binding cassette, sub-family B, member 10
-	Subclass: ATP-binding cassette, sub-family B (MDR/TAP), member 11; ABC member 16, MDR/TAP subfamily; progressive familial
	intrahepatic cholestasis 2; bile salt export pump
T	
	U.(C-D) amyloid protein
NP_031497.1 +2	+2.16

Subclass: amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease); Amyloid beta (A4) precursor protein; amyloid beta-peptide Subclass: amyloid precursor protein homolog HSD-2 Subclass: amyloid A4 protein	neuro-oncological ventral antigen Subclass: neuro-oncological ventral antigen 1 isoform 1; Neurooncological ventral antigen 1; paraneoplastic Ri antigen Subclass: neuro-oncological ventral antigen 1 isoform 2; Neurooncological ventral antigen 1; paraneoplastic Ri antigen Subclass: neuro-oncological ventral antigen 2; neuro-oncological ventral antigen 3 Subclass: astrocytic NOVA-like RNA-binding protein Subclass: RNA-binding protein Nova-2 [AA 29-492]; astrocytic NOVA-like RNA-binding protein	3-hydroxyacyl-CoA dehydrogenase Subclass: Short chain 3-hydroxyacyl-CoA dehydrogenase, mitochondrial precursor (HCDH) (Medium and short chain 2-hydroxyacyl-coenzyme A dehydrogenase). L-3-hydroxyacyl-coenzyme A dehydrogenase, isoform 2	Down syndrome critical protein Subclass: Down syndrome critical region protein 3; Down syndrome critical region protein A Subclass: Down syndrome critical protein A - human	4 monooxygenase Subclass: Flavin containing monooxygenase 1; Flavin-containing monooxygenase 2; Flavin containing monooxygenase 2; Flavin-containing monooxygenase 2 (adult liver)
	U:(C-D) +2.15	U:(C-D) +2.15	U:(C-D) +2.14	U:(C-D) +2.14
	AF232828 AAF35907.1	NM_008212 NP_032238.1	NM_007834 NP_031860.1	NM_008030

		Subclass: Dimethylaniline monooxygenase [N-oxide forming] 2 (Pulmonary flavin-containing monooxygenase 2) (FMO 2) (Dimethylaniline
		oxidase 2) (FMO 1B1).
		Subclass: Flavin containing monooxygenase 3
		Subclass: Dimethylaniline monooxygenase [N-oxide forming] 3 (Hepatic flavin-containing monooxygenase 3) (FMO 3) (Dimethylaniline
		oxidase 3) (FMO form 2) (FMO II).
		Subclass: flavin containing monooxygenase 4
		Subclass: flavin containing monooxygenase 5
		Subclass: Dimethylaniline monooxygenase [N-oxide forming] 5 (Hepatic flavin-containing monooxygenase 5) (FMO 5) (Dimethylaniline
		oxidase 5).
		Subclass: dimethylaniline monooxygenase [N-oxide forming] 6 (Flavin-containing monooxygenase 6) (FMO 6) (Dimethylaniline oxidase 6).
NM_009073	U:(C-D)	
NP_033099.1	+2.13	retinal outer segment membrane protein _
		Subclass: retinal outer segment membrane protein 1; rod outer segment membrane protein 1
NM_020568	U:(C-D)	
NP_065593.1	+2.12	KIAA1881 protein
NM_033327	U:(C-D)	
NP_201584.1	+2.12	zinc finger protein
		Subclass: OLF-1/EBF associated zinc finger protein; Smad- and Olf-interacting zinc finger protein
		Subclass: FLJ00107 protein
		Subclass: zinc finger protein 91 (HPF7, HTF10)
		Subclass: zinc finger protein 208
NM_010902	U:(C-D)	
NP_035032.1	+2.11	Nuclear transcription factor
		Subclass: transcription factor Nrf1
		Subclass: transcription factor Nrf2
		Subclass: nuclear factor (erythroid-derived 2)-like 1; transcription factor 11 (basic leucine zipper type)

		Subclass: nuclear factor (erythroid-derived 2)-like 2
· ·		Subclass: transcription factor LCR-F1.
14.38		
NM_010217	U:(C-D)	
NP_034347.1	+2.1	growth factor
		Subclass: connective tissue growth factor
		Subclass: CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61) (Insulin-like growth factor-binding protein 10) (GIG1 protein).
		Subclass: WNT1 inducible signaling pathway protein 1 isoform 1 precursor; wnt-1 signaling pathway protein 1; Wnt1 signaling pathway
		protein 1; Wnt-1 inducible signaling pathway protein 1
		Subclass: WNT1 inducible signaling pathway protein 2 precursor; wnt-1 signaling pathway protein 2; connective tissue growth factor-like
		protein
		Subclass: WNT1 inducible signaling pathway protein 3 isoform 1; wnt-1 signaling pathway protein 3; Wnt1 signaling pathway protein 3;
		Wnt-1 inducible signaling pathway protein 3
		Subclass: WNT1 inducible signaling pathway protein 3 isoform 2; wnt-1 signaling pathway protein 3; Wnt1 signaling pathway protein 3;
		Wnt-1 inducible signaling pathway protein 3
		Subclass: bA6918.1 (connective tissue growth factor)
NM_011812	U:(C-D)	
NP_035942.1	+2.1	glycoprotein
	٠.	Subclass: Fibulin
	·	Subclass: EGF-containing fibulin-like extracellular matrix protein 2 precursor (Fibulin-4) (FIBL-4) (UPH1 protein).
		Subclass: fibulin 5 precursor; urine p50 protein; developmental arteries and neural crest epidermal growth factor-like
		Subclass: EGF-containing fibulin-like extracellular matrix protein 1 isoform a precursor; fibrillin-like
9		Subclass: EGF-containing fibulin-like extracellular matrix protein 1 isoform b; fibrillin-like
		Subclass: fibulin 1
		Subclass: fibulin 2
NM_011391	U:(C-D)	
NP_035521.1	+2.08	Monocarboxylate transporter
		Subclass: solute carrier family 16 (monocarboxylic acid transporters), member 7; Monocarboxylate transporter 2 (MCT 2).

	-	
		Subclass: monocarboxylate transporter isoform 1
-		Subclass: solute carrier family 16 (monocarboxylic acid transporters), member 1
٠.		Subclass: monocarboxylate transporter 1
		Subclass: solute carrier family 16 (monocarboxylic acid transporters), member 3; monocarboxylate transporter 3 Subclass: Monocarboxylate transporter 3 (MCT 3)
		Subclass: solute carrier 16 (monocarboxylic acid transporters), member 8, monocarboxylate transporter 3
		Subclass: solute carrier family 16 (monocarboxylic acid transporters), member 5; monocarboxylate transporter 5
NM 010225	U:(C-D)	
NP_034355.1	+2.08	Transcription factor
		Subclass: Torkhead box F1; Torkhead (Drosophila)-like 3; Forkhead, drosophila, homolog-like 3; Torkhead-felated achvator 1
		Subclass: forkhead box F2; forkhead (Drosophila)-like 6
NM_011851	U:(C-D)	
NP_035981.1	+2.08	nucleotidase
		Subclass: 5' nucleotidase, ecto; Purine 5-Prime-Nucleotidase; 5' nucleotidase (CD73); ecto-5'-nucleotidase
NM_019759	U:(C-D)	
NP 062733.1	+2.07	Regulator of extracellular matrix formation
		Subclass: dermatopontin
NM_011456	U:(C-D)	
NP_035586.1	+2.06	proteinase inhibitor
		Subclass: serine (or cysteine) proteinase inhibitor
		Subclass: serine (or cysteine) proteinase inhibitor, clade B
		Subclass: serme (or cysteme) proteinase inhibitor, clade B (ovalbumin), member 1; protease inhibitor 2 (anti-elastase),monocyte/neutrophil;
		protease inhibitor 2 (anti-elastase), monocyte/neutrophil derived
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2; plasminogen activator inhibitor, type II (arginine-serpin)
		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3; squamous cell carcinoma antigen 1

	· *		Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 4; protease inhibitor (leucine-serpin); squamous cell
			carcinoma antigen 2; leupin
			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 5; protease inhibitor 5 (maspin)
			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6; protease inhibitor 6 (placental thrombin inhibitor)
			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 7; mesangium predominant gene, megsin
5			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 8; protease inhibitor 8 (ovalbumin type)
			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 9; protease inhibitor 9 (ovalbumin type)
٠			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 10; protease inhibitor 10 (ovalbumin type, bomapin)
			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 11
			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 12
10			Subclass: serine (or cysteine) proteinase inhibitor, clade B (ovalbunin), member 13; hurpin; protease inhibitor 13 (hurpin, headpin)
			Subclass: serine (or cysteine) proteinase inhibitor, clade A
			Subclass: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1; Protease inhibitor
			(alpha-1-antitypsin); protease inhibitor 1 (anti-elastase), alpha-1-antitypsin
			Subclass: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
			Subclass: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5; Protein C inhibitor (plasminogen
			activator inhibitor-3); protein C inhibitor; protein C inhibitor (plasminogen activator inhibitor III)
15			Subclass: serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1; antithrombin III
		-	
	NM_008880	U:(C-D)	
	NP 032906.1	+2.06	Apoptosis-associated enzyme
			Subclass: phospholipid scramblase
20			Subclass: phospholipid scramblase 1
			Subclass: phospholipid scramblase 2
			Subclass: Phospholipid scramblase 3 (PL scramblase 3) (Ca(2+)-dependent phospholipid scramblase 3).
			Subclass: phospholipid scramblase 4
	962800 MM	U:(C-D)	
25	NP_032822.1	+2.05	phosphatidylcholine transfer protein Subclass: Phosphatidylcholine transfer protein (PC-TP) (StAR-related lipid transfer protein 2) (StARD2) (START domain-containing protein
			2).

NM_011717 U	U:(C-D)- +2.04	Protein containing widely-interspaced zinc finger motifs
		Subclass: WIZ protein Subclass: Human homolog of Mus musculus wizJ protein [AA 4-1561] Subclass: Human homolog of Mus musculus wizS protein [AA 64-934]
NM_009197 NP_033223.1	U:(C-D) +2.04	monocarboxylic acid transporter Subclass: solute carrier family 16 (monocarboxylic acid transporters), member 2; X-linked PEST-containing transporter Subclass: solute carrier family 16 (monocarboxylic acid transporters), member 10; T-type amino acid transporter 1
NM_009632 NP_033762.1	U:(C-D) +2.04	Polymerase
		Subclass: Poly [ADP-ribose] polymerase
		Subclass: Poly [ADP-ribose] polymerase-2 (PARP-2) (NAD(+) ADP-ribosyltransferase-2) (Poly[ADF-ribose] synmerase-2) (PADF-12) (IPARP-2).
		Subclass: Poly [ADP-ribose] polymerase-1 (PARP-1) (ADPRT) (NAD(+) ADP-ribosyltransferase-1) (Poly[ADP-ribose] syntherase-1).
		Subclass: poly(ADP-ribosyl)transferase; ADP-ribosyltransferase NAD(+); poly(ADP-ribose) syntherase Subclass: poly (ADP-ribosyl) transferase-like 3; ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)-like 2; poly(ADP-ribose)
		synthetase
NM_011176	U:(C-D)	
NP_035306.2	+2.03	Serine protease Sammession of himorigenicity 14 (colon carcinoma); membrane-type serine protease; serine protease TADG-15; tumor
-		associated differentially expressed gene 15 protein
		Subclass: prostamin
		Subclass: matriptase-2
		Subclass: serine protease SNC19
		Subclass: type II transmembrane serine protease 6; membrane-bound mosaic serine protemase maniplase-2

15

2

Subclass: enterokinase	Subclass: DESC1 protein	Subclass: Atrial natriuteric peptide-converting enzyme (pro-ANP-converting enzyme) (Corin) (Heart specific serine proteinase ATC2).	Subclass: epitheliasin	Subclass: androgen-regulated serine protease TMPRSS2		3 Carboxylase	Subclass: Pyruvate carboxylase.	Subclass: Propionyl-Coenzyme A carboxylase, alpha polypeptide precursor	Subclass: methylcrotonoyl-Coenzyme A carboxylase 1 (alpha); 3-methylcrotonyl-CoA carboxylase biotin-containing subunit	Subclass: acetyl-CoA carboxylase		2 Endoplasmic reticulum protein	Subclass: reticulon 1: neuroendocrine-specific protein	Subclass: reticulon 2	Subclass: RTN2-B	Subclass: RTN2-C	Subclass: nueroendocrine-specific protein B	Subclass: neuroendocrine-specific protein C - human	U:(C-D) Collagen		Subclass: type I collagen	Subclass: alpha 2 type I collagen; Collagen I, alpha-2 polypeptide; Collagen of skin, tendon and bone, alpha-2 chain	Subclass: alpha 1 type I collagen preproprotein; Collagen I, alpha-1 polypeptide; osteogenesis imperfecta type IV; collagen of skin, tendon and	bone, alpha-1 chain	Subclass: alpha 1 type II collagen isoform 2, preproprotein; collagen II, alpha-1 polypeptide; cartilage collagen; chondrocalcin, included;
-					U:(C-D)	1 +2.03		_	,		U:(C-D)	1 +2.02	•							+5					
				-	NM_008797	NP_032823.1					NM_013648	NP_038676.1							NM_007743	NP_031769.1		-			

10

L

20

		Subclass: alpha 1 type III collagen; Collagen III, alpha-1 polypeptide; collagen, fetal
		Subclass: alpha 2 type V collagen
		Subclass: alpha 2 type V collagen preproprotein; Collagen V, alpha-2 polypeptide; AB collagen; collagen, fetal membrane, A polypeptide
		Subclass: Collagen alpha 1 type XI
		Subclass: Collagen alpha 1(XI) chain
		Subclass: Collagen alpha 1 type XI isoform A preproprotein; collagen XI, alpha-1 polypeptide
		Subclass: alpha 1 type XI collagen isoform B preproprotein; collagen XI, alpha-1 polypeptide
		Subclass: alpha 1 type XI collagen isoform C preproprotein; collagen XI, alpha-1 polypeptide
	٠	
NM_023873	U:(C-D)	
NP_076362.1	+1.9	p10-binding protein
NM_011905	U:(C-D)	
NP_036035.1	+1.6	Cell surface receptor
		Subclass: Toll-like receptor
		Subclass: toll-like receptor 2; toll/interleukin 1 receptor-like 4
		Subclass: toll-like receptor 1; Toll/interleukin-1 receptor-like
	-	Subclass: toll-like receptor 10
		Subclass: toll-like receptor 6
NM_010721	U:(C-D) lamin	lamin
NP_034851.1	7.08	
		Subclass: lamin B1
		Subclass: Similar to lamin B1
		Subclass: Lamin B2
		Subclass: lamin A/C isoform 2; 70 kDa lamin
		Subclass: Similar to lamin A/C
		Alternate: lamin A protein

2

20

NIN 076778	11.(0,0)	11/C-D) protein un-requisted by BCG-CWS
	(a) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	
NP_080504.1	4.88	
		Alternate: unnamed protein product
		Alternate: KIAA0062
		Alternate: similar to KIAA0062
		Alternate: Unknown (protein for MGC:23235)
NM_026156	U:(C-D)	U:(C-D) similar to PP3898
NP_080432.1	3.75	
		Alternate: XAB2
		Alternate: KIAA1177 protein
		Alternate: HCNP protein; XPA-binding protein 2
		Alternate: Similar to HCNP protein; XPA-binding protein 2
		Alternate: FLJ00081 protein
U70139	U:(C-D)	U:(C-D) nocturnin
AAB62717.1	3.08,	
	U:(HI-D	
;) 2.08	
		Alternate: CCR4 carbon catabolite repression 4-like (S. cerevisiae); CCR4-like (carbon catabolite repression 4, S. cerevisiae)
NM_008137	U:(C-D)	U:(C-D) guanine nucleotide binding protein (G protein)
NP_032163.1	3.01	
		Subclass: guanine nucleotide binding protein (G protein), alpha 14; guanine nucleotide-binding protein 14
,		Subclass: GTP-binding protein alpha q
		Subclass: Guanine nucleotide-binding protein G(Y), alpha subunit (Alpha-11)
		Subclass: guanine nucleotide binding protein (G protein), alpha 15 (Gq class)
		Subclass: similar to GNA15; ALPHA-16
		Subclass: similar to Guanine nucleotide-binding protein, alpha-11 subunit (GL2)
		Subclass: Guanine nucleotide-binding protein G(O), alpha subunit 2

		Subclass: guanine nucleotide binding protein alpha oB
		Subclass: Guanine nucleotide-binding protein G(I), alpha- i suburin (Aueriyiate cyclase-illinbring G alpha protein)
		Subclass: Similar to guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 Subclass: cuanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3; 87U6
		Subclass: similar to Guanine nucleotide-binding protein G(T), alpha-3 subunit (Gustducin alpha-3 chain)
	-	
AK009292	(C-D)	
BAB26196.1	2.94,	
÷	O:(HI-D	
) 2.87	solute carrier family 27 (fatty acid transporter)
		Subclass: solute carrier family 27 (fatty acid transporter), member 4; fatty acid transport protein 4
		Subclass: solute carrier family 27 (fatty acid transporter), member 5; very long-chain acyl-CoA synthetase homolog 2; very
		long-chain acyl-CoA synthetase-related protein; likely ortholog of mouse solute carrier family 27 (fatty acid transporter), member 5
		Subclass: solute carrier family 27 member 3, fatty acid transport protein 3
		Subclass: solute carrier family 27 (fatty acid transporter), member 2; very long-chain fatty-acid-coenzyme A ligase 1;
		very-long-chain acyl-CoA synthetase
		Alternate: Unknown (protein for MGC:16752)
		Alternate: very long-chain acyl-CoA synthetase homolog 1
		Alternate: Unknown (protein for IMAGE:3613739)
		Alternate: Similar to hypothetical protein MGC4365
M12573	(c-p)	U:(C-D) heat shock 70kDa protein
AAA37863.1	2.94	
		Subclass: heat shock 70kDa protein 1A; heat shock 70kD protein 1A; heat shock-induced protein; dnaK-type molecular
	! ! !	chaperone HSP70-1
		Subclass: heat shock 70kDa protein 1B; heat shock 70kD protein 1B
		Subclass: heat shock 70kD protein 1-like
		Subclass: heat shock 70kDa protein 6 (HSP70B')
		Subclass: heat shock 70kDa protein 2; heat shock 70kD protein 2; Heat-shock 70kD protein-2

AK017185	U:(C-D)	U:(C-D) Ras-related protein Rab-30
.1	2.9	
	U:(C-D)	U:(C-D) KIAA1001 protein
BAB31086.1	2.44	
		Alternate: Similar to KIAA1001 protein
		Alternate: Anylsulfatase A; Chain: P; Synonym: Cerebroside-3-Sulfate-Sulfatase; EC. 3.1.0.0
		Alternate: Similar to anylsulfatase A
		Alternate: N-acetylgalactosamine-6-sulfatase precursor; Galactosamine (N-acetyl) o comercial descriptions of the control of th
		Alternate: Unknown (protein for MGC:24090)
		Alternate: arylsulfatase F
		Alternate: similar to arylsulfatase F
		Alternate: Unknown (protein for MGC:31932)
		Alternate: arylsulfatase D precursor, isoform a
AK004984	U:(C-D)	U:(C-D) cytochrome P450, subfamily IID, polypeptide 6; debrisoquine 4-hydroxylase; microsomal monooxygenase; xenobiotic
BAB23719.1	2.38	monooxygenase; flavoprotein-linked monooxygenase
AK013002	U:(C-D)	U.(C-D) general transcription factor IIF, polypeptide 1 (74kD subunit)
BAB28588.1	2.21	
		Alternate: RAP74
		Alternate: Transcription Initiation Factor Iif, Subunit; Chain: A, C, E, G; Fragment: Residues 2-113, Oylionym: Transcription
		Initiation Factor Rap30
AK007293	0.(C-D	U.(C-D) KIAA1879 protein
BAB24937.1	2.19,	
	U:(HI-D	
) 2.62	
NM_019521	0-0):n	U:(C-D) growth arrest-specific 6; AXL stimulatory factor
NP 062394.1	2.14	
		Alternate: protein S (alpha); Protein S, alpha

NM_011693 U.(C-D) NP_033823.1 U.(C-D) NP_033823.2 U.(C-D) NP_033823.1 U.(C-D) Subclass: vascular cell adhesion molecule Subclass: vascular cell adhesion molecule 1, isoform a : CD106 antigen Subclass: Vascular Cell Adhesion Protein 1; Chain: A, Fragment: Vcam-D1, D2 (Integri Subclass: Vascular Cell Adhesion Protein 1; Chain: A, Bragment: N-Terminal Two Engineered: Yes; Mutation: V196D; Other_Details: Hybrid Molecule Composed Of Vcan and Fc U.(C-D) Amyloid beta A4 precursor protein-binding family B member 2 (Fe65-like prot Subclass: similar to Amyloid beta A4 precursor protein-binding family B member 2 (Fe65-like prot Subclass: similar to Amyloid beta A4 precursor protein-binding family B member 1 isoform delta protein-binding family B member 1 isoform delta protein-binding family B member 1 isoform of the protein-binding family B member 1 isoform of the protein-binding family B member 1 isoform delta broteins: Subclass: Similar to FE65-like protein 2 isoform a; amyloid precursor interacting protein Subclass: Similar to FE65-like protein 2 isoform a; amyloid precursor interacting protein Subclass: FE65-like protein 2 isoform a; amyloid precursor interacting protein Subclass: Te65-like protein 2 isoform c; amyloid precursor interacting protein Subclass: transient receptor potential cation channel subfamily M, member 5, MLSNi is TRP-related; LTRPC5 protein Subclass: transient receptor potential cation channel, subfamily M, member 4 Subclass: transient receptor potential cation channel 7, a novel putative Ca2+ channel	Alterna	Alternate: Vitamin K-dependent protein Sprecursor
U:(C-D) 2.06 U:(C-D) 2.06 U:(HI-D) 12.32		
1 2.08 U:(C-D) 2.06 U:(C-D) 1 2.05, U:(HI-D) 1 2.32		
U:(C-D) 2.06 U:(C-D) U:(C-D) 2.05, U:(HI-D)) 2.32	2.08	ar cell adhesion molecule
U:(C-D) 2.06 2.06 U:(C-D) U:(HI-D) 1.2.32	Subcla	
U:(C-D) 2.06 U:(C-D) U:(C-D) 2.05, U:(HI-D)) 2.32	Subcla	ss: vascular cell adhesion molecule 1, isoform b precursor; CD106 antigen
U:(C-D) 2.06 2.06 U:(C-D) U:(HI-D) 1.2.32	Subcla	ss: Vascular Cell Adhesion Protein 1; Chain: A; Fragment: Vcam-D1, D2 (Integrin Binding Fragment); Synonym: Vcam-1
U:(C-D) 2.06 U:(C-D) U:(C-D) 2.05, U:(HI-D)) 2.32	Subcla	iss: Vascular Cell Adhesion Molecule-1; Chain: A, B; Fragment: N-Terminal Two-Domain Fragment; Synonym: Vcam-1;
U:(C-D) 2.06 U:(C-D) U:(HI-D) 1.2.32	Engine	Engineered: Yes; Mutation: Y196D; Other_Details: Hybrid Molecule Composed Of Vcam-1 Domains 1 and 2 Fused To IgG, Hinge
U:(C-D) 2.06 U:(C-D) 2.05, U:(HI-D)) 2.32	and Fc	
2.06 U:(C-D) U:(HI-D)) 2.32		d beta A4 precursor protein-binding family B (Fe65-like protein)
U:(C-D) 2.05, U:(HI-D)) 2.32		
U:(C-D) 2.05, U:(HI-D)) 2.32		ss: Amyloid beta A4 precursor protein-binding family B member 2 (Fe65-like protein)
U:(C-D) 2.05, U:(HI-D)) 2.32	Subcla	ss: similar to Amyloid beta A4 precursor protein-binding family B member 2 (Fe65-like protein)
U:(C-D) 2.05, U:(HI-D)) 2.32	Subcla	Subclass: amyloid beta A4 precursor protein-binding, family B, member 1 isoform delta E9; amyloid beta A4 precursor
U:(C-D) 2.05, U:(HI-D)) 2.32	protein	
U:(C-D) 2.05, U:(HI-D)) 2.32	Subcla	ss: adaptor protein FE65a2
U:(C-D) 2.05, U:(HI-D) 2.32	Subcla	ss: FE65-like protein 2 isoform a; amyloid precursor interacting protein
U:(C-D) 2.05, U:(HI-D)) 2.32	Subcla	ss: Similar to FE65-LIKE 2
U:(C-D) 2.05, U:(HI-D) 2.32	Subcla	ss: FE65-like protein 2 isoform b; amyloid precursor interacting protein
U:(C-D) 2.05, U:(HI-D) 2.32	Subclar	ss; FE65-like protein 2 isoform c; amyloid precursor interacting protein
U:(C-D) 2.05, U:(HI-D) 2.32		
2.05, U:(HI-D) 2.32		nt receptor potential cation channel
0		
	O-IH):N	
Subclass: transient receptor potential cation channel, subfamily M, member 5; MLSN1 a TRP-related; LTRPC5 protein Subclass: transient receptor potential cation channel, subfamily M, member 4 Subclass: transient receptor potential-related channel 7, a novel putative Ca2+ channel) 2.32	
TRP-related; LTRPC5 protein Subclass: transient receptor potential cation channel, subfamily M, member 4 Subclass: transient receptor potential-related channel 7, a novel putative Ca2+ channel	Subcla	Subclass: transient receptor potential cation channel, subfamily M, member 5; MLSN1 and TRP-related; MLSN1- and
Subclass: transient receptor potential cation channel, subfamily M, member 4 Subclass: transient receptor potential-related channel 7, a novel putative Ca2+ channel	TRP-re	lated; LTRPC5 protein
Subclass: transient receptor potential-related channel 7, a novel putative Ca2+ channel	Subclas	ss: transient receptor potential cation channel, subfamily M, member 4
	Subcla	Subclass: transient receptor potential-related channel 7, a novel putative Ca2+ channel protein

 $\vec{}$

근

NM_011676 NP_035806.1 AF241249 AAG02285.1	U.(C-D) 2.03 2.03	
-		Alternate: unnamed protein product
NM_010220 NP_034350.1	U:(C-D)	
		Subclass: FK506-binding protein 5; 51 kDa FK506-binding protein 5; 54 kDa progesterone receptor-associated immunophilin; T-cell FK506-binding protein; peptidylprolyl cis-trans isomerase; rotamase; FF1 antigen; HSP90-binding immunophilin
		Subclass: similar to FK506-binding protein 4 (Peptidyl-prolyl cis-trans isomerase) (PPiase) (Rotamase) (p59 protein) (HSP binding immunophilin) (HBI) (FKBP52 protein) (52 kDa FK506 binding protein) (FKBP59)

NIM_016696	U:(C-D)	
NP_057905.1	2.02	glypican
		Subclass: glypican 1
		Subclass: glypican 6
		Subclass: glypican 4
		Subclass: similar to Glypican-2 (Cerebroglycan) (HSPG M13)
NM_013692	U:(C-D)	U:(C-D) TGFB inducible early growth response
NP_038720.1	2.01	
		Alternate: EGR alpha transcription factor - human
		Alternate: TGFB inducible early growth response 2
AK004865	U:(C-D)	U:(C-D) HMG CoA synthase (3-hydroxy-3-methylglutaryl-Coenzyme A synthase)
BAB23626.1	2	
		Subclass: 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial); 3-hydroxy-3-methylglutaryl-Coenzyme A synthase
		7
		Subclass: 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble); 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
		Subclass: hydroxymethylglutaryl-CoA synthase (EC 4.1.3.5), cytosolic, fibroblast isoform
		Subclass: similar to Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMG-CoA synthase) (3-hydroxy-3-methylglutaryl
		coenzyme A synthase)
NM_019810	U:(C-D)	U:(C-D) Sodium/glucose cotransporter
NP_062784.1	2	
		Subclass: solute carrier family 5 (sodium/glucose cotransporter), member 1; Human Na+/glucose cotransporter 1 mRNA,
		complete cds; solute carrier family 5 (sodium/glucose transporter), member 1
		Subclass: solute carrier family 5 (low affinity glucose cotransporter), member 4; solute carrier family 5 (neutral amino acid
		transporters, system A), member 4; low affinity sodium glucose cotransporter
		Subclass: solute carrier family 5 (sodium/glucose cotransporter), member 2; solute carrier family 5 (sodium/glucose transporter),
		member 2
		Subclass: solute carrier family 5 (inositol transporters), member 3; solute carrier family 5 (inositol transporter), member 3; human
		solute carrier family 5, member 3, Sodium/myo-inositol cotransporter; sodium/myo-inositol cotransporter 1

Ľ

 $\ddot{\vdash}$

끔

 $\tilde{\sim}$

Subclass: Cleaved Antichymotrypsin A349R	NM_028780 U:(C-D) NP_083056.1 2 NM_009252 U:(C-D) NP_033278.1 1.77	Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Alternate: Alternate: Alternate: Alternate: Alternate: Alternate: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass: Subclass:
Subclass: Cleaved Antichymotrypsin T345R		Subclass: Cleaved Antichymotrypsin T345R

Subclass: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 4; protease inhibitor 4 (kallistatin)	Subclass: Kallistatin precursor (Kallikrein inhibitor) (Protease inhibitor 4) Subclass: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5; Protein C inhibitor (plasminogen activator inhibitor III)	Subclass: protein C inhibitor	Subclass: plasma serine protease inhibitor precursor	Subclass: Similar to serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1	Alternate: hypothetical protein DKFZp434P131 1	(D)	Ras-related protein	Subclass: Ras-related protein Rab-30			, and the same of				Vanin	Vanin 1 (VNN1); pantetheinase	vanin 3 isoform 1; VNN3 protein; pantetheinase	vanin 2, isoform 1; Vannin 2; pantetheinase	vanin 2, isoform 2; Vannin 2; pantetheinase	Alternate: Biotinidase	
			_	1	_	U:(C-D	+2.9		η	(S-મુ)	4.37, U	(C-D)	3.14, U	(H-D)	2.37						
						AK017185	BAB30625.1		NM_011704	NP_035834.1											

NM_007468	<u>n</u>	Apolipoprotein A-IV (Apo-AIV)
NP_031494.1	(C-HI)	
	2.98, U	
	(C-D)	
	2.42, U	
	(H-D)	
	2.16	
		-
NM_016974	n	D-site-binding protein (Albumin D box-binding protein) (TAXREB302)
NP_058670.1	(C-HI)	
	2.79, U	
	(C-D)	
	4.24,	
	⊃	
	(HI-D)	
	2.47	
NM_019634	−IH):∩	
NP_062608.1	D) 2.86	transmembrane 4 superfamily
	• •	Subclass: transmembrane 4 superfamily member 2; membrane component, x chromosome, surface marker 1; T-cell acute
	 	lymphoblastic leukemia associated antigen 1; transmembrane protein A15; tetraspanin protein; cell surface glycoprotein A15;
		CD231 antigen; transmembrane 4 superfamily 2b
		Subclass: transmembrane 4 superfamily member 6; tetraspan TM4SF; A15 homolog; tetraspanin TM4-D; tetraspanin 6
NM_008597	−IH):N	matrix Gla protein
NP_032623.1	D) 2.36	
NM_009234	−IH):Ω	SRY (sex determining region Y)-box 11; SRY (sex-determining region Y)-box 11
NP_033260.1	D) 2.36	

170000 3 44	11.07.11	ate of the Discontallia olabe 2. December fiber component: heat-shock 20 kD like-nrotein	_
NM_009964	-E):0	CIVSCAIIII, AIDITA D. CIVSCAIIII, AIDITA-L, NOSCITUTATION TO COMPONENT, INCAPANION ZO NO "INC PICCI".	
NP_034094.1	D) 2.06		_
NM 013565	U:(HI-	integrin alpha	
NP_038593.1	D) 2.05		
		Subclass: VLA-3 alpha subunit	
		Subclass: integrin alpha-3 (Galactoprotein B3) (GAPB3) (VLA-3 alpha chain) (CD49c)	
		Subclass: integrin alpha 3 isoform b	
		Subclass: integrin alpha 6	
		Subclass: integrin alpha-6 chain precursor, splice form A	
		Subclass: integrin alpha-6 chain precursor, splice form B	
		Subclass: integrin alpha 7	
			_
NM_013805	−IH):∩	transmembrane protein claudin 5; androgen withdrawal and apoptosis induced protein RVP1 (rat)-like; Claudin-5 (transmembrane	
NP 038833.1	D) 2.04	protein deleted in velocardiofacial syndrome)	
AK014697	−IH):∩	DC-specific transmembrane protein	
BAB29508.1	D) 2.01		_
	U:(C-HI		_
)+3.19		
AK007868	U:(C-D)		
BAB25319.1	+2.42	chromosome 11 open reading frame 24	
NM_017480	U:(C-HI	inducible T-cell co-stimulator; activation-inducible lymphocyte immunomediatory molecule; inducible costimulator	
NP_059508.1	9.9 (
		Alternate: Similar to inducible T-cell co-stimulator	
M12571	U:(C-HI	heat shock 70kDa protein	
AAA57234.1	3.58		
			1

		Subclass: heat shock 70kDa protein 1A, heat shock 70kD protein 1A; heat shock-induced protein; dnaK-type molecular
		Chanarona HSD70-1
		Subdiscontinuo 700 norte profession 18: heat shock 70kD profess 18
		Subclass, Heat shown bottom in the shown shows the property of the shown shown in the shown shown in the shown shown in the shown shown in the shown shown in the shown shown in the shown shown in the shown show
		Subclass: heat shock / UKD protein 1-like
		Subclass: heat shock 70kDa protein 6 (HSP70B')
		Subclass: heat shock 70kDa protein 2; heat shock 70kD protein 2; Heat-shock 70kD protein-2
NM_007585	U:(C-HI	U:(C-HI Annexin
NP_031611.1	3.49,	
	U:(C-D)	
	4.83	
		Subclass: annexin A2; annexin II; lipocortin II; Annexin II (lipocortin I); calpactin I, heavy polypeptide (p36); annexin II (lipocortin II;
		calpactin I, heavy polypeptide); annexin II (lipocortin II)
		Subclass: bA255A11.8 (novel protein similar to annexin A2 (ANXA2) (lipocortin II, calpactin I heavy chain, chromobindin 8,
		PAP-IV))
		Subclass: annexin I; annexin I (lipocortin I); lipocortin I
		Subclass: Annexin A4 (Annexin IV) (Lipocortin IV) (Endonexin I) (Chromobindin 4) (Protein II) (P32.5) (Placental anticoagulant
	•	protein II) (PAP-II) (PP4-X) (35-beta calcimedin) (Carbohydrate-binding protein P33/P41) (P33/41)
		Subclass: annexin A11; annexin XI; autoantigen, 56-kD; calcyclin-associated annexin 50
		Subclass: annexin VI isoform 2; annexin VI (p68); calcium-binding protein p68; calphobindin II;
		Subclass: annexin VI isoform 1; annexin VI (p68); calcium-binding protein p68; calphobindin II; calelectrin F498
		Subclass: Annexin III
		Subclass: annexin A3; Annexin III (lipocortin III); annexin III (lipocortin III, 1,2-cyclic-inositol-phosphate phosphodiesterase,
		placental anticoagulant protein III, calcimedin 35-alpha); calcimedin 35-alpha
		Subclass: Annexin V (Lipocortin V, Endonexin II, Placental Anticoagulant Protein) (Calcium Ions Are Visible) Mutation With Glu 17
•		Replaced By Gly (E17G)
		Subclass: annexin A5
		Subclass: annexin VIII; Annexin VII
		Subclass: similar to annexin A8
		Subclass: annexin VII isoform 2; annexin VII (synexin); synexin

		Subclass: annexin VII isoform 1: annexin VII (synexin); synexin
-		Subclass: annexin A13 isoform b
		Subclass: annexin 31; annexin XXXI
		Subclass: keratinocyte annexin-like protein
		Alternate: protein PP4-X
		Alternate: protein p68 (1 - 673)
NM_007980	U:(C-H	U:(C-HI intestinal fatty acid binding protein 2; Fatty acid-binding protein, intestinal; I-FABP; fatty acid binding protein 2, intestinal
NP_032006.1	3.49,	
	U:(C-D)	
	2.22	
MM_007809	U:(C-HI	U:(C-HI cytochrome P450
NP_031835.1) 3.41,	
	U:(C-D)	
	3.69	
		Subclass: cytochrome P450, subfamily XVII polypeptide; steroid 17-alpha-monooxygenase; steroid 17-alpha-hydroxylase/17,20
		lyase; cytochrome p450 XVIIA1
· .		Subclass: cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1; flavoprotein-linked monooxygenase;
		cytochrome P1-450, dioxin-inducible; aryl hydrocarbon hydroxylase; P450 form 6; xenobiotic monooxygenase; mlcrosomal
		monooxygenase
		Subclass: cytochrome P450-1A2
		Subclass: cytochrome P450 4
		Subclass: Cytochrome P450 XXIB (Steroid 21-hydroxylase) (P450-C21B)
		Subclass: cytochrome P450, subfamily XXIA polypeptide 2; steroid 21-monooxygenase; steroid 21-hydroxylase
		Subclass: cytochrome P450 CYP1B1

AK007868	U:(C-HI	U.(C-HI chromosome 11 open reading frame 24
BAB25319.1	3.19,	
	U:(C-D)	
	2.42	
		CONTROL COURT IN THE COURT IN T
U67189	U:(C-HI	Regulator of G-protein signaling 16 (RGS16) (Retinally abundant regulator of G-protein signaling) (RGS-K) (AZช-หนรานหา)
AAB50619.1	3.17	
M63245	U:(C-HI	U:(C-HI aminolevulinate synthase
AAA91867.1	3.05	
		Subclass: aminolevulinate synthase 1
		Subclass: 5-aminolevulinic acid synthase
		Subclass: 5-aminolevulinic acid synthase, erythroid-specific, mitochondrial precursor (Delta-aminolevulinate synthase) (Delta-ALA
		synthetase) (ALAS-E)
		Subclass: aminolevulinate, delta-, synthase 2; Aminolevulinate, delta-, synthase-2
		Subclass: Similar to aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)
NM_007437	U:(C-H	
NP 031463.1	3.05	Aldehyde dehydrogenase
		Subclass: similar to fatty aldehyde dehydrogenase
	,	Subclass: aldehyde dehydrogenase 3A2; aldehyde dehydrogenase 10; aldehyde dehydrogenase 3 family, member A2; fatty
		aldehyde dehydrogenase
		Subclass: aldehyde dehydrogenase 3 family, member A1; aldehyde dehydrogenase, dimeric NADP-preferring; acetaldehyde
		dehydrogenase; ALDH, stomach type
		Subclass: aldehyde dehydrogenase 3B1; aldehyde dehydrogenase 7; aldehyde dehydrogenase 3 family, member B1
		Subclass: Similar to aldehyde dehydrogenase 3 family, member B1
		Subclass: aldehyde dehydrogenase 3B2; aldehyde dehydrogenase 8; aldehyde dehydrogenase 3 family, member B2
	,	Subclass: Similar to aldehyde dehydrogenase 3 family, member B2
	ì	

 $\ddot{}$

15

 \sim

U:(C-HI homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1; MMS-inducible gene) 3.00, U:(C-D)	Alternate: Similar to homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1	DNA damage inducible transcript 3: C/EBP homologous protein; growth arrest- and DNA damage-inducible	olay-dallage-llouding		Alternate: TLS-CHOP	Alternate: DNA-damage-inducible protein GADD153 - human	Type I iodothyronine deiodinase (Type-I 5'deiodinase) (DIOI) (Type 1 DI) (5DI)			Alternate: Similar to deiodinase, iodothyronine, type I	U:(C-HI hypothetical protein MGC4504	Synthase (M3) Synthase	U.(C-HI sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpna-z,3-sialylitansferase, Gw3 synulase), gangiloside C(w3) cynulase		Alternate: Gal beta 1,3(4) GlcNAc alpha 2,3-sialyltransferase	
U:(C-HI) 3.00, U:(C-D)	2.29	0,1	U.(C-III)) 2.98,	U:(C-D) 2.16			U;(C-HI) 2.84,	U:(C-D) 2.06		U:(C-H) 2.77	U:(C-H) 2.65, U:(C-D) 2.16		
NM_022331 NP_071726.1		E00500 3 65	NM_00/85/ NP_031863.1	1			MM 007860	NP_031886.1			AK007378	BAB24997.1	NM_011375	NP_035505.1		

9

끕

 \sim

NIM 022710	H-()-H	11-/C_HI Ithioredoxin interacting profein: uprequilated by 1.25-dihydroxyvitamin D-3
NP_076208.1) 2.36,	
•	U:(C-D)	
	2.42	
NM_013760	U.(C-HI	DnaJ (Hsp40) homolog, subfamily B, member 9; microvascular endothelial differentiation gene 1; DKFZP564F1862 protein;
NP_038788.1) 2.34,	endoplasmic reticulum DnaJ homolog 4
	U:(C-D)	
	2.1	
,		Alternate: similar to putative microvascular endothelial differentiation gene 1; similar to X98993 (PID:g1771560)
NM_023184	IH-0):N	U:(C-HI Kruppel-like factor 15; KKLF protein; kidney-enriched Kruppel-like factor
NP_075673.1) 2.34	
NM_018791	U:(C-HI	U.(C-HI Zinc finger protein
NP_061261.1) 2.32	
		Subclass: zinc finger protein 93 homolog; zinc finger protein homologous to mouse Zfp93; zinc finger protein homologous to Zfp93
		in mouse; zinc finger protein 93 homolog (mouse)
		Subclass: zinc finger protein 226; Kruppel-associated box protein
		Subclass: Zinc finger protein ZNF45
		Subclass: similar to Zinc finger protein 229
		Subclass: zinc finger protein 224
		Subclass: zinc finger protein 228
		Subclass: similar to ZNF228 protein
		Subclass: Zinc finger protein 234 (Zinc finger protein HZF4)
		Subclass: similar to Zinc finger protein 234 (Zinc finger protein HZF4)
		Subclass: zinc finger protein 225
AK007864	IH-0):N	U:(C-HI similar to RIKEN cDNA 1810054O13
BAB25316.1) 2.31	

 $\ddot{\vdash}$

7

 $\tilde{\mathbf{z}}$

NM 019545	U:C-H	
NP_062418.1) 2.31	hydroxyacid oxidase
		Subclass: hydroxyacid oxidase 3; medium-chain 2-hydroxy acid oxidase HAOX3; (S)-2-hydroxy-acid oxidase; glycolate oxidase
		Subclass: hydroxyacid oxidase 2; long-chain L-2-hydroxy acid oxidase; (S)-2-hydroxy-acid oxidase; glycolate oxidase
		Subclass: hydroxyacid oxidase 1; (S)-2-hydroxy-acid oxidase; glycolate oxidase
	٠.	
NM_011058	U.C-HI	platelet-derived growth factor receptor
NP_035188.1) 2.3	
		Subclass: platelet-derived growth factor receptor alpha polypeptide
		Subclass: platelet-derived growth factor receptor beta; beta platelet-derived growth factor receptor
	.,	Alternate: vascular endothelial growth factor receptor
		Subclass: Vascular endothelial growth factor receptor 3 (VEGFR-3) (Tyrosine-protein kinase receptor FLT4)
		Subclass: vascular endothelial growth factor receptor 2
		Alternate: KIT protein
		Alternate: colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog
		Alternate: Macrophage colony stimulating factor I receptor (CSF-1-R) (Fms proto-oncogene) (c-fms) (CD115 antigen)
		Alternate: FLT3 receptor tyrosine kinase
		Alternate: fms-related tyrosine kinase 3
		Alternate: fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
		Alternate: fms-related tyrosine kinase 4; fms-related tyrosine kinase-4 (vascular endothelial growth factor receptor 3)
NM_010565	U:(C-HI	U:(C-HI inhibin beta C chain preproprotein; activin beta-C chain
NP_034695.1) 2.28	
		Alternate: activin beta E
NM_011994	П:(С-НІ	ATP-binding cassette, sub-family D
NP_036124.1) 2.27	
		Subclass: ATP-binding cassette, sub-family D, member 2; adrenoleukodystrophy-like 1; hALDR
		Subclass: ATP-binding cassette, sub-family D (ALD), member 1; adrenoleukodystrophy protein
		Subclass: ATP-binding cassette, sub-family D, member 3; Peroxisomal membrane protein-1 (70kD); peroxisomal membrane
		protein 1 (70kD, Zellweger syndrome); peroxisomal membrane protein-1

NM_018817 NP 061287.1	U:(C-HI) 2.27	U:(C-HI SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a-like 1; HepA-related protein; SMARCA-like protein 1) 2.27
AK006096	U:(C-HI	U:(C-HI Similar to RIKEN cDNA 1700018O18 gene
DAB2440/.1	72.24	
NM_019682	U:(C-HI	U:(C-HI dynein, cytoplasmic, light polypeptide; Dynein, cytoplasmic, light chain (protein inhibitor of neuronal NOS); protein inhibitor of
NP_062656.1) 2.24	neuronal nitric oxide synthase
NM_009154	U:(C-HI	sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic
NP_033180.1) 2.23	domain, (semaphorin) 5A; semaphorin F; sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane
		domain (TM) and short cytoplasmic domain, 5A
		Alternate: KIAA1445 protein
		Alternate: similar to KIAA1445 protein
AK005274	U:(C-HI	U:(C-HI hypothetical protein MGC2605
BAB23924.1) 2.22,	
	U:(C-D)	
	2.15	
		Alternate: similar to hydroxyacyl glutathione hydrolase 2
NM_009315	U:(C-HI	TBP-associated factor 6 Subclass:
NP_033341.1) 2.2	
		Subclass: TBP-associated factor 6 isoform gamma; TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor,
		80 kD; TATA box binding protein (TBP)-associated factor, RNA polymerase II, E, 70/85kD; transcription initiation factor TFIID 70
		kD subunit
	·	Subclass: TBP-associated factor 6 isoform delta; TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 80
		kD; TATA box binding protein (TBP)-associated factor, RNA polymerase II, E, 70/85kD; transcription initiation factor TFIID 70 kD
		subunit

NM_011361	U:(C-HI	U.(C-HI serine/threonine protein kinase sgk (serum/glucocorticoid regulated kinase)
NP_035491.1) 2.2	
		Alternate: serum/glucocorticoid regulated kinase-like; cytokine-independent survival kinase
		Alternate: v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma); protein kinase B
NM_011844	U:(C-HI	U:(C-HI monoglyceride lipase
NP_035974.1) 2.19	
NM_018861	U:(C-HI	
NP_061349.1) 2.18	solute carrier family 1 (glutamate/neutral amino acid transporter)
		Subclass: solute carrier family 1 (glutamate/neutral amino acid transporter), member 4; Solute carrier family 1 (glutamate/neutral
		amino acid transporter),
		Subclass: solute carrier family 1 (neutral amino acid transporter), member 5; baboon M7 virus receptor; RD114 virus receptor;
		neutral amino acid transporter B
		Alternate: sodium-dependent neutral amino acid transporter type 2 truncated isoform
		Alternate: neutral amino acid transporter B
AF213258	П:(С-НІ	membrane-associated guanylate kinase-related 3
AAG43836) 2.17,	
	U:(C-D)	
	2.34	
		Alternate: similar to membrane-associated guanylate kinase MAGI3
		Alternate: MAGI-1A
		Alternate: MAGI-1C beta
		Alternate: MAGI-1B alpha beta
		Alternate: dJ730K3.2 (similar to BAI1-associated protein)
,		Alternate: atrophin-1 interacting protein 1; activin receptor interacting p; KIAA0705 gene product
		Alternate: BAI1-associated protein 1; WW domain-containing protein 3
		Alternate: brain-specific angiogenesis inhibitor-associated protein 1
		The second secon

 Ξ

15

20

ហ

_

15

		Subclass: solute carrier family 12, (potassium-chloride transporter) member 5
AK002693 BAB22288.1	U:(C-HI) 2.04	U:(C-HI diacylglycerol O-acyltransferase 2 like 1; diacylglycerol acyltransferase 2-like
AK003722	U:(C-HI	U:(C-HI ubiquitin-conjugating enzyme E2C; ubiquitin carrier protein E2-C
BAB22939.1	7 2.04	
		() (Ol Ol Oliver and include forther binding 40) (Ol Oliver)
NM_010516 NP_034646.1	U:(C-HI) 2.04	CYR61 protein (Cysteine-rich, angiogenic inducer, 61) (Insulin-like growth tactor-binding protein าย) (ษเษา protein)
		Alternate: connective tissue growth factor
		Alternate: WNT1 inducible signaling pathway protein 1, isoform 1 precursor; Wnt1 signaling pathway protein 1; Wnt-1 inducible
		signaling pathway protein 1; wnt-1 signaling pathway protein 1; connective tissue growth factor related protein WISP-1; Wnt-1
		induced secreted protein 1
		Alternate: WNT1 inducible signaling pathway protein 3, isoform 2; Wnt1 signaling pathway protein 3; lost in inflammatory breast
		cancer tumor suppressor protein; connective tissue growth factor like protein; connective tissue growth factor related protein
		WISP-3
		Alternate: WNT1 inducible signaling pathway protein 3, isoform 1; Wnf1 signaling pathway protein 3; lost in inflammatory breast
		cancer tumor suppressor protein; connective tissue growth factor like protein; connective tissue growth factor related protein
		WISP-3
NM_010354	U:(C-HI	gelsolin (amyloidosis, Finnish type); Gelsolin
NP_034484.1) 2.03	
	-	Alternate: scinderin; adseverin; KIAA1905 protein
		Alternate: villin 1; Villin-1
		Alternate: similar to mouse adseverin(D5); similar to PID:g2218019
		Alternate: Advillin (p92)
		Alternate: Similar to gelsolin (amyloidosis, Finnish type)
		Alternate: Similar to advillin

៤

(

AK002717	U:(C-HI	U:(C-HI RNA, U transporter 1; snurportin-1; snuportin-1
XP_134867) 2.02	
AK004600	U:(C-HI	Rho guanine nucleotide exchange factor 3; RhoGEF protein; 59.8 kDA protein
BAB23401.1) 2.02	
		Alternate: Similar to Rho guanine nucleotide exchange factor (GEF) 3
	3	
M62766	U:(C-H	U:(C-HI 3-hydroxy-3-methylglutaryi-Coenzyme A reductase
AAA37819.1) 2.02	
		Subclass: Similar to 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
NM_008299	U:(C-HI	
NP_032325.1) 2.02	DnaJ (Hsp40) homolog
		Subclass: DnaJ (Hsp40) homolog, subfamily B, member 6 isoform b; Heat shock protein J2
		Subclass: similar to DnaJ (Hsp40) homolog, subfamily B, member 6 isoform b; Heat shock protein J2
		Subclass: similar to DnaJ homolog subfamily B member 8 (mDJ6)
NM_010877	U:(C-HI	U:(C-HI Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox)
NP_035007.1) 2.02	
		Alternate: Similar to neutrophil cytosolic factor 2 (65kD, chronic granulomatous disease, autosomal 2)
		Alternate: p67phox-like protein
NM_019643	N:(C-HI	U:(C-HI TERA protein
NP_062617.1) 2.02	
NM_013594	N:(C-HI	U:(C-HI methyl-CpG binding protein 1
NP_038622.1) 2.01,	
	U:(C-D)	
	2.15	
		Subclass: methyl-CpG binding domain protein 1 isoform 1
		Subclass: methyl-CpG binding protein splice variant 1

Ц

 $\ddot{}$

H

20

7)

		Subclass: methyl-CpG binding domain protein 1 Isoform 2
		Subclass: methyl-CpG binding protein splice variant 2
		Subclass: methyl-CpG binding domain protein 1 isoform PCM1
		Subclass: methyl-CpG binding domain protein 1 isoform 3
		Subclass: methyl-CpG binding domain protein 1 isoform 4
NM 025566	U:(C-HI	U.(C-HI hypothetical protein MGC17791
NP 079842.1)2	
		Alternate: similar to RIKEN cDNA 2600017JZ3
AK004002	U:(C-HI	U:(C-HI five-lipoxygenase activating protein (FLAP)
BAB23117.1)2	
		The strangerington factor. RANTES factor of late activated T
NM 021366	U:(C-HI	U:(C-HI Kruppel-like factor 13; transcription factor NSLP1; novel Sp1 like zinc linger uanscription (c-HI
NP 067341.1)2	lymphocytes-1; basic transcription element binding protein 3
		Alternate: similar to Krueppel-like factor 13 (Transcription factor BTEDS) (Dasic it all Scription factor NSI D1) (Novel
		(BTE-binding protein 3) (RANTES factor of late activated T lymphocytes-1) (RFLA1-1) (Transcription received to the contract of late activated T lymphocytes-1) (RFLA1-1) (Transcription received to the contract of late activated T lymphocytes-1) (RFLA1-1)
		Sp1-like zinc fi
NM_025566	U:(C-HI	U.(C-HI hypothetical protein MGC17791
NP 079842.1) +2	
		Alternate: similar to RIKEN cDNA 2600017123

Master Table 2: Subtable 2C Classes of Mixed Genes/Proteins

	T											_												_
Mouse Gene Behavior Human Protein Name		U:(HI-D) germ cell specific Y-box binding protein; contrin							zinc finger protein,	Subclass: similar to zinc finger protein, subfamily 1A, 3 (Aiolos)	Subclass: zinc finger protein, subfamily 1A, 3 (Aiolos)	Subclass: AlOlos isoform four	Subclass: AIOLOS isoform two	Subclass: AIOLOS isoform three	Subclass: AIOLOS isoform six	Subclass: AIOLOS isoform five	Subclass: zinc finger protein, subfamily 1A, 1 (ikaros); Ikaros (zinc finger protein)	Subclass: zinc finger protein, subfamily 1A, 2 (Helios); zinc finger DNA binding protein Helios	Subclass: Similar to zinc finger protein, subfamily 1A, 2 (Helios)	Subclass: zinc finger protein, subfamily 1A, 4 (Eos); zinc finger transcription factor Eos				
Вепаулог	: : : : : : : : : : : : : : : : : : :	U:(HI-D)	2.73	F:(C-D)	-4.72	(a-IH):N	2.59	F:(C-D)	-3.71												U:(HI-D)	2.45	F:(C-D)	
Mouse Gene	7	NM_016875	NP_058571.1 2.73			AF001293	AAB58795.1		-												NM_009895	NP_034025.1 2.45		

 $\vec{\vdash}$

Η.

Ñ

		Subclass: cytokine-inducible SH2-containing protein isoform 2; cytokine-inducible SH2-containing protein; cytokine-inducible
		Subclass: cytokine-inducible SH2-containing protein isoform 1; cytokine-inducible SH2-containing protein; cytokine-inducible
		inhibitor of signaling type 1B; suppressor of cytokine signaling
NM_018830	(HI-D)	U:(HI-D) N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2; N-acylsphingosine amidohydrolase 2; mitochondrial
NP_061300.1 2.42	2.42	ceramidase; N-acylsphingosine amidohydrolase (acid ceramidase) 2
	F:(C-D)	
•	-2.62	
AF398969	U:(HI-D)	U.(HI-D) ankyrin repeat and SOCS box-containing 8
AAK97491.1	2.35	
	F:(C-D).	
	-2.5	
NM_016970	U:(HI-D)	U:(HI–D) killer cell lectin-like receptor subfamily G, member 1; mast cell function-associated antigen (ITIM-containing)
NP_058666.1	2.13	
	F:(C-D)	
	-2.74	
NM_009344	U:(HI-D)	U:(HI-D) pleckstrin homology-like domain, family A, member 1; PQ-rich protein
NP_033370.1 2.1	2.1	
	F:(C-D)	
•	-3.91	
		Alternate: Similar to T-cell death associated gene
NM_009255	U:(HI-D)	U:(HI-D) similar to tropomyosin, fibroblast - human
NP_033281.1 2.01	2.01	
- 	F:(C-D)	
	-2.61	
		Alternate: Protease Inhibitor; Proteinase Inhibitor
		Subclass: Glia derived nexin precursor (GDN) (Protease nexin I) (PN-1) (Protease inhibitor 7)
		Subclass: Plasminogen Activator Inhibitor-1; Chain: A; Synonym: Pai-1, Endothelial Plasminogen Activator Inhibitor, Pai

js.		Subclass: serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; plasminoger
		activator inhibitor, type I; Synonym: Pai-1, Endothelial Plasminogen Activator Inhibitor, Pai
·		Subclass: prebeta-migrating plasminogen activator inhibitor
		Subclass: Cleaved Substrate Variant Of Plasminogen Activator Inhibitor-1
		Subclass: Active Form Of Human Pai-1
		Subclass: serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1; protease inhibitor 12 (neuroserpin)
		Subclass: serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1
		Subclass: protease inhibitor 14; pancpin
	·	
NM_020013	(IH-O):N	fibroblast growth factor 21
NP_064397.1	6.00,	
	U:(C-D)	
	5.03,	
	F:(HI-D) -3.06	
X82786 CAA58026.1		antigen identified by monoclonal antibody Ki-67; Proliferation-related Ki-67 antigen
-	F:(HI-D) -4.25	
NM_010000	U:(C-HI)	U.(C-HI) cytochrome P450
NP_034130.1 34.21,	34.21,	
	U:(C-D)	
	8.32,	
	F:(HI-D)	
	-3.81	
	·	Subclass: cytochrome P450-2B6
	,	Subclass: Cytochrome P450 2A13 (CYPIIA13)

		Subclass: cytochrome P450 ZAb
		Subclass: P-450 IIA3 protein (1 is 3rd base in codon)
		Subclass: cytochrome P450 2A4
		Subclass: Cytochrome P450 2A7 (CYPIIA7) (P450-IIA4)
		Subclass: cytochrome P450 2C8
		Subclass: cytochrome P450 2F1
		Subclass: cytochrome P450 2C18
		Subclass: cytochrome P450 2C9
		Subclass: cytochrome P450 2C19
		Subclass: cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7 isoform 1
689600 MN	U:(C-HI)	U:(C-HI) baculoviral IAP repeat-containing protein 5; apoptosis inhibitor 4; survivin
NP_033819.1	3.67,	
	F:(HI-D)	
	-3.5	
		Alternate: survivin-beta
NM_010634	U:(C-HI)	U:(C-HI) fatty acid binding protein 5 (psoriasis-associated); E-FABP
NP_034764.1 3.17,	3.17,	
	F:(HI-D)	
•	-5.62	
NM_007659	U:(C-HI)	
NP_031685.1 3.00,	3.00,	
	F:(HI-D)	
	-2.87	Protein Kinase
		Subclass: cell division cycle 2 protein, isoform 1; cell division control protein 2 homolog; cyclin-dependent kinase 1; p34 protein
		kinase; cell cycle controller CDC2

ហ

 $\stackrel{\circ}{\dashv}$

15

 \approx

		Subclass: cyclin-dependent kinase 3
		Subclass: Pcdk2/Cyclin A In Complex With Mgadp, Nitrate and Peptide Substrate
		Subclass: Cyclin-Dependent Kinase-2; Chain: A, C; Synonym: Cdk2; Ec: 2.7.1
		Subclass: Cell Division Protein Kinase 2; Chain: A; Synonym: Cyclin Dependent Kinase 2; Ec: 2.7.1.37
		Subclass: PCTAIRE protein kinase 2; serine/threonine-protein kinase PCTAIRE-2; protein kinase cdc2-related PCTAIRE-2
		Subclass: Cdk5-P25(Nck5A) Complex - Protein Kinase II Catalytic Subunit, Cdk5 - Cdk5 Activator 1, Cyclin-Dependent Kinase 5
·		Regulatory Subunit 1, Protein Kinase II 23 Kda Subunit, Tpkii Regulatory Subunit, P23, P25, P35
NM_007822	U:(C-HI)	U:(C-HI) cytochrome P450,
NP_031848.1 24.5,	24.5,	
	F:(C-D)	
	-5.06,	
	F:(HI-D)	
	-7.06	
		Subclass: cytochrome P450, subfamily IVA, polypeptide 11; fatty acid omega-hydroxylase; P450HL-omega; alkane-1
		monooxygenase; lauric acid omega-hydroxylase (CYP4A11)
		Subclass: cytochrome P450, subfamily IVB, polypeptide 1; cytochrome P450, subfamily IVB, member 1; microsomal
		топоохуденаѕе
		Subclass: cytochrome P450, subfamily IVF, polypeptide 2; leukotriene B4 omega-hydroxylase; leukotriene-B4 20-monooxygenase
		Subclass: cytochrome P450, subfamily IVF, polypeptide 3; leukotriene B4 omega hydroxylase; leukotriene-B4
·		20-monooxygenase; cytochrome P450-LTB-omega
		Subclass: cytochrome P450, subfamily IVF, polypeptide 11
		Subclass: Cytochrome P450 4F12 (CYPIVF12)
		Subclass: cytochrome P450, subfamily IVF, polypeptide 8; microsomal monooxygenase; flavoprotein-linked monooxygenase
		Subclass: similar to CYTOCHROME P450 4F6 (CYPIVF6)
		Subclass: cytochrome P-450LTBV

NM_010286	U:(C-HI)	NM_010286 U:(C-HI) Glucocorticoid-induced leucine zipper protein (Delta sleep-inducing peptide immunoreactor) (DSIP-immunoreactive peptide) (DIP
NP_034416.1 2.83,	2.83,	
	F:(HI-D)	
	-2.17	
		Alternate: hypothetical protein DKFZp566A093.1
NM_008362	U:(C-HI)	U:(C-HI) Interleukin 1 receptor
NP_032388.1 2.59,	2.59,	
	F:(HI-D)	
	-2.22	
		Subclass: interleukin 1 receptor, type I
		_
		Subclass: interleukin 1 receptor accessory protein-like 2
NM_019977	U:(C-HI)	U:(C-HI) unknown protein
NP_064361.1 2.51	2.51	
	F:(C-D)	
	-2.15	
		Alternate: aldehyde reductase (aldose reductase) like 6; similar to mouse aldehyde reductase 6 (renal); myo-inositol oxygenase; kidney-specific protein 32
NM_010544	€	Indian hedgehog protein (IHH) (HHG-2)
NP_034674.1 2.45,		
	F:(HI-D)	
	-2.47	
		Alternate: similar to Indian hedgehog protein precursor (IHH) (HHG-2)

NM 01.1819	U:(C-HI)	U:(C-HI) Growth/differentiation factor 15 (GDF-15); (Placental bone morphogenic protein) (Placental TGF-beta) (Macrophage inhibitory
NP 035949.1	2.39,	cytokine-1) (MIC-1) (Prostate differentiation factor) (NSAID-regulated protein 1) (NRG-1)
· .	(c-p)	
	2.00,	
	F:(HI-D)	
	-2.52	
		Alternate similar to Growth/differentiation factor 15 precursor (GDF-15) (Placental bone morphogenic protein) (Placental
	·	TGF-beta) (Macrophage inhibitory cytokine-1) (MIC-1) (Prostate differentiation factor) (NSAID-regulated protein 1) (NRG-1)
NM_019641	U:(C-HI)	stathmin 1; metablastin; prosolin; oncoprotein 18; phosphoprotein 19; stathmin; leukemia-associated phosphoprotein p18
NP_062615.1 2.29,	2.29,	
	F:(HI-D)	
•	-2.08	
		Alternate: Similar to stathmin 1/oncoprotein 18
NM_010121	U:(C-HI)	
NP_034251.1 2.15,	2.15,	(HSPEK)
	F:(HI-D)	
	-2.13	
		U:(C-HI) hypothetical protein R30953_1
NP_035709.1	2.13	
	F:(C-D)	
	-2.1	
NM_011318	U:(C-HI)	Serum Amyloid P Component (Sap)
NP_035448.1 2.03,	2.03,	
	F:(HI-D)	
	-2.37	
		Alternate: C-reactive protein, pentraxin-related; C-reactive protein

PCT/US2004/010191

wo	2004/092416	
----	-------------	--

72. 3 98 102. 3 98 3 98 3 10 and the vasopressin receptor Subclass: arginine vasopressin receptor 14. Via vasopressin receptor; vasoular/hepatic-type arginine vasopressin receptor; vasopressin receptor; vasopressin receptor; vasopressin receptor; subclass: arginine vasopressin receptor; vasopressin vasopressin receptor; vasopressin vasopressin receptor; vasopressin
1. C. C. C. C. C. C. C. C. C. C. C. C. C.
NM_016847 U NP_058543.1 2-2-2-37 NP_035258.1 2.35 U:(C-D) NP_035258.1 2.35 U:(H-D-2.35 E:(C-D) 2.73 E:(C-D) 2.85 E:(C

...

NM 008239	(C-D)	NM_008239 U:(C-D) winged helix/forkhead transcription factor
NP_032265.2 2.23,	2.23,	
-	(HI-D)	
	2.15	
	F:(C-D)	
	-2.79	
		Alternate: HNF-3/forkhead-like protein 1
NM_019922	(c-p)	cartilage associated protein
NP_064306.1 2.05	2.05	
	F:(C-D)	
	-2.29	
AF047725	F:(HI-D)	
AAD13720.1 -2.06	-2.06	
	U:(C-D)	
	2.35	cytochrome P450, subfamily IIC
		Subclass: cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 18; cytochrome P450, subfamily IIC
		(mephenytoin 4-hydroxylase), polypeptide 17; microsomal monooxygenase; flavoprotein-linked monooxygenase
		Subclass: cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19; mephenytoin 4'-hydroxylase; microsoma
		monooxygenase; xenobiotic monooxygenase; flavoprotein-linked monooxygenase
	-	Subclass: Cytochrome P450 2C8 (CYPIIC8) (P450 form 1) (P450 MP-12/MP-20) (P450 IIC2) (S-mephenytoin 4-hydroxylase)
		Subclass: cytochrome P450, subfamily IIC, polypeptide 9; cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase),
		polypeptide 10; mephenytoin 4-hydroxylase; microsomal monooxygenase; xenobiotic monooxygenase; flavoprotein-linked
		monooxygenase
		Subclass: Cytochrome P450 2C10 (CYPIIC10) (P450 MP-8) (S-mephenytoin 4-hydroxylase) (P-450MP)

AK007530	F.(C.H.)	F-(C-H) N-acetyltransferase 8: kidney, and liver-specific gene product: kidney, and liver-specific gene
B & B25001 1	(α Δ	י מסניליוו מו זכן ממני כל י מומי ולכן יאף כיווס אכיויס אכיויס אינויס נויס אינויס אינויס אינויס אינויס אינויס אינויס אינויס אינויס אינויס אינוי
1.15002000	5 G	
	F:(C-2)	
	-2.61,	
	U:(HI-D)	
	2.99	
		Alternative: putative N-acetyltransferase Camello 2
		Alternative: GLA
		Alternative: kidney- and liver-specific gene
		Alternative: hypothetical protein TSC501 [imported]
NM_007825	F:(C-HI)	F:(C-HI) cytochrome P450, subfamily VIIB, polypeptide 1; oxysterol 7alpha-hydroxylase
NP_031851.1 -6.41,	-6.41,	
	U:(HI-D)	
	5.83	
NM_015763	F:(C-HI)	Lipin
NP_056578.1 -3.7,	-3.7,	
	U:(C-D)	
	3.14	
		Subclass: lipin 1
		Subclass: Similar to lipin 1
		Subclass: similar to Hypothetical protein KIAA0188
		Subclass: lipin 2
X71479	F:(C-HI)	cytochrome P450, subfamily IVA, polypeptide 11; fatty acid omega-hydroxylase; P450HL-omega; alkane-1 monooxygenase: lauric
CAA50585.1	-3.57,	acid omega-hydroxylase
	F:(C-D)	
	-2.54,	
	(G-IH):n	
	2.82	

	,	
699600 MN	F:(C-HI)	Alpha-Amylase
NP 033799.1	-3.13	
	U:(C-D)	
	3.23	
		Subclass: amylase, alpha 2A; pancreatic; Amylase, pancreatic, alpha-2A
		Subclass: amylase, alpha 2B; pancreatic; Amylase, pancreatic, alpha-2B
		Subclass: similar to Alpha-amylase, salivary precursor (1,4-alpha-D-glucan glucanohydrolase)
		Subclass: amylase, alpha 1A; salivary, Amylase, salivary, alpha-1A
	!	
NM_007643	F:(C-HI)	CD36 antigen (collagen type I receptor, thrombospondin receptor); CD36 antigen (collagen type I)
NP 031669.1	-3.03,	
ı .	U:(C-D)	
	2.05,	
	U:(HI-D)	
	3.33	
AK007264	F:(C-HI)	similar to uridine phosphorylase; similar to Q16831 (PID:g2494059)
BAB24924.1	-2.95,	
	U:(HI-D)	
	50.4	Alternate: Uridine phosphorylase
NM_010379	F:(C-HI)	MHC class II histocompatibility antigen
NP_034509.1	-2.87,	
	U:(HI-D)	
	2.37	
		Subclass: MHC class II histocompatibility antigen DQw1-beta chain precursor
		Subclass: MHC class II HLA-DQ-beta-1

		Subclass: HI & class II histocompatibility antinen DO(W3) beta chain precursor
NM_020564 F:(C-F) NP_065589.1 -2.84,	F:(C-HI) -2.84,	sulfotransferase family, cytosolic; 2B, member 1; sulfotransferase family 2B, member 1
L 1	F:(C-D) -2.36.	
	U:(HI-D)	
V	2.6	- LOCAL 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10
		Subciass: hydroxysteroid suirotransferase SUL1261a
		Subclass: hydroxysteroid sulfotransferase SULT2B1b
NM_032400 F	:(C-HI)	F:(C-HI) G protein-coupled receptor 91
NP_115776.1 -2.79,	.2.79,	
	U:(HI-D)	
(,)	3.03	
		Alternate: P2Y purinoceptor 1
NM_008495 F	F:(C-HI)	beta-galactosidase binding lectin precursor; Lectin, galactose-binding, soluble, 1; galectin
NP_032521.1	-2.65,	
<u></u>	U:(C-D)	
CV.	2.32	
AK003129 F	=:(C-HI)	F:(C-HI) Unknown (protein for IMAGE:2819455)
BAB22589.1 -2.51,	.2.51,	
<u> </u>	F:(C-D)	
<u> </u>	-3.41,	
<u></u>	U:(HI-D) 3.46	
		Alternate: translocase of inner mitochondrial membrane 17 homolog A (yeast); preprotein translocase

NM_011596	F:(C-HI)	TJ6 protein
NP_035726.1 -2.51,	-2.51,	
	F.(C-D)	
	-2.34,	
	U:(HI-D)	
-	4.16	
		Alternate: ATPase, H+ transporter
		Subclass: ATPase, H+ transporting, lysosomal, non-catalytic accessory protein 1A, 110/116 KDa subulint, ATFase,
		transporting, lysosomal non-catalytic accessory protein 1 (110/116kD); vacuolar proton pump, subunit 1; clatiful-coated
		vesicle/synaptic vesicle proton pump 116 kDa subunit; vacuolar proton translocating ATPase 116 kDa subunit A isoform 1,
		vacuolar adenosine triphosphatase subunit Ac116; H(+)-transporting two-sector ATPase, 116 kDa accessory protein A1;
		vacuolar-type H(+)-ATPase 115 kDa subunit
		Subclass: ATPase, H+ transporting, lysosomal V0 subunit a isoform 4; vacuolar proton pump 116 kDa accessory subunit,
		vacuolar proton pump, subunit 2; H(+)-transporting two-sector ATPase, noncatalytic accessory protein 1B; ATPase, H+
<u> </u>		transporting, lysosomal (vacuolar proton pump) non-catalytic accessory protein 1B; renal tubular acidosis; ATPase, H+
		transporting lysosomal (vacuolar proton pump) non-catalytic accessory protein 2 (38kD)
		Subclass: T-cell. immune regulator 1, isoform a; ATPase, H+ transporting, 116kD; vacuolar proton translocating ATPase 116 kDa
		subunit A isoform 3; V-ATPase 116-kDa isoform a3; osteoclastic proton pump 116 kDa subunit; T cell immune response cDNA7
		protein; specific 116-kDa vacuolar proton pump subunit; T-cell, immune regulator 1; infantile malignant osteopetrosis
AF193796	F:(C-HI)	Homeobox protein Hox-C13 (Hox-3G)
AAL09298.1	-2.33,	
	U:(HI-D)	
	3.03	
		Alternate: similar to homeo box protein C13; Hox-C13 (Hox-3G)
		Alternate: unnamed protein product
		Pitaliary, alliant process

NM_016704	F:(C-H)	
NP_057913.1 -2.26,	-2.26,	
	U:(HI-D)	
	3.29	complement component
		Subclass: complement component C6
		Subclass: similar to Complement component C6 precursor
		Subclass: complement C7
NM_007870	F:(C-HI)	
NP_031896.1 -2.2,	-2.2,	
	U:(HI-D)	
	2.24	deoxyribonuclease I
		Subclass: deoxyribonuclease I-like 3
	٠	Subclass: DNase gamma
		Subclass: deoxyribonuclease I
		Subclass: deoxyribonuclease I-like 2
		Subclass: deoxyribonuclease I-like 1
		Subclass: DNL1L gene product
NM_010187	F:(C-HI)	Low affinity immunoglobulin gamma FC region receptor II-B precursor (FC-gamma RII-B) (FCRII-B) (IGG FC receptor II-B)
NP_034317.1 -2.18,	-2.18,	(FC-gamma-RIIB) (CD32) (CDW32)
	U:(HI-D)	
	2.55	
NM_007472	F:(C-HI)	aquaporin (water channel protein)
NP_031498.1 -2.17,	-2.17,	
	U:(HI-D) 2.38	
		Subclass: aquaporin 1 (channel-forming integral protein, 28kD)
		1

വ

2

12

Ŋ

		O. Laterantia interioris are flowe filters an importin
	1	Subclass: Major ministic protein or lens most, advaporing
		Subclass: aquaporin 2; Aquaporin-2 (collecting duct)
		Subclass: hAQP-CD=collecting duct aquaporin [human, kidney, Peptide, 271 aa]
		Subclass: aquaporin 4 C2 isoform; mercurial-insensitive water channel
		Subclass: aquaporin 4 isoform a; mercurial-insensitive water channel
		Subclass: aquaporin 4, long splice form - human
		Subclass: aquaporin 5; Aquaporin-5
NM_010024	€	dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2); Dopachrome tautomerase (dopachrome
NP_034154.1 -2.14,	-2.14,	delta-isomerase; tyrosinase-related protein 2)
	F:(C-D)	
	-2.01,	
	(O-IH):0	
	2.28	
		Alternate: tyrosinase-related protein 1
		Alternate: tyrosinase (oculocutaneous albinism IA); Tyrosinase
AF385682	F:(C-HI)	EGF-TM7-latrophilin-related protein
AAK62363.1	-2.04,	
	U:(HI-D)	
	2.02	
		Alternate: egf-like module containing, mucin-like, hormone receptor-like sequence
		Subclass: egf-like module containing, mucin-like, hormone receptor-like sequence 1; egf-like module containing, mucin-like,
-		hormone receptor-like
		Subclass: egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform a
		Subclass: egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform b
		Subclass: egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform c
		Subclass: egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform e
		Subclass: egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform d

20

Ŋ

		Subclass: egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform g
		Subclass: egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform f
		Subclass: egf-like module-containing mucin-like receptor 3 isoform a
		Subclass: EGF-like module EMR2
		Alternate: lectomedin
		Subclass: lectomedin-3
		Subclass: latrophilin 1; KIAA0786 protein; lectomedin-1; latrophilin
		Subclass: lectomedin-1 alpha
		vlectomedin-2
		Subclass: lectomedin-2; KIAA0821 protein
		Alternate: CD97 antigen, isoform 1 precursor; leukocyte antigen CD97; seven-span transmembrane protein
		Alternate: CD97 antigen, isoform 2 precursor; leukocyte antigen CD97; seven-span transmembrane protein
NM_010016	F:(C-HI)	NM_010016 F:(C-HI) decay-acceleration factor
NP_034146.1 -2.04,	-2.04,	
	U:(HI-D) 2.14	
		Subclass: decay accelerating factor for complement (CD55, Cromer blood group system); Decay-accelerating factor of
		complement
		Subclass: decay-accelerating factor, splice form 1
		Subclass: decay-accelerating factor 1 ab
		Subclass: decay-accelerating factor 4ab
		Subclass: decay-accelerating factor 3

	111111111111111111111111111111111111111	
NM_023740 F:(C-HI) PP3774	F:(C-HI)	PP3774
NP_076229.1 -1.7,	-1.7,	
	F:(C-D)	
	-2.35,	
	U:(HI-D)	
	2.52	
		Alternate: Similar to RIKEN cDNA 1500015N03 gene
	-	Alternate: similar to Abl-philin 2
		Alternate: hypothetical protein MGC2993
NM_009744	F:(C-D)	NM_009744 F:(C-D) B-cell lymphoma 6 (BCL6) protein; B-cell CLL/lymphoma-6; cys-his2 zinc finger transcription factor BCL5: zinc finger protein 51.
NP_033874.1 -4.15,	-4.15,	lymphoma-associated zinc finger gene on chromosome 3
	U:(HI-D)	
	2.11	
		Alternate: similar to BcL6-associated zinc finger protein
٠		
NM_008245	F:(C-D)	NM_008245 F:(C-D) hematopoletically expressed homeobox; proline-rich homeodomain-containing transcription factor (HEX)
NP_032271.1 -2.62,	-2.62,	
	U:(HI-D)	
	2.05	
		Alternate: Similar to hematopoietically expressed homeobox

PCT/US2004/010191 WO 2004/092416

408

References

5

10

... 25

... . 30

- Unger, R.H., Foster, D.W. (1998) Diabetes mellitus. Williams Textbook of Endocrinology, J.D. Wilson, D.W. Foster, H.M. Kronenberg, and P.R. Larsen, eds. (Philadelphia, W.B. Saunders Company), pp. 973-1059.
- Polonsky, K.S. (1995) The beta-cell in diabetes: from 2. molecular genetics to clinical research. Diabetes 44:705-717
- Velho, G., Froguel, P. (1997) Genetic determinants of non-insulin-dependent diabetes mellitus: strategies and recent results. Diabete et Metabolisme 23:7-17
- Groop, L.C., Tuomi, T. (1997) Non-insulin-dependent 4. diabetes mellitus-a collision between thrifty genes and an affluent society. Ann. Med. 29:37-53.
- Reaven, G.M. (1988) Role of insulin resistance in human 15 disease. Diabetes 37:1595-1607.
 - Clark, M.G., Rattigan, S., Clark, D.G. (1983) Obesity with insulin resistance: experimental insights. Lancet (ii) 1236-1240.
- Kissebah, A.H., Vydelingum, N., Murray, R., Evans, D.J., 20 Hartz, A.J., Kakloff, R.K., Adams, P.W. (1982) Relation of body fat distribution to metabolic complications of obesity. Clin. Endo and Metab 54(2):254-260.
 - Kissebah, A.H. (1996) Intra-abdominal fat: is it a 8. major factor in developing diabetes and coronary artery disease? Diabetes Res Clin Pract 30 (Suppl):25-30.
 - Friedman, J.M., Leibel, R. (1992) Tackling a weighty 9. problem. Cell 69:217-220
 - Bjorntorp, P. (1991) Metabolic implications of body fat 10. distribution. Diabetes Care 14:1132-1143.
 - Emery, E.M., Schmid, T.L., Kahn, H.S., Filozof, P.P. (1993) A review of the association between abdominal fat distribution, health outcome measures, and modifiable risk factors. Am J Health Promot 7:342-353.
- Wickelgren, I. (1998) Obesity: how big a problem? 12. 35 Science 280:1365.

409

- Surwit, R.S., Kuhn, C.M., Cochrane, C., McCubbin, J.A., Feinglos, M.N. (1988) Diet-induced type-II diabetes in C57BL/6J mice. Diabetes 37:1163-11672.
- Surwit, R.S., Feinglos, M.N., Rodin, J., Sutherland, A., Petro, A.E., Opara, E.C., Kuhn, C.M., Rebuffe-Scrive, M. (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. 44(5):645-651.
- Ahren, B.E., Simonson, E., Scheurink, A.J.W., Mulder, H., 15. Myerson, U., Sundler, F. (1997) Dissociated insulinotropic 10 sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46(1):97-106. Page, R., Morris, C., Williams, J., von Ruhland, C., Malik, Isolation of diabetes-associated kidney genes A.N. (1997)
- using differential display. Biochem Biophys Res Commun 15 232(1):49-53
 - 17. Condorelli, G., Vigliotta, G., Iavarone, C., Caruso, M., Tocchetti, C.G., Andreozzi, F., Cafieri, A., Tecce, M.F., Formisano, P., Beguinot, L., Beguinot, F. (1998) PED/PEA-15
- qene controls glucose transport and is overexpressed in type 2 20 diabetes mellitus. Embo J 17(14):3858-66
 - Peraldi, M.N., Berrou, J., Hagege, J., Rondeau, E., Sraer, J.D. (1998) Subtractive hybridization cloning: an efficient technique to detect overexpressed mRNAs in diabetic nephropathy.
- Kidney Int 53(4):926-31 25

5

- Song, Y., Ailenberg, M., Silverman, M. (1998) Cloning of a novel gene in the human kidney homologous to rat munc13s: its potential role in diabetic nephropathy. Kidney Int 53(6):1689-95 Imagawa, M., Tsughiya, T., and Nishihara, T. (1999)
- Identification of inducible genes at the early stage of 30 adipocyte differentiation of 3T3-L1 cells. Biochem. Biophys. Res. Comm. 254:299-305.
 - Nadler, S.T., Stoehr, J.P., Schueler, K.L., Tanimoto, G., Yandell, B.S., Attie, A.D. (2000) The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 97:11371-11376
 - Lan H, Rabaglia ME, Stoehr JP, Nadler ST, Schueler KL, Zou F, Yandell BS, Attie AD. (2003) Gene expression profiles of

WO 2004/092416 PCT/US2004/010191

410

nondiabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes 52:688-700.

5 .

CLAIMS

5

- 1. A method of protecting a human subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises administering to the subject a protective amount of at least one agent which is
- (1) a polypeptide which is substantially structurally identical or conservatively identical in sequence to a reference protein which is (a) selected from the group consisting of mouse and human proteins set forth in master table 1, subtables 1A and 1C, or (b) selected from the group consisting of human proteins within at least one of the human protein classes set forth in master table 2, subtables 2A and 2C,

or

25

30

- (2) an expression vector encoding the polypeptide of (1) above and expressible in a human cell, under conditions conducive to expression of the polypeptide of (1);
 - where said agent protects said subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state.
 - 2. A method of protecting a human subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state which comprises administering to the subject a protective amount of at least one agent which is
 - (1) an antagonist of a polypeptide, occurring in said subject, which is substantially structurally identical or conservatively identical in sequence to a reference protein which is (a) selected from the group consisting of mouse and human proteins set forth in master table 1, subtable 1B and 1C, or (b) selected from the group consisting of human proteins belonging to at

WO 2004/092416 PCT/US2004/010191

412

least one of the human protein classes set forth in master table 2, subtables 2B and 2C,

(2) an anti-sense vector which inhibits expression of said polypeptide in said subject,

where said agent protects said subject from progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state.

10

15

20

25

30

35

5

3. A method of screening for human subjects who are prone to progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises assaying tissue or body fluid samples from said subjects to determine the level of expression of at least one "favorable" human marker gene, said human marker gene encoding a human protein which is substantially structurally identical or conservatively identical in sequence to a reference protein which is (a) selected from the group consisting of mouse and human proteins set forth in master table 1, subtables 1A and 1C, or (b) selected from the group consisting of human proteins within at least one of the human protein classes set forth in master table 2, subtables 2A and 2C,

and directly correlating the level of expression of said marker gene with the propensity to progression in said patient.

4. A method of screening for human subjects who have a propensity for progression from a normoinsulinemic state to a hyperinsulinemic state, or from either to a type II diabetic state, which comprises assaying tissue or body fluid samples from said subjects to determine the level of expression of at least one "unfavorable" human marker gene, said human marker gene encoding a human protein which is substantially structurally identical or conservatively identical in sequence to a reference protein which is (a) selected from the group consisting of mouse and human proteins set forth in master table 1, subtable 1B and 1C, or (b) selected from the group consisting

WO 2004/092416

of human proteins belonging to at least one of the human protein classes set forth in master table 2, subtables 2B and 2C,

413

PCT/US2004/010191

- and inversely correlating the level of expression of said marker gene with the propensity to progression in said patient.
 - 5. The method of claims 1 or 3 in which the reference protein is of subtable 1A or of a class set forth in subtable 2A.
- 10 6. The method of claims 1 or 3 in which the reference protein is of subtable 1B or of a class set forth in subtable 2B.
 - 7. The method of any one of claims 1-6 in which (a) applies.
- 15 8. The method of any one of claims 1-7 in which the reference protein is a human protein.

20

- 9. The method of any one of claims 1-7 in which the reference protein is a mouse protein.
- 10. The method of any one of claims 3 or 4 in which the level of expression of the marker protein is ascertained by measuring the level of the corresponding messenger RNA.
- 11. The method of any one of claims 3 or 4in which the level of expression is ascertained by measuring the level of a protein encoded by said marker gene.
 - 12. The method of any one of claims 1-9 in which said polypeptide is at least 80% identical or at least highly conservatively identical to said reference protein.
 - 13. The method of any one of claims 1-10 in which said polypeptide is at least 90% identical to said reference protein.
- 14. The method of any one of claims 1-11 in which said35 polypeptide is identical to said reference protein.
 - 15. The method of any one of claims 1-14 in which the E-value cited for the reference protein in Master Table 1 is not more

WO 2004/092416 PCT/US2004/010191

414

than e-6.

16. The method of claim 15 in which the E-value cited for the reference protein in Master Table 1 is less than e-10.

5

- 17. The method of claim 17 in which the E value calculated by BLASTN or BLASTX would be less than e-15, more preferably less than e-20, still more preferably less than e-40, even more preferably less than e-60, considerably more preferably less than e-80, and most preferably less than e-100.
- 18. The method of any of claims 2-17 in which the antagonist is an antibody, or an antigen-specific binding fragment of an antibody.

15

- 19. The method of any of claims 2-17 in which the antagonist is a peptide, peptoid, nucleic acid, or peptide nucleic acid oligomer.
- 20 20. The method of any of claims 2-17 in which the antagonist is an organic molecule with a molecular weight of less than 500 daltons.
- 21. The method of claim 20 in which said organic molecule is identifiable as a molecule which binds said polypeptide by screening a combinatorial library.

Abstract of the Disclosure

Mouse genes differentially expressed in comparisons of normal vs. which hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic liver by gene chip analysis have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against hyperinsulinemia or type 2 diabetes, or their sequelae.

INTERNATIONAL SEARCH REPORT

II ational Application No

		101/002001/010131			
A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS S	SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12Q					
Documentati	on searched other than minimum documentation to the extent that su	ch documents are inch	uded in the fields se	arched	
		and whom practice	approb torms used		
	ata base consulted during the international search (name of data base		, search terms used,		
EPO-Int	ternal, BIOSIS, EMBASE, WPI Data, CH	EM ABS Data	14		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT	· · · · · · · · · · · · · · · · · · ·			
Category °	Citation of document, with indication, where appropriate, of the rele	vant passages		Relevant to claim No.	
А	COROMINOLA H ET AL: "Identificat novel genes differentially expres omental fat of obese subjects and type 2 diabetic patients."	sed in			
	DIABETES. DEC 2001, vol. 50, no. 12, December 2001 (2 pages 2822-2830, XP002293068 ISSN: 0012-1797 the whole document	001-12),			
Α .	HIDA K ET AL: "Identification of specifically expressed in the acc visceral adipose tissue of OLETF JOURNAL OF LIPID RESEARCH. OCT 20 vol. 41, no. 10, October 2000 (20 pages 1615-1622, XP002293069 ISSN: 0022-2275 the whole document	rats."			
		/	•		
X Fur	ther documents are listed in the continuation of box C.	Patent family	members are listed	in annex.	
"A" docum consi "E" earlier filing	 Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "E" earlier document but published on or after the international filing date "E" earlier document but published on or after the international filing date invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention 		n the application but neory underlying the claimed invention of the considered to ocument is taken alone		
citatio	citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art				
P docum	*P* document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family				
Date of the	e actual completion of the international search	Date of mailing of	f the international se	arch report	
	19 August 2004	31/08/	2004		
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized office	er		
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 LUZZatto, E		to, E	·	

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	I Delevent to state to
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CONDORELLI G ET AL: "PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus." THE EMBO JOURNAL. 15 JUL 1998, vol. 17, no. 14, 15 July 1998 (1998-07-15), pages 3858-3866, XP002293070 ISSN: 0261-4189 cited in the application the whole document	1
A	ZVONIC SANJIN ET AL: "The regulation and activation of ciliary neurotrophic factor signaling proteins in adipocytes." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 24 JAN 2003, vol. 278, no. 4, 24 January 2003 (2003-01-24), pages 2228-2235, XP002293071	1
	ISSN: 0021-9258 the whole document	
A	WALDER KEN ET AL: "Tanis: a link between type 2 diabetes and inflammation?" DIABETES. JUN 2002,	
	vol. 51, no. 6, June 2002 (2002-06), pages 1859-1866, XP002293072 ISSN: 0012-1797 the whole document	
T	DATABASE NCBI NIH; cyclin B1 20 December 2003 (2003-12-20), XP002293073 Database accession no. NP_114172 abstract	
T	DATABASE NCBI NIH; Cyclin B2 (Homo sapiens) 23 January 2004 (2004-01-23), XP002293074 Database accession no. NP_004692 abstract	
Т	DATABASE NCBI NIH; XP002293075 Database accession no. XP_172630 abstract	
	_/	

INTERNATIONAL SEARCH REPORT

n ational Application No PCT/US2004/010191

Category °	tion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Γ	DATABASE NCBI NIH; Unnamed protein product 30 April 2004 (2004-04-30), XP002293076 Database accession no. BBA92054 abstract	
		·
• •		

rnational application No. PCT/US2004/010191

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
20,21 Claims Nos.: 20,21 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 20,21

dependent thereon.

1) The molecule to which claim 20 relates is only characterised in that its molecular weight is less than 500 daltons and that it has to be an antagonist of any of the polypeptides listed in tables 1B, 1C, 2B or 2C. This sole feature, however, does not allow the skilled person to understand the scope of the claim. In order to do that he would have to determine whether any of the numerous compounds disclosed in the prior art falling within the given MW range and used to treat and/or prevent diabetes antagonise the effects of the said polypeptides. However, many of the proteins listed in the tables have a plurality of effects, yet the description provides no indication whatsoever as to which specific effect should be tested and by which kind of assay. Moreover, many of the said proteins (see e.g. BAA92054.1/NM_033373, i.e. the first protein listed in table 1B) is an unnamed protein for which no function/effect is disclosed either in the application or in the prior art (see printout from the NCBI database (Acc. Nr: BBA92054). The claim lacks thus clarity to such an extent as to render a meaningful search with respect to its subject-matter impossible. Moreover, the

2) A further reason for not searching these claims is that they also lack support (Art. 6 PCT) due to the absence of any example of any treatment method falling within the scope of claims 20-21.

20, thus, cannot be searched at all. The same applies to claim 21

description provides no indication whatsoever as to any compound having a MW of less than 500 d which could be used in the claimed method. Claim

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.